<SEC-DOCUMENT>0001628280-22-022469.txt : 20220811
<SEC-HEADER>0001628280-22-022469.hdr.sgml : 20220811
<ACCEPTANCE-DATETIME>20220811161306
ACCESSION NUMBER:		0001628280-22-022469
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		55
CONFORMED PERIOD OF REPORT:	20220630
FILED AS OF DATE:		20220811
DATE AS OF CHANGE:		20220811

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adverum Biotechnologies, Inc.
		CENTRAL INDEX KEY:			0001501756
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				205258327
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36579
		FILM NUMBER:		221156010

	BUSINESS ADDRESS:	
		STREET 1:		100 CARDINAL WAY
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063
		BUSINESS PHONE:		(650) 649-1004

	MAIL ADDRESS:	
		STREET 1:		100 CARDINAL WAY
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Avalanche Biotechnologies, Inc.
		DATE OF NAME CHANGE:	20100921
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>advm-20220630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:4ac67419-c73c-4942-8754-fc53d915184d,g:dfc73ebd-49d4-42d9-8e60-60c5f25a86bb,d:26ccaa4e5746469982cbf0d18a526b99--><html xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:advm="http://www.adverum.com/20220630" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>advm-20220630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80L2ZyYWc6YTI3Nzc4MTlkYjY4NGU4YjlhMmUxZjYyZWU0NzVjMmEvdGFibGU6YTEyMzk3OTljMjQwNDQ0M2JiMDMyYTI1MGNjZGQ1ODIvdGFibGVyYW5nZTphMTIzOTc5OWMyNDA0NDQzYmIwMzJhMjUwY2NkZDU4Ml8zLTEtMS0xLTI1NTg1_72ce18c5-f2d0-46a6-89aa-68adbac89ca3">false</ix:nonNumeric><ix:nonNumeric contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80L2ZyYWc6YTI3Nzc4MTlkYjY4NGU4YjlhMmUxZjYyZWU0NzVjMmEvdGFibGU6YTEyMzk3OTljMjQwNDQ0M2JiMDMyYTI1MGNjZGQ1ODIvdGFibGVyYW5nZTphMTIzOTc5OWMyNDA0NDQzYmIwMzJhMjUwY2NkZDU4Ml80LTEtMS0xLTI1NTg1_ab939531-fbfb-46e5-a971-678810461920">2022</ix:nonNumeric><ix:nonNumeric contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80L2ZyYWc6YTI3Nzc4MTlkYjY4NGU4YjlhMmUxZjYyZWU0NzVjMmEvdGFibGU6YTEyMzk3OTljMjQwNDQ0M2JiMDMyYTI1MGNjZGQ1ODIvdGFibGVyYW5nZTphMTIzOTc5OWMyNDA0NDQzYmIwMzJhMjUwY2NkZDU4Ml81LTEtMS0xLTI1NTg1_93883f81-bb7d-47f1-b7e5-5eb177ae263a">Q2</ix:nonNumeric><ix:nonNumeric contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80L2ZyYWc6YTI3Nzc4MTlkYjY4NGU4YjlhMmUxZjYyZWU0NzVjMmEvdGFibGU6YTEyMzk3OTljMjQwNDQ0M2JiMDMyYTI1MGNjZGQ1ODIvdGFibGVyYW5nZTphMTIzOTc5OWMyNDA0NDQzYmIwMzJhMjUwY2NkZDU4Ml82LTEtMS0xLTI1NTg1_cf618ea7-59c3-4126-8c7e-fa91af03a36a">0001501756</ix:nonNumeric><ix:nonNumeric contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80L2ZyYWc6YTI3Nzc4MTlkYjY4NGU4YjlhMmUxZjYyZWU0NzVjMmEvdGFibGU6YTEyMzk3OTljMjQwNDQ0M2JiMDMyYTI1MGNjZGQ1ODIvdGFibGVyYW5nZTphMTIzOTc5OWMyNDA0NDQzYmIwMzJhMjUwY2NkZDU4Ml83LTEtMS0xLTI1NTg1_d160ec34-c2ad-4d5d-a59b-a8f08c7cc8be">12-31</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="advm-20220630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e8682aed96f487494756de2720f7cd8_I20220805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-08-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i091c63ec0288436c847c3d7e1c66f29c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i38e7641014c24f42802a0e767f3da33c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ifcdb30088bf7428a9bf0c7fa1ccdf887_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i534d16e402214e46a2178eacb5f3be48_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ad64833b2574d27bcaca620f8c24d6b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f8ccf2148a9492d902f6f94eb01174d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2dfcbaeefa9147cbba60bd2882f576de_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6634e2f52a847768604489aa9f3c9d0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie027bd425de348d4a1b5300009c35102_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if00e0b0ca7644910be332f543006ae0f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc708e5b6b094b4eb7fec66b6dc66928_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9159386fd0b64a19afc5728875da6262_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3aa715f29516471b9cfbccd6ee4ca148_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0900f39f6ae64609b5f0340334613281_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82b81bdc53d24ac3a2e37e5e289e00bd_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i336f4d10ad0f4bd6b4dc2747d0a2fc24_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05db59da08cd4440a613ffe932afc6bb_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91d4178a225048af85608fbbcfdf8470_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c2897cfbbc9414b88969fe82f79f015_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0be82e64c27c4cbfa000b526606d88fc_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff5e67a5e9f74fac86ac20f5900ace2a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2429e191daf4063aea94b7ed34f5388_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f9caab9d43a43f19ba39650948dd3f0_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69ca4e98b7be4f1fa546888688ac9c03_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb516b66f76b47e181f2514f175fa2b4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf31d645ca1d4dd890e884ed2b7dac54_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00073676a06748c68637a40a8727c8cf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9949cffe4b48436aa01e854017183fe5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68011d96733242bca48e8a0c3b302d00_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69bcd14ab3b84bb88d6e42f9230125ce_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15be9234201549dda36ced82a7e6393c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4d154fca0034bb5b7b0269881994a59_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id91817d16c8345b4ada12e9b1a9a6273_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53cdb9cd0dd642dc92e3c0646c561cff_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide35349f92374b249c80c109cd124d77_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc847f307933433ba6f7b36aea3dfb93_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d15881335174b83b764439f173aa254_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaee3a372f64b4aad8aacb35b2978dd58_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i426bcccc21194024aad7653f13ebe0d4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fb91db49e124d13ab1d36083ab22b1d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie945c879a02d4d6ba31708f37ae74b95_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf886eae67904297903b8421e1e1c8fe_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie982d1e05e884a6482e7a9e4298e528e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09c847c9c0fa46b89a2903bd45f6e881_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8044234398d04dcab0c8561aec8f0bc0_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9538b6ec79b846f7908793997055ff12_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie78b9ce6001d4e5ab1cc5c46bce0747b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i078c4a42f2414969902183a5d669406c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i482d42d854f34847aff3836171ba55a7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i675426f71ab9487190495924b6d0e2dd_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae693632f44f47d4a8883d9933e4355c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e8996fffaaf4fa6a89db9103b7e7b7c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2861affa7475415584f86dff3b7e4c46_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">advm:CashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5c48a2ec7314c31b6eca960c2f2a9ee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20a2357f1ee944a3981e58fb135760d0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d29995dc41841af867793064df8a5d2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2089649fd507474b8a8f30cdaa43c325_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2f748a77951427c94225f30126754e7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">advm:CashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9056b729e8546fab8f001340cc9fdf3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia76becc1500d43a2a228fe82d7febe92_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieffb39be45a94c67a589adccd5ca2de7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf62e11c42f84334ba360a7fcd68e94a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02800f7274124fe1971aafbaacb2bacf_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbb879dcd01e4d5bacd3fcbb94f010f6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7566ab2be1484f1db090914aa37ba934_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbe21a83e6804a47850aa04b8d75d01a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66e76679aad44f1985ba7be517dc7768_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2281372e2bd3421693ab7f4489600be1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b6fb5c50aa542bf9198fb1cb8a23705_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i799e2367d7a44cd3ab31610e4082fe1a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61c1bc0d431a4a5cb89f8a7d9bd2ef9a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2977397029043bc8e1c6fb7a9d878ca_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6819ea354434909b8b5bc79270cf986_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie97980ff64894dfe89ceaa2199851660_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd2c662c3d65454a9af244685ed76367_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11fb6fa11226421b9721333c446b487e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f2c878dab744d72a09fd050e76b040e_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7921ddb1395c47e497a4d22dceba9142_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8275590de8c4107a7250156ea0c4f5d_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia558ece0e92049239ba7ef43bde0bf94_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie17cab1a780b48bf993da64124f1616e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00290c3bbf024183bc58b3da064c1719_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf067933631d446ea2d6ff5ad2ba89f6_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id35485ffc22d4b6d97a32ff7a9e6516a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7873e824c2c453082de63de06e7151c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d3546d871c340909747af982e7e0cf1_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76f0e181dd5b4835a9cf93e9fd673c58_I20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="employee"><xbrli:measure>advm:employee</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ic30a812f292d467f80a69160b83e189b_D20220701-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i26ccaa4e5746469982cbf0d18a526b99_1"></div><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">___________________________________________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGV4dHJlZ2lvbjplZWQzMGI1Yjc1MzI0MGU1YjFiNmRlZDJmOTYwMTc3MV8yNDI4_4e515436-188b-403c-95e0-8eb3c97ce22b">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">___________________________________________________________________</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGFibGU6NmU2MmIxZmQ4YTJjNGQ3MWI0YzJlM2U1YzY0MzhlMWUvdGFibGVyYW5nZTo2ZTYyYjFmZDhhMmM0ZDcxYjRjMmUzZTVjNjQzOGUxZV8wLTAtMS0xLTI1NTg1_219ad9ba-aff4-4410-8201-a47f09f9c87b">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGV4dHJlZ2lvbjplZWQzMGI1Yjc1MzI0MGU1YjFiNmRlZDJmOTYwMTc3MV8yNjY_f442c929-026d-4023-9634-d4ffc9518a7a">June&#160;30, 2022</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGFibGU6NDIwZjY5ZmMyZTNhNDA1NTk5Zjk4ZDBiOTEzNzE4YzkvdGFibGVyYW5nZTo0MjBmNjlmYzJlM2E0MDU1OTlmOThkMGI5MTM3MThjOV8wLTAtMS0xLTI1NTg1_fd5875fb-fcdb-434b-900d-44fe2ac4aa70">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGV4dHJlZ2lvbjplZWQzMGI1Yjc1MzI0MGU1YjFiNmRlZDJmOTYwMTc3MV8yNDM1_20c288af-436a-4d79-914a-aab8d4f6b5c5">001-36579</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">___________________________________________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGV4dHJlZ2lvbjplZWQzMGI1Yjc1MzI0MGU1YjFiNmRlZDJmOTYwMTc3MV8yNDI5_e5163b1d-3f9c-4005-b7a7-bad88cb326a7">Adverum Biotechnologies, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">___________________________________________________________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.439%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGFibGU6OGFiY2NkNzBkMmZmNDkwNmFhYTY1MjhmYTE4M2M3YjYvdGFibGVyYW5nZTo4YWJjY2Q3MGQyZmY0OTA2YWFhNjUyOGZhMTgzYzdiNl8wLTAtMS0xLTI1NTg1_7c372df2-a150-4d40-81a4-e72b34734c0a">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGFibGU6OGFiY2NkNzBkMmZmNDkwNmFhYTY1MjhmYTE4M2M3YjYvdGFibGVyYW5nZTo4YWJjY2Q3MGQyZmY0OTA2YWFhNjUyOGZhMTgzYzdiNl8wLTItMS0xLTI1NTg1_485af396-9be9-49c7-9163-9cae60591cbd">20-5258327</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">incorporation or organization)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Identification No.)</span></div></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGV4dHJlZ2lvbjplZWQzMGI1Yjc1MzI0MGU1YjFiNmRlZDJmOTYwMTc3MV8yNDMx_4b53ed4a-aa29-422f-8b18-b604af4ae837">100 Cardinal Way</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGV4dHJlZ2lvbjplZWQzMGI1Yjc1MzI0MGU1YjFiNmRlZDJmOTYwMTc3MV8yNDMy_e23cca69-0424-4640-a953-2b9bcd824c03">Redwood City</ix:nonNumeric>, <ix:nonNumeric contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGV4dHJlZ2lvbjplZWQzMGI1Yjc1MzI0MGU1YjFiNmRlZDJmOTYwMTc3MV8yNDMz_6c5055f8-f3ab-4b5d-879d-bcc4df0c1383">CA</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGV4dHJlZ2lvbjplZWQzMGI1Yjc1MzI0MGU1YjFiNmRlZDJmOTYwMTc3MV8yNDI0_9ce00c97-1487-4df5-ab07-fd37c8329d8e">94063</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Zip Code)</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGV4dHJlZ2lvbjplZWQzMGI1Yjc1MzI0MGU1YjFiNmRlZDJmOTYwMTc3MV82OTk_7d233fdd-c4c0-4a8e-86ab-268ff8b67526">650</ix:nonNumeric>) <ix:nonNumeric contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGV4dHJlZ2lvbjplZWQzMGI1Yjc1MzI0MGU1YjFiNmRlZDJmOTYwMTc3MV8yNDI1_5b62b5e0-2cf3-443c-9812-4a307d798189">656-9323</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">___________________________________________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:33.307%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.308%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Title of each class</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Trading symbol</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Name of each exchange on which registered</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGFibGU6NjBmYmNkMWRmYjlkNDA4ZTg4OTlhODY1NzMzNjc1MGUvdGFibGVyYW5nZTo2MGZiY2QxZGZiOWQ0MDhlODg5OWE4NjU3MzM2NzUwZV8xLTAtMS0xLTI1NTg1_0e81e76d-9c20-4257-ae85-64b865b82d44">Common Stock, $0.0001 par value</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGFibGU6NjBmYmNkMWRmYjlkNDA4ZTg4OTlhODY1NzMzNjc1MGUvdGFibGVyYW5nZTo2MGZiY2QxZGZiOWQ0MDhlODg5OWE4NjU3MzM2NzUwZV8xLTEtMS0xLTI1NTg1_6e2af716-6da3-4dd6-aa80-2cc7c835bf18">ADVM</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGFibGU6NjBmYmNkMWRmYjlkNDA4ZTg4OTlhODY1NzMzNjc1MGUvdGFibGVyYW5nZTo2MGZiY2QxZGZiOWQ0MDhlODg5OWE4NjU3MzM2NzUwZV8xLTItMS0xLTI1NTg1_3411d1fa-c0d3-4019-b42c-fd252b705d70">The Nasdaq Global Market</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGV4dHJlZ2lvbjplZWQzMGI1Yjc1MzI0MGU1YjFiNmRlZDJmOTYwMTc3MV8yNDM0_5bfbac19-e7a4-494a-83aa-229706fc65cc">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#168;</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGV4dHJlZ2lvbjplZWQzMGI1Yjc1MzI0MGU1YjFiNmRlZDJmOTYwMTc3MV8yNDI2_8dab60bf-3e43-42d7-a0a4-800a37921ea5">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#168;</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Large accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGFibGU6MjhkMjc2Njc2OTQ1NDc4NDk2MTRmMjMxMWQwYzgzN2IvdGFibGVyYW5nZToyOGQyNzY2NzY5NDU0Nzg0OTYxNGYyMzExZDBjODM3Yl8xLTAtMS0xLTI1NTg1_1bb3a632-a37d-4a9a-8d2a-0fbb953b4fbd">Non-accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">x</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Smaller reporting company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGFibGU6MjhkMjc2Njc2OTQ1NDc4NDk2MTRmMjMxMWQwYzgzN2IvdGFibGVyYW5nZToyOGQyNzY2NzY5NDU0Nzg0OTYxNGYyMzExZDBjODM3Yl8xLTQtMS0xLTI1NTg1_2bc87bd2-0d9b-438a-983c-f7285cae956f">x</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Emerging growth company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGFibGU6MjhkMjc2Njc2OTQ1NDc4NDk2MTRmMjMxMWQwYzgzN2IvdGFibGVyYW5nZToyOGQyNzY2NzY5NDU0Nzg0OTYxNGYyMzExZDBjODM3Yl8yLTQtMS0xLTI1NTg1_3c1860fd-a927-473f-983b-3f822a4d93d4">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#168;</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGV4dHJlZ2lvbjplZWQzMGI1Yjc1MzI0MGU1YjFiNmRlZDJmOTYwMTc3MV8xMzc0Mzg5NTM0OTY0OQ_1ad39ec6-5e21-47c0-9b61-8b557cff8fb0">x</ix:nonNumeric></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">As of August&#160;5, 2022, there were <ix:nonFraction unitRef="shares" contextRef="i7e8682aed96f487494756de2720f7cd8_I20220805" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGV4dHJlZ2lvbjplZWQzMGI1Yjc1MzI0MGU1YjFiNmRlZDJmOTYwMTc3MV8yMzM4_15f4db5c-892f-4d5b-b670-02418dc43abc">99,333,578</ix:nonFraction> shares of the registrant&#8217;s common stock, par value $0.0001 per share, outstanding.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i26ccaa4e5746469982cbf0d18a526b99_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adverum Biotechnologies, Inc.</span></div><div style="margin-top:24pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:91.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.672%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Page</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_13">PART I&#8212;FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i26ccaa4e5746469982cbf0d18a526b99_13">5</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_16">Item 1. Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i26ccaa4e5746469982cbf0d18a526b99_16">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_19">Condensed Consolidated Balance Sheets as of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_19">June </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_19">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_19">0</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_19">, 2022 and December 31, 2021 (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i26ccaa4e5746469982cbf0d18a526b99_19">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_22">Condensed Consolidated Statements of Operations and Comprehensive Loss for the three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_22">and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_22">six</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_22"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_22">months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_22">June </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_22">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_22">0</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_22">, 2022 and 2021 (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i26ccaa4e5746469982cbf0d18a526b99_22">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_25">Condensed Consolidated Statements of Stockholders&#8217; Equity for the three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_25">and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_25">six </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_25">months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_25">June</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_25"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_25">0</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_25">, 2022 and 2021 (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i26ccaa4e5746469982cbf0d18a526b99_25">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_28">Condensed Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_28">six</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_28"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_28">June</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_28"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_28">0</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_28">, 2022 and 2021 (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i26ccaa4e5746469982cbf0d18a526b99_28">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_31">Notes to Condensed Consolidated Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i26ccaa4e5746469982cbf0d18a526b99_31">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_70">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i26ccaa4e5746469982cbf0d18a526b99_70">14</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_100">Item 3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i26ccaa4e5746469982cbf0d18a526b99_100">21</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_103">Item 4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i26ccaa4e5746469982cbf0d18a526b99_103">21</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_106">PART II&#8212;OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i26ccaa4e5746469982cbf0d18a526b99_106">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_109">Item 1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i26ccaa4e5746469982cbf0d18a526b99_109">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_112">Item 1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i26ccaa4e5746469982cbf0d18a526b99_112">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_139">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i26ccaa4e5746469982cbf0d18a526b99_139">61</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_142">Item 3. Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i26ccaa4e5746469982cbf0d18a526b99_142">61</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_145">Item 4. Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i26ccaa4e5746469982cbf0d18a526b99_145">61</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_148">Item 5. Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i26ccaa4e5746469982cbf0d18a526b99_148">61</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_151">Item 6. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i26ccaa4e5746469982cbf0d18a526b99_151">62</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_154">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i26ccaa4e5746469982cbf0d18a526b99_154">64</a></span></div></td></tr></table></div><div><span><br/></span></div><div id="i26ccaa4e5746469982cbf0d18a526b99_10"></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTORS SUMMARY</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing in common stock involves numerous risks, including the risks described in &#8220;Item 1A. Risk Factors&#8221; of this Quarterly Report on Form 10-Q. Below are some of these risks, any one of which could materially adversely affect our business, financial condition, results of operations, and prospects. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred significant operating losses since inception, and we expect to incur significant losses for the foreseeable future. We may never become profitable or, if achieved, be able to sustain profitability.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We expect that our cash, cash equivalents, and short-term investments will be sufficient to fund our lead gene therapy programs for at least twelve months from the date of this filing. If this expectation proves to be wrong, we may be forced to delay, limit or terminate certain of our development efforts before then.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will need to raise additional funding, which may not be available on acceptable terms, or at all. If we fail to obtain additional capital necessary to fund our operations, we will be unable to successfully develop and commercialize our product candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business will depend substantially on the success of one or more of our product candidates. If we are unable to develop, obtain regulatory approval for, or successfully commercialize, any or all of our product candidates, our business will be materially harmed.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Drug development is a long, expensive and uncertain process, and delay or failure can occur at any stage of development, including after commencement of any of our clinical trials or any clinical trials using our proprietary viral vectors.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The occurrence of serious complications or side effects that outweigh the therapeutic benefit in connection with or during use of our product candidates, either in nonclinical studies or clinical trials or post-approval, could lead to discontinuation of our clinical development program, refusal of regulatory authorities to approve our product candidates or, post-approval, revocation of marketing authorizations or refusal to approve new indications, which could severely harm our business prospects, financial condition and results of operations.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The results of nonclinical studies and early clinical trials are not always predictive of future results. Any product candidate we or any of our future development partners advance into clinical trials may not have favorable results in later clinical trials, if any, or receive regulatory approval.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to successfully develop and maintain robust and reliable manufacturing processes for our product candidates, we may be unable to advance clinical trials or licensure applications and may be forced to delay or terminate a program.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to produce sufficient quantities of our products at acceptable costs, we may be unable to meet clinical or potential commercial demand, lose potential revenue, have reduced margins, or be forced to terminate a program.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We and our contractors are subject to significant regulation with respect to manufacturing and testing our product candidates. We have a limited number of vendors on which we rely, including, in some cases, single source vendors, and the contract vendors on which we rely may not continue to meet regulatory requirements, may have limited capacity, or may have other factors limiting their ability to comply with their contracts with us.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to many manufacturing and distribution risks, any of which could substantially increase our costs and limit supply of our product candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have relied, and expect to continue to rely, on third parties to conduct some or all aspects of our vector production, process development, assay development, product manufacturing, product testing, protocol development, and research, and these third parties may not perform satisfactorily.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will rely on third parties to conduct some nonclinical testing and all of our planned clinical trials. If these third parties do not meet our deadlines or otherwise fail to conduct the trials as required, our clinical development programs could be delayed or unsuccessful and we may not be able to obtain regulatory approval for or commercialize our product candidates when expected or at all.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our success depends on our ability to protect our intellectual property and our proprietary technologies.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our rights to develop and commercialize our product candidates are subject in part to the terms and conditions of licenses granted to us by other companies and universities.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The patent protection and patent prosecution for some of our product candidates are dependent on third parties.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third party patent rights could delay or otherwise adversely affect our planned development and sale of product candidates of our programs.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to obtain intellectual property rights or protect our intellectual property rights throughout the world.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we do not obtain patent term extensions for patents covering our product candidates, our business may be materially harmed.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any suspension of, or delays in the commencement or completion of, clinical trials for our product candidates could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Final marketing approval for our product candidates by the FDA or other regulatory authorities outside the U.S. for commercial use may be delayed, limited or denied, any of which would adversely affect our ability to generate operating revenue.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if we receive regulatory approval, we still may not be able to successfully commercialize any of our product candidates, and the revenue that we generate from its sales, if any, could be limited.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If our competitors develop treatments for the target indications of our product candidates that are approved, marketed more successfully, or demonstrated to be safer or more effective or easier to administer than our product candidates, our commercial opportunity will be reduced or eliminated.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if we obtain marketing approval for any of our product candidates, they could be subject to restrictions or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates profitably.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Negative public opinion and increased regulatory scrutiny of gene therapy and genetic research may damage public perception of our product candidates or adversely affect our ability to conduct our business or obtain marketing approvals for our product candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are dependent on the services of our key executives and clinical and scientific staff, and if we are not able to retain these members of our management or recruit additional management, clinical and scientific personnel, our business will suffer.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may encounter difficulties in managing our growth and expanding our operations successfully.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The coronavirus (&#8220;COVID-19&#8221;) pandemic has impacted our business practices and the effects of its continued impact on our business, results of operations, and financial condition will depend on future developments, which cannot be predicted.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The trading price of the shares of our common stock has been and could continue to be highly volatile, and purchasers of our common stock could incur substantial losses.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we sell shares of our common stock or securities convertible into or exercisable for shares of our common stock in future financings, pursuant to our at-the-market sales agreement, licensing or collaboration arrangements, or acquisitions, stockholders may experience immediate dilution and, as a result, our stock price may decline.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our failure or perceived failure to comply with existing or future laws, regulations, contracts, self-regulatory schemes, standards, and other obligations related to privacy, data protection, and data security (including security incidents) could harm our business.  Our compliance or the actual or perceived failure to comply with such obligations could increase the costs of our services, limit their use or adoption, and otherwise negatively affect our operating results and business.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i26ccaa4e5746469982cbf0d18a526b99_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I&#8212;FINANCIAL INFORMATION</span></div><div id="i26ccaa4e5746469982cbf0d18a526b99_16"></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-108pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;Financial Statements</span></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-108pt"><span><br/></span></div><div id="i26ccaa4e5746469982cbf0d18a526b99_19"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adverum Biotechnologies, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current assets:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMy0xLTEtMS0yNTU4NQ_517207e3-2636-40f3-9503-19278b6af7a2">91,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMy0zLTEtMS0yNTU4NQ_f8f5d9b0-978c-4cae-bd1d-2a8b50bd8d05">34,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfNC0xLTEtMS0yNTU4NQ_3a06cfd8-3259-4f70-bc4f-787cae513ec3">143,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfNC0zLTEtMS0yNTU4NQ_e0265e3c-551b-4d47-8f3e-346c2d414f33">270,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease incentive receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" name="us-gaap:IncentiveToLessee" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfNS0xLTEtMS0yNTU4NQ_fd901910-70f1-4c31-a52b-63e61ca06a5f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231" decimals="-3" name="us-gaap:IncentiveToLessee" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfNS0zLTEtMS0yNTU4NQ_716bad88-c629-4069-9c33-38e991b19843">5,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfNi0xLTEtMS0yNTU4NQ_526b5a02-f072-4eed-8695-880aab90383f">10,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfNi0zLTEtMS0yNTU4NQ_19ac6410-5ff0-4cea-bbb9-3a861b16fbd9">6,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfNy0xLTEtMS0yNTU4NQ_ef58c7da-500e-4cc9-af75-c6b7c5e6b4da">246,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfNy0zLTEtMS0yNTU4NQ_70e3f936-f330-4202-bf52-f600f39e8ad7">317,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfOC0xLTEtMS0yNTU4NQ_34542e18-28d3-4bbb-93cc-38a3b0c96f16">83,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfOC0zLTEtMS0yNTU4NQ_b7a725af-f864-4780-9a17-e26ba84e12aa">86,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfOS0xLTEtMS0yNTU4NQ_7d9c9919-f091-4a15-80ed-797a82feb7da">38,233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfOS0zLTEtMS0yNTU4NQ_f15e494b-cc01-4e5d-b373-b0020b810f41">33,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMTEtMS0xLTEtMjU1ODU_6fad9ada-e277-4d57-a8d0-a25d0ec7b236">2,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMTEtMy0xLTEtMjU1ODU_fa2df4b5-e79d-4c4c-a1fb-2cb155d53cc3">2,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred rent receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" name="us-gaap:DeferredRentReceivablesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMTItMS0xLTEtMjU1ODU_121b1fa0-e8a7-4f4c-8fbc-a07a908f2537">4,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231" decimals="-3" name="us-gaap:DeferredRentReceivablesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMTItMy0xLTEtMjU1ODU_e48ed11e-aed9-44cf-b6ff-b22dcf243027">769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deposit and other long-term assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMTMtMS0xLTEtMjU1ODU_5d666cca-a920-4847-8f23-75984ec717ce">277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMTMtMy0xLTEtMjU1ODU_f67dbfcd-d371-4f91-962a-0d6765b38ae7">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMTQtMS0xLTEtMjU1ODU_d84a1d6c-baf2-4465-a627-521cc2c63986">374,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMTQtMy0xLTEtMjU1ODU_9cc3fafb-5226-4ecf-a7b6-ad8b6e3451a6">439,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities and stockholders&#8217; equity</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMTctMS0xLTEtMjU1ODU_fa29fce6-5975-4772-a512-117084fb6c98">4,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMTctMy0xLTEtMjU1ODU_15916d41-0d72-4805-8a1e-1f3ac65d31f1">1,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" name="advm:AccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMTgtMS0xLTEtMjU1ODU_1fbbdbef-d87f-4cbe-b07d-eabc5069f39a">19,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231" decimals="-3" name="advm:AccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMTgtMy0xLTEtMjU1ODU_ac1f2b28-d4b5-4c5c-b2f8-71b874a0308f">18,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liability, current portion</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMTktMS0xLTEtMjU1ODU_947b5156-2e44-43e8-b12f-3e57a19b4319">6,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMTktMy0xLTEtMjU1ODU_b9753dd7-7458-48a8-b7dd-66c7532b538e">1,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMjEtMS0xLTEtMjU1ODU_e46e6658-798e-4747-93d4-997547003ce8">30,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMjEtMy0xLTEtMjU1ODU_77dd6f89-9390-4977-a3b4-ad170c2a2184">21,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liability, net of current portion</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMjMtMS0xLTEtMjU1ODU_068bd2b4-202f-4423-b9ef-63148fa55e2d">99,193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMjMtMy0xLTEtMjU1ODU_e4b2b4f9-e942-4aac-9dd7-537d21bd305c">101,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMjQtMS0xLTEtMjU1ODU_d7bfe519-198b-4eb0-a73a-c81bbcda0c2a">1,020</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMjQtMy0xLTEtMjU1ODU_f66ec82b-4943-49b5-a190-af7d5b0dec81">1,114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMjUtMS0xLTEtMjU1ODU_d0d74c8a-1f9c-40a2-ba4d-0391197a0de7">130,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMjUtMy0xLTEtMjU1ODU_6573ac7f-9b15-4174-be00-692f215d4537">123,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217; equity:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMjgtMS0xLTEtMjU1ODU_3bdf17da-dac4-4dcb-8920-3225e5e4dcd1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMjgtMy0xLTEtMjU1ODU_7127adc4-366a-45c3-88cd-fd042f4b9350">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMjktMS0xLTEtMjU1ODU_6ae239e1-c15e-4620-9f0e-6e93c94d915a">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMjktMy0xLTEtMjU1ODU_c4fcb621-1e87-4902-aa58-82a268b944b8">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMzAtMS0xLTEtMjU1ODU_27c5f4a4-6e14-4514-b7b8-85cb7b8e0e68">975,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMzAtMy0xLTEtMjU1ODU_0739e2ed-9d9a-4206-acd7-73ec91ad0ef8">964,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMzEtMS0xLTEtMjU1ODU_d4e6fe15-216e-4bc5-9ece-15b358b99bfb">1,796</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMzEtMy0xLTEtMjU1ODU_24d4527e-e444-4db4-b7ab-2ad344fb7f42">714</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMzItMS0xLTEtMjU1ODU_338c8af4-035a-4b05-a694-9c6092ae8dee">729,745</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMzItMy0xLTEtMjU1ODU_00cbf8d4-6676-47d1-971c-13d1654166b5">648,076</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stockholders&#8217; equity</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMzMtMS0xLTEtMjU1ODU_a9e84a19-f661-467e-a1c7-2b12b472a900">244,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMzMtMy0xLTEtMjU1ODU_7a771e13-0bbb-4824-ac35-4971b0834fd2">316,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMzQtMS0xLTEtMjU1ODU_d6806a02-ea5b-4a26-8bd9-3dbb415666e1">374,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMzQtMy0xLTEtMjU1ODU_9e1a6440-fbd4-4465-b36a-094e1d0cb156">439,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i26ccaa4e5746469982cbf0d18a526b99_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adverum Biotechnologies, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except per share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMi0xLTEtMS0yNTU4NQ_f62e60c8-019c-4511-804e-34a7dba9f887">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMi0zLTEtMS0yNTU4NQ_8164808a-4911-46d3-80bc-1850bd2d648c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMi01LTEtMS0yNTU4NQ_f40e6eb8-1b65-4b6e-a515-55455d7cfe1a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMi03LTEtMS0yNTU4NQ_0bb3000f-fa2f-4ac3-9008-81853f130c91">7,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfNS0xLTEtMS0yNTU4NQ_9545158c-6a80-418f-8ca8-cb0d36b28fc6">30,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfNS0zLTEtMS0yNTU4NQ_fe0481d7-7284-4204-8e5e-b324d93e8da3">22,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfNS01LTEtMS0yNTU4NQ_ee545c76-bc2c-4b50-b29d-44a456e19022">53,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfNS03LTEtMS0yNTU4NQ_9d92ca60-dae2-454a-af7b-6cb5c95f3ad0">42,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfNi0xLTEtMS0yNTU4NQ_5a4a1891-ffef-4e5d-936b-29c44a4dc39e">13,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfNi0zLTEtMS0yNTU4NQ_585e90c3-2896-4250-aded-11c2f675eaaf">21,930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfNi01LTEtMS0yNTU4NQ_a283f9c4-4d23-4931-be30-f1efb7c77976">28,929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfNi03LTEtMS0yNTU4NQ_70da8e12-7938-4430-916d-f2dbd784658d">38,093</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfOC0xLTEtMS0yNTU4NQ_12ed834a-7b07-4459-b312-6c3f66a01603">44,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfOC0zLTEtMS0yNTU4NQ_3250046b-e701-40be-a526-f439ca3c16a3">44,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfOC01LTEtMS0yNTU4NQ_1bfdc061-2613-4b59-8de3-44be3aa13302">82,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfOC03LTEtMS0yNTU4NQ_3b5e1ee7-b6e5-4de3-bf24-22c244bde2f2">80,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfOS0xLTEtMS0yNTU4NQ_1b964c84-cd30-4f49-94ba-05ade6f02e7b">44,025</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfOS0zLTEtMS0yNTU4NQ_537a541a-47e5-485c-9b8f-274e5845f338">44,538</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfOS01LTEtMS0yNTU4NQ_11f8de1d-a813-4bd5-ad7d-873134b1028a">82,158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfOS03LTEtMS0yNTU4NQ_3a2bef43-d80b-4392-963e-c5c940559c39">73,181</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTAtMS0xLTEtMjU1ODU_e4cc63ac-6b79-41d5-86c1-8507ef992f0f">283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTAtMy0xLTEtMjU1ODU_655dfa70-38d7-4a84-82c1-d3e856420063">205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTAtNS0xLTEtMjU1ODU_59378717-bddc-4d21-80c2-986f9c19b13f">527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTAtNy0xLTEtMjU1ODU_9d29d616-b13f-4f63-bbd7-2a5a08d21567">412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTEtMS0xLTEtMjU1ODU_80660eaf-910c-4d30-a5f9-2160f2216ccb">43,742</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTEtMy0xLTEtMjU1ODU_4416563e-3051-4697-9ac9-a8802fecf713">44,333</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTEtNS0xLTEtMjU1ODU_958113bf-dafd-4e2e-aeed-47c53c10d583">81,631</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTEtNy0xLTEtMjU1ODU_faf04b79-e4b6-46e2-9720-0899523a7a2a">72,769</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTItMS0xLTEtMjU1ODU_94c497f7-1ada-4217-8286-ed71c8bbb2dc">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTItMy0xLTEtMjU1ODU_f4548fb1-0f72-489e-a369-f11be6d95720">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTItNS0xLTEtMjU1ODU_d3bac694-fd1e-4f94-a844-40d530063d50">38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTItNy0xLTEtMjU1ODU_8bdf5f3c-acd2-4012-9f15-e2eebe9907a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTMtMS0xLTEtMjU1ODU_f188d11e-e9e3-4331-8f78-4fe0150484a9">43,761</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTMtMy0xLTEtMjU1ODU_d4abe721-603d-411c-ae7f-45d907d979e3">44,333</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTMtNS0xLTEtMjU1ODU_fb91d3dd-8b97-46ea-b1ff-e0915a401ee8">81,669</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTMtNy0xLTEtMjU1ODU_bdd9876b-e646-40ba-9e36-a0fae50d33af">72,769</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized loss on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTUtMS0xLTEtMjU1ODU_0471de2e-5ccc-4968-84f6-d2c985ccae0e">339</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTUtMy0xLTEtMjU1ODU_2f264cd7-4d09-4b5d-aed6-c86d1b72d980">62</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTUtNS0xLTEtMjU1ODU_9bdf459c-10c1-4501-92b1-fc5ef1141abe">1,062</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTUtNy0xLTEtMjU1ODU_8733a66a-2de0-4665-a7e2-d7de1384f069">84</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTYtMS0xLTEtMjU1ODU_57a95728-c3a6-4c6f-9a66-e000b52db2c6">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTYtMy0xLTEtMjU1ODU_1630f49a-d121-4802-ac79-2f3a63c186bd">39</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTYtNS0xLTEtMjU1ODU_beaba5e5-d9d2-46e8-b64f-b3c2e1957436">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTYtNy0xLTEtMjU1ODU_8482453d-7d1c-484a-af3f-84fd8dd4f80a">72</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTctMS0xLTEtMjU1ODU_c7d79aea-e438-41bb-a128-2b7381af8f55">44,134</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTctMy0xLTEtMjU1ODU_34d04c41-73a5-4692-a090-c72313403795">44,434</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTctNS0xLTEtMjU1ODU_6e5fda33-a376-44be-b90e-d56874008464">82,751</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTctNy0xLTEtMjU1ODU_511500f3-a414-4c3c-a092-09e328106a3c">72,925</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share &#8212; basic and diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTgtMS0xLTEtMjU1ODU_205a0cce-bac1-4d38-b9a6-3c0d7e97ce58"><ix:nonFraction unitRef="usdPerShare" contextRef="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTgtMS0xLTEtMjU1ODU_b8e2df86-e0a3-4046-bf5f-874c7ed87896">0.44</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTgtMy0xLTEtMjU1ODU_37b8979e-6c04-4957-ae9b-87d101ace996"><ix:nonFraction unitRef="usdPerShare" contextRef="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTgtMy0xLTEtMjU1ODU_aabc10eb-dab9-459d-b905-667f7f533406">0.45</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTgtNS0xLTEtMjU1ODU_0f1c3ac9-26af-426b-971a-5551101ddf0b"><ix:nonFraction unitRef="usdPerShare" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTgtNS0xLTEtMjU1ODU_989b0d0c-6239-43f1-b398-0e4ef53553d9">0.83</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTgtNy0xLTEtMjU1ODU_77a8ca7d-0423-46e2-8092-fe40f5353ec2"><ix:nonFraction unitRef="usdPerShare" contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTgtNy0xLTEtMjU1ODU_ef6dc18e-e817-442c-af9c-92e4bba22b8e">0.74</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares used to compute net loss per share - basic and diluted</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTktMS0xLTEtMjU1ODU_87bda0ca-05cf-44a1-8826-285cb3d7dbe8"><ix:nonFraction unitRef="shares" contextRef="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTktMS0xLTEtMjU1ODU_940ca20d-c135-4d67-954b-56357e4779e3">99,000</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTktMy0xLTEtMjU1ODU_df229c5b-2039-4c16-94e3-e5f5c2a23428"><ix:nonFraction unitRef="shares" contextRef="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTktMy0xLTEtMjU1ODU_e8dac063-7d25-44c8-a08c-340b1055753d">98,018</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTktNS0xLTEtMjU1ODU_5d242f00-ef2a-46ef-9c47-a3ff34cd3ba1"><ix:nonFraction unitRef="shares" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTktNS0xLTEtMjU1ODU_e3b040f6-fab6-4df0-b9c9-2c3f1b1cff0f">98,799</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTktNy0xLTEtMjU1ODU_0e60b495-76c5-42d5-88fa-ecf6f78d4b8d"><ix:nonFraction unitRef="shares" contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTktNy0xLTEtMjU1ODU_97115788-d2ee-4e93-a487-6a8c94d91a3d">97,885</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i26ccaa4e5746469982cbf0d18a526b99_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adverum Biotechnologies, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.458%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other<br/>Comprehensive<br/>(Loss)/Income</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Stockholders'<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifcdb30088bf7428a9bf0c7fa1ccdf887_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMi0xLTEtMS0yNTU4NQ_9854d324-3d2b-4ffd-8877-a4d69f0c8958">98,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcdb30088bf7428a9bf0c7fa1ccdf887_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMi0zLTEtMS0yNTU4NQ_ddc919f3-4c23-4864-8a3d-29becc426fdb">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i534d16e402214e46a2178eacb5f3be48_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMi01LTEtMS0yNTU4NQ_1a1044c7-16ed-44bd-af80-bc7c58fddb87">964,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ad64833b2574d27bcaca620f8c24d6b_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMi03LTEtMS0yNTU4NQ_c1af19dc-bc03-483a-8e70-a3a82b12e2da">714</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f8ccf2148a9492d902f6f94eb01174d_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMi05LTEtMS0yNTU4NQ_408cb823-a405-4d1c-82de-099f0268df2d">648,076</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMi0xMS0xLTEtMjU1ODU_d5540da6-b8b3-4320-a139-deaceaef33a7">316,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dfcbaeefa9147cbba60bd2882f576de_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMy01LTEtMS0yNTU4NQ_3821b3c0-90f6-433e-8596-98d6525f9813">5,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6634e2f52a847768604489aa9f3c9d0_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMy0xMS0xLTEtMjU1ODU_772dbf8e-15c2-4858-a6bf-433f56a4c5ba">5,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued upon exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie027bd425de348d4a1b5300009c35102_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfNC0xLTEtMS0yNTU4NQ_94cc8056-12e0-4e8a-ae72-6e66d28ce71c">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dfcbaeefa9147cbba60bd2882f576de_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfNC01LTEtMS0yNTU4NQ_286cac2a-0543-40db-916f-65b2aff75855">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6634e2f52a847768604489aa9f3c9d0_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfNC0xMS0xLTEtMjU1ODU_fccb90ca-e719-4577-8486-e748caac22c8">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued upon release of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie027bd425de348d4a1b5300009c35102_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfNS0xLTEtMS0yNTU4NQ_fb20cf13-4f0d-4e27-b9dd-d422a6ceea32">371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if00e0b0ca7644910be332f543006ae0f_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfNy03LTEtMS0yNTU4NQ_17f47c73-bfd6-46cd-8a92-ab4cf3498837">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6634e2f52a847768604489aa9f3c9d0_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfNy0xMS0xLTEtMjU1ODU_c1bc4f4c-283b-4fbc-9407-13d38692760b">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on marketable securities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if00e0b0ca7644910be332f543006ae0f_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfOC03LTEtMS0yNTU4NQ_eed1b09c-4168-4321-adb2-3f50c0971906">723</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6634e2f52a847768604489aa9f3c9d0_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfOC0xMS0xLTEtMjU1ODU_5c3194f0-2ac1-47b6-9e5d-b353d10075b7">723</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc708e5b6b094b4eb7fec66b6dc66928_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfOS05LTEtMS0yNTU4NQ_63211526-0abf-4185-814f-c767348db56a">37,908</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6634e2f52a847768604489aa9f3c9d0_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfOS0xMS0xLTEtMjU1ODU_393ca379-82d5-4fc7-a3dd-bffa16975399">37,908</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9159386fd0b64a19afc5728875da6262_I20220331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTAtMS0xLTEtMjU1ODU_aff223d6-9902-4394-9298-f2abdb1deb35">98,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9159386fd0b64a19afc5728875da6262_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTAtMy0xLTEtMjU1ODU_d713e408-f88b-48b6-a9fc-9efd0f538a54">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aa715f29516471b9cfbccd6ee4ca148_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTAtNS0xLTEtMjU1ODU_3b94c8c8-e838-4df0-a020-d41518f479f5">970,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0900f39f6ae64609b5f0340334613281_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTAtNy0xLTEtMjU1ODU_d9d56f63-51ea-46e0-8eea-259c665d77ec">1,423</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82b81bdc53d24ac3a2e37e5e289e00bd_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTAtOS0xLTEtMjU1ODU_a1a9e25c-89e4-4374-8515-386082782d21">685,984</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i336f4d10ad0f4bd6b4dc2747d0a2fc24_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTAtMTEtMS0xLTI1NTg1_f13ae01a-be67-434f-9d27-539d20cb6e8b">282,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05db59da08cd4440a613ffe932afc6bb_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTEtNS0xLTEtMjU5MTM_23cad5af-4638-4893-b0a6-40b47bb6aaed">4,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTEtMTEtMS0xLTI2MjQ3_1c59345d-2426-4fcd-a8fe-e5cef99df089">4,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued upon release of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i91d4178a225048af85608fbbcfdf8470_D20220401-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTItMS0xLTEtMjU5MjA_2bb365ee-eb72-40a4-8c30-62779e2bbf06">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i91d4178a225048af85608fbbcfdf8470_D20220401-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTMtMS0xLTEtMjY3Nzk_9f325af7-32d4-4585-a30d-c76686c49877">499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05db59da08cd4440a613ffe932afc6bb_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTMtNS0xLTEtMjY3Nzk_1d41c7f6-9296-47da-97d5-1b3d468b9930">362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTMtMTEtMS0xLTI3NDQw_93e22b52-d273-4261-a9aa-552de3724b2e">362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c2897cfbbc9414b88969fe82f79f015_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTMtNy0xLTEtMjU5Mjk_8b2fa5cb-bd6c-4b5d-a1d3-bdea35b7bb52">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTMtMTEtMS0xLTI2MjQ3_755d8894-d711-4222-8281-623ccac710ea">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on marketable securities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c2897cfbbc9414b88969fe82f79f015_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTQtNy0xLTEtMjU5Mjk_d45b2a68-60b2-4c0a-9e16-184757483d39">339</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTQtMTEtMS0xLTI2MjQ3_be0c24f7-23fc-46fe-a014-d951fc952b66">339</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0be82e64c27c4cbfa000b526606d88fc_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTUtOS0xLTEtMjU5Mjk_05000f35-2bc6-4b07-bb57-912cee66dc28">43,761</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTUtMTEtMS0xLTI2MjQ3_0c7656d1-0cab-403c-abc3-faee15d93af7">43,761</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff5e67a5e9f74fac86ac20f5900ace2a_I20220630" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTYtMS0xLTEtMjYyNDU_4cc1a345-82e6-49f8-848f-6fd159e04baa">99,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5e67a5e9f74fac86ac20f5900ace2a_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTYtMy0xLTEtMjYyNDU_2b958e52-392d-4143-a0ca-c1ee41842298">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2429e191daf4063aea94b7ed34f5388_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTYtNS0xLTEtMjYyNDU_1f2435fa-f134-4b3c-9d85-39def560a482">975,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f9caab9d43a43f19ba39650948dd3f0_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTYtNy0xLTEtMjYyNDU_ce5d50d9-fec9-4f6e-afa5-327d4a398370">1,796</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69ca4e98b7be4f1fa546888688ac9c03_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTYtOS0xLTEtMjYyNDU_00abf1df-3a3b-4982-b69d-d96bfb298bc3">729,745</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTYtMTEtMS0xLTI2MjQ1_297b5102-fe20-43b9-8205-bcc2ce2bf55a">244,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb516b66f76b47e181f2514f175fa2b4_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMi0xLTEtMS0yNTU4NQ_8abdb35e-a8bc-4b26-861a-c1653df220e3">97,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb516b66f76b47e181f2514f175fa2b4_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMi0zLTEtMS0yNTU4NQ_be8d5d46-e3c3-4d67-8bd0-b18513502136">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf31d645ca1d4dd890e884ed2b7dac54_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMi01LTEtMS0yNTU4NQ_e578243c-1f5f-46ba-a2ac-8c8af7f00e3b">937,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00073676a06748c68637a40a8727c8cf_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMi03LTEtMS0yNTU4NQ_a847d74d-2a5c-490e-aadb-0f95c25ad3e8">261</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9949cffe4b48436aa01e854017183fe5_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMi05LTEtMS0yNTU4NQ_30ad9b33-14d3-47e2-9f76-e3e093cf98af">502,536</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68011d96733242bca48e8a0c3b302d00_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMi0xMS0xLTEtMjU1ODU_1daae6c2-5656-4a0f-82c0-3a5bf2a81ccc">434,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69bcd14ab3b84bb88d6e42f9230125ce_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMy01LTEtMS0yNTU4NQ_ba5504b4-5be5-4c9d-8c95-7fbfe6f7b404">7,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15be9234201549dda36ced82a7e6393c_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMy0xMS0xLTEtMjU1ODU_329917ee-0eef-4cb9-9aea-873964711d62">7,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i15be9234201549dda36ced82a7e6393c_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfNC0wLTEtMS0yNTU4NS90ZXh0cmVnaW9uOjE1MWYxODdiYmFjNjRiZjU5ZTY5YjA0NTZiNTRjODA1XzU1_c101c65f-737e-43db-9399-e00e37cdf853">5</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie4d154fca0034bb5b7b0269881994a59_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfNC0xLTEtMS0yNTU4NQ_80469c0d-46b3-4d52-adef-2c6f6c04469b">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69bcd14ab3b84bb88d6e42f9230125ce_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfNC01LTEtMS0yNTU4NQ_43f1668f-0911-4275-a512-f2b78cedecf1">1,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15be9234201549dda36ced82a7e6393c_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfNC0xMS0xLTEtMjU1ODU_4b4b18f2-ed80-4e65-a3fe-9f17e7b551a7">1,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued upon exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie4d154fca0034bb5b7b0269881994a59_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfNS0xLTEtMS0yNTU4NQ_b75ae76b-fbdb-46cb-91b3-942ee6c23866">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69bcd14ab3b84bb88d6e42f9230125ce_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfNS01LTEtMS0yNTU4NQ_88ee4c67-fe6e-4f36-b278-9a4a40211de7">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15be9234201549dda36ced82a7e6393c_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfNS0xMS0xLTEtMjU1ODU_160216cd-e396-422e-b95c-83b131214fca">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued upon release of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie4d154fca0034bb5b7b0269881994a59_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfNi0xLTEtMS0yNTU4NQ_464256d3-7ad0-4027-aa58-a0d4e1038ad1">248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id91817d16c8345b4ada12e9b1a9a6273_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfOC03LTEtMS0yNTU4NQ_4b2dbcf5-9a72-41a4-b191-3fe38fefd2da">33</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15be9234201549dda36ced82a7e6393c_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfOC0xMS0xLTEtMjU1ODU_40de1c35-62b4-4db4-a8d2-fcba925df930">33</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on marketable securities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id91817d16c8345b4ada12e9b1a9a6273_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfOS03LTEtMS0yNTU4NQ_01a5ca0f-1c2f-4133-884a-36c6a92a3a9e">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15be9234201549dda36ced82a7e6393c_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfOS0xMS0xLTEtMjU1ODU_7ab0ccaa-84b7-441c-8e38-1921b5ee1d4b">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53cdb9cd0dd642dc92e3c0646c561cff_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTAtOS0xLTEtMjU1ODU_150d790c-e268-4c52-a616-e3cbddaf85e3">28,436</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15be9234201549dda36ced82a7e6393c_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTAtMTEtMS0xLTI1NTg1_e069ae33-bccb-44d9-9a9d-3b40b994492f">28,436</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide35349f92374b249c80c109cd124d77_I20210331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTEtMS0xLTEtMjU1ODU_1859996c-60c3-40ef-868b-156c7802c0ac">97,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide35349f92374b249c80c109cd124d77_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTEtMy0xLTEtMjU1ODU_f3b36994-0d46-4387-ad31-8ea4c41938a0">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc847f307933433ba6f7b36aea3dfb93_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTEtNS0xLTEtMjU1ODU_b48f1aad-5bd1-47ca-9cfe-c994e406d104">946,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d15881335174b83b764439f173aa254_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTEtNy0xLTEtMjU1ODU_8c45c979-d7ed-4c5c-8f3e-a19849536c74">316</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaee3a372f64b4aad8aacb35b2978dd58_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTEtOS0xLTEtMjU1ODU_32540efa-b827-49b0-bed5-634587aa330d">530,972</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i426bcccc21194024aad7653f13ebe0d4_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTEtMTEtMS0xLTI1NTg1_26bf5c95-9311-42e1-917f-b91b63611be3">414,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fb91db49e124d13ab1d36083ab22b1d_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTItNS0xLTEtMjU1ODU_ed862641-5071-4482-bae1-f440554fd848">8,234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTItMTEtMS0xLTI1NTg1_7b8fd20d-0137-4607-b85a-13f27164c2d4">8,234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, additional issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fb91db49e124d13ab1d36083ab22b1d_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTMtNS0xLTEtMjU1ODU_7aa8f6ad-decc-48bf-8ed0-117fb96a1011">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTMtMTEtMS0xLTI1NTg1_903f65ba-34eb-410b-865d-d4ccbd8def7d">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued upon release of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie945c879a02d4d6ba31708f37ae74b95_D20210401-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTQtMS0xLTEtMjU1ODU_c52afba2-00ba-498b-9d18-c3cf8d3d164d">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie945c879a02d4d6ba31708f37ae74b95_D20210401-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTUtMS0xLTEtMjU1ODU_072900e9-7b16-4b99-a5c9-07664e01b097">176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fb91db49e124d13ab1d36083ab22b1d_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTUtNS0xLTEtMjU1ODU_3110d9e7-e652-4867-b8f2-0bea819cd097">526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTUtMTEtMS0xLTI1NTg1_42daff2a-a421-4f96-beb0-01cf5e3b1830">526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf886eae67904297903b8421e1e1c8fe_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTYtNy0xLTEtMjU1ODU_0efc3389-cbf3-4bbd-be63-6a751a1f9f38">39</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTYtMTEtMS0xLTI1NTg1_e7df4169-0a12-4a76-8a44-37af707cbafb">39</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on marketable securities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf886eae67904297903b8421e1e1c8fe_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTctNy0xLTEtMjU1ODU_0da320b5-c55e-4aa8-939a-7d9173d35624">62</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTctMTEtMS0xLTI1NTg1_1576fa81-7425-4864-9dd3-757371d72f5c">62</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie982d1e05e884a6482e7a9e4298e528e_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTgtOS0xLTEtMjU1ODU_9ab5bb93-98b8-4e6a-96e3-254fa220777d">44,333</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTgtMTEtMS0xLTI1NTg1_3537dd4c-89d9-4465-b40c-1266238ae42f">44,333</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i09c847c9c0fa46b89a2903bd45f6e881_I20210630" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTktMS0xLTEtMjU1ODU_5007d170-8a9e-497c-aa5a-8c19d699fd5c">98,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09c847c9c0fa46b89a2903bd45f6e881_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTktMy0xLTEtMjU1ODU_96ca11d3-9218-415e-b2d0-161b764f4767">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8044234398d04dcab0c8561aec8f0bc0_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTktNS0xLTEtMjU1ODU_896a8c69-27a6-42d9-9f93-095f9ed00aaa">954,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9538b6ec79b846f7908793997055ff12_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTktNy0xLTEtMjU1ODU_887dd1ae-9449-4104-9507-70b5de37d2c6">417</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie78b9ce6001d4e5ab1cc5c46bce0747b_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTktOS0xLTEtMjU1ODU_0919d371-c2f3-45af-862d-96009a80e93d">575,305</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i078c4a42f2414969902183a5d669406c_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTktMTEtMS0xLTI1NTg1_936ff70b-8ea6-4f22-953a-edd2bf5cba80">379,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i26ccaa4e5746469982cbf0d18a526b99_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adverum Biotechnologies, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMy0xLTEtMS0yNTU4NQ_ac247d19-edbb-447a-948e-de676cf7e19d">81,669</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMy0zLTEtMS0yNTU4NQ_5060ac42-1fc4-417e-978d-1a408d8c683c">72,769</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfNS0xLTEtMS0yNTU4NQ_95b10397-a88c-48a5-b98c-4288342f0afe">3,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfNS0zLTEtMS0yNTU4NQ_525f069d-b57b-4248-81e9-2bf1b282dcbe">2,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfNi0xLTEtMS0yNTU4NQ_ca451dcc-4644-4767-b216-63dda2c50841">10,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfNi0zLTEtMS0yNTU4NQ_cffc0b85-1acf-41bc-9d22-f6b02e3b0af5">15,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of premium and accrued interest on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfNy0xLTEtMS0yNTU4NQ_df949be7-cfdf-4ae0-827d-50e45bbc3a86">258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfNy0zLTEtMS0yNTU4NQ_4108a1e9-a03d-491b-8b1f-b3f8ee75b0c7">1,398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfOC0xLTEtMS0yNTU4NQ_39c47cc3-f7ea-40c0-ba8d-bbcef05bcb9d">101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfOC0zLTEtMS0yNTU4NQ_6c8bd5ef-0673-45fe-994d-d9298336f6fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of long-lived assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfOS0xLTEtMS0yNzUyMQ_099ffd01-3921-48a2-a93b-7152c1452049">2,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfOS0zLTEtMS0yNzUyMQ_0bacacc6-dc7f-420a-a5df-e3c02e66a4a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfOS0xLTEtMS0yNTU4NQ_72efaf7f-53a9-45c7-b834-a5980b547bdc">76</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfOS0zLTEtMS0yNTU4NQ_54f4ae72-81cf-493c-9a84-c5e14c5b1b9f">81</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMTEtMS0xLTEtMjU1ODU_31a2ff97-998d-4e3d-92e3-0a0ba63badca">4,165</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMTEtMy0xLTEtMjU1ODU_76c0125f-6947-4368-a1ef-02767ffc7cd3">1,653</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMTItMS0xLTEtMjU1ODU_ca760281-bd0e-4845-af4f-a20515f686bc">3,403</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMTItMy0xLTEtMjU1ODU_915ffd75-6ed4-41a0-b070-9532305324c9">99</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="-3" sign="-" name="advm:IncreaseDecreaseOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMTMtMS0xLTEtMjU1ODU_cf5f6ad2-e7ce-4fe0-9545-0a077db66840">2,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630" decimals="-3" sign="-" name="advm:IncreaseDecreaseOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMTMtMy0xLTEtMjU1ODU_0eacc879-0c2d-425d-845f-4e404ea47188">1,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMTQtMS0xLTEtMjU1ODU_2b7d957c-318f-4b9e-88ed-9c60d3307d7a">3,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMTQtMy0xLTEtMjU1ODU_48d5a207-2610-4cb2-bd75-d4b90696c7ff">394</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMTUtMS0xLTEtMjU1ODU_6402f75b-eb14-455c-a88b-86af0834c776">2,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMTUtMy0xLTEtMjU1ODU_c2012464-8354-4bcd-9528-518d90eb74e7">583</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMTYtMS0xLTEtMjU1ODU_0a610738-df9a-441c-8722-cbc8357d990a">38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMTYtMy0xLTEtMjU1ODU_41d3c664-f7a2-4ab1-a9e5-ec7212f25dc2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability and lease incentive receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="-3" name="advm:IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMTgtMS0xLTEtMjU1ODU_989f3141-8964-4c41-93a0-a991b272e583">8,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630" decimals="-3" sign="-" name="advm:IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMTgtMy0xLTEtMjU1ODU_c0cc8fac-90d8-4a7e-8606-8a9907da6c8d">1,363</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMjAtMS0xLTEtMjU1ODU_31b19040-825f-4468-9c48-022ebf2cc852">57,808</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMjAtMy0xLTEtMjU1ODU_2ef03ad9-855c-4777-a51e-d15e9e904f5a">56,220</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMjItMS0xLTEtMjU1ODU_810521e3-295a-4ae5-a8c7-bfd5c459ef30">57,674</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMjItMy0xLTEtMjU1ODU_a1196a3f-4706-42a0-8952-13a033a97484">199,959</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMjMtMS0xLTEtMjU1ODU_fadf6a33-a8fd-455f-a4ae-bb156f89be03">183,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMjMtMy0xLTEtMjU1ODU_6f236b02-eb1d-4193-bedc-623f2378ace3">240,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMjQtMS0xLTEtMjU1ODU_65d59cb4-1154-4004-8b03-7581f169e286">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMjQtMy0xLTEtMjU1ODU_b91cee59-c654-4816-8fd8-8b89c9ef7a8c">8,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMjUtMS0xLTEtMjU1ODU_cd45310c-c26b-4104-8594-f21da6746d1d">10,807</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMjUtMy0xLTEtMjU1ODU_cd9ee65d-3910-4822-848e-69bd78072eff">5,052</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMjYtMS0xLTEtMjU1ODU_3df2f18f-9224-4ff6-9349-cb42d53270ae">115,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMjYtMy0xLTEtMjU1ODU_d8b52230-bf75-4648-9d04-b7b078b199bf">44,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from offerings of common stock, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMjgtMS0xLTEtMjU1ODU_19bc6799-7845-4633-967b-fdc1b97170bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMjgtMy0xLTEtMjU1ODU_72985551-724d-407d-9a6d-44d506552fbe">1,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock pursuant to option exercises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMzAtMS0xLTEtMjU1ODU_3ffeccf8-5100-475e-8568-f134a1b66c2a">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMzAtMy0xLTEtMjU1ODU_5bc3ad70-0d43-4ae0-ad6c-143a07fcfd2a">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMzItMS0xLTEtMjU1ODU_ee585514-ff05-4072-83df-903ee850b518">362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMzItMy0xLTEtMjU1ODU_7d2e9d69-4828-48a7-b0ef-31de3f6b2e8b">526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="-3" name="us-gaap:RepaymentsOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMzQtMS0xLTEtMjU1ODU_f89874fb-3d45-467c-a854-1b6e5d7bda51">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630" decimals="-3" name="us-gaap:RepaymentsOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMzQtMy0xLTEtMjU1ODU_cab7f54c-fda7-49a9-82e8-79fc5438ed2e">240</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMzUtMS0xLTEtMjU1ODU_62eac42e-5dc4-456a-a541-1a83dcd47ba4">365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMzUtMy0xLTEtMjU1ODU_b6ec8b33-3a82-4ab3-8873-26041f0970e6">2,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMzYtMS0xLTEtMjU1ODU_741e93d2-7307-4a2e-9cf4-e9f48fee5a89">57,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMzYtMy0xLTEtMjU1ODU_da5705d8-6161-45c6-b680-16aeead52b49">9,842</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMzctMS0xLTEtMjU1ODU_a0eb4c50-570e-4b43-ba87-1b87b9b4a7e1">36,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68011d96733242bca48e8a0c3b302d00_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMzctMy0xLTEtMjU1ODU_a8494d57-a237-42d9-aae5-987fdc242c9a">63,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMzgtMS0xLTEtMjU1ODU_7224ffbe-d39a-4455-8864-4a6a2df0142e">94,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i078c4a42f2414969902183a5d669406c_I20210630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMzgtMy0xLTEtMjU1ODU_7fb8c96c-cf94-4907-bf2a-08334b8bb66a">53,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMzktMS0xLTEtMjU1ODU_517207e3-2636-40f3-9503-19278b6af7a2">91,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i078c4a42f2414969902183a5d669406c_I20210630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMzktMy0xLTEtMjU1ODU_f6307e2d-5cfe-4d3a-b797-c88824a0bd56">47,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfNDAtMS0xLTEtMjU1ODU_6fad9ada-e277-4d57-a8d0-a25d0ec7b236">2,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i078c4a42f2414969902183a5d669406c_I20210630" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfNDAtMy0xLTEtMjU1ODU_88a1d28b-1562-4b52-80b1-0ac532f381e3">6,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfNDEtMS0xLTEtMjU1ODU_231b0ae1-dbff-469c-855b-288a87d4b2ca">94,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i078c4a42f2414969902183a5d669406c_I20210630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfNDEtMy0xLTEtMjU1ODU_6a5922d7-04d3-4523-9a24-181563a90932">53,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental schedule of noncash investing and financing information</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfNDMtMS0xLTEtMjU1ODU_01b39afd-260d-419b-be58-7eb3d625c8ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfNDMtMy0xLTEtMjU1ODU_38446064-7596-4cc2-b351-f0216c363f54">84,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets in accounts payable, accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfNDQtMS0xLTEtMjU1ODU_de1ff934-2fa5-42c0-b52d-c5577afce9a9">908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfNDQtMy0xLTEtMjU1ODU_210112e5-80fb-41d0-9942-701ff10a08bc">1,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i26ccaa4e5746469982cbf0d18a526b99_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adverum Biotechnologies, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="i26ccaa4e5746469982cbf0d18a526b99_34"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8zNC9mcmFnOjk5ZGZkYjg4NzRjOTRkZWNiZWNhNjc1MjA3OTZmNDgzL3RleHRyZWdpb246OTlkZmRiODg3NGM5NGRlY2JlY2E2NzUyMDc5NmY0ODNfMjU0MA_179f87ff-d8f8-42a5-8599-ab89674ce655" continuedAt="i806b3d9cead1419eb27bb4ee1c92c401" escape="true">Organization and Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="i806b3d9cead1419eb27bb4ee1c92c401"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverum Biotechnologies, Inc. (the &#8220;Company&#8221; or &#8220;Adverum&#8221;) was incorporated in Delaware on July 17, 2006 and is headquartered in Redwood City, California. The Company is a clinical-stage company that aims to establish gene therapy as a new standard of care for a number of highly prevalent ocular diseases. The Company develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not generated any revenue from the sale of products since its inception. The Company has experienced net losses since its inception and had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8zNC9mcmFnOjk5ZGZkYjg4NzRjOTRkZWNiZWNhNjc1MjA3OTZmNDgzL3RleHRyZWdpb246OTlkZmRiODg3NGM5NGRlY2JlY2E2NzUyMDc5NmY0ODNfNjQ2_853bb8b5-8680-4a76-913b-a8b840657235">729.7</ix:nonFraction> million as of June&#160;30, 2022. The Company expects to incur losses and have negative net cash flows from operating activities as it engages in further research and development activities. As of June&#160;30, 2022, the Company had cash, cash equivalents and short-term investments of $<ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8zNC9mcmFnOjk5ZGZkYjg4NzRjOTRkZWNiZWNhNjc1MjA3OTZmNDgzL3RleHRyZWdpb246OTlkZmRiODg3NGM5NGRlY2JlY2E2NzUyMDc5NmY0ODNfODk1_3e50aa20-8b7f-4b94-9585-8571571c8d3f">235.8</ix:nonFraction> million, which the Company believes will be sufficient to fund its operations for at least twelve months from the date of issuance of these financial statements.</span></div><div style="margin-top:6pt"><ix:nonNumeric contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8zNC9mcmFnOjk5ZGZkYjg4NzRjOTRkZWNiZWNhNjc1MjA3OTZmNDgzL3RleHRyZWdpb246OTlkZmRiODg3NGM5NGRlY2JlY2E2NzUyMDc5NmY0ODNfMjU0MQ_982fdefc-e86f-4ed0-99b2-f7a00d2af89f" continuedAt="i0bca478a9e534f23b41fd6b3311c6bed" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation &#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and follow the requirements of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company&#8217;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair statement of the Company&#8217;s consolidated financial information. The results of operations for the three and six months ended June&#160;30, 2022 are not necessarily indicative of the results to be expected for the full year or any other future period. The balance sheet as of December&#160;31, 2021 is derived from the audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete consolidated financial statements. </span></ix:nonNumeric></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0bca478a9e534f23b41fd6b3311c6bed">The accompanying unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021 filed with the SEC</ix:continuation>.</span></div></ix:continuation><div id="i26ccaa4e5746469982cbf0d18a526b99_37"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8zNy9mcmFnOjgwZTg2ZTliMmQzMzRlNzU4MWY1NTk3NTBmYTRlNTIwL3RleHRyZWdpb246ODBlODZlOWIyZDMzNGU3NTgxZjU1OTc1MGZhNGU1MjBfMjMxMg_93ec7180-520e-4f9a-b422-a78258219f60" continuedAt="i4d6d9425007d47d7ba57e25844661c3d" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i4d6d9425007d47d7ba57e25844661c3d"><ix:nonNumeric contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8zNy9mcmFnOjgwZTg2ZTliMmQzMzRlNzU4MWY1NTk3NTBmYTRlNTIwL3RleHRyZWdpb246ODBlODZlOWIyZDMzNGU3NTgxZjU1OTc1MGZhNGU1MjBfMjMxMw_bf13e16a-268a-409a-aca2-5a4d400f311f" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities and the reported amounts of expenses in the condensed consolidated financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to clinical trial accruals, fair value of assets and liabilities, impairment of long-lived assets, income taxes, and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8zNy9mcmFnOjgwZTg2ZTliMmQzMzRlNzU4MWY1NTk3NTBmYTRlNTIwL3RleHRyZWdpb246ODBlODZlOWIyZDMzNGU3NTgxZjU1OTc1MGZhNGU1MjBfMjMxNQ_d16e2a9b-f159-4254-9097-6dfe968dda3c" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8211; Credit Losses: Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Topic 326</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and also issued subsequent amendments to the initial guidance: ASU&#160;2018-19, ASU&#160;2019-04, ASU&#160;2019-05, and ASU&#160;2019-11. The standard requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect collectability. Topic&#160;326 also eliminates the concept of &#8220;other-than-temporary&#8221; impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an allowance for credit losses on available-for-sale debt securities rather than an other-than-temporary impairment that reduces the cost basis of the investment. Topic 326 will become effective for the Company on January 1, 2023. Early adoption is permitted. The Company does not expect the effect of adoption to be material.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i26ccaa4e5746469982cbf0d18a526b99_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RleHRyZWdpb246ZTZmM2I3ZjdmMWRhNGRiZGJlMDc3Y2VhNmU2MTFhNzZfMjYwMw_1ff274d6-cc4f-4f3f-a1d6-3d234b21fab3" continuedAt="ifdec4e4fc33441a19d6cc603d6251bcc" escape="true">Fair Value Measurements and Fair Value of Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="ifdec4e4fc33441a19d6cc603d6251bcc" continuedAt="i475ee68244f649fbb4ce92fc63093714"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authoritative guidance on the fair value hierarchy for disclosure of fair value measurements is as follows:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Level 1 securities is determined using quoted prices in active markets for identical assets. Level 1 securities consist of highly liquid money market funds. Financial assets and liabilities are considered Level 2 when their fair values are determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis. U.S. government and agency securities, commercial paper, and corporate bonds are valued primarily using market prices of comparable securities, bid/ask quotes, interest rate yields and prepayment spreads and are included in Level 2. </span></div><ix:nonNumeric contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RleHRyZWdpb246ZTZmM2I3ZjdmMWRhNGRiZGJlMDc3Y2VhNmU2MTFhNzZfMjYwNA_989c995e-b98b-4508-b20d-3ab3e8e0e69e" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s cash equivalents and short-term investments:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost Basis</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Level 1:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i482d42d854f34847aff3836171ba55a7_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfNC0xLTEtMS0yNTU4NQ_1f6c962a-3f0a-4631-90ab-bb8b7f8050a4">10,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i482d42d854f34847aff3836171ba55a7_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfNC0zLTEtMS0yNTU4NQ_19abfc26-eb87-4644-b457-05bf27d0a7c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i482d42d854f34847aff3836171ba55a7_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfNC01LTEtMS0yNTU4NQ_848aa9ee-7961-4dd0-9e50-0173522d91b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i482d42d854f34847aff3836171ba55a7_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfNC03LTEtMS0yNTU4NQ_60e30462-506d-4ea3-ae07-0cdcc61b561d">10,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Level 2:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government and agency securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i675426f71ab9487190495924b6d0e2dd_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfNi0xLTEtMS0yNTU4NQ_a7985a92-b155-441c-977f-03da4b282405">55,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i675426f71ab9487190495924b6d0e2dd_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfNi0zLTEtMS0yNTU4NQ_9f4ca624-742f-4c5f-bdc5-55da5581ef85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i675426f71ab9487190495924b6d0e2dd_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfNi01LTEtMS0yNTU4NQ_83356ea4-f0ad-4b3f-bcae-9e0d9c7ac6be">1,008</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i675426f71ab9487190495924b6d0e2dd_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfNi03LTEtMS0yNTU4NQ_99b38257-9e40-4759-99dd-243721dc4694">54,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae693632f44f47d4a8883d9933e4355c_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfNy0xLTEtMS0yNTU4NQ_75eddbb4-1d9c-4e67-a6e6-7609a76feff4">150,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae693632f44f47d4a8883d9933e4355c_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfNy0zLTEtMS0yNTU4NQ_d7ad792b-deb4-4393-a9bf-45a75fcf1f39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae693632f44f47d4a8883d9933e4355c_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfNy01LTEtMS0yNTU4NQ_742145de-206b-42cb-9ad8-1508e669ddd1">323</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae693632f44f47d4a8883d9933e4355c_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfNy03LTEtMS0yNTU4NQ_50c4a021-d874-467c-b33c-0329e35f6b46">150,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8996fffaaf4fa6a89db9103b7e7b7c_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfOC0xLTEtMS0yNTU4NQ_6017243d-47af-45e7-b747-8311c8daed65">7,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8996fffaaf4fa6a89db9103b7e7b7c_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfOC0zLTEtMS0yNTU4NQ_c76cdfd0-854d-435a-ab21-30bcc79a6fba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e8996fffaaf4fa6a89db9103b7e7b7c_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfOC01LTEtMS0yNTU4NQ_f7e0db9d-8993-41bb-b76a-f5d550a1c4fd">48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8996fffaaf4fa6a89db9103b7e7b7c_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfOC03LTEtMS0yNTU4NQ_548d7b22-b800-4c7c-8d5c-9e3f0ac27a80">7,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash equivalents and short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2861affa7475415584f86dff3b7e4c46_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfOS0xLTEtMS0yNTU4NQ_1235610f-4a80-4cc2-b5be-0afbf943630b">222,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2861affa7475415584f86dff3b7e4c46_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfOS0zLTEtMS0yNTU4NQ_8c3f28f5-f0f9-4a87-98e1-1c1f7397d884">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2861affa7475415584f86dff3b7e4c46_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfOS01LTEtMS0yNTU4NQ_542bbf6e-c21c-4d32-88ca-74368d0acf29">1,379</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2861affa7475415584f86dff3b7e4c46_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfOS03LTEtMS0yNTU4NQ_086a13e3-aa82-4049-8b5d-364a14064cf5">221,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: cash equivalents</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" name="advm:CashAndCashEquivalentAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfMTAtMS0xLTEtMjU1ODU_6b6833bf-17b3-4f51-a4b6-193b95c30c30">77,342</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" name="advm:CashAndCashEquivalentGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfMTAtMy0xLTEtMjU1ODU_fd19ab53-eb22-45c4-b6a6-4da3d0f4c9e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" name="advm:CashAndCashEquivalentGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfMTAtNS0xLTEtMjU1ODU_50807bad-1d09-4c12-909d-896b99f88c9e">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfMTAtNy0xLTEtMjU1ODU_07a94061-2f52-4b67-ad21-9ca1a64ade7d">77,332</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfMTEtMS0xLTEtMjU1ODU_d8356d6a-c59d-4555-aa67-cff2e92e75df">145,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfMTEtMy0xLTEtMjU1ODU_f57e87fd-f7cc-4f0d-adf8-64e401fe7062">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfMTEtNS0xLTEtMjU1ODU_0bdde4bc-67f2-4115-8d3c-fff0f651b1ff">1,369</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfMTEtNy0xLTEtMjU1ODU_14a8dc8f-2c48-42ae-9ff0-0e97292ca592">143,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost Basis</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c48a2ec7314c31b6eca960c2f2a9ee_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfNC0xLTEtMS0yNTU4NQ_f5c0f261-a35a-47fe-94a8-d8d9598ad6ab">10,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c48a2ec7314c31b6eca960c2f2a9ee_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfNC0zLTEtMS0yNTU4NQ_71984156-e5b8-4033-951f-b11e4f1b07ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c48a2ec7314c31b6eca960c2f2a9ee_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfNC01LTEtMS0yNTU4NQ_6d8f7af4-0a0c-4337-a897-6a8ea2be6503">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c48a2ec7314c31b6eca960c2f2a9ee_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfNC03LTEtMS0yNTU4NQ_886ed5de-f5b8-43b2-9d92-2d2fd5b0bf8e">10,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 2:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20a2357f1ee944a3981e58fb135760d0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfNi0xLTEtMS0yNTU4NQ_c3e251bd-0b15-4b03-8387-2fa8373273fc">62,268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20a2357f1ee944a3981e58fb135760d0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfNi0zLTEtMS0yNTU4NQ_40ff631b-b39c-40f3-811b-dbac7b7981e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20a2357f1ee944a3981e58fb135760d0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfNi01LTEtMS0yNTU4NQ_3803accd-7aa4-4a60-9dce-b3f1734819ef">218</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20a2357f1ee944a3981e58fb135760d0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfNi03LTEtMS0yNTU4NQ_59270d01-0f1b-4eec-8d99-27e1869fa4d4">62,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d29995dc41841af867793064df8a5d2_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfNy0xLTEtMS0yNTU4NQ_05e51554-281d-4154-bf67-4afd7351fa9f">177,215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d29995dc41841af867793064df8a5d2_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfNy0zLTEtMS0yNTU4NQ_7f8fb408-d8db-4b22-a012-d895a19ec83e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d29995dc41841af867793064df8a5d2_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfNy01LTEtMS0yNTU4NQ_18905c0f-a74c-4511-820e-1918d99efaa6">61</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d29995dc41841af867793064df8a5d2_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfNy03LTEtMS0yNTU4NQ_1c37d873-57e2-4059-b141-add905c71239">177,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2089649fd507474b8a8f30cdaa43c325_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfOC0xLTEtMS0yNTU4NQ_0b09bdbe-f226-4d7c-b6da-a356197aa382">47,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2089649fd507474b8a8f30cdaa43c325_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfOC0zLTEtMS0yNTU4NQ_0388b77d-22ef-4427-820f-8df889685dd5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2089649fd507474b8a8f30cdaa43c325_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfOC01LTEtMS0yNTU4NQ_3d383178-8705-4add-9e49-0b9fc3cf176d">39</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2089649fd507474b8a8f30cdaa43c325_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfOC03LTEtMS0yNTU4NQ_bfe0c31e-77ec-4ac6-ad2a-8cee955b518c">47,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash equivalents and short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2f748a77951427c94225f30126754e7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfMTAtMS0xLTEtMjU1ODU_4af2e5b7-6577-47af-a48f-27141b753d22">297,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2f748a77951427c94225f30126754e7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfMTAtMy0xLTEtMjU1ODU_704de7d9-6e07-4213-b677-d998826098a7">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2f748a77951427c94225f30126754e7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfMTAtNS0xLTEtMjU1ODU_0f6db98e-f4ed-482d-8521-50584f7d1fd9">318</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2f748a77951427c94225f30126754e7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfMTAtNy0xLTEtMjU1ODU_a1e6ad7d-9025-4fc7-88d2-583f8f46e5f4">296,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231" decimals="-3" name="advm:CashAndCashEquivalentAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfMTEtMS0xLTEtMjU1ODU_1b2961c8-0552-45c7-a3d2-52194b1a3bb1">25,808</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231" decimals="-3" name="advm:CashAndCashEquivalentGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfMTEtMy0xLTEtMjU1ODU_6a807ec8-034a-49ea-bd23-295169ed4945">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231" decimals="-3" name="advm:CashAndCashEquivalentGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfMTEtNS0xLTEtMjU1ODU_08b4e1db-d51b-4abd-adc8-4aff200e78c0">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfMTEtNy0xLTEtMjU1ODU_b0cebef0-5464-4160-bb10-1b868fa1cef1">25,807</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfMTItMS0xLTEtMjU1ODU_988fa0a1-f954-4756-926d-6916bd6e0466">271,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfMTItMy0xLTEtMjU1ODU_f92439ae-a11f-4d26-9748-efd0c838f43b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfMTItNS0xLTEtMjU1ODU_a8da0be9-6adf-42d1-af7c-ff7717e90306">317</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfMTItNy0xLTEtMjU1ODU_d08750ae-6614-486e-9940-b9244f21cd03">270,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><ix:continuation id="i475ee68244f649fbb4ce92fc63093714"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, all of the marketable securities have a remaining maturity of less than one year. Management regularly reviews all of the Company&#8217;s investments for other-than-temporary declines in estimated fair value. Management determined that the gross unrealized losses on the Company&#8217;s marketable securities as of June&#160;30, 2022 were temporary in nature and none were in a continuous loss position for 12 months or more. The Company does not intend to sell the investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases. Management concluded that <ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="INF" name="advm:OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RleHRyZWdpb246ZTZmM2I3ZjdmMWRhNGRiZGJlMDc3Y2VhNmU2MTFhNzZfMjUwMw_7e36ff89-b31e-4ae0-bdcd-eee9cf44eb26">none</ix:nonFraction> of the Company&#8217;s marketable securities were other-than-temporarily impaired as of June&#160;30, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June&#160;30, 2022, the Company performed an impairment test to measure certain laboratory equipment at fair value. The assets are measured at fair value using Level 3 inputs on a non-recurring basis as a result of the occurrence of certain triggering events indicating the carrying value of the assets may not be recoverable. Refer to Note 4, Balance Sheet Components for additional information.</span></div></ix:continuation><div id="i26ccaa4e5746469982cbf0d18a526b99_46"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RleHRyZWdpb246ZDJkNmI4YzU2YmRiNDkyZmJkYTZiNWNiNTNjZDY1NTdfMjM5_4925a248-3004-4341-bf9a-0508c373f708" continuedAt="ib845ebfac26a43348231b3a56e23e559" escape="true">Balance Sheet Components</ix:nonNumeric></span></div><ix:continuation id="ib845ebfac26a43348231b3a56e23e559"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-top:6pt"><ix:nonNumeric contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RleHRyZWdpb246ZDJkNmI4YzU2YmRiNDkyZmJkYTZiNWNiNTNjZDY1NTdfMjM3_794e86df-3ff9-4ed7-a5b0-ba6f03e9908a" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consists of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9056b729e8546fab8f001340cc9fdf3_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOmZhODhiNWQwYTViZTQ3MzY4MDljOWZiMDRlMGVhYjdjL3RhYmxlcmFuZ2U6ZmE4OGI1ZDBhNWJlNDczNjgwOWM5ZmIwNGUwZWFiN2NfMi0xLTEtMS0yNTU4NQ_42ef546f-e0d2-4977-9203-9f6ee5b8d0bb">1,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia76becc1500d43a2a228fe82d7febe92_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOmZhODhiNWQwYTViZTQ3MzY4MDljOWZiMDRlMGVhYjdjL3RhYmxlcmFuZ2U6ZmE4OGI1ZDBhNWJlNDczNjgwOWM5ZmIwNGUwZWFiN2NfMi0zLTEtMS0yNTU4NQ_21fc4e89-2164-47dc-94fe-a07fc95208d7">1,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieffb39be45a94c67a589adccd5ca2de7_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOmZhODhiNWQwYTViZTQ3MzY4MDljOWZiMDRlMGVhYjdjL3RhYmxlcmFuZ2U6ZmE4OGI1ZDBhNWJlNDczNjgwOWM5ZmIwNGUwZWFiN2NfMy0xLTEtMS0yNTU4NQ_3cc0dc31-b38c-4245-8688-6c1bd6a6dd00">15,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf62e11c42f84334ba360a7fcd68e94a_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOmZhODhiNWQwYTViZTQ3MzY4MDljOWZiMDRlMGVhYjdjL3RhYmxlcmFuZ2U6ZmE4OGI1ZDBhNWJlNDczNjgwOWM5ZmIwNGUwZWFiN2NfMy0zLTEtMS0yNTU4NQ_9ccc410e-690d-49a1-ad3d-cbc891fd46e8">12,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02800f7274124fe1971aafbaacb2bacf_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOmZhODhiNWQwYTViZTQ3MzY4MDljOWZiMDRlMGVhYjdjL3RhYmxlcmFuZ2U6ZmE4OGI1ZDBhNWJlNDczNjgwOWM5ZmIwNGUwZWFiN2NfNC0xLTEtMS0yNTU4NQ_4b915a8d-f650-4dd4-8ea8-e6972cebda42">868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbb879dcd01e4d5bacd3fcbb94f010f6_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOmZhODhiNWQwYTViZTQ3MzY4MDljOWZiMDRlMGVhYjdjL3RhYmxlcmFuZ2U6ZmE4OGI1ZDBhNWJlNDczNjgwOWM5ZmIwNGUwZWFiN2NfNC0zLTEtMS0yNTU4NQ_d7714621-03d3-4950-962a-f9269e93bd06">1,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7566ab2be1484f1db090914aa37ba934_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOmZhODhiNWQwYTViZTQ3MzY4MDljOWZiMDRlMGVhYjdjL3RhYmxlcmFuZ2U6ZmE4OGI1ZDBhNWJlNDczNjgwOWM5ZmIwNGUwZWFiN2NfNS0xLTEtMS0yNTU4NQ_49656911-f919-4129-af6b-f1ada1bac936">34,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbe21a83e6804a47850aa04b8d75d01a_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOmZhODhiNWQwYTViZTQ3MzY4MDljOWZiMDRlMGVhYjdjL3RhYmxlcmFuZ2U6ZmE4OGI1ZDBhNWJlNDczNjgwOWM5ZmIwNGUwZWFiN2NfNS0zLTEtMS0yNTU4NQ_3a6cd4d0-d33c-4230-b628-ffabd2470597">26,701</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66e76679aad44f1985ba7be517dc7768_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOmZhODhiNWQwYTViZTQ3MzY4MDljOWZiMDRlMGVhYjdjL3RhYmxlcmFuZ2U6ZmE4OGI1ZDBhNWJlNDczNjgwOWM5ZmIwNGUwZWFiN2NfNi0xLTEtMS0yNTU4NQ_0708d800-dee7-4db0-aa8d-abe9652eb387">2,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2281372e2bd3421693ab7f4489600be1_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOmZhODhiNWQwYTViZTQ3MzY4MDljOWZiMDRlMGVhYjdjL3RhYmxlcmFuZ2U6ZmE4OGI1ZDBhNWJlNDczNjgwOWM5ZmIwNGUwZWFiN2NfNi0zLTEtMS0yNTU4NQ_1547400e-3e14-4d3a-a7ad-7a928eb2003a">4,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOmZhODhiNWQwYTViZTQ3MzY4MDljOWZiMDRlMGVhYjdjL3RhYmxlcmFuZ2U6ZmE4OGI1ZDBhNWJlNDczNjgwOWM5ZmIwNGUwZWFiN2NfNy0xLTEtMS0yNTU4NQ_4885a7df-a773-46e5-a3ef-d4918d8af851">53,874</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOmZhODhiNWQwYTViZTQ3MzY4MDljOWZiMDRlMGVhYjdjL3RhYmxlcmFuZ2U6ZmE4OGI1ZDBhNWJlNDczNjgwOWM5ZmIwNGUwZWFiN2NfNy0zLTEtMS0yNTU4NQ_d27c9491-6d36-4dc5-b7d7-bbeba1537e40">46,234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOmZhODhiNWQwYTViZTQ3MzY4MDljOWZiMDRlMGVhYjdjL3RhYmxlcmFuZ2U6ZmE4OGI1ZDBhNWJlNDczNjgwOWM5ZmIwNGUwZWFiN2NfOC0xLTEtMS0yNTU4NQ_ed2cb535-3967-493f-b9ba-344c11ee00c1">15,641</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOmZhODhiNWQwYTViZTQ3MzY4MDljOWZiMDRlMGVhYjdjL3RhYmxlcmFuZ2U6ZmE4OGI1ZDBhNWJlNDczNjgwOWM5ZmIwNGUwZWFiN2NfOC0zLTEtMS0yNTU4NQ_78ee2b30-9be8-4faf-9b76-9bcce3a17f0c">13,174</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOmZhODhiNWQwYTViZTQ3MzY4MDljOWZiMDRlMGVhYjdjL3RhYmxlcmFuZ2U6ZmE4OGI1ZDBhNWJlNDczNjgwOWM5ZmIwNGUwZWFiN2NfOS0xLTEtMS0yNTU4NQ_4da52dd3-0858-4923-a7da-ba6d2c9630fe">38,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOmZhODhiNWQwYTViZTQ3MzY4MDljOWZiMDRlMGVhYjdjL3RhYmxlcmFuZ2U6ZmE4OGI1ZDBhNWJlNDczNjgwOWM5ZmIwNGUwZWFiN2NfOS0zLTEtMS0yNTU4NQ_c3c50597-9d49-4e61-8090-902180fc8718">33,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed an impairment analysis for certain laboratory equipment assets based on the identification of impairment indicators during the three months ended June&#160;30, 2022. The analysis determined that the fair value of the assets, which was determined using a market approach, was lower than the carrying value. As a result of the evaluation, an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630" decimals="-5" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RleHRyZWdpb246ZDJkNmI4YzU2YmRiNDkyZmJkYTZiNWNiNTNjZDY1NTdfMjE5OTAyMzI2MTUzMQ_36fd17ef-5cf3-474c-af9d-c9954f53d21f">2.0</ix:nonFraction> million was recognized for the three months ended June&#160;30, 2022. The assets indicated as impaired were written down to their estimated fair value.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other Current Liabilities</span></div><div style="margin-top:6pt"><ix:nonNumeric contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RleHRyZWdpb246ZDJkNmI4YzU2YmRiNDkyZmJkYTZiNWNiNTNjZDY1NTdfMjM4_74931b0b-67bc-498b-a8a5-4d8ac066f462" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consist of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOjI5M2ExYjllYTQwZDQwMWE4OTE5OTNlY2E0Njg2MDk0L3RhYmxlcmFuZ2U6MjkzYTFiOWVhNDBkNDAxYTg5MTk5M2VjYTQ2ODYwOTRfMi0xLTEtMS0yNTU4NQ_b9f9c520-482f-4b4a-80ba-50109c1d3c75">8,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOjI5M2ExYjllYTQwZDQwMWE4OTE5OTNlY2E0Njg2MDk0L3RhYmxlcmFuZ2U6MjkzYTFiOWVhNDBkNDAxYTg5MTk5M2VjYTQ2ODYwOTRfMi0zLTEtMS0yNTU4NQ_95c4a588-54a0-462f-8379-5046eb8d2ef0">9,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued nonclinical, clinical and process development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" name="advm:AccruedNonclinicalClinicalAndDevelopmentProcessCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOjI5M2ExYjllYTQwZDQwMWE4OTE5OTNlY2E0Njg2MDk0L3RhYmxlcmFuZ2U6MjkzYTFiOWVhNDBkNDAxYTg5MTk5M2VjYTQ2ODYwOTRfMy0xLTEtMS0yNTU4NQ_c971b87c-f59f-4ef6-9c6b-3a25ab5c5a22">8,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231" decimals="-3" name="advm:AccruedNonclinicalClinicalAndDevelopmentProcessCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOjI5M2ExYjllYTQwZDQwMWE4OTE5OTNlY2E0Njg2MDk0L3RhYmxlcmFuZ2U6MjkzYTFiOWVhNDBkNDAxYTg5MTk5M2VjYTQ2ODYwOTRfMy0zLTEtMS0yNTU4NQ_e06ce549-559e-485a-b2e0-c2fd4856b90b">4,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" name="us-gaap:TaxesPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOjI5M2ExYjllYTQwZDQwMWE4OTE5OTNlY2E0Njg2MDk0L3RhYmxlcmFuZ2U6MjkzYTFiOWVhNDBkNDAxYTg5MTk5M2VjYTQ2ODYwOTRfNC0xLTEtMS0yNTU4NQ_7db37464-a93d-473c-9975-7d20f79fea16">178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231" decimals="-3" name="us-gaap:TaxesPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOjI5M2ExYjllYTQwZDQwMWE4OTE5OTNlY2E0Njg2MDk0L3RhYmxlcmFuZ2U6MjkzYTFiOWVhNDBkNDAxYTg5MTk5M2VjYTQ2ODYwOTRfNC0zLTEtMS0yNTU4NQ_88ae60f1-94aa-45a8-b839-cc17412c8801">1,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOjI5M2ExYjllYTQwZDQwMWE4OTE5OTNlY2E0Njg2MDk0L3RhYmxlcmFuZ2U6MjkzYTFiOWVhNDBkNDAxYTg5MTk5M2VjYTQ2ODYwOTRfNS0xLTEtMS0yNTU4NQ_e6b85c34-da96-4079-8101-2333927c20ed">986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOjI5M2ExYjllYTQwZDQwMWE4OTE5OTNlY2E0Njg2MDk0L3RhYmxlcmFuZ2U6MjkzYTFiOWVhNDBkNDAxYTg5MTk5M2VjYTQ2ODYwOTRfNS0zLTEtMS0yNTU4NQ_d6440f6e-5639-4f5c-9dae-ff2a6f8629a5">550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOjI5M2ExYjllYTQwZDQwMWE4OTE5OTNlY2E0Njg2MDk0L3RhYmxlcmFuZ2U6MjkzYTFiOWVhNDBkNDAxYTg5MTk5M2VjYTQ2ODYwOTRfNi0xLTEtMS0yNTU4NQ_833a7ff9-aeeb-4961-8e5a-b438d304df4d">1,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOjI5M2ExYjllYTQwZDQwMWE4OTE5OTNlY2E0Njg2MDk0L3RhYmxlcmFuZ2U6MjkzYTFiOWVhNDBkNDAxYTg5MTk5M2VjYTQ2ODYwOTRfNi0zLTEtMS0yNTU4NQ_809ffe0a-fed2-4e64-928d-d7984d50259f">2,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" name="advm:AccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOjI5M2ExYjllYTQwZDQwMWE4OTE5OTNlY2E0Njg2MDk0L3RhYmxlcmFuZ2U6MjkzYTFiOWVhNDBkNDAxYTg5MTk5M2VjYTQ2ODYwOTRfNy0xLTEtMS0yNTU4NQ_5ab3790d-067d-4de4-8eec-55537908df9c">19,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231" decimals="-3" name="advm:AccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOjI5M2ExYjllYTQwZDQwMWE4OTE5OTNlY2E0Njg2MDk0L3RhYmxlcmFuZ2U6MjkzYTFiOWVhNDBkNDAxYTg5MTk5M2VjYTQ2ODYwOTRfNy0zLTEtMS0yNTU4NQ_5e4570b9-60f4-47ac-aa57-d69e197440f3">18,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="i26ccaa4e5746469982cbf0d18a526b99_52"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RleHRyZWdpb246MTg5Y2UwNjk3YmFiNDU3N2E5N2EzZGIzYTI4YzcyMjVfNjg4_dff13e4a-7c76-48ff-a1fb-027832bcd412" continuedAt="iaa09d0ab04ca4da2b015b5fc0ab97e48" escape="true">Equity Incentive Awards</ix:nonNumeric></span></div><ix:continuation id="iaa09d0ab04ca4da2b015b5fc0ab97e48"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt"><ix:nonNumeric contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RleHRyZWdpb246MTg5Y2UwNjk3YmFiNDU3N2E5N2EzZGIzYTI4YzcyMjVfNjg5_a405e3dd-12e7-431f-a25c-4226c6ff8a6c" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s option activity and related information:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Options<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjI5MmZlMzM5NzU3ZTQ3NjlhYzVkZjgyZTdkYzI0NjEwL3RhYmxlcmFuZ2U6MjkyZmUzMzk3NTdlNDc2OWFjNWRmODJlN2RjMjQ2MTBfMS0xLTEtMS0yNTU4NQ_edfb7d74-2836-401f-a2a2-243ee1e65a63">13,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjI5MmZlMzM5NzU3ZTQ3NjlhYzVkZjgyZTdkYzI0NjEwL3RhYmxlcmFuZ2U6MjkyZmUzMzk3NTdlNDc2OWFjNWRmODJlN2RjMjQ2MTBfMS0zLTEtMS0yNTU4NQ_2074fe9c-f704-419b-bc8e-5fbcf326b38e">9.34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjI5MmZlMzM5NzU3ZTQ3NjlhYzVkZjgyZTdkYzI0NjEwL3RhYmxlcmFuZ2U6MjkyZmUzMzk3NTdlNDc2OWFjNWRmODJlN2RjMjQ2MTBfMi0xLTEtMS0yNTU4NQ_2d743c1d-beea-462d-9b19-1840ec22286d">6,994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjI5MmZlMzM5NzU3ZTQ3NjlhYzVkZjgyZTdkYzI0NjEwL3RhYmxlcmFuZ2U6MjkyZmUzMzk3NTdlNDc2OWFjNWRmODJlN2RjMjQ2MTBfMi0zLTEtMS0yNTU4NQ_378647f4-d9b8-4125-aa80-12f14216dc01">1.33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjI5MmZlMzM5NzU3ZTQ3NjlhYzVkZjgyZTdkYzI0NjEwL3RhYmxlcmFuZ2U6MjkyZmUzMzk3NTdlNDc2OWFjNWRmODJlN2RjMjQ2MTBfMy0xLTEtMS0yNTU4NQ_d1aaeff9-6088-402b-b56f-b66384492326">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjI5MmZlMzM5NzU3ZTQ3NjlhYzVkZjgyZTdkYzI0NjEwL3RhYmxlcmFuZ2U6MjkyZmUzMzk3NTdlNDc2OWFjNWRmODJlN2RjMjQ2MTBfMy0zLTEtMS0yNTU4NQ_213be4e5-5fb9-409d-b92f-ff62fd192aae">0.19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjI5MmZlMzM5NzU3ZTQ3NjlhYzVkZjgyZTdkYzI0NjEwL3RhYmxlcmFuZ2U6MjkyZmUzMzk3NTdlNDc2OWFjNWRmODJlN2RjMjQ2MTBfNC0xLTEtMS0yNTU4NQ_94603295-7239-4a56-8b17-ca71711ad300">3,469</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjI5MmZlMzM5NzU3ZTQ3NjlhYzVkZjgyZTdkYzI0NjEwL3RhYmxlcmFuZ2U6MjkyZmUzMzk3NTdlNDc2OWFjNWRmODJlN2RjMjQ2MTBfNC0zLTEtMS0yNTU4NQ_2438f829-6f57-4fd6-8e13-d8b0c342e026">5.96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjI5MmZlMzM5NzU3ZTQ3NjlhYzVkZjgyZTdkYzI0NjEwL3RhYmxlcmFuZ2U6MjkyZmUzMzk3NTdlNDc2OWFjNWRmODJlN2RjMjQ2MTBfNS0xLTEtMS0yNTU4NQ_207fbf40-4628-429f-a259-8782ae385bf0">16,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjI5MmZlMzM5NzU3ZTQ3NjlhYzVkZjgyZTdkYzI0NjEwL3RhYmxlcmFuZ2U6MjkyZmUzMzk3NTdlNDc2OWFjNWRmODJlN2RjMjQ2MTBfNS0zLTEtMS0yNTU4NQ_6f0bf50c-981a-4c40-ba36-203ab3540ff2">6.71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjI5MmZlMzM5NzU3ZTQ3NjlhYzVkZjgyZTdkYzI0NjEwL3RhYmxlcmFuZ2U6MjkyZmUzMzk3NTdlNDc2OWFjNWRmODJlN2RjMjQ2MTBfNi0xLTEtMS0yNTU4NQ_ee8559de-5727-433b-a262-b06d37d9c147">4,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjI5MmZlMzM5NzU3ZTQ3NjlhYzVkZjgyZTdkYzI0NjEwL3RhYmxlcmFuZ2U6MjkyZmUzMzk3NTdlNDc2OWFjNWRmODJlN2RjMjQ2MTBfNi0zLTEtMS0yNTU4NQ_baa9a9a4-90a2-4681-861e-ac94f5ffaa5b">12.02</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted during the six months ended June&#160;30, 2022 include <ix:nonFraction unitRef="shares" contextRef="i7b6fb5c50aa542bf9198fb1cb8a23705_D20220101-20220630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RleHRyZWdpb246MTg5Y2UwNjk3YmFiNDU3N2E5N2EzZGIzYTI4YzcyMjVfMTkx_0ce5a170-b15d-424e-85e3-cfedb820b847">0.9</ix:nonFraction>&#160;million shares of performance-based non-qualified options with both performance and service vesting conditions.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units (&#8220;RSUs&#8221;)</span></div><div style="margin-top:6pt"><ix:nonNumeric contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RleHRyZWdpb246MTg5Y2UwNjk3YmFiNDU3N2E5N2EzZGIzYTI4YzcyMjVfNjkw_b757477a-8f18-4785-9e14-d5546c3b0013" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s RSUs activity and related information:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Units<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average Grant-<br/>Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i799e2367d7a44cd3ab31610e4082fe1a_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjYyYWQ3NTcxZGUxZDQ0MzM5OWM4ZThjN2FiYWYyMmNhL3RhYmxlcmFuZ2U6NjJhZDc1NzFkZTFkNDQzMzk5YzhlOGM3YWJhZjIyY2FfMS0xLTEtMS0yNTU4NQ_496ecdc0-828e-4c71-a3f9-fdfe484e1391">2,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i799e2367d7a44cd3ab31610e4082fe1a_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjYyYWQ3NTcxZGUxZDQ0MzM5OWM4ZThjN2FiYWYyMmNhL3RhYmxlcmFuZ2U6NjJhZDc1NzFkZTFkNDQzMzk5YzhlOGM3YWJhZjIyY2FfMS0zLTEtMS0yNTU4NQ_b96fbba6-b3c6-4e13-9d5b-d7e12f2a1fc7">3.76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i61c1bc0d431a4a5cb89f8a7d9bd2ef9a_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjYyYWQ3NTcxZGUxZDQ0MzM5OWM4ZThjN2FiYWYyMmNhL3RhYmxlcmFuZ2U6NjJhZDc1NzFkZTFkNDQzMzk5YzhlOGM3YWJhZjIyY2FfMi0xLTEtMS0yNTU4NQ_8637be6a-23c3-4ff7-9328-a27db5467bd7">857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i61c1bc0d431a4a5cb89f8a7d9bd2ef9a_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjYyYWQ3NTcxZGUxZDQ0MzM5OWM4ZThjN2FiYWYyMmNhL3RhYmxlcmFuZ2U6NjJhZDc1NzFkZTFkNDQzMzk5YzhlOGM3YWJhZjIyY2FfMi0zLTEtMS0yNTU4NQ_67f7c0a7-97f4-406a-b341-1d47fbae506d">1.43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i61c1bc0d431a4a5cb89f8a7d9bd2ef9a_D20220101-20220630" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjYyYWQ3NTcxZGUxZDQ0MzM5OWM4ZThjN2FiYWYyMmNhL3RhYmxlcmFuZ2U6NjJhZDc1NzFkZTFkNDQzMzk5YzhlOGM3YWJhZjIyY2FfMy0xLTEtMS0yNTU4NQ_b8d62315-be03-48c6-a74c-1d74ad4cff36">376</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i61c1bc0d431a4a5cb89f8a7d9bd2ef9a_D20220101-20220630" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjYyYWQ3NTcxZGUxZDQ0MzM5OWM4ZThjN2FiYWYyMmNhL3RhYmxlcmFuZ2U6NjJhZDc1NzFkZTFkNDQzMzk5YzhlOGM3YWJhZjIyY2FfMy0zLTEtMS0yNTU4NQ_2ead4bc0-6933-472b-a58b-fa5270ae743d">4.64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i61c1bc0d431a4a5cb89f8a7d9bd2ef9a_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjYyYWQ3NTcxZGUxZDQ0MzM5OWM4ZThjN2FiYWYyMmNhL3RhYmxlcmFuZ2U6NjJhZDc1NzFkZTFkNDQzMzk5YzhlOGM3YWJhZjIyY2FfNC0xLTEtMS0yNTU4NQ_75088ca4-9f7d-4379-91ca-b8bb146a2729">220</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i61c1bc0d431a4a5cb89f8a7d9bd2ef9a_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjYyYWQ3NTcxZGUxZDQ0MzM5OWM4ZThjN2FiYWYyMmNhL3RhYmxlcmFuZ2U6NjJhZDc1NzFkZTFkNDQzMzk5YzhlOGM3YWJhZjIyY2FfNC0zLTEtMS0yNTU4NQ_e6c5b999-ce49-4faf-9579-3947d9ca563a">2.51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic2977397029043bc8e1c6fb7a9d878ca_I20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjYyYWQ3NTcxZGUxZDQ0MzM5OWM4ZThjN2FiYWYyMmNhL3RhYmxlcmFuZ2U6NjJhZDc1NzFkZTFkNDQzMzk5YzhlOGM3YWJhZjIyY2FfNS0xLTEtMS0yNTU4NQ_6c21fa0a-d88f-4f0e-ad9a-3e92ae1da989">2,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic2977397029043bc8e1c6fb7a9d878ca_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjYyYWQ3NTcxZGUxZDQ0MzM5OWM4ZThjN2FiYWYyMmNhL3RhYmxlcmFuZ2U6NjJhZDc1NzFkZTFkNDQzMzk5YzhlOGM3YWJhZjIyY2FfNS0zLTEtMS0yNTU4NQ_e4d9906a-e496-463b-86c0-a657d3ce9c2c">2.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs granted during the six months ended June&#160;30, 2022 include <ix:nonFraction unitRef="shares" contextRef="i7b6fb5c50aa542bf9198fb1cb8a23705_D20220101-20220630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RleHRyZWdpb246MTg5Y2UwNjk3YmFiNDU3N2E5N2EzZGIzYTI4YzcyMjVfNDY5_d3816711-0d7a-40bd-80ed-c47d597d7bf9">0.4</ix:nonFraction> million shares of performance units with both performance and service vesting conditions.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:6pt"><ix:nonNumeric contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RleHRyZWdpb246MTg5Y2UwNjk3YmFiNDU3N2E5N2EzZGIzYTI4YzcyMjVfNjg3_4f2c7083-0099-4621-9446-43f594dcf8ab" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents, by operating expense, the Company&#8217;s stock-based compensation expense:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.332%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6819ea354434909b8b5bc79270cf986_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjlmZWIwNmZhMGZkMTQ3NzI5MWZkNzVjNDllZjJlZDVmL3RhYmxlcmFuZ2U6OWZlYjA2ZmEwZmQxNDc3MjkxZmQ3NWM0OWVmMmVkNWZfMy0xLTEtMS0yNTU4NQ_9b407cc8-a0e5-4376-a6e3-644b8f0f8b36">1,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie97980ff64894dfe89ceaa2199851660_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjlmZWIwNmZhMGZkMTQ3NzI5MWZkNzVjNDllZjJlZDVmL3RhYmxlcmFuZ2U6OWZlYjA2ZmEwZmQxNDc3MjkxZmQ3NWM0OWVmMmVkNWZfMy0zLTEtMS0yNTU4NQ_e2d5fa0b-fbc4-4d0a-8aa0-05573bb649ac">2,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd2c662c3d65454a9af244685ed76367_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjlmZWIwNmZhMGZkMTQ3NzI5MWZkNzVjNDllZjJlZDVmL3RhYmxlcmFuZ2U6OWZlYjA2ZmEwZmQxNDc3MjkxZmQ3NWM0OWVmMmVkNWZfMy01LTEtMS0yNTU4NQ_d2f08435-5bb4-4a93-ba33-bdd257392fff">3,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11fb6fa11226421b9721333c446b487e_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjlmZWIwNmZhMGZkMTQ3NzI5MWZkNzVjNDllZjJlZDVmL3RhYmxlcmFuZ2U6OWZlYjA2ZmEwZmQxNDc3MjkxZmQ3NWM0OWVmMmVkNWZfMy03LTEtMS0yNTU4NQ_521bdd7e-4114-4071-bbde-94023a9e7d47">4,918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c878dab744d72a09fd050e76b040e_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjlmZWIwNmZhMGZkMTQ3NzI5MWZkNzVjNDllZjJlZDVmL3RhYmxlcmFuZ2U6OWZlYjA2ZmEwZmQxNDc3MjkxZmQ3NWM0OWVmMmVkNWZfNC0xLTEtMS0yNTU4NQ_b04a5d01-3ce1-480d-810b-98186ae0a3b0">3,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7921ddb1395c47e497a4d22dceba9142_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjlmZWIwNmZhMGZkMTQ3NzI5MWZkNzVjNDllZjJlZDVmL3RhYmxlcmFuZ2U6OWZlYjA2ZmEwZmQxNDc3MjkxZmQ3NWM0OWVmMmVkNWZfNC0zLTEtMS0yNTU4NQ_dd669939-5bdb-49ba-a776-b429c497a383">5,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8275590de8c4107a7250156ea0c4f5d_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjlmZWIwNmZhMGZkMTQ3NzI5MWZkNzVjNDllZjJlZDVmL3RhYmxlcmFuZ2U6OWZlYjA2ZmEwZmQxNDc3MjkxZmQ3NWM0OWVmMmVkNWZfNC01LTEtMS0yNTU4NQ_755cc9c9-972a-4b87-a62c-280174fd7c62">6,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia558ece0e92049239ba7ef43bde0bf94_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjlmZWIwNmZhMGZkMTQ3NzI5MWZkNzVjNDllZjJlZDVmL3RhYmxlcmFuZ2U6OWZlYjA2ZmEwZmQxNDc3MjkxZmQ3NWM0OWVmMmVkNWZfNC03LTEtMS0yNTU4NQ_17965c24-6d34-4474-98c5-7f27300c725e">10,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjlmZWIwNmZhMGZkMTQ3NzI5MWZkNzVjNDllZjJlZDVmL3RhYmxlcmFuZ2U6OWZlYjA2ZmEwZmQxNDc3MjkxZmQ3NWM0OWVmMmVkNWZfNS0xLTEtMS0yNTU4NQ_fd3226af-e1f5-4b27-ba15-c79242ff2e40">4,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjlmZWIwNmZhMGZkMTQ3NzI5MWZkNzVjNDllZjJlZDVmL3RhYmxlcmFuZ2U6OWZlYjA2ZmEwZmQxNDc3MjkxZmQ3NWM0OWVmMmVkNWZfNS0zLTEtMS0yNTU4NQ_db2e588c-f073-44dd-aff9-e5f56537bf06">8,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjlmZWIwNmZhMGZkMTQ3NzI5MWZkNzVjNDllZjJlZDVmL3RhYmxlcmFuZ2U6OWZlYjA2ZmEwZmQxNDc3MjkxZmQ3NWM0OWVmMmVkNWZfNS01LTEtMS0yNTU4NQ_7547a4b5-5e4b-47ae-9628-3afe2311f1b2">10,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjlmZWIwNmZhMGZkMTQ3NzI5MWZkNzVjNDllZjJlZDVmL3RhYmxlcmFuZ2U6OWZlYjA2ZmEwZmQxNDc3MjkxZmQ3NWM0OWVmMmVkNWZfNS03LTEtMS0yNTU4NQ_72b8aca1-d57b-4990-8dee-3d4e2031600a">15,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-top:9pt"><span><br/></span></div><div id="i26ccaa4e5746469982cbf0d18a526b99_55"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81NS9mcmFnOjFmZDZkNWMyM2E3YzQ3NmQ4OTFkMzBlMTEyZWM3ZTEyL3RleHRyZWdpb246MWZkNmQ1YzIzYTdjNDc2ZDg5MWQzMGUxMTJlYzdlMTJfODMz_27455c37-2ec3-4abe-b887-1d43ddcb7878" continuedAt="ia8a72317601b46f0917dcc6e17f888cd" escape="true">Net Loss per Share</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia8a72317601b46f0917dcc6e17f888cd" continuedAt="i3b45c66db074464facf084a16e994a8e">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period using the treasury stock method. Outstanding stock options, RSUs, rights under the employee stock purchase plan (&#8220;ESPP&#8221;) and warrants are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><ix:continuation id="i3b45c66db074464facf084a16e994a8e"><ix:nonNumeric contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81NS9mcmFnOjFmZDZkNWMyM2E3YzQ3NmQ4OTFkMzBlMTEyZWM3ZTEyL3RleHRyZWdpb246MWZkNmQ1YzIzYTdjNDc2ZDg5MWQzMGUxMTJlYzdlMTJfODM1_a4751694-63dc-40aa-98bb-feca84518aed" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents outstanding at the end of the periods presented were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie17cab1a780b48bf993da64124f1616e_D20220101-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81NS9mcmFnOjFmZDZkNWMyM2E3YzQ3NmQ4OTFkMzBlMTEyZWM3ZTEyL3RhYmxlOjA5MWVlMmExNDdiNDQ0YTQ5ODVkNGFmYjgyNzUzZGZkL3RhYmxlcmFuZ2U6MDkxZWUyYTE0N2I0NDRhNDk4NWQ0YWZiODI3NTNkZmRfMi0xLTEtMS0yNTU4NQ_cb8f367d-8ae3-48e6-a91a-18f4bf3a6214">16,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i00290c3bbf024183bc58b3da064c1719_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81NS9mcmFnOjFmZDZkNWMyM2E3YzQ3NmQ4OTFkMzBlMTEyZWM3ZTEyL3RhYmxlOjA5MWVlMmExNDdiNDQ0YTQ5ODVkNGFmYjgyNzUzZGZkL3RhYmxlcmFuZ2U6MDkxZWUyYTE0N2I0NDRhNDk4NWQ0YWZiODI3NTNkZmRfMi0zLTEtMS0yNTU4NQ_882d8153-9e59-407d-b148-f6de7d885e79">14,435</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idf067933631d446ea2d6ff5ad2ba89f6_D20220101-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81NS9mcmFnOjFmZDZkNWMyM2E3YzQ3NmQ4OTFkMzBlMTEyZWM3ZTEyL3RhYmxlOjA5MWVlMmExNDdiNDQ0YTQ5ODVkNGFmYjgyNzUzZGZkL3RhYmxlcmFuZ2U6MDkxZWUyYTE0N2I0NDRhNDk4NWQ0YWZiODI3NTNkZmRfMy0xLTEtMS0yNTU4NQ_2fa62212-6761-4d23-aef0-a18627bcf18e">2,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id35485ffc22d4b6d97a32ff7a9e6516a_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81NS9mcmFnOjFmZDZkNWMyM2E3YzQ3NmQ4OTFkMzBlMTEyZWM3ZTEyL3RhYmxlOjA5MWVlMmExNDdiNDQ0YTQ5ODVkNGFmYjgyNzUzZGZkL3RhYmxlcmFuZ2U6MDkxZWUyYTE0N2I0NDRhNDk4NWQ0YWZiODI3NTNkZmRfMy0zLTEtMS0yNTU4NQ_84300546-239f-47d3-8d1d-dc2c0e16c63d">591</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie7873e824c2c453082de63de06e7151c_D20220101-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81NS9mcmFnOjFmZDZkNWMyM2E3YzQ3NmQ4OTFkMzBlMTEyZWM3ZTEyL3RhYmxlOjA5MWVlMmExNDdiNDQ0YTQ5ODVkNGFmYjgyNzUzZGZkL3RhYmxlcmFuZ2U6MDkxZWUyYTE0N2I0NDRhNDk4NWQ0YWZiODI3NTNkZmRfNC0xLTEtMS0yNTU4NQ_c35c07ba-a16f-4340-b93e-1db025cd6f67">303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7d3546d871c340909747af982e7e0cf1_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81NS9mcmFnOjFmZDZkNWMyM2E3YzQ3NmQ4OTFkMzBlMTEyZWM3ZTEyL3RhYmxlOjA5MWVlMmExNDdiNDQ0YTQ5ODVkNGFmYjgyNzUzZGZkL3RhYmxlcmFuZ2U6MDkxZWUyYTE0N2I0NDRhNDk4NWQ0YWZiODI3NTNkZmRfNC0zLTEtMS0yNTU4NQ_a1dee597-040f-4b2d-9c44-edaf86162c51">104</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81NS9mcmFnOjFmZDZkNWMyM2E3YzQ3NmQ4OTFkMzBlMTEyZWM3ZTEyL3RhYmxlOjA5MWVlMmExNDdiNDQ0YTQ5ODVkNGFmYjgyNzUzZGZkL3RhYmxlcmFuZ2U6MDkxZWUyYTE0N2I0NDRhNDk4NWQ0YWZiODI3NTNkZmRfNi0xLTEtMS0yNTU4NQ_f3ff6e59-cc4b-4b61-805e-3259a98f3bab">19,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81NS9mcmFnOjFmZDZkNWMyM2E3YzQ3NmQ4OTFkMzBlMTEyZWM3ZTEyL3RhYmxlOjA5MWVlMmExNDdiNDQ0YTQ5ODVkNGFmYjgyNzUzZGZkL3RhYmxlcmFuZ2U6MDkxZWUyYTE0N2I0NDRhNDk4NWQ0YWZiODI3NTNkZmRfNi0zLTEtMS0yNTU4NQ_8ba495b3-79aa-4740-a4a7-5cbe88b49f26">15,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></ix:continuation></div><div><span><br/></span></div><div><span><br/></span></div><div id="i26ccaa4e5746469982cbf0d18a526b99_61"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV82MS9mcmFnOjI4MWY1NjcyYmYzNTRhYWE5ODU4Njk3ZTUzMmVkYmEzL3RleHRyZWdpb246MjgxZjU2NzJiZjM1NGFhYTk4NTg2OTdlNTMyZWRiYTNfMjY_0c374164-0f31-45c2-868d-de73f8d7f4ce" continuedAt="i2f9b8a1b84a64ae091810188a6f9b0f0" escape="true">Subsequent Event</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2f9b8a1b84a64ae091810188a6f9b0f0" continuedAt="i8b26a61b448a481190b89f841e43977e">In July 2022, the Company implemented a restructuring of operations, including reductions in both headcount and expenses, to prioritize its clinical development of ixoberogene soroparvovec (&#8220;Ixo-vec&#8221;), formerly referred to as ADVM-022, and focus its pipeline strategy on certain highly prevalent ocular diseases. The Company expects these restructuring measures will be sufficient to fully support its Ixo-vec development plan and extend its expected cash runway into 2025. The Company expects the restructuring to be completed in the fourth quarter of 2022.</ix:continuation></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8b26a61b448a481190b89f841e43977e">Under the restructuring plan, the Company reduced its workforce by <ix:nonFraction unitRef="employee" contextRef="i76f0e181dd5b4835a9cf93e9fd673c58_I20220731" decimals="INF" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV82MS9mcmFnOjI4MWY1NjcyYmYzNTRhYWE5ODU4Njk3ZTUzMmVkYmEzL3RleHRyZWdpb246MjgxZjU2NzJiZjM1NGFhYTk4NTg2OTdlNTMyZWRiYTNfMzg0ODI5MDcwOTgwNg_0ff223ec-7b94-4013-b7de-a9ff33854fc0">78</ix:nonFraction> employees (approximately <ix:nonFraction unitRef="number" contextRef="i76f0e181dd5b4835a9cf93e9fd673c58_I20220731" decimals="2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV82MS9mcmFnOjI4MWY1NjcyYmYzNTRhYWE5ODU4Njk3ZTUzMmVkYmEzL3RleHRyZWdpb246MjgxZjU2NzJiZjM1NGFhYTk4NTg2OTdlNTMyZWRiYTNfMzg0ODI5MDcwOTgxMA_fa201976-2006-4054-96b2-4594970888da">38</ix:nonFraction>%) and will incur aggregate restructuring charges of approximately $<ix:nonFraction unitRef="usd" contextRef="i76f0e181dd5b4835a9cf93e9fd673c58_I20220731" decimals="-5" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV82MS9mcmFnOjI4MWY1NjcyYmYzNTRhYWE5ODU4Njk3ZTUzMmVkYmEzL3RleHRyZWdpb246MjgxZjU2NzJiZjM1NGFhYTk4NTg2OTdlNTMyZWRiYTNfMzg0ODI5MDcwOTk0Nw_230c2d34-f131-48b4-a5e2-708a002e67ba">4.2</ix:nonFraction>&#160;million, of which it expects approximately $<ix:nonFraction unitRef="usd" contextRef="ic30a812f292d467f80a69160b83e189b_D20220701-20221231" decimals="-5" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV82MS9mcmFnOjI4MWY1NjcyYmYzNTRhYWE5ODU4Njk3ZTUzMmVkYmEzL3RleHRyZWdpb246MjgxZjU2NzJiZjM1NGFhYTk4NTg2OTdlNTMyZWRiYTNfMzg0ODI5MDcwOTk2MQ_e5adbf0b-783c-44fb-b2a9-709be84ee066">4.1</ix:nonFraction>&#160;million will be cash expenditures. The restructuring costs will be recorded primarily in the third quarter of 2022.</ix:continuation> </span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="i26ccaa4e5746469982cbf0d18a526b99_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-108pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The interim financial statements included in this Quarterly Report on Form 10-Q and this Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the financial statements and notes thereto for the year ended December&#160;31, 2021, and the related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, contained in our Annual Report on Form 10-K, as filed with the U.S. Securities and Exchange Commission (SEC) on March&#160;29, 2022. In addition to historical information, this discussion and analysis contains forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended (&#8220;Securities Act&#8221;), and Section&#160;21E of the Securities Exchange Act of 1934, as amended (&#8220;Exchange Act&#8221;). In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These forward-looking and other statements are subject to risks and uncertainties, including those discussed in the section titled &#8220;Risk Factors,&#8221; set forth in Part II &#8211; Other Information, Item&#160;1A below and elsewhere in this report that could cause actual results to differ materially from historical results or anticipated results. In particular, we encourage you to review the risk factor related to the impact of the coronavirus pandemic titled &#8220;The coronavirus (&#8220;COVID-19&#8221;) pandemic has impacted our business practices and the effects of its continued impact on our business, results of operations, and financial condition will depend on future developments, which cannot be predicted.&#8221;</span></div><div id="i26ccaa4e5746469982cbf0d18a526b99_73"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverum is a clinical-stage company that aims to establish gene therapy as a new standard of care for a number of highly prevalent ocular diseases. We develop gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include novel vector discovery, nonclinical and clinical development, and pre-commercial planning. In addition, we have in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices (&#8220;GMP&#8221;) quality control.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ixo-vec (ADVM-022)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidate, ixoberogene soroparvovec (&#8220;Ixo-vec&#8221;), which we previously referred to as ADVM-022, is a single, in-office intravitreal (&#8220;IVT&#8221;) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent bolus anti-vascular endothelial growth factor (&#8220;VEGF&#8221;) IVT injections. Ixo-vec utilizes an engineered, proprietary vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette capable of transducing retinal cells after a single in-office IVT injection. This product is intended to improve both real-world vision and quality of life outcomes for patients. Ixo-vec is currently being developed for the treatment of patients with wet age-related macular degeneration (&#8220;wet AMD&#8221;) who are responsive to anti-VEGF therapy. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Wet AMD is a leading cause of blindness in patients over 65 years of age, with a prevalence of approximately 20 million individuals worldwide living with wet AMD. Age-related macular degeneration (&#8220;AMD&#8221;) is expected to impact 288 million people worldwide by 2040, with wet AMD accounting for approximately ten percent of those cases.  In recognition of the need for new treatment options for wet AMD, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) granted Fast Track designation for Ixo-vec for the treatment of wet AMD.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, we initiated the OPTIC trial, designed as a multi-center, open-label, dose-ranging, safety and efficacy trial of Ixo-vec in patients with wet AMD who have demonstrated responsiveness to anti-VEGF treatment. Patients in OPTIC are treatment experienced, and previously required frequent anti-VEGF injections to manage their wet AMD and to maintain functional vision. We completed enrollment for OPTIC in July 2020 and continue to regularly present updated efficacy, aflibercept protein expression and safety data from the trial out to two years and have initiated an extension study to continue to follow our patients for an additional three years for a total of five years.  To date, we have seen strong signals of therapeutic efficacy in OPTIC in both the 6 x 10&#94;11 vg/eye (&#8220;6E11&#8221;) and 2 x 10&#94;11 vg/eye (&#8220;2E11&#8221;) doses, including continuous stable aflibercept levels from 10 weeks to three years, and a dose-dependent adeno-associated virus (&#8220;AAV&#8221;) associated ocular inflammation that has been responsive to topical corticosteroid therapy.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nonclinical studies have indicated that a 6 x 10&#94;10 vg/eye (&#8220;6E10&#8221;) dose has the potential to achieve therapeutic levels of aflibercept. In April 2022, we announced having received feedback via a Type C meeting written response from the FDA related to our planned Phase 2 trial of Ixo-vec in wet AMD. We requested the FDA&#8217;s feedback to ensure alignment with the regulatory agency ahead of filing the Investigational New Drug (&#8220;IND&#8221;) amendment for our Phase 2 trial, which IND amendment was submitted on May 26, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are initiating our Phase 2 LUNA (&#8220;LUNA&#8221;) trial of Ixo-vec and anticipate dosing the first patient in the third quarter of 2022. The LUNA trial is a multicenter, double-masked, randomized, parallel-group Phase 2 trial evaluating two doses of Ixo-</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vec, including 2E11 and a new, lower 6E10 dose, in up to 72 patients with wet AMD. The LUNA trial will assess four new enhanced prophylactic steroid regimens, including local steroids and combinations of local and systemic steroids to test the relative contribution of local versus systemic AAV exposure on ocular inflammation. Specific regimens include topical difluprednate (Durezol&#174;), IVT Ozurdex&#174;, or a combination of either topical Durezol&#174; or IVT Ozurdex&#174; with oral prednisone.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trial will randomize the participants equally between the 2E11 and 6E10 Ixo-vec doses across four prophylactic steroid regimens and will be conducted at approximately 40 sites in the U.S. and Europe. The primary endpoints will be similar to the OPTIC trial and focus on mean change in best-corrected visual acuity and central subfield thickness (&#8220;CST&#8221;) from baseline to one year, and incidence and severity of adverse events. Other data points will include protein expression of aflibercept starting at 10 weeks and an interim analysis at 26 weeks, including fluctuations in CST. The study will also evaluate the effectiveness and tolerability of the prophylactic steroid regimens.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, we announced that the European Medicines Agency (&#8220;EMA&#8221;) has granted Ixo-vec Priority Medicines (&#8220;PRIME&#8221;) designation. PRIME is a program launched by the EMA to enhance support for research on and development of medicines that target a significant unmet medical need.  This regulatory program offers developers of promising medicines enhanced interaction and early dialogue and is designed to optimize development plans and speed evaluation ensuring these medicines reach patients as early as possible. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we initiated the INFINITY trial, a multi-center, Phase 2, randomized, double-masked, active comparator-controlled study evaluating a single IVT injection of Ixo-vec in patients with diabetic macular edema (&#8220;DME&#8221;). A dose limiting toxicity at the 6E11 dose in this diabetic population was identified in April of 2021. Consequently, we are no longer pursuing Ixo-vec for DME, nor are we evaluating the 6E11 dose in wet AMD. We have not seen similar patient safety concerns in any of our patients at either the 2E11 dose in the INFINITY or OPTIC trials or the 6E11 dose in the OPTIC trial. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunogenicity to AAV therapy has been broadly reported to be associated both with systemic and with ocular gene therapies. Based on an extensive evaluation of data from all of our subjects treated with Ixo-vec and all of our nonclinical data by internal and external experts, we believe new enhanced prophylactic steroid regimens, which will include local steroids and a combination of local and systemic steroids, will allow us to minimize post-prophylaxis inflammation in our trial subjects going forward. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we advance Ixo-vec for wet AMD, we are continuing to develop our manufacturing expertise for ongoing supply. We maintain control of key aspects of the manufacturing process, specifically in scalable process development, assay development, and GMP quality controls.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ADVM-062</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a novel gene therapy product candidate being developed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy (&#8220;BCM&#8221;) via a single IVT injection. ADVM-062 utilizes Adverum&#8217;s propriety vector capsid, AAV.7m8.  In January 2022, we announced that the FDA granted Orphan Drug Designation to ADVM-062.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BCM affects approximately 1 to 9 in 100,000 males, worldwide. This X-linked recessive hereditary condition is caused by mutations in either the L or the M opsin gene(s) and can manifest in loss of visual acuity, photosensitivity, myopia and infantile nystagmus that can persist into adulthood. Consequently, individuals with BCM have visual impairments to important aspects of daily living such as facial recognition, learning, reading, and daylight vision. Currently, there is no cure for BCM and to our knowledge, no other therapies to treat BCM are in development. We are collaborating with the families of patients affected with BCM to help advance our therapies. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Restructuring</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, we announced we had taken measures to restructure our operations, including reductions in both headcount and expenses to prioritize Ixo-vec&#8217;s clinical development, and focus our pipeline strategy on certain highly prevalent ocular diseases. We expect these restructuring measures will be sufficient to fully support our Ixo-vec development plan and extend our expected cash runway into 2025. We expect the restructuring to be completed in the fourth quarter of 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact of COVID-19</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations and financial condition for the three and six months ended June 30, 2022 were not significantly impacted by the COVID-19 pandemic. However, the full extent to which the COVID-19 pandemic will directly or indirectly impact these areas in the future is unknown at this time and will depend on future developments that are unpredictable. We are actively monitoring and managing our response and assessing actual and potential impacts to these areas. Please refer to the &#8220;Risk Factors&#8221; section for further discussion of the risks we face as a result of the COVID-19 pandemic.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact on Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are continuously evaluating and addressing potential impacts of the COVID-19 pandemic on our operations. To date, we have experienced limited impact due to COVID-19 on our operations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to the health and safety of our employees and their families and to doing our part to slow the community spread of COVID-19. We have reopened our offices to allow our employees more flexibility to mix virtual and in-person work and to advance our culture and corporate goals. We believe this will also enable greater balance and well-being of our employees. We continue to update our policies and implement new practices to align with the current guidance from state and federal governments and health authorities. We believe these measures and others have allowed us to mitigate, but not eliminate, the effects and risks on our on-site operations posed by the COVID-19 pandemic.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact on Clinical Trials</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ultimate impact of the COVID-19 pandemic on our ongoing and planned clinical trials is uncertain and subject to change. To date, we believe we have experienced limited impact due to COVID-19 on our ongoing clinical programs, including the OPTIC and INFINITY clinical trials. We are working closely with our clinical trial sites to monitor and attempt to address or limit the potential negative impacts of the evolving COVID-19 outbreak and the emergence of COVID-19 variants on patient safety, continued participation and follow-up of patients already enrolled in our clinical studies, protocol compliance, data quality, and overall study integrity. Despite these efforts, we are unsure as to whether the COVID-19 pandemic will significantly impact future trial enrollment or completion of our current or planned clinical studies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact on Supply Chain and Manufacturing</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have not yet experienced significant disruptions to our supply chain and manufacturing as a result of the COVID-19 pandemic, we cannot be certain that this trend will continue. Based on current information, we believe that our partners in our supply chain have been and will continue to serve us continuously during the COVID-19 pandemic. The COVID-19 pandemic and other factors have also adversely impacted the global supply chain for other supplies and materials which could impact our future operations. To mitigate against future potential delays in supplies and materials we use in our operations, including product supply, we are continuously implementing additional measures to address potential risks as we identify them, including securing additional supplies and manufacturing capacity reserve, which have resulted in additional expenses and may result in other additional expenses in the future. Given the uncertainty regarding the impact delays and disruption in the global supply chain may have on our operations, we are unable to quantify the ultimate impact on our future results at this time.</span></div><div id="i26ccaa4e5746469982cbf0d18a526b99_76"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Overview </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not generated positive cash flow or net income from operations since our inception and, as of June&#160;30, 2022, we had an accumulated deficit of $729.7 million. We expect to incur substantial expenses and increasing losses from operations in the foreseeable future as we continue our research and development efforts, advance our product candidates through nonclinical and clinical development, manufacture clinical study materials, seek regulatory approval, and prepare for and, if approved, proceed to commercialization. We are at an early stage of development and may never be successful in developing or commercializing our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we may in the future generate revenue from a variety of sources, including license fees, milestone and research and development payments in connection with strategic partnerships, and potentially revenue from product sales if any of our product candidates are approved, to date we have not generated any revenue from product sales.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have no operational clinical or commercial manufacturing facilities, and all of our clinical manufacturing activities are currently contracted out to third parties. Additionally, we use third-party contract research organizations (&#8220;CRO&#8221;) to carry out our clinical development and we do not have a sales organization.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to incur substantial and increasing expenditures in the foreseeable future for the development and potential commercialization of our product candidates. We will need substantial additional funding in the future to support our operating activities as we advance our product candidates through nonclinical and clinical development, seek regulatory approval and prepare for and, if approved, proceed to commercialization. Adequate funding may not be available to us on acceptable terms, or at all. If we are unable to raise capital, or to do so on acceptable terms, when needed, or to form additional collaboration partnerships to support our efforts, we could be forced to delay, reduce or eliminate our research and development programs or potential commercialization efforts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, we had $235.8 million in cash, cash equivalents and short-term investments. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date we have not generated any revenue from the sale of our products. We have generated revenue through research, collaboration and license arrangements with strategic partners. Our ability to generate product revenue and become profitable depends upon our ability to successfully develop and commercialize our product candidates. Because of the numerous risks and uncertainties associated with product development, we are unable to predict the amount or timing of product revenue. Even if we are able to generate revenue from the sale of our products, our sales may not be sufficient to generate cash from operations, in which case we may be unable to continue our operations at planned levels and be forced to reduce our operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conducting a significant amount of research and development is central to our business model. Research and development expenses primarily include personnel-related costs, stock-based compensation expenses, laboratory supplies, consulting costs, external contract research and development expenses, including expenses incurred under agreements with CROs, the cost of acquiring, developing and manufacturing clinical study materials, and overhead expenses, such as rent, equipment depreciation, insurance and utilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development costs as incurred. We defer and expense advance payments for goods or services for future research and development activities as the goods are delivered or the related services are performed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate nonclinical study and clinical trial expenses based on the services performed pursuant to contracts with research institutions and CROs that conduct and manage nonclinical studies and clinical trials on our behalf. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. We estimate the amounts incurred through communications with third party service providers and our estimates of accrued expenses as of each balance sheet date are based on information available at the time. If the actual timing of the performance of services or the level of effort varies from the estimate, we will adjust the accrual accordingly.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At this time, we cannot reasonably estimate the nature, timing or aggregate costs of the efforts that will be necessary to complete the development of any of our product candidates. The successful development and commercialization of a product candidate is highly uncertain, and clinical development timelines, the probability of success, and development and commercialization costs can differ materially from expectations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses primarily include personnel-related costs, stock-based compensation, professional fees for legal, consulting, audit and tax services, overhead expenses, such as rent, equipment depreciation, insurance and utilities, and other general operating expenses not otherwise included in research and development expenses. Our general and administrative expenses may increase in future periods if and to the extent we elect to increase our investment in infrastructure to support continued research and development activities and potential commercialization of our product candidates. We will continue to evaluate the need for such investment in conjunction with our ongoing consideration of our pipeline of product candidates. We anticipate increased expenses related to audit, legal and regulatory functions, as well as director and officer insurance premiums and investor relations costs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, we implemented a restructuring of operations, including reductions in both headcount and expenses, to prioritize our clinical development of Ixo-vec and focus our pipeline strategy on certain highly prevalent ocular diseases, which included a reduction in our workforce by approximately 38%. We expect the restructuring to be completed in the fourth quarter of 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net primarily comprises interest income on our cash equivalents and investments in marketable securities.</span></div><div id="i26ccaa4e5746469982cbf0d18a526b99_79"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of financial condition and results of operations are based upon our unaudited condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. On an on-going basis, we evaluate our critical accounting policies and estimates. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable in the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions and conditions. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes in our critical accounting policies and estimates during the six months ended June&#160;30, 2022 as compared to the critical accounting policies and estimates disclosed in the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in our most recent Annual Report on Form 10-K filed with the SEC on March 29, 2022.</span></div><div id="i26ccaa4e5746469982cbf0d18a526b99_85"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three and Six Months Ended June&#160;30, 2022 and 2021</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June&#160;30,</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,608&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,930&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,170)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,929&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,093&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,164)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,025&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,538&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(513)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,158&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,681&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,477&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,025)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,538)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">513&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82,158)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73,181)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,977)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,742)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,333)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81,631)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,769)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,862)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax provision</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,761)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,333)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81,669)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,769)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,900)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $7.5 million license revenue for the six months ended June&#160;30, 2021 was related to an upfront payment received in January 2021 upon execution of a license agreement entered with Lexeo Therapeutics, Inc (&#8220;Lexeo&#8221;). </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expense</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense increased $7.7 million to $30.3 million for the three months ended June&#160;30, 2022 from $22.6&#160;million for the three months ended June&#160;30, 2021. The overall increase was primarily related to: a $2.3 million increase in clinical trial-related expenses in preparation for the Phase&#160;2 trial, a $2.0 million increase in license cost arising from amounts due under a sublicense agreement, a $2.0 million impairment of property and equipment, and a $1.0 million increase in personnel-associated costs including higher salaries and bonuses as a result of headcount increases and retention efforts. Stock-based compensation expense included in research and development expenses was $1.8&#160;million for the three months ended June&#160;30, 2022, compared to $2.6 million for the three months ended June&#160;30, 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense increased $10.6 million to $53.2 million for the six months ended June&#160;30, 2022 from $42.6&#160;million for the six months ended June&#160;30, 2021. The overall increase was primarily related to: a $3.3 million increase in clinical trial-related expenses as we prepare to initiate our LUNA trial, a $3.2 million increase in personnel-associated costs including higher salaries and bonuses as a result of headcount increases and retention efforts; a $2.4&#160;million increase in allocated rent and facilities expenses, driven by new leases which commenced during the second quarter of 2021; a $2.0 million increase in license costs arising from amounts due under a sublicense agreement; and a $2.0 million of impairment of property and equipment. These increases were partially offset by a $2.1&#160;million decrease in material production and bioanalytical expenses driven by nonclinical research. Stock-based compensation expense included in research and development expenses was $3.8&#160;million for the six months ended June&#160;30, 2022, compared to $4.9&#160;million for the six months ended June&#160;30, 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the periods presented, our research and development activities were attributable to our wet AMD, DME, and rare disease programs, as well as earlier-stage research programs. We expect that research and development expenses will decrease in future periods as we focus on advancing our gene therapy product candidate Ixo-vec for the treatment of wet AMD.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expense</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expense decreased $8.2&#160;million to $13.8 million for the three months ended June&#160;30, 2022 from $21.9&#160;million for the three months ended June&#160;30, 2021, primarily related to decreases of $4.4 million in professional services mainly related to investor relations and legal fees incurred in connection with the prior year's proxy contest; a $3.1 million decrease in personnel-associated costs driven by lower headcount and lower fair value of equity related awards and a $0.4&#160;million decrease in consultants and contractors. Stock-based compensation expense included in general and administrative expenses was $3.1&#160;million for the three months ended June&#160;30, 2022, compared to $5.7 million for the three months ended June&#160;30, 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expense decreased $9.2 million to $28.9 million for the six months ended June&#160;30, 2022 from $38.1&#160;million for the six months ended June&#160;30, 2021, primarily related to decreases of $5.2 million in professional services mainly related to investor relations and legal fees incurred in connection with the prior year's proxy contest; and a $4.9 million decrease in personnel-associated costs driven by lower headcount and lower fair value of equity related awards; these decreases were partially offset by a $1.0&#160;million increase in insurance expense. Stock-based compensation expense included in general and administrative expenses was $6.6&#160;million for the six months ended June&#160;30, 2022, compared to $10.5 million for the six months ended June&#160;30, 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that general and administrative expenses will decrease in future periods as we streamline our operations. We anticipate decreased expenses related to the human resources, legal, and finance functions brought about by the restructuring measures.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income, Net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net remained relatively flat at $0.3 million and $0.5 million for the three and six months ended June&#160;30, 2022, respectively and $0.2 million and $0.4 million for the three and six months ended June&#160;30, 2021, respectively. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Provision</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized an income tax provision of $19,000 and $38,000 for the three and six months ended June&#160;30, 2022, respectively, related to foreign operations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized no income tax provision for the three and six months ended June&#160;30, 2021.</span></div><div id="i26ccaa4e5746469982cbf0d18a526b99_88"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not generated positive cash flow or net income from operations since our inception and as of June&#160;30, 2022, we had an accumulated deficit of $729.7 million. As of June&#160;30, 2022, we had $235.8 million in cash, cash equivalents and short-term investments compared to $305.2 million as of December 31, 2021. We believe that our existing cash and cash equivalents and short-term investments as of June&#160;30, 2022 will be sufficient to fund our operations and meet our existing contractual obligations and other cash requirements into 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to incur substantial expenditures in the foreseeable future for the development and potential commercialization of our product candidates and ongoing internal research and development programs. At this time, we cannot reasonably estimate the nature, timing or aggregate amount of costs for our development, potential commercialization, and internal research and development programs. However, in order to complete our planned nonclinical trials and current and future clinical trials, and to complete the process of obtaining regulatory approval for our product candidates, as well as to build the sales, marketing and distribution infrastructure that we believe will be necessary to commercialize our product candidates, if approved, we will require substantial additional funding in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If and when we seek additional funding, we will do so through equity or debt financings, collaborative or other arrangements with corporate sources or through other sources of financing. Adequate additional funding may not be available to us on acceptable terms or at all. Our failure to raise capital in the future could have a negative impact on our financial condition and our ability to pursue our business strategies. To complete development and commercialization of any of our product candidates, we anticipate that we will need to raise substantial additional capital, the requirements of which will depend on many factors, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, progress, timing, costs and results of nonclinical studies and any clinical trials for our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome, timing of and costs involved in, seeking and obtaining approvals from the FDA and other regulatory authorities, including the potential for the FDA and other regulatory authorities to require that we perform more studies than those that we currently expect;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of our product candidates to progress through clinical development activities successfully;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our need to expand our research and development activities;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate of progress and cost of our commercialization of our products;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of preparing to manufacture our products on a larger scale;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of commercialization activities including product sales, marketing, manufacturing and distribution;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the degree and rate of market acceptance of any products launched by us or future partners;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our need to implement additional infrastructure and internal systems;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to hire additional personnel;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enter into additional collaboration, licensing, commercialization or other arrangements and the terms and timing of such arrangements;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the emergence of competing technologies or other adverse market developments; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effects of the COVID-19 pandemic on our business, results of operations, and financial condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to raise additional funds when needed, we may be required to delay, reduce, or terminate some or all of our development programs and clinical trials. We may also be required to sell or license other technologies or clinical product candidates or programs that we would prefer to develop and commercialize ourselves.</span></div><div id="i26ccaa4e5746469982cbf0d18a526b99_91"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,808)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,220)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net increase (decrease) in cash and cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,675&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,842)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Used in Operating Activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2022, net cash used in operating activities was $57.8 million, primarily as a result of net loss of $81.7 million due to the continued activities developing our product candidates partially offset by $15.6 million of non-cash charges mainly related to $10.3 million of stock-based compensation expense, $3.0 million of depreciation and amortization expenses, and $2.0 million of impairment of property and equipment and by $8.2 million of change in operating assets and liabilities, which fluctuate due to timing of expenses and payments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2021, net cash used in operating activities was $56.2 million, primarily as a result of net loss of $72.8 million due to the continued activities developing our product candidates and $2.6 million of net decrease in operating assets and liabilities, partially offset by $19.1 million of non-cash charges mainly related to $15.5 million of stock-based compensation expense, and $2.4 million of depreciation and amortization expenses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Provided by Investing Activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities for the six months ended June&#160;30, 2022 consisted of $125.9 million of net maturities from our marketable securities, partially offset by $10.8 million of purchases of property and equipment primarily related to laboratory equipment and facility construction. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities for the six months ended June 30, 2021 consisted of $49.4 million of net proceeds from marketable securities, partially offset by $5.1 million of purchases of property and equipment primarily related to facility constructions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Provided by Financing Activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the six months ended June&#160;30, 2022 consisted mainly of $0.4 million of proceeds from our employee purchase plan.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the six months ended June 30, 2021 consisted of $1.7 million of net proceeds from the sale of our common stock pursuant to our sales agreement with Cowen and Company, LLC and $0.5 million proceeds from employee stock purchase plan, partially offset by $0.2 million for repayment of the Banque Publique d&#8217;Investissement loan.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="i26ccaa4e5746469982cbf0d18a526b99_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-108pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under SEC rules and regulations, as a smaller reporting company, we are not required to provide the information required by this item.</span></div><div><span><br/></span></div><div id="i26ccaa4e5746469982cbf0d18a526b99_103"></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-108pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;Controls and Procedures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evaluation of disclosure controls and procedures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Management, including our Chief Executive Officer and Acting Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of June&#160;30, 2022. The evaluation of our disclosure controls and procedures included a review of our processes and implementation and the effect on the information generated for use in this Quarterly Report on Form 10-Q. We conduct this type of evaluation quarterly so that our conclusions concerning the effectiveness of these controls can be reported in our periodic reports filed with the SEC. The overall goals of these evaluation activities are to monitor our disclosure controls and procedures and to make modifications as necessary. We intend to maintain these disclosure controls and procedures, modifying them as circumstances warrant.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on that evaluation, our Chief Executive Officer and Acting Chief Financial Officer concluded that, as of June&#160;30, 2022, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is (i)&#160;recorded, processed, summarized and reported as and when required and (ii)&#160;accumulated and communicated to our management, including the Chief Executive Officer and our Acting Chief Financial Officer, as appropriate to allow timely discussion regarding required disclosure.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in internal control over financial reporting. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our internal control over financial reporting during the three months ended June&#160;30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:12pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Limitations on the Effectiveness of Controls</span></div><div style="margin-top:6pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our Chief Executive Officer and Acting Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefit of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within Adverum have been detected. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="i26ccaa4e5746469982cbf0d18a526b99_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II &#8211; OTHER INFORMATION</span></div><div id="i26ccaa4e5746469982cbf0d18a526b99_109"></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-108pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;Legal Proceedings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i26ccaa4e5746469982cbf0d18a526b99_112"></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-108pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.&#160;&#160;&#160;&#160;Risk Factors</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should consider carefully the risks and uncertainties described below, together with all of the other information in this Quarterly Report on Form 10-Q. If any of the following risks are realized, our business, financial condition, results of operations and prospects could be materially and adversely affected. The risks described below are not the only risks facing us. Risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, results of operations and prospects. Further, the current coronavirus (&#8220;COVID-19&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">pandemic and actions taken to address the pandemic may exacerbate the risks described below.</span></div><div><span><br/></span></div><div id="i26ccaa4e5746469982cbf0d18a526b99_115"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Capital</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant operating losses since inception, and we expect to incur significant losses for the foreseeable future. We may never become profitable or, if achieved, be able to sustain profitability.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant operating losses since we were founded in 2006 and expect to incur significant losses for the foreseeable future as we continue development of our product candidates. Losses have resulted principally from costs incurred in our research and development programs and from our general and administrative expenses. In the future, we intend to continue to conduct research and development, regulatory compliance activities and, if any of our product candidates is approved, sales and marketing activities that, together with anticipated general and administrative expenses, will likely result in us incurring significant losses for the next several years or longer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently generate no revenue from sales, and we may never be able to commercialize any of our product candidates. We do not currently have the required approvals to market any of our product candidates, and we may never receive such approvals. We may not be profitable even if we or any of our future development partners succeed in commercializing any of our product candidates. Because of the numerous risks and uncertainties associated with developing and commercializing our product candidates, we are unable to predict the extent of any future losses or when we will become profitable, if at all.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect that our cash, cash equivalents, and short-term investments will be sufficient to fund our lead gene therapy programs for at least twelve months from the date of this filing. If this expectation proves to be wrong, we may be forced to delay, limit or terminate certain of our development efforts before then.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently expect our cash, cash equivalents and short-term investments to fund our planned operations into 2025. However, this estimate is based on a number of assumptions that may prove to be wrong, including our expectations about the timing of planned clinical trials, forecasted employee attrition, investments into our manufacturing capabilities, and changing circumstances beyond our control may cause capital to be consumed more rapidly than currently anticipated. As a result, our operating plan may change, and we may need to seek additional funds sooner than planned through collaboration agreements and public or private financings. If we run low on capital and are unable to successfully raise additional funds on terms acceptable to us, we may need to significantly curtail some or all of our development activities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need to raise additional funding, which may not be available on acceptable terms, or at all. If we fail to obtain additional capital necessary to fund our operations, we will be unable to successfully develop and commercialize our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will require substantial future capital in order to complete the nonclinical and clinical development for our product candidates and potentially to commercialize these product candidates. Any future clinical trials or ongoing clinical trials of our product candidates could cause an increase in our spending levels, as would other corporate activities, such as expenses related to manufacturing supply of our product candidates. The amount and timing of any expenditure needed to implement our development and commercialization programs will depend on numerous factors, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the type, number, scope, progress, expansion costs, results of and timing of any future nonclinical studies and clinical trials of any of our product candidates which we are pursuing or may choose to pursue in the future;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the need for, and the progress, costs and results of, any additional clinical trials or nonclinical studies of our product candidates we may initiate based on the results of any clinical trials that we may plan or discussions with the U.S. Food and Drug Administration (&#8220;FDA&#8221;), including any additional clinical trials or nonclinical studies the FDA or other regulatory authorities outside the U.S. may require evaluating the safety of our product candidates;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of obtaining, maintaining and enforcing our patents and other intellectual property rights;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of obtaining or maintaining manufacturing for our product candidates, including internal and external commercial manufacturing;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of establishing sales and marketing capabilities and enhanced internal controls over financial reporting;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms and timing of establishing collaborations, license agreements and other partnerships;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs associated with any new product candidates that we may develop, in-license or acquire;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of competing technological and market developments;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain partnering arrangements for development; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with being a public company.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of these factors are outside of our control. We do not expect our existing capital resources to be sufficient to enable us to fund the completion of our clinical trials and remaining development programs through commercial introduction. We expect that we will need to raise additional funds in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no product candidate approved by any regulatory authority, have not sold any products, and we do not expect to sell or derive revenue from any product sales for the foreseeable future. We may seek additional funding through collaboration agreements and public or private financings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional funding may not be available to us on acceptable terms or at all and the terms of any financing may adversely affect the holdings or the rights of our stockholders. General market conditions resulting from global supply chain issues, Russia&#8217;s invasion of Ukraine, the COVID-19 pandemic, as well as other market conditions, may make it difficult for us to obtain adequate additional financing when needed or on attractive terms, or at all. In addition, the issuance of additional shares by us, or the possibility of such issuance, may cause the market price of our shares to decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to obtain funding on a timely basis, we will be unable to complete any future clinical trials for our product candidates and we may be required to significantly curtail some or all of our activities. We also could be required to seek funds through arrangements with collaborative partners or otherwise that may require us to relinquish rights to our product candidates or some of our technologies or otherwise agree to terms unfavorable to us.</span></div><div><span><br/></span></div><div id="i26ccaa4e5746469982cbf0d18a526b99_118"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Discovery and Development of Our Product Candidates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business will depend substantially on the success of one or more of our product candidates. If we are unable to develop, obtain regulatory approval for, or successfully commercialize, any or all of our product candidates, our business will be materially harmed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are in the early stages of development and will require substantial nonclinical and/or clinical development and testing, manufacturing process improvement and validation, bridging studies and regulatory approval prior to commercialization. It is critical to our business to successfully develop and ultimately obtain regulatory approval for one or more of these product candidates. Our ability to commercialize our product candidates effectively will depend on several factors, including the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful completion of nonclinical studies and clinical trials, including the ability to demonstrate safety and efficacy of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receipt of marketing approvals for any future products for which we complete clinical trials, including securing regulatory exclusivity to the extent available;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing commercial manufacturing capabilities, for example, by engaging third-party manufacturers or developing our own manufacturing capabilities that can provide products and services to support clinical development and the market demand for our product candidates, if approved;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful launch and commercial sales of the product, whether alone or in collaboration with potential partners;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of the product as a viable treatment option by patients, the medical community and third-party payers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing market share while competing with other therapies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a continued acceptable safety profile of our products following regulatory approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining compliance with post-approval regulations and other requirements; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">qualifying for, identifying, registering, maintaining, enforcing and defending intellectual property rights and claims covering our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our collaborators do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to commercialize our product candidates, which would materially and adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the large number of biologics and drugs in development in the pharmaceutical industry, only a small percentage result in the submission of a biologics license application (&#8220;BLA&#8221;) to the FDA or marketing authorization application (&#8220;MAA&#8221;) to the European Medicines Agency (&#8220;EMA&#8221;) and even fewer are approved for commercialization. Furthermore, even if we do receive regulatory approval to market any of our product candidates, any such approval may be subject to limitations on the indicated uses for which we may market the product, or limitations related to its distribution. Accordingly, even if we are able to obtain the requisite financing to continue to fund our development programs, there can be no assurance that any of our product candidates will be successfully developed or commercialized. If we or any of our future development partners are unable to develop, or obtain regulatory approval, or, if approved, successfully commercialize, any of our product candidates, we may not be able to generate sufficient revenue to continue our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Drug development is a long, expensive and uncertain process, and delay or failure can occur at any stage of development, including after commencement of any of our clinical trials or any clinical trials using our proprietary viral vectors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug development has inherent risk. Our lead product candidate, ixoberogene soroparvovec (&#8220;Ixo-vec&#8221;), which we previously referred to as ADVM-022, for the treatment of wet age-related macular degeneration (&#8220;wet AMD&#8221;) uses a proprietary vector, AAV.7m8, which has undergone limited human testing, and may experience unexpected results in clinical trials in the future, such as the dose-limiting toxicity at the 6 x 10&#94;11 vg/eye (&#8220;6E11&#8221;) dose tested in the INFINITY trial in diabetic macular edema (&#8220;DME&#8221;) patients. Although we will be bound by the generally applicable laws governing approval, the fact that our product is a gene therapy and the broad patient population that it is intended to treat means that the safety and efficacy of our product and the related clinical data will be under increased scrutiny by competent authorities. There have been several significant adverse side effects in gene therapy treatments in the past, including reported cases of leukemia and death seen in other trials using other genomic therapies. Gene therapy is still a relatively new approach to disease treatment and additional adverse side effects could develop. There also is the potential risk of significantly delayed adverse events following exposure to gene therapy products due to persistent biologic activity of the genetic material or other components of products used to carry the genetic material. Possible adverse side effects that could occur with treatment with gene therapy products include an immunologic reaction early after administration that, while not necessarily adverse to the patient&#8217;s health, could substantially limit the effectiveness of the treatment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, or any licensee or development partner, will be required to demonstrate through adequate and well-controlled clinical trials that our product candidate or another party&#8217;s product candidate containing one of our proprietary viral vectors is safe and effective for use in its target indications before seeking regulatory approvals for commercial sale. Drug development is a long, expensive and uncertain process, and delay or failure can occur at any stage of development, including after commencement of any of our clinical trials or any clinical trials using our proprietary viral vectors. Any such delay or failure could significantly harm our business prospects, financial condition and results of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The occurrence of serious complications or side effects that outweigh the therapeutic benefit in connection with or during use of our product candidates, either in nonclinical studies or clinical trials or post-approval, could lead to discontinuation of our clinical development program, refusal of regulatory authorities to approve our product candidates or, post-approval, revocation of marketing authorizations or refusal to approve new indications, which could severely harm our business prospects, financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the conduct of nonclinical studies and clinical trials, animal models and patients may experience changes in their health, including illnesses, injuries and discomforts. Often, it is not possible to determine whether or not the product candidate being studied caused these conditions. In addition, patients may not comply with the requirements of the study, such as missing physician visits or not taking eye drops as prescribed, which may result in changes to their health or vision that are then attributed to the product candidate. Various illnesses, injuries, and discomfort may be reported from time-to-time in clinical trials of our product candidates. For example, a dose-limiting toxicity at the 6E11 dose tested in our INFINITY trial in DME patients resulted in our announcement on July 22, 2021 that we were discontinuing development of Ixo-vec for the DME indication. It is possible that as we test Ixo-vec and other product candidates, in current and future clinical programs, or as use of these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomfort and other adverse events that were observed in earlier trials, including the dose-limiting toxicity at the 6E11 dose tested in the INFINITY trial, as well as conditions that did not occur or went undetected in previous trials, will be reported by patients. Many times, side effects are only detectable after investigational products are tested in large-scale, Phase 3 clinical trials or later stage clinical trials, or, in some cases, after they are made available to patients on a commercial scale after approval. If </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional clinical experience indicates that one or more of our product candidates causes serious or life-threatening side effects, or side effects that outweigh the therapeutic benefit of the product candidate, the development of one or more of our product candidates may fail or be delayed, or, if one or more of our product candidates has received regulatory approval, such approval may be revoked, which would severely harm our business prospects, financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When a patient experiences a negative health event during a clinical trial, we must determine if it is related to our product candidate in order to understand the safety of our product candidates. The patients we enroll in our clinical trials for our current product candidates are generally less healthy than the general population, which increases the likelihood that a negative health event, unrelated to our product candidate, may occur. These health events may be misattributed to our product candidate, either by us, our investigators, or by regulators. Such misattribution could cause regulatory approval of our product candidates to be denied or delayed. For example, the patients enrolled in our wet AMD trials are often geriatric and have other health conditions unrelated to wet AMD. We cannot assure you that we will be able to accurately determine whether or not a negative health event experienced by a patient in any of these or subsequent trials was related to Ixo-vec, nor can we assure you that the FDA or other regulatory authorities outside the U.S. responsible for reviewing the safety of Ixo-vec will agree with our determination. If a patient in one of our clinical trials experiences a negative health event, and that event is misattributed to Ixo-vec, the trial and other trials of Ixo-vec may be placed on clinical hold, and regulatory approval of Ixo-vec may be delayed or denied.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if a patient enrolled in one of our clinical trials experiences a negative health event, they may be forced to withdraw from our trial, or may become temporarily unavailable for follow-up visits, which may impact the amount or quality of data we obtain from our trial, which in turn may delay or prevent regulatory approval of our product candidate. Because patients we enroll in our clinical trials for any of our product candidates are likely to be less healthy than the general population, and particularly in trials like OPTIC that enroll a small number of patients, this risk is increased.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates built on adeno-associated viral vector (&#8220;AAV&#8221;) vectors have similar risks to other gene therapy vectors, including inflammation, cytotoxic T-cell responses, anti-AAV antibodies and immune response to the transgene product, such as T-cell responses and/or antibodies against the expressed protein. For example, based on our current clinical experience, ocular inflammation is a known side effect of Ixo-vec administration, but the duration of inflammation caused by Ixo-vec, our ability to manage that inflammation using steroids or other anti-inflammatory or immunomodulatory treatments, and any potential clinical sequelae of that inflammation and treatments used to manage inflammation are not fully understood. The primary purpose of our LUNA trial is to identify the best prophylactic steroid regimen with two doses of ADVM-022 that reduces post-prophylactic inflammation while at the same time providing efficacy. If we are unable to manage this inflammation appropriately, we may not be able to further develop Ixo-vec and the FDA or other regulatory authorities outside the U.S. may not approve Ixo-vec. Even if we achieve marketing approval, doctors may not prescribe, and patients may not use, Ixo-vec or our other product candidates if they deem the levels or risk of inflammation to be unacceptable. Further, patients treated with Ixo-vec could develop antibodies against AAV.7m8 capsid and/or aflibercept protein. These antibodies could preclude these patients from receiving other AAV-based gene therapies in the future. In addition, patients previously treated with or exposed to other AAV-based gene therapies could develop antibodies against AAV.7m8 and/or the aflibercept protein, which could reduce or eliminate the effectiveness of Ixo-vec or could cause unanticipated adverse reactions to Ixo-vec. Studies have also found that intravenous delivery of certain AAV vectors at high doses may result in adverse events and have prompted the recommendation that studies involving high doses of AAV vectors should be monitored carefully for such adverse events. In addition, patients given infusions of any protein or injection of gene therapies that express a therapeutic protein may develop severe hypersensitivity reactions, infusion reactions, or serious side effects including transaminitis. With respect to our product candidates that are being or may be studied in diseases of the eye, there are additional potential serious complications related to intravitreal injection, such as retinal detachment, endophthalmitis, ocular inflammation, cataract formation, glaucoma, damage to the retina or cornea, and bleeding in the eye. Serious complications or serious, unexpected side effects in connection with the use of our product candidates could materially harm our business prospects, financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our lead product candidate, Ixo-vec, is designed for long-term, sustained expression of an exogenous protein, aflibercept. Even though EYLEA&#174; (aflibercept) has been approved by several regulatory authorities, including the FDA, for the treatment of wet AMD, there may be side effects associated with aflibercept being expressed as a gene therapy treatment modality. If such side effects are serious or life-threatening, the development of our product candidate and future product candidates may fail or be delayed, or, if such product candidate(s) have received regulatory approval, such approval may be revoked, which would severely harm our business prospects, financial condition and results of operation.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The results of nonclinical studies and early clinical trials are not always predictive of future results. Any product candidate we or any of our future development partners advance into clinical trials may not have favorable results in later clinical trials, if any, or receive regulatory approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our product candidates are not shown to be safe and effective, we may not realize the value of our investment in our technology. Promising nonclinical results generated with a product candidate in animal models do not guarantee similar results when the candidate is tested in humans. For example, the levels of protein expression achieved from a vector in a nonclinical model, including non-human primate models, may be significantly higher than the level of protein expression achieved in humans. Similarly, human subjects administered our product candidates may develop side effects that were not observed in animal models and/or are more severe than those observed in animal models. In addition, even industry-accepted animal models may not accurately replicate human disease. Success in nonclinical studies or in early clinical trials does not mean that later clinical trials will be successful, because product candidates in later-stage clinical trials may fail to demonstrate sufficient safety or efficacy despite having progressed through nonclinical and initial clinical testing. Further, safety and/or efficacy issues with a product candidate may only become apparent when the candidate is tested in human patients suffering from the relevant disease. Furthermore, the initiation of future trials for a product candidate, such as our planned Phase 2 LUNA clinical trial for Ixo-vec in wet AMD to explore additional doses with new enhanced prophylactic steroid regimens, which will include local steroids and a combination of local and systemic steroids, will be dependent upon demonstrating sufficient safety and efficacy to the relevant regulatory authorities in preceding or other ongoing trials using the same product candidate. We will still need to conduct Phase 3 pivotal trials in which Ixo-vec will need to be compared to available therapies and utilize longer term endpoints in order to support submission and approval of a BLA. Companies frequently suffer significant setbacks in advanced clinical trials, even after earlier clinical trials have shown promising results. In addition, only a small percentage of products under development result in the submission of a marketing application and even fewer are approved for commercialization. Even if our clinical trials successfully meet their endpoints for safety and efficacy, the FDA and/or other regulatory authorities outside the U.S. may still conclude that the product candidate has not demonstrated a beneficial risk/benefit profile or otherwise does not meet the relevant standard for approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot guarantee that results from any clinical trials that we plan will be successful, and any safety or efficacy concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our gene therapy platform is based on a novel technology, which makes it difficult to predict the time and cost of product candidate development and subsequently obtaining regulatory approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have concentrated our research and development efforts on our gene therapy platform and our future success depends on the successful development of product candidates based on this platform. There can be no assurance that any development problems we have experienced or may experience in the future related to our platform will not cause significant delays or unanticipated costs, or that such development problems can be solved. We may also experience delays in developing a sustainable, reproducible, and scalable manufacturing process or transferring that process to external commercial manufacturing sites, which may prevent us from completing our clinical trials or commercializing our product candidates on a timely or profitable basis, if at all.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the clinical trial requirements of the FDA, EMA and other regulatory authorities outside the U.S. and the criteria these regulators may use to determine the quality, safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel gene therapy products such as ours can be more expensive and take longer than for other product types, which are better known or more extensively studied to date. The FDA only recently approved the first in vivo gene therapies, LUXTURNA&#174; and ZOLGENSMA&#174;, and FDA approvals of gene therapy products to date have been generally for rare diseases with limited treatment options. Because we are targeting a broad population of patients with wet AMD, the benefit-risk profile of Ixo-vec may be subject to greater scrutiny by regulatory authorities. Regulatory approaches and requirements for gene therapy products continue to evolve, and any changes could create significant delay and unpredictability for product development and approval as compared to technologies with which regulatory authorities have more substantial experience.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, before a clinical trial can begin to enroll at a site, each clinical site's Institutional Review Board (&#8220;IRB&#8221;) and its Institutional Biosafety Committee will have to review the proposed clinical trial to assess appropriateness to conduct the clinical trial at that site. In addition, adverse events in clinical trials of gene therapy products conducted by others may cause the FDA or other regulatory authorities outside the U.S. to change the requirements for human research on or for approval of any of our product candidates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These regulatory review committees and advisory groups, and the guidelines they promulgate, may lengthen our regulatory review process, require us to perform additional studies, increase our development costs, increase or otherwise change chemistry, manufacturing, and controls requirements, lead to changes in our regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. As we advance our product candidates, we will usually be required to consult with these, and potentially other, regulatory and advisory groups and comply with applicable guidelines or recommendations. If we fail to do so or the consultations take longer than we expect, we may be required to delay or discontinue development of our product candidates. Delay or failure to obtain, or unexpected costs incurred in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue to maintain our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifying and qualifying patients to participate in our clinical trials will be critical to our success. The timing of current and future clinical trials will depend on the speed at which we can recruit patients to participate in future testing of these product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, competing clinical trials, clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating and patient&#8217;s safety concerns over participating in a clinical trial, including during a pandemic. We will be required to identify and enroll a sufficient number of patients for any clinical trials for our product candidates. Potential patients may not be adequately diagnosed or identified with the diseases which we are targeting or may not meet the entry criteria for our trials. Additionally, some patients may have neutralizing antibodies at titer levels that would prevent them from being enrolled in a clinical trial for any of our product candidates, or may meet other exclusion criteria. As a consequence, enrollment in our clinical trials may be limited or slowed. We also may encounter difficulties in identifying and enrolling patients with a stage of disease appropriate for such future clinical trials. We may not be able to identify, recruit and enroll a sufficient number of patients, or those with required or desired characteristics to achieve diversity in a trial.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the case of rare diseases, a relatively small number of individuals in the U.S. (fewer than 200,000) are impacted, and therefore, there is a limited patient pool from which to draw for clinical trials. Enrollment of eligible patients with rare or orphan diseases may be limited or slower than we anticipate in light of the small patient populations involved.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to seek initial marketing approval of our product candidates in the U.S. and/or Europe and we may not be able to successfully conduct clinical trials if we cannot enroll a sufficient number of eligible patients to participate in the clinical trials required by the FDA or the EMA or other regulatory authorities outside the U.S. In addition, the process of finding and diagnosing patients may prove costly.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, if patients and investigators are unwilling to participate in our gene therapy studies because of the dose-limiting toxicity at the 6E11 dose tested in the INFINITY trial, or because of negative publicity from other adverse events in the biotechnology or gene therapy industries or inadequate results in our nonclinical studies or clinical trials or for other reasons, including competitive clinical trials for similar patient populations or available approved therapies, our recruitment of patients, or conduct of clinical trials and ability to obtain regulatory approval of our product candidates may be hindered.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trials using early versions of retroviral vectors, which integrate into, and thereby alter, the host cell&#8217;s DNA, have led to several well-publicized adverse events. Our product candidates use an AAV delivery system, with which host integration has been less of a concern. Nonetheless, if patients negatively associate our product candidates with the adverse events caused by previous gene therapy products, they may choose not to enroll in our clinical trials, which would have a material adverse effect on our business and operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we have difficulty enrolling a sufficient number of patients to conduct clinical trials on our product candidates as planned, we may need to delay, limit or terminate future clinical trials, any of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates are subject to extensive regulation, compliance with which is costly and time consuming, and such regulation may cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The nonclinical and clinical development, manufacturing, analytical testing, labeling, storage, record-keeping, advertising, promotion, import, export, marketing and distribution of our product candidates are subject to extensive regulation by the FDA and by comparable regulatory authorities outside the U.S. In the U.S., we are not permitted to market our product candidates until we receive regulatory approval from the FDA. The process of obtaining regulatory approval is expensive, often takes many years and can vary substantially based upon the type, complexity and novelty of the products involved, as well as the target indications and patient population. Approval policies or regulations may change, and the regulatory authorities have substantial discretion in the drug approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons. Despite the time and expense invested in clinical development of product candidates, regulatory approval is never guaranteed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA or comparable regulatory authorities outside the U.S. can delay, limit or deny approval of a product candidate for many reasons, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such authorities may disagree with the design or implementation of our or any of our future development partners&#8217; clinical trials;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or any of our future development partners may be unable to demonstrate to the satisfaction of the FDA or other regulatory authorities outside the U.S. that a product candidate is safe and effective for any indication;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or other regulatory authorities outside the U.S. may not accept clinical data from trials which are conducted at multinational clinical facilities or in countries where the standard of care is potentially different from that of the U.S. or the other regulatory authorities outside the U.S.;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of clinical trials may not demonstrate the safety or efficacy required by such authorities for approval;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or any of our future development partners may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such authorities may disagree with our interpretation of data from nonclinical studies or clinical trials;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approval may be granted only for indications that are significantly more limited than what we apply for and/or with other significant restrictions on distribution and use;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such authorities may find deficiencies in the manufacturing processes, analytical testing, our facilities, or facilities of third-party manufacturers or testing laboratories with which we or any of our future development partners contract for clinical and commercial supplies; or</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the approval policies or regulations of such authorities may significantly change in a manner rendering our or any of our future development partners&#8217; clinical data insufficient for approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to foreign markets, approval procedures vary among countries and, in addition to the aforementioned risks, can involve additional product testing, administrative review periods and agreements with pricing authorities. In addition, events raising questions about the safety of related products, including those already on the market, may result in increased cautiousness by the FDA and comparable regulatory authorities outside the U.S. in reviewing our product candidates based on safety, efficacy or other regulatory considerations and may result in significant delays in obtaining regulatory approvals. Any delay in obtaining, or inability to obtain, applicable regulatory approvals would prevent us or any of our future development partners from commercializing our product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preliminary and interim data from our clinical trials that we may announce or publish from time to time may change as each clinical trial progresses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may announce or publish preliminary or interim data from our clinical trials. Preliminary and interim results of a clinical trial are not necessarily predictive of final results. Preliminary and interim data are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues or further patient follow up occurs and more patient data become available. For example, although we have periodically announced interim data from patients in our OPTIC trial, which showed all Ixo-vec related adverse events as mild to moderate in severity, there is no guarantee that in the future, we will not have more severe drug- or treatment-related adverse events in patients treated with Ixo-vec, such as the dose-limiting toxicity at the 6E11 dose tested in our INFINITY trial. In addition, in certain clinical trials, such as our OPTIC trial, individual cohorts of patients are enrolled with different dosages and other treatment conditions under our protocol. These different doses, populations, and other treatment conditions may affect clinical outcomes, including safety profiles or efficacy, such as the number of supplemental injections required, in each of the cohorts. As a result, preliminary and interim data should be viewed with caution and not relied upon until the final data from a locked database for the entire clinical trial are available. Material changes in the final data compared to preliminary or interim data could significantly harm our business prospects.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fast Track designation for ADVM&#8209;022 may not lead to a faster development, regulatory review or approval process, and it does not increase the likelihood that ADVM&#8209;022 will receive marketing approval in the United States.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received Fast Track designation for ADVM&#8209;022 in September 2018 for the treatment of wet AMD. The FDA may grant Fast Track designation to a drug that is intended to treat a serious condition and nonclinical or clinical data demonstrate the potential to address unmet medical needs. The FDA provides opportunities for frequent interactions with the review team for a Fast Track product, including pre-investigational new drug application (&#8220;IND&#8221;) meetings, end-of-phase 1 meetings, and end-of-phase 2 meetings with the FDA to discuss study design, extent of safety data required to support approval, dose-response concerns, and use of biomarkers. A Fast Track product may also be eligible for rolling review, where the FDA reviews portions of a marketing application before the sponsor submits the complete application.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, Fast Track designation for ADVM&#8209;022 may not result in a faster development process, review or approval compared to products considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, the FDA may rescind the Fast Track designation for ADVM&#8209;022 if FDA later determines that ADVM&#8209;022 no longer meets the qualifying criteria for Fast Track designation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in our efforts to identify or discover additional product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our business depends primarily upon our ability to identify, develop and commercialize products based on our platform technology. Our research programs may fail to identify other potential product candidates for clinical development for a number of reasons. For example, our research methodology may be unsuccessful in identifying potential product candidates or our potential product candidates may be shown to lack efficacy, have harmful side effects, or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these events occur, we may be forced to abandon our development efforts for a program or programs, which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Research programs to identify new product candidates require substantial technical, financial and human resources. We may focus our efforts and resources on potential programs or product candidates that may ultimately prove to be unsuccessful.</span></div><div id="i26ccaa4e5746469982cbf0d18a526b99_121"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Manufacturing</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to successfully develop and maintain robust and reliable manufacturing processes for our product candidates, we may be unable to advance clinical trials or licensure applications and may be forced to delay or terminate a program.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development of commercially viable manufacturing processes typically is very difficult to achieve, is often very expensive and may require extended periods of time. As we develop, seek to optimize, and operate the Ixo-vec manufacturing process, we will likely face technical and scientific challenges, considerable capital costs, and potential difficulty in recruiting and hiring experienced, qualified personnel. There may also be unexpected technical or operational issues during clinical manufacturing campaigns or process validation campaigns. For example, all Good Manufacturing Practices (&#8220;GMP&#8221;) activities at our Redwood City facility, and external manufacturing, testing, and distribution partners are subject to significant health authority regulation with respect to manufacturing and testing our product candidates. If we are unable to satisfy these regulatory requirements, or if we are unable to solve the technical, scientific, and other challenges described above, we may be unable to manufacture a sufficient supply of our product candidates for our clinical trials and may be forced to delay or terminate our development programs. Additionally, changes in manufacturing processes (including cell lines), equipment or facilities (including moving manufacturing or testing from one of our facilities to another one of our facilities or a third-party facility, or from a third-party facility to one of our facilities) may require us to conduct additional studies to demonstrate comparability in order to receive regulatory approval of any manufacturing modifications. As a result, we could experience manufacturing delays that prevent us from completing our clinical studies in a timely manner, if at all.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may revise the process that we used to manufacture Ixo-vec for our Phase 1 clinical trial. Before we use a revised process in future clinical trials, we must submit analytical comparability data to the FDA to demonstrate that the process changes have not altered Ixo-vec in a manner that undermines the applicability of the clinical data from our Phase 1 clinical trial. If the FDA does not find our analytical comparability data sufficient, the FDA could place our IND on clinical hold until we conduct additional nonclinical or clinical comparability studies demonstrating that the Ixo-vec manufactured by our revised process and our previous process are materially equivalent, which could substantially delay the development process. If we make further changes to the manufacturing process, equipment or facilities of Ixo-vec in the future, the FDA may require us to demonstrate comparability between Ixo-vec manufactured before and after the change. For example, the FDA could require comparability studies to demonstrate that Ixo-vec manufactured in its current facilities is comparable to Ixo-vec manufactured at future commercial supply sites.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not know whether any required comparability studies will begin as planned, will need to be restructured or will be completed on schedule, or at all. If the results of these comparability studies are not positive or are only modestly positive or if there are safety concerns, we may be delayed in obtaining marketing approval for Ixo-vec or not obtain marketing approval at all. Our product development costs also will increase if we experience delays in testing or regulatory approvals.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to produce sufficient quantities of our products at acceptable costs, we may be unable to meet clinical or potential commercial demand, lose potential revenue, have reduced margins, or be forced to terminate a program.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the complexity of manufacturing our products, we may not be able to manufacture sufficient quantities to meet clinical or potential commercial demand. Our inability to produce enough of a product meeting all release acceptance criteria at acceptable costs may cause us to be unable to meet clinical or potential commercial demand, to lose potential revenue, to have reduced margins, or to be forced to discontinue such product.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we develop, seek to optimize and operate the Ixo-vec manufacturing process, we will likely face technical and scientific challenges, considerable costs, and potential difficulty in recruiting and hiring experienced, qualified personnel. There may also be unexpected technical or operational issues during clinical or commercial manufacturing campaigns. As a result, we could experience manufacturing delays that prevent us from commercializing Ixo-vec, if approved, on a profitable basis, if at all.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our manufacturing processes will subject us to a variety of U.S. federal, state and local laws and regulations governing the use, generation, manufacture, storage, handling and disposal of hazardous materials and wastes resulting from their use, as well as comparable legislation and regulations outside of the U.S. We will incur significant costs in complying with these laws and regulations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gene therapy products are novel and complex and have only in limited cases been manufactured at scales sufficient for pivotal trials and commercialization. Few pharmaceutical contract manufacturers specialize in gene therapy products and those that do are still developing appropriate processes and facilities for large-scale production. If we are unable to secure adequate manufacturing capacity from our contract manufacturing partners, or if our currently contracted slots are cancelled or delayed in order to prioritize other projects, we may be unable to produce sufficient quantities of our product candidates for our development programs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our contractors are subject to significant regulation with respect to manufacturing and testing our product candidates. We have a limited number of vendors on which we rely, including, in some cases, single source vendors, and the contract vendors on which we rely may not continue to meet regulatory requirements, may have limited capacity, or may have other factors limiting their ability to comply with their contracts with us.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have relationships with a limited number of suppliers for the manufacturing and testing of our vector product candidates. Our suppliers may require licenses to manufacture or test such components if such processes are not owned by the suppliers or in the public domain, and we may be unable to transfer or sublicense the intellectual property rights we may have with respect to such activities, and may be unable to acquire such rights, to the extent that we do not already have them.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All entities involved in the preparation of therapeutics for clinical trials or commercial sale, including our existing contract vendors for our product candidates, are subject to extensive regulation. Components of a finished therapeutic product used in clinical trials or approved for commercial sale must be manufactured and tested in accordance with GMP regulations. These regulations govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of adventitious agents or other contaminants, or to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our contract manufacturers must supply all necessary documentation in support of a BLA on a timely basis and must adhere to the FDA&#8217;s GMP regulations enforced by the FDA through its facilities inspection program as well as other regulations enforced by other regulatory authorities outside the U.S. Our contract manufacturers have not produced a commercially-approved AAV product and therefore have not yet demonstrated compliance with GMP regulations to the satisfaction of the FDA or other regulatory authorities outside the U.S. Our facilities and quality systems and the facilities and quality systems of some or all of our third-party contractors must pass a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of our product candidates. If the facility does not pass a pre-approval plant inspection, the FDA or other regulatory approval of the products will not be granted. In addition, the regulatory authorities may, at any time, audit or inspect any manufacturing facility we may have or those of our third-party contractors involved with the preparation of our product candidates or the associated quality systems for compliance with the regulations applicable to the activities being conducted. Should the FDA or other regulatory authorities outside the U.S. determine that the facility is not in compliance with applicable regulations, the manufacture and release of our product candidates may not be possible, and our business could be harmed.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in laws and governmental policies may have an effect on regulations. For example, on January 31, 2020, the United Kingdom (&#8220;UK&#8221;) withdrew from the European Union (&#8220;EU&#8221;), commonly referred to as Brexit. Pursuant to the formal withdrawal arrangements agreed between the UK and the EU, the UK was subject to a transition period until December 31, 2020, or the Transition Period, during which EU rules continued to apply. The UK-EU Trade and Cooperation Deal, which has applied since the end of the Transition Period, provides for tariff-free trade of goods, but not services, between the UK and the EU, but there may however be additional non-tariff costs which did not exist prior to the end of the Transition Period. Further, should the UK further diverge from the EU from a regulatory perspective in relation to medical products, tariffs could be put into place in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the body of the UK-EU Trade and Cooperation Agreement includes general terms which apply to medicinal products, greater detail on sector-specific issues is provided in an Annex to the Agreement. The Annex provides a framework for the recognition of GMP inspections and for the exchange and acceptance of official GMP documents. The regime does not, however, extended to procedures such as batch release certification. Among the changes that will now occur are that Great Britain (England, Scotland and Wales) will be treated as a third country. Northern Ireland will, with regard to EU regulations, continue to follow the EU regulatory rules. As part of the UK-EU Trade and Cooperation Agreement, the EU and the UK will recognize GMP inspections carried out by the other Party and the acceptance of official GMP documents issued by the other Party. The UK-EU Trade and Cooperation Agreement also encourages, although it does not oblige, the parties to consult one another on proposals to introduce significant changes to technical regulations or inspection procedures. Among the areas of absence of mutual recognition are batch testing and batch release. The UK has unilaterally agreed to continue to accept EU batch testing and batch release, two years notice will be provided of any change to such a policy. However, the EU continues to apply EU laws that require batch testing and batch release to take place in the EU territory. This means that medicinal products that are tested and released in the UK must be retested and re-released when entering the EU market for commercial use. As regards marketing authorizations, Great Britain will have a separate regulatory submission process, approval process and a separate national MA. Northern Ireland will, however, continue to be covered by the marketing authorizations granted by the European Commission (&#8220;EC&#8221;).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are currently delays on cross-border trade between the UK and the EU as businesses and governmental bodies adapt to the arrangements. We and our contract vendors currently rely on other contractors based in the UK. The end of the Transition Period and implementation of new governmental policies associated with Brexit may affect our UK-based contractors&#8217; ability to comply with applicable regulations, including existing EU regulations. If they are unable to return to compliance, or if an acceptable substitute vendor cannot be identified, it may negatively impact our business. Further, to the extent that our UK-based contractors have supply relationships with vendors in the EU, these contractors may experience difficulties, delay or increased costs in receiving materials from their vendors in the EU, which could have a material adverse effect on our UK-based contractors&#8217; ability to provide the services or materials to us.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory authorities also may, at any time, inspect any manufacturing facility we may have or those of our third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations or if we become aware of a violation of our product specifications or applicable regulations, independent of an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time-consuming for us or a third party to implement and which may include the temporary or permanent suspension of a clinical trial or commercial sales or the temporary or permanent closure of a facility. Such violations could also result in civil and/or criminal penalties. Any such remedial measures or other civil and/or criminal penalties imposed upon us or third parties with whom we contract could materially harm our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our third-party contractors fail to maintain regulatory compliance, the FDA or other regulatory authorities outside the U.S. can impose regulatory sanctions including, among other things, refusal to approve a pending application for a new biologic product, revocation of a pre-existing approval, injunction, seizure of product, or other civil or criminal penalties or closing one or more manufacturing or testing facilities. As a result, our business, financial condition and results of operations may be materially harmed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if the service provided by an approved manufacturing or testing contractor is interrupted, there could be a significant disruption in commercial supply. Alternative contractors could need to be qualified through a BLA supplement which could result in further delay. The regulatory authorities may also require additional studies showing comparability between approved product or testing, and product or testing provided after a contractor change, if a new manufacturing or testing contractor is relied upon for commercial production. Changing contractors may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These factors could cause the delay of clinical trials, regulatory submissions, required approvals or commercialization of our product candidates, causing us to incur higher costs, and preventing us from commercializing our product candidates successfully. Furthermore, if our suppliers fail to meet contractual requirements, and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical trials may be delayed, or we could lose potential revenue.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to many manufacturing and distribution risks, any of which could substantially increase our costs and limit supply of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of manufacturing our product candidates is complex, highly regulated and subject to several risks, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Due to the complexity of manufacturing our product candidates, we may not be able to manufacture sufficient quantities to support our clinical trials. Delays in manufacture and supply by our contract manufacturing partners, including as a result of the COVID-19 pandemic, may also cause delays in their ability to supply the amount of our product that we have ordered and on which we have based our expected development timelines. Our inability to produce enough of a product candidate at acceptable costs may result in the delay or termination of development programs. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The manufacturing and distribution of biologics is extremely susceptible to product loss due to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error, or transportation or storage conditions of the product. Even minor deviations from prescribed manufacturing processes could result in reduced production yields, product defects, and other supply disruptions. If microbial, viral, or other contaminations are discovered in our product candidates or in the manufacturing facility in which our product candidates are made, such manufacturing facility may need to be closed for an extended period of time to investigate and remedy the contamination.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The manufacturing facilities in which our product candidates are made could be adversely affected by equipment failures, labor shortages, contaminants, raw materials shortages, natural disasters, power failures, and numerous other factors.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We and our contract manufacturers must comply with the FDA&#8217;s GMP regulations and guidelines. We and our contract manufacturers may encounter difficulties in achieving quality control and quality assurance and may experience shortages in qualified personnel. We and our contract manufacturers are subject to inspections by the FDA and comparable regulatory authorities in other jurisdictions to confirm compliance with applicable regulatory requirements. Any failure to follow GMP or other regulatory requirements or any delay, interruption, or other issues that arise in the manufacture, fill-finish, packaging, storage, or distribution of our product candidates as a result of a failure of our facilities, or the facilities or operations of third parties, to comply with regulatory requirements or pass any regulatory authority inspection could significantly impair our ability to develop and commercialize our product candidates. This may lead to significant delays in the availability of sufficient supply of the product candidate substance for our clinical trials or the termination or hold on a clinical trial, or the delay or prevention of a filing or approval of marketing applications for our product candidates.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Significant noncompliance could also result in the imposition of sanctions, including fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approvals for our product candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions, and criminal prosecutions, any of which could be costly and damage our reputation. If we are not able to maintain regulatory compliance, we may not be permitted to market our product candidates, if approved, and/or may be subject to product recalls, seizures, injunctions or criminal prosecution.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our product candidates are biologics and require processing steps that are more complex than those required for most chemical pharmaceuticals. Moreover, unlike chemical pharmaceuticals, the physical and chemical properties of a biologic such as our product candidates generally cannot be adequately characterized prior to manufacturing the final product. As a result, an assay of the finished product is not sufficient to ensure that the product will perform in the intended manner. Accordingly, we expect to employ multiple steps to attempt to control our manufacturing process and assure that the product or product candidate is made strictly and consistently in compliance with the process.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We continue to develop the manufacturing process for late-stage clinical product, and our current process has not been fully characterized and therefore is open to potential variations that could lead to defective product substance that does not meet specification.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Problems with the manufacturing, storage or distribution of our product candidates, including even minor deviations from our established parameters, could result in product defects or manufacturing failures that result in lot failures, product recalls, product liability claims and insufficient inventory.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Some of the raw materials required in our manufacturing process are derived from biological sources. Such raw materials are difficult to procure and may also be subject to contamination or recall. A material shortage, contamination, recall or restriction on the use of biologically derived substances in the manufacture of our product candidates could adversely impact or disrupt commercialization.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any adverse developments affecting manufacturing operations for our product candidates may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our product candidates. We may also have to take inventory write-offs and incur other charges and expenses for product that fails to meet specifications, undertake costly remediation efforts, or seek more costly manufacturing alternatives. We may encounter problems manufacturing sufficient research-, clinical-, or commercial-grade materials that meet FDA, EMA or other applicable standards or specifications with consistent and acceptable production yields and costs.</span></div><div><span><br/></span></div><div id="i26ccaa4e5746469982cbf0d18a526b99_124"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Reliance on Third Parties</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have relied, and expect to continue to rely, on third parties to conduct some or all aspects of our vector production, process development, assay development, product manufacturing, product testing, protocol development, and research, and these third parties may not perform satisfactorily.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect to independently conduct all aspects of our vector production, product manufacturing, product testing, protocol development, protocol performance, and research. We currently rely, and expect to continue to rely, on third parties with respect to these items. We may not be able to enter into agreements with these third parties and if we do enter into agreements with these third parties, any of these third parties may not be successful at fulfilling their contractual obligations or may choose to terminate their engagements with us at any time. If we need to enter into alternative arrangements, it could delay our product development activities. Our reliance on these third parties for vector production, process development, assay development, product manufacturing, product testing, protocol development, protocol performance, and research activities will reduce our control over these activities but will not relieve us of our responsibility to ensure compliance with all required regulations. If any of these third parties on which we rely do not perform satisfactorily, we will remain responsible for ensuring that:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">each of our nonclinical studies and clinical trials are conducted in accordance with the study plan and protocols and applicable regulatory requirements;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">vector production, product manufacturing, and product testing are conducted in accordance with applicable GMP requirements and other applicable regulatory requirements; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other research, process development, and assay development are conducted in accordance with applicable industry and regulatory standards and norms</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any of which we may not be able to do.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to rely on third-party manufacturers, which entails risks, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to negotiate manufacturing agreements with third parties under commercially reasonable terms;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced control as a result of using third-party manufacturers for some or all aspects of manufacturing activities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that is costly or damaging to us; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruptions to the operations of our third-party manufacturers or suppliers caused by conditions unrelated to our business or operations, including the acquisition, change in control, or bankruptcy of the manufacturer or supplier, or their commitments to COVID-19 vaccine and therapeutics production projects that may reduce available manufacturing capacity.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could lead to clinical trial delays or failure to obtain regulatory approval, or impact our ability to successfully commercialize future products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will rely on third parties to conduct some nonclinical testing and all of our planned clinical trials. If these third parties do not meet our deadlines or otherwise fail to conduct the trials as required, our clinical development programs could be delayed or unsuccessful and we may not be able to obtain regulatory approval for or commercialize our product candidates when expected or at all.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have the ability to conduct all aspects of our nonclinical testing, clinical testing, or clinical trials ourselves. We are dependent on third parties to conduct nonclinical studies and clinical trials for our product candidates, and, therefore, the timing of the initiation and completion of these studies or trials is controlled in part by these third parties and may occur at times substantially different from our estimates. Specifically, we use and rely on medical institutions, clinical investigators, contract research organizations (&#8220;CROs&#8221;) and consultants to conduct our trials in accordance with our clinical protocols and regulatory requirements. Our CROs, investigators and other third parties play a significant role in the conduct of these trials and subsequent collection and analysis of data.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no guarantee that any CROs, investigators or other third parties on which we rely for administration and conduct of our clinical trials will devote adequate time and resources to such trials or perform as contractually required. If any of these third parties fails to meet expected deadlines, fails to adhere to our clinical protocols, fails to meet regulatory requirements, or otherwise performs in a substandard manner, our clinical trials may be extended, delayed or terminated. If any of our clinical trial sites terminates for any reason, we may experience the loss of follow-up information on patients enrolled in our ongoing clinical trials unless we are able to transfer those patients to another qualified clinical trial site.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, the utility of certain data from the clinical trial may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of any IND or BLA we submit to the FDA, or equivalent submissions to other regulatory authorities outside the U.S. Any such delay or rejection could prevent us from commercializing our product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our reliance on third parties requires us to share our trade secrets and other confidential information, which increases the possibility that a competitor will discover them or that our confidential information, including trade secrets, will be misappropriated or disclosed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we rely on third parties to conduct research and to develop and manufacture our product candidates, we must, at times, share confidential information, including trade secrets, with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements containing confidentiality provisions with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that they become known by our competitors, are purposefully or inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Public disclosure of our confidential information also prevents us from seeking patent protection for that or related discoveries. Given that our proprietary position is based, in part, on our know-how and trade secrets, the unauthorized use or disclosure of our trade secrets would impair our competitive position and may have a material adverse effect on our business, financial conditions, results of operations and prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our confidential information and trade secrets, although our agreements may contain certain limited publication rights. For example, academic institution that we collaborate with often require rights to publish data arising out of such collaboration, provided that we are notified in advance and given the opportunity to delay publication for a limited time period in order for us to secure patent protection of intellectual property rights arising from the collaboration, in addition to the opportunity to remove confidential information or trade secrets from any such publication. However, we may fail to recognize or identify to our collaborator such confidential information or trade secrets during the appropriate timeframe prior to publication, and they may be publicly disclosed without us filing for patent or other protection. In the future we may also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development or similar agreements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, or publication of information by any of our third-party collaborators. A competitor&#8217;s discovery of our trade secrets could impair our competitive position and have an adverse impact on our business, financial condition, results of operations and prospects.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="i26ccaa4e5746469982cbf0d18a526b99_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Our Intellectual Property</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success depends on our ability to protect our intellectual property and our proprietary technologies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our ability to obtain and maintain patent protection and trade secret protection for our product candidates, proprietary technologies, and their uses as well as our ability to operate without infringing upon the proprietary rights of others. There can be no assurance that any of our product candidates will have patent protection, that our patent applications or those of our licensors will result in patents being issued or that issued patents, if any, will afford sufficient protection against competitors with similar technology, nor is there any assurance that the patents issued will not be infringed, designed around or invalidated by third parties. Issued patents may later be found unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. The degree of future protection for our proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. This failure to properly protect the intellectual property rights relating to our product candidates could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own and license certain composition-of-matter patents and applications covering components of our product candidates. Composition-of-matter patents on the biological or chemical active pharmaceutical ingredient are generally considered to be the strongest form of intellectual property protection for pharmaceutical products, as such patents provide protection without regard to any method of use. We cannot be certain that the claims in our patent applications covering composition-of-matter of any of our product candidates will be considered patentable by the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;) and courts in the U.S. or by the patent offices and courts in foreign countries, nor can we be certain that the claims in our issued composition-of-matter patents will not be found invalid or unenforceable if challenged.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own and license certain method-of-use patents and applications covering methods of treating certain diseases with our product candidates. Method-of-use patents protect the use of a product for the specified method or for treatment of a particular indication. However, methods of treating human diseases are considered unpatentable in many jurisdictions, and even where available this type of patent does not prevent a competitor from making and marketing a product that is identical to our product candidate for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products &#8220;off-label.&#8221; Although off-label prescriptions may infringe or contribute to the infringement of method-of-use patents, the practice is common and such infringement is difficult to prevent or prosecute.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our future development partners will be successful in protecting our product candidates by obtaining and defending patents. These risks and uncertainties include the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patent applications may not result in any patents being issued;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patents that may be issued or in-licensed may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patents may expire before or soon after the product they cover is commercialized;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitors, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with, or eliminate our ability to make, use, and sell our product candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the U.S. for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">countries other than the U.S. may have patent laws less favorable to patentees than those upheld by the U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we rely on the protection of our trade secrets and know-how. Although we have taken steps to protect our trade secrets and know-how, including entering into confidentiality agreements with third parties, and confidential information and inventions agreements with employees, consultants and advisors, we cannot provide any assurances that all such agreements have been duly executed, and third parties may still obtain this information or may come upon this or similar information independently.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade secrets do not provide any protection against the independent development of the trade secret by a competitor or other third party. If a competitor independently obtains or develops our trade secret, either by reverse engineering our product or other legal means, we would be unable to prevent them from using the trade secret, and our competitive position would be harmed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating our trade secrets. If any of these events occurs or if we otherwise lose protection for our trade secrets or proprietary know-how, the value of this information may be greatly reduced.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology industry has been characterized by frequent litigation regarding patent and other intellectual property rights. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. As the biotechnology industry expands, especially in the field of gene therapy, and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. Because patent applications are maintained in secrecy until the application is published, we may be unaware of third-party patents that may be infringed by commercialization of our product candidates. Moreover, because patent applications can take many years to issue, there may be currently-pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. Any claims of patent infringement asserted by third parties would be time consuming to defend against and could:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">result in costly litigation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">divert the time and attention of our technical personnel and management;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cause development delays;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prevent us from commercializing our product candidates until the asserted patent expires or is held finally invalid or not infringed in a court of law;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require us to develop non-infringing technology, which may not be possible on a cost-effective basis; or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Others may hold proprietary rights that could prevent our product candidates from being marketed. Any patent-related legal action against us claiming damages and seeking to enjoin commercial activities relating to our product candidate or processes could subject us to potential liability for damages and require us to obtain a license to continue to manufacture or market our product candidates. We cannot predict whether we would prevail in any such actions or that any license required under any of these patents would be made available on commercially acceptable terms, if at all. In addition, we cannot be sure that we could redesign our product candidate or processes to avoid infringement, if necessary. Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could prevent us from developing and commercializing our product candidates, which could harm our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have rights to intellectual property, through licenses from third parties and under patents that we own, to develop our product candidates. Because our programs may require the use of proprietary rights held by third parties, the growth of our business will depend in part on our ability to acquire, in-license, or use these proprietary rights. For example, our product candidates may require specific formulations to work effectively and efficiently and the rights to these formulations may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes, or other intellectual property rights from third parties that we identify as necessary for our product candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources, and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sometimes collaborate with U.S. and foreign academic institutions to accelerate our research or development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our program.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of that program and our business, financial condition, results of operations and prospects could be materially and adversely affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our rights to develop and commercialize our product candidates are subject in part to the terms and conditions of licenses granted to us by other companies and universities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently are heavily reliant upon licenses of certain patent rights and proprietary technology from third parties that are important or necessary to the development of our technology and products, including technology related to our manufacturing process and our gene therapy product candidates. These and other licenses may not provide adequate rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and products in the future, or may contain other limitations on our ability to use such intellectual property or technology. As a result, our ability to develop or commercialize our processes and product candidates may be limited by the terms of such agreements. Further, the third parties from whom we license certain patent rights and proprietary technology may attempt to terminate their agreements with us. For example, in 2019 we received from Virovek a notice of intent to terminate our non-exclusive license to certain Virovek technology and know-how related to methods and materials for manufacturing adeno-associated virus. Although no further action has been taken in that matter, it illustrates that if one of our licenses were to be terminated, we may be unable to obtain a new license to that technology on commercially reasonable terms, if at all.</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we need to develop or acquire alternative manufacturing technology, our product development activities may be significantly delayed, and if we were unable to develop or acquire alternative manufacturing technology, it could have a material adverse effect on our business. In addition, we may not be able to prevent competitors from developing and commercializing competitive products to the extent our licenses to patents are non-exclusive or limited with respect to fields of use or territories.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that licenses to additional third-party technology will be required to advance our current development programs, as well as additional development programs we may initiate in the future. If these licenses are not available on commercially reasonable terms or at all, we may not be able to commercialize our current and future development programs, which will have a material adverse effect on our business and financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The patent protection and patent prosecution for some of our product candidates are dependent on third parties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we normally seek to obtain the right to control the prosecution and maintenance of the patents relating to our product candidates, there may be times when the filing and prosecution activities for platform technology patents that relate to our product candidates are controlled by our licensors. For example, we do not have the right to prosecute and maintain the patent rights licensed to us under agreements with Regents of the University of California, Cornell University, and Virovek, and our ability to have input into such filing and prosecution activities is limited. If these licensors or any of our future licensors fail to appropriately prosecute and maintain patent protection for patents covering any of our product candidates, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents or other intellectual property. We require all employees to sign proprietary information and invention assignment agreements, but they may fail to do so, or our agreements may be found invalid or unenforceable. We may be subject to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third party patent rights could delay or otherwise adversely affect our planned development and sale of product candidates of our programs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of patent rights held by third parties that could be construed to cover certain aspects of our product candidates. In addition, changes to our product candidates or their uses or manufacture may cause them to infringe patents held by third parties. A patent holder has the right to prevent others from making, using, or selling a drug that incorporates the patented compositions while the patent remains in force. While we believe that third party patent rights will not affect our planned development, regulatory clearance, and eventual marketing, commercial production, and sale of our product candidates, there can be no assurance that this will be the case. In addition, the Hatch-Waxman exemption provided by U.S. patent law permits uses of compounds and biologics in clinical trials and for other purposes reasonably related to obtaining FDA approval of drugs and biologics that will be sold only after patent expiration, so our use of our product candidates in those FDA-related activities does not infringe any patent holder&#8217;s rights. However, were a patent holder to assert its rights against us before expiration of such patent holder&#8217;s patent for activities unrelated to seeking FDA approval, the development and ultimate sale of our product candidates could be significantly delayed, and we could incur the expense of defending a patent infringement suit and potential liability for damages for periods prior to the patent&#8217;s expiration.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to obtain intellectual property rights or protect our intellectual property rights throughout the world.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting, obtaining and defending patents on our product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the U.S. can be less extensive than those in the U.S. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the U.S. Further, following Russia&#8217;s invasion of Ukraine in February 2022, the U.S. government has levied sanctions against Russia and Belarus, Russia has issued a decree that removes protections for some patent holders who are registered in unfriendly countries, including the U.S., and the USPTO has terminated its engagement with officials from intellectual property agencies in Russia, Belarus and Eurasia, so we are not currently maintaining certain intellectual property filings in these jurisdictions. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S., or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the U.S. These products may compete with our product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing as patents and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded to us, if any, may not be commercially meaningful.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve a high degree of technological and legal complexity. Therefore, obtaining and enforcing biopharmaceutical patents is costly, time consuming and inherently uncertain. In addition, Congress may pass patent reform legislation that is unfavorable to us. The Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents we might obtain in the future.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain patent term extensions for patents covering our product candidates, our business may be materially harmed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent terms may not be able to protect our competitive position for an adequate period of time with respect to our current or future technologies or product candidates. Patents have a limited lifespan. In the U.S., if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. As a result, our owned and in-licensed patent portfolio provides us with limited rights that may not last for a sufficient period of time to exclude others from commercializing product candidates similar or identical to ours. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars. For example, given the large amount of time required for the research, development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Extensions of patent term may be available, but there is no guarantee that we would have patents eligible for extension, or that we would succeed in obtaining any particular extension&#8212;and no guarantee any such extension would confer patent term for a sufficient period of time to exclude others from commercializing product candidates similar or identical to ours. If we are able to secure FDA marketing approval for one of our product candidates that is covered by an issued U.S. patent, that patent may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984 (&#8220;Hatch-Waxman Act&#8221;). Depending upon the timing, duration and specifics of FDA marketing approval of product candidates, the Hatch-Waxman Act permits a patent restoration term of up to five years beyond the normal expiration of the patent, which is limited to the approved product or approved indication. In the United States, patent term extension cannot extend the remaining term of a patent beyond 14 years from the date of product approval; only one patent may be extended; and extension is available for only those claims covering the approved drug, a method for using it, or a method for manufacturing it. Similar extensions of patent term are available in Europe and other jurisdictions. However, we may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial conditions and results of operations may be materially and adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interpretation by the regulatory authorities in the EU of applicable EU regulations governing data and market exclusivity may impact our entitlement to data and market exclusivity. The revisions to the orphan drug legislation in the EU and the EU rules governing Supplementary Protection Certificates that are currently being discussed may also impact our entitlement to this exclusivity. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming, and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged administratively or in court.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or any of our future development partners were to initiate or threaten legal proceedings against a third party to enforce a patent directed at one of our product candidates, or one of our future product candidates, the accused infringer could claim that our patent is invalid and/or unenforceable in whole or in part. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, as are claims seeking declaratory judgment of invalidity. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a false or misleading statement during prosecution. Third parties may also raise similar claims before the USPTO, even outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on such product candidate. Such a loss of patent protection would have a material adverse impact on our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interference proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our defense of litigation or patent office proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research and development programs, license necessary technology from third parties, or enter into development or manufacturing partnerships that would help us bring our product candidates to market.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if resolved in our favor, litigation or other legal or patent office proceedings relating to our intellectual property rights may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some intellectual property that we have in-licensed may have been discovered through government funded programs and thus may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights, and limit our ability to contract with non-U.S. manufacturers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property rights we have licensed, including certain rights related to our proprietary AAV.7m8 capsid, were generated through the use of U.S. government funding and are therefore subject to certain federal regulations. As a result, the U.S. government may have certain rights to intellectual property embodied in our current or future product candidates pursuant to the Bayh-Dole Act of 1980, or Bayh-Dole Act, and implementing regulations. These U.S. government rights in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right to require us or our licensors to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (i) adequate steps have not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;). The U.S. government also has the right to take title to these inventions if we, or the applicable licensor, fail to disclose the invention to the government and fail to file an application to register the intellectual property within specified time limits. These time limits have recently been changed by regulation, and may change in the future. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us or the applicable licensor to expend substantial resources. In addition, the U.S. government requires that any products embodying the subject invention or produced through the use of the subject invention be manufactured substantially in the United States. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. manufacturers may limit our ability, or that of our sublicensees, to contract with non-U.S. product manufacturers for products covered by such intellectual property. To the extent any of our current or future intellectual property is generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may fail to comply with any of our obligations under existing agreements pursuant to which we license or have otherwise acquired intellectual property rights or technology, which could result in the loss of rights or technology that are material to our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Licensing of intellectual property is of critical importance to our business and involves complex legal, business, and scientific issues. Disputes may arise regarding our rights to intellectual property licensed to us from a third party, including but not limited to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sublicensing of patent and other rights;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our diligence obligations under the license agreement, what activities satisfy those diligence obligations, and to what extent those obligations are relieved or delayed by external factors beyond our control, such as the COVID-19 pandemic;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ownership of inventions and know-how resulting from the creation or use of intellectual property by us, alone or with our licensors and collaborators;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope and duration of our payment obligations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our rights upon termination of such agreement; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope and duration of exclusivity obligations of each party to the agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If disputes over intellectual property and other rights that we have licensed or acquired from third parties prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may be able to make gene therapies that are similar to our product candidates but that are not covered by the claims of any patents that we own or have exclusively licensed;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our licensors or future collaborators might not have been the first to make the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our licensors or future collaborators might not have been the first to file patent applications covering certain of our inventions;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any patent applications that we have filed or may file in the future may not lead to issued patents;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any of the issued patents that we own or have exclusively licensed may be held invalid or unenforceable, as a result of legal challenges by our competitors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any of the issued patents that we have filed or may file in the future may expire before or shortly after commercialization of the covered product;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitors might conduct research and development activities in countries where, or for products for which, we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop additional proprietary technologies that are patentable; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patents of others may have an adverse effect on our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should any of these events occur, they could significantly harm our business, financial condition, results of operations and prospects.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is common in the biotechnology and pharmaceutical industry, in addition to our employees, we engage the services of consultants to assist us in the development of our product candidates. Many of our employees and consultants were previously employed at, or may have previously provided or may be currently providing consulting services to, other biotechnology or pharmaceutical companies including our competitors or potential competitors. We may become subject to claims that our company, our employees or a consultant inadvertently or otherwise used or disclosed trade secrets or other information proprietary to their former employers or their former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could materially and adversely impact our business, financial condition, results of operations, or prospects.</span></div><div><span><br/></span></div><div id="i26ccaa4e5746469982cbf0d18a526b99_130"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Commercialization of Our Product Candidates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any suspension of, or delays in the commencement or completion of, clinical trials for our product candidates could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before we can initiate clinical trials in the U.S. for our product candidates, we need to submit the results of nonclinical testing to the FDA, along with other information including information about product candidate chemistry, manufacturing and controls and our proposed clinical trial protocol, as part of an IND. We may rely in part on nonclinical, clinical and quality data generated by CROs and other third parties for regulatory submissions for our product candidates. If these third parties do not provide timely data for our product candidates, it will delay our plans for our IND submissions and clinical trials. If those third parties do not make this data available to us, we will likely have to develop all necessary nonclinical and clinical data on our own, which will lead to significant delays and increase development costs of the product candidate. In addition, the FDA may require us to conduct additional nonclinical testing for any product candidate before it allows us to initiate clinical testing under any IND, or at any stage of clinical development based on concerns that arise as the clinical program progresses or if significant manufacturing change are made to the product during the program, which may lead to additional delays and increase the costs of our nonclinical development. Delays with any regulatory authority or agency may significantly affect our product development timeline. Delays in the commencement or completion of any clinical trials that we plan for our product candidates could significantly affect our product development costs. We do not know whether any clinical trials that we plan will begin on time or be completed on schedule, if at all. The commencement and completion of clinical trials can be delayed or terminated for a number of reasons, including delays or terminations related to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or other regulatory authorities outside the U.S. failing to grant permission to proceed or placing the clinical trial on hold;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patients failing to enroll or remain in our trial at the rate we expect;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patients choosing an alternative treatment for the indication for which we are developing our product candidates, or participating in competing clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of adequate funding to continue the clinical trial;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patients experiencing severe or unexpected drug-related adverse effects;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a facility manufacturing any of our product candidates or any of their components being ordered by the FDA or other government or regulatory authorities outside the U.S. to temporarily or permanently shut down due to violations of GMP or other applicable requirements, or infections or cross-contaminations of product candidates in the manufacturing process, or in the manufacturing facilities in which our product candidates are made;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any changes to our manufacturing process that may be necessary or desired;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, lacking the ability or resources to appropriately handle our product candidates, not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, Good Clinical Practice or regulatory requirements, or other third parties not performing data collection or analysis in a timely and accurate manner;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inspections of clinical trial sites by the FDA or other regulatory authorities outside the U.S., or the finding of regulatory violations by the FDA or other regulatory authorities outside the U.S., or an IRB that require us to undertake corrective action, result in suspension or termination of one or more clinical sites or the imposition of a clinical hold on the IND or that prohibit us from using some or all of the data in support of our marketing applications;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities outside the U.S. for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications; or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">one or more IRBs refusing to approve, suspending or terminating the trial at a clinical site, precluding enrollment of additional patients, or withdrawing its approval of the trial.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product development costs will increase if we have delays in testing or approval of any of our product candidates, or if we need to perform more or larger clinical trials than planned. Additionally, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to reflect these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for review and approval, which may impact the costs, timing or successful completion of a clinical trial. If we experience delays in completion of our clinical trials, or if we, the FDA or other regulatory authorities outside the U.S., the IRB, other reviewing entities, or any of our clinical trial sites suspend or terminate any of our clinical trials, the commercial prospects for our product candidate may be harmed and our ability to generate product revenue may be delayed. In addition, many of the factors that cause, or lead to, termination or suspension of, or a delay in the commencement or completion of, clinical trials, may also ultimately lead to the denial of regulatory approval of a product candidate. If we make manufacturing or formulation changes to our product candidates, we may need to conduct additional studies to bridge our modified product candidates to earlier versions. Further, if one or more clinical trials are delayed or terminated, our competitors may be able to bring products to market before we do, and the commercial viability of our product candidates could be significantly reduced.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Final marketing approval for our product candidates by the FDA or other regulatory authorities outside the U.S. for commercial use may be delayed, limited or denied, any of which would adversely affect our ability to generate operating revenue.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are able to successfully complete our clinical trials and submit a BLA, and/or an MAA, we cannot predict whether or when we will obtain regulatory approval to commercialize our product candidates, and we cannot, therefore, predict the timing of any future revenue. We cannot commercialize our product candidates until the appropriate regulatory authorities have reviewed and approved the applicable applications. We cannot assure you that the regulatory authorities will complete their review processes in a timely manner or that we will obtain regulatory approval for our product candidates. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action or changes in policies from the FDA or other regulatory authorities outside the U.S. during the period of product development, clinical trials and FDA regulatory review. If marketing approval for any product candidate is delayed, limited or denied, our ability to market the product candidate, and our ability to generate product sales, would be adversely affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we receive regulatory approval, we still may not be able to successfully commercialize any of our product candidates, and the revenue that we generate from its sales, if any, could be limited.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if any of our product candidates receive regulatory approval, they may not gain market acceptance among physicians, patients, healthcare payers or the medical community. Coverage and reimbursement of our product candidates by third-party payers, including government payers, is also generally necessary for commercial success. The degree of market acceptance of our product candidates will depend on a number of factors, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">demonstration of clinical efficacy, including duration of efficacy, and safety compared to other more-established products;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the limitation of our targeted patient population and other limitations or warnings contained in any labeling approved for our products by the FDA or other applicable regulatory authorities outside the U.S., including the possible inclusion of a &#8220;black box warning&#8221; from the FDA or other applicable regulatory authorities outside the U.S. alerting health care providers to potential serious side effects associated with using a product or the imposition of a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;);</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of new therapeutic options by health care providers and their patients;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any adverse effects;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new procedures or methods of treatment that may be more effective in treating or may reduce the incidences of wet AMD, or other conditions that our product candidates are intended to treat;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pricing and cost-effectiveness;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of our or any future collaborators&#8217; sales and marketing strategies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain sufficient third-party coverage and reimbursement from government health care programs, including Medicare and Medicaid, private health insurers and other third-party payers;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unfavorable publicity relating to the product candidate; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of patients to pay out-of-pocket in the absence of third-party coverage and reimbursement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any product candidate is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payers or patients, we may not generate sufficient revenue from that product candidate and may not become or remain profitable. Our efforts to educate the medical community and third-party payers on the benefits of such a product candidate may require significant resources and may never be successful. In addition, our ability to successfully commercialize any of our product candidates will depend on our ability to manufacture our products, differentiate our products from competing products and defend and enforce our intellectual property rights relating to our products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our competitors develop treatments for the target indications of our product candidates that are approved, marketed more successfully, or demonstrated to be safer or more effective or easier to administer than our product candidates, our commercial opportunity will be reduced or eliminated.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in highly competitive segments of the biopharmaceutical markets. We face competition from many different sources, including larger and better-funded pharmaceutical, specialty pharmaceutical, biotechnology, and gene therapy companies, as well as from academic institutions, government agencies and private and public research institutions. Our product candidates, if successfully developed and approved, will compete with established therapies as well as with new treatments that may be introduced by our competitors. There are a variety of drug candidates and gene therapies in development or being commercialized by our competitors for the indications that we intend to test. Many of our competitors have significantly greater financial, product candidate development, manufacturing, and marketing resources than we do. Large pharmaceutical and biotechnology companies have extensive experience in clinical testing and obtaining regulatory approval for drugs. In addition, universities and private and public research institutes may be active in our target disease areas, and some could be in direct competition with us. We also may compete with these organizations to recruit management, scientists, and clinical development personnel. We will also face competition from these third parties in establishing clinical trial sites, registering patients for clinical trials, and in identifying and in-licensing new product candidates. For example, REGENXBIO is developing RGX-314, an AAV-based gene therapy delivering a gene encoding a therapeutic antibody fragment similar to ranibizumab (LUCENTIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for the treatment of wet AMD and diabetic retinopathy, which competes for the same patients, study site resources, and personnel as Ixo-vec. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New developments, including the development of other biotechnology and gene therapy technologies and methods of treating disease, occur in the pharmaceutical, biotechnology and gene therapy industries at a rapid pace. Developments by competitors may render our product candidates obsolete or noncompetitive. Competition in drug development is intense. In addition, we believe that duration of efficacy is an important consideration by physicians and patients when choosing a therapy. However, we do not know and may not know prior to any potential approval the duration of efficacy of our product candidates. We anticipate that we will face intense and increasing competition as new treatments enter the market and advanced technologies become available.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain regulatory approval for our product candidates, the availability and price of our competitors&#8217; products could limit the demand, and the price we are able to charge, for our product candidates. For example, LUCENTIS and EYLEA are currently available in the U.S. for treatment of wet AMD. We will not achieve our business plan if the acceptance of our product candidates is inhibited by price competition or the reluctance of physicians to switch from existing methods of treatment to our product candidates, or if physicians switch to other new drug products or choose to reserve our product candidates for use in limited circumstances. Our inability to compete with existing or subsequently introduced drug products or other therapies would have a material adverse impact on our business, prospects, financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our potential competitors in these diseases may be developing novel therapies that may be safer or more effective or easier to administer than our product candidates. For example, if we continue clinical development of, and seek to commercialize, Ixo-vec for the treatment of wet AMD, it will compete with a variety of therapies currently marketed and in development for wet AMD, using therapeutic modalities such as biologics, small molecules, long-acting delivery devices and gene therapy. LUCENTIS and EYLEA are anti-VEGF therapies that are well established and widely accepted by physicians, patients and third-party payers as the standard of care for the treatment of wet AMD. There are several other companies with marketed products or products in development for the treatment of wet AMD, including 4D Molecular Therapeutics, Bayer, Graybug Vision, Hoffmann-La Roche Ltd., Kodiak Sciences, Novartis, Opthea, Regeneron and REGENXBIO. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we obtain marketing approval for any of our product candidates, they could be subject to restrictions or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if U.S. regulatory approval is obtained, the FDA may still impose significant restrictions on a product&#8217;s indicated uses, marketing or distribution or impose ongoing requirements for potentially costly and time-consuming post-approval studies, post-market surveillance or clinical trials. Following approval, if at all, of any of our product candidates, such candidate will also be subject to ongoing FDA requirements governing the labeling, packaging, storage, distribution, safety surveillance, advertising, promotion, recordkeeping and reporting of safety and other post-market information. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities outside the U.S. for compliance with GMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents. If we or a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility or us, including requesting recall or withdrawal of the product from the market or suspension of manufacturing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or the manufacturing facilities for any product candidate that may receive regulatory approval fail to comply with applicable regulatory requirements, a regulatory agency may:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issue warning letters or untitled letters;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek an injunction or impose civil or criminal penalties or monetary fines;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend or withdraw regulatory approval;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend any ongoing clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refuse to approve pending applications or supplements or applications filed by us;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">institute import holds;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend or impose restrictions on operations, including costly new manufacturing requirements; or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seize or detain products, refuse to permit the import or export of product or request us to initiate a product recall.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue. The FDA has the authority to require a REMS plan as part of a BLA or after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug, such as limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria and requiring treated patients to enroll in a registry.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if any of our product candidates is approved, our product labeling, advertising and promotion would be subject to regulatory requirements and ongoing regulatory review. The FDA and other regulatory authorities outside the U.S. strictly regulate the promotional claims that may be made about prescription products. In particular, a product may not be promoted for uses that are not approved by the competent regulatory authority as reflected in the product&#8217;s approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability. The FDA and regulatory and enforcement authorities outside the U.S. actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant sanctions. The U.S. federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or be subject to permanent injunctions under which specified promotional conduct is changed or curtailed.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates profitably.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market acceptance and sales of our product candidates will depend significantly on the availability of adequate coverage and reimbursement from third-party payers for any of our product candidates and may be affected by existing and future health care reform measures. Government authorities and third-party payers, such as private health insurers and health maintenance organizations, decide which drugs they will pay for and establish reimbursement levels.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursement by a third-party payer may depend upon a number of factors including the third-party payer&#8217;s determination that use of a product candidate is:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a covered benefit under its health plan;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">safe, effective and medically necessary;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">appropriate for the specific patient; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cost-effective.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining coverage and reimbursement approval for a product candidate from a government or other third-party payer is a time-consuming and costly process that could require us to provide supporting scientific, clinical and cost effectiveness data for the use of the applicable product candidate to the payer. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. While there is no uniform coverage and reimbursement policy among payers in the United States, private payers often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. We cannot be sure that coverage or adequate reimbursement will be available for any of our product candidates. Further, reimbursement amounts may reduce the demand for, or the price of, our product candidates. If reimbursement is not available or is available only in limited levels, we may not be able to commercialize certain of our product candidates profitably, or at all, even if approved.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of cell and gene therapy products recently have been approved by the FDA. Although the U.S. Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) approved its first method of coverage and reimbursement for one such product, the methodology has been subject to challenge by members of Congress. CMS&#8217;s decision as to coverage and reimbursement for one product does not mean that all similar products will be eligible for analogous coverage and reimbursement. As there is no uniform policy for coverage and reimbursement amongst third-party payers in the United States, even if CMS approves coverage and reimbursement for any of our product candidates, it is unclear what affect, if any, such a decision will have on our ability to obtain and maintain coverage and adequate reimbursement from other private payers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payers are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. In order to obtain coverage and reimbursement for any product that might be approved for sale, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain regulatory approvals. Our product candidates may not be considered medically necessary or cost-effective. If third-party payers do not consider a product to be cost-effective compared to other available therapies, they may not cover the product after approval as a benefit under their plans. or, if they do, the level of payment may not be sufficient to allow the company to sell its products at a profit. The United States government, state legislatures, and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid health care costs, including price controls, restrictions on reimbursement, and requirements for substitution of generic products for branded prescription drugs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By way of example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the &#8220;Affordable Care Act&#8221;), was enacted with a goal of reducing the cost of healthcare and substantially changing the way healthcare is financed by both government and private insurers. The Affordable Care Act, among other things, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program, extended the rebate program to individuals enrolled in Medicaid managed care organizations and established annual fees and taxes on manufacturers of certain prescription drugs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain provisions of the Affordable Care Act have been subject to executive, Congressional, and judicial challenges as well as efforts to repeal, replace, or otherwise modify them or alter their interpretation and implementation. For example, the Tax Cuts and Jobs Act of 2017 included a provision that repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; Additionally, on June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the Affordable Care Act is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the Affordable Care Act will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the Affordable Care Act marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including, among others, policies that undermine protections for people with pre-existing conditions, demonstrations and waivers under Medicaid and the Affordable Care Act that may reduce coverage or undermine the programs thereunder, including work requirements, and policies that make it more difficult to access health benefits through Medicaid or the Affordable Care Act. Additional legislative changes, regulatory changes, and judicial challenges related to the Affordable Care Act remain possible. Any such changes could affect the number of individuals with health coverage. It is possible that the Affordable Care Act, as currently enacted or as it may be amended in the future, and other healthcare reform measures that may be adopted in the future could have a material adverse effect on our industry generally and on our ability to successfully commercialize our product candidates, if approved.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have also been proposed and adopted in the U.S. since the Affordable Care Act was enacted. For example, on August 2, 2011, the Budget Control Act of 2011 created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This included aggregate reductions of Medicare payments to providers of, on average, 2% per fiscal year, which went into effect on April 1, 2013 and due to subsequent legislative changes to the statute, will stay in effect through 2030 unless additional congressional action is taken. However, COVID-19 relief support legislation suspended the 2% Medicare sequester from May 1, 2020, through March 31, 2022. Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 3% in the final fiscal year of this sequester. Further, Congress is considering additional health reform measures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These cost reduction initiatives could decrease the coverage and reimbursement that we receive for any approved products and could seriously harm our business. The Biden administration expressed its intent to pursue certain policy initiatives to reduce drug prices. For example, in July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, Health and Human Services (&#8220;HHS&#8221;) released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. No legislation or administrative actions have been finalized to implement these principles.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that additional healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal, state and foreign governments will pay for healthcare products and services, which could result in reduced demand for our product candidates, if approved, or additional pricing pressures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The continuing efforts of the government, insurance companies, managed care organizations and other payers of healthcare services to contain or reduce costs of health care may adversely affect:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the demand for any product candidates for which we may obtain regulatory approval;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to set a price that we believe is fair for our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to generate revenue and achieve or maintain profitability;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of taxes that we are required to pay; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of capital.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that additional governmental action could be taken in response to the COVID-19 pandemic, and that such action could affect our business. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">If the market for our product candidate, if approved, in the treatment of wet AMD or any other indication we seek to treat is smaller than we believe it is, or if our product candidate is approved with limitations that reduce the market size, our future revenue may be adversely affected, and our business may suffer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are advancing the development of Ixo-vec for the treatment of wet AMD, a disease we believe to be the most common cause of vision loss in adults over the age of 50 in developed countries. If the size of the market for wet AMD or any other indication we seek to treat is smaller than we anticipate (including in our rare disease programs), we may not be able to achieve profitability and growth. Our projections of the number of people who have wet AMD and other indications, as well as the subset of people with the disease who have the potential to benefit from treatment with Ixo-vec or other future product candidates, are based on estimates. These estimates have been derived from a variety of sources, including the scientific literature, surveys of clinics, patient foundations and market research and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of patients may turn out to be lower than expected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effort to identify patients with diseases we seek to treat is in early stages as we conduct the OPTIC trial of Ixo-vec for the treatment of wet AMD, and we cannot accurately predict the number of patients for whom treatment might be possible or whether the FDA or other regulatory authorities may approve indications for Ixo-vec that are more limited than we expect due to efficacy or safety concerns. For example, some patients have neutralizing antibodies at titer levels that may prevent them from benefiting from Ixo-vec. If this patient population is larger than we estimate, the market for Ixo-vec may be smaller than we anticipate, and our future revenue may be adversely affected. In addition, we expect prophylactic steroid treatment will be required to manage inflammation associated with treatment with Ixo-vec, and certain patients cannot be treated with prophylactic steroids. If this proportion of patient population is larger than we estimate, the market for Ixo-vec may be smaller than we anticipate. Additionally, the potentially addressable patient population may be limited or may not be amenable to treatment with our product candidates for other reasons, and new patients may become increasingly difficult to identify or gain access to, which would adversely affect our results of operations and our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, even if we obtain significant market share for any of our rare disease programs, because the potential target population is very small, we may never achieve profitability despite obtaining such significant market share.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, because the target patient population for any of our rare disease programs is relatively small, the pricing and reimbursement of these product candidates, if approved, must be adequate to support commercial infrastructure. If we are unable to obtain adequate levels of reimbursement, our ability to successfully market and sell any of our product candidates targeting such rare disease will be adversely affected. The manner and level at which reimbursement is provided for services related to this product candidate (e.g., for administration of such product to patients) is also important. Inadequate reimbursement for such services may lead to physician resistance and adversely affect our ability to market or sell our product candidates targeting such rare disease.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not achieve our projected development goals in the time frames we announce and expect, the commercialization of our product candidates, if approved, may be delayed and the credibility of our management team may be adversely affected and, as a result, our stock price may decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we estimate the timing of the accomplishment of various scientific, clinical, regulatory and other product development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of, or the availability of data from, scientific studies and clinical trials and the submission of regulatory filings. From time to time, we may publicly announce the expected timing of some of these milestones. All of these milestones will be based on a variety of assumptions. The actual timing of these milestones can vary dramatically compared to our estimates, in some cases for reasons beyond our control. If we do not meet these milestones as publicly announced, the commercialization of our products may be delayed and the credibility of our management team may be adversely affected and, as a result, our stock price may decline.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Due to the novel nature of our technology and the potential for our product candidates to offer therapeutic benefit in a single administration, we face uncertainty related to pricing and reimbursement for these product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are designed to provide potential therapeutic benefit after a single administration and, therefore, the pricing and reimbursement of our product candidates, if approved, must be adequate to support commercial infrastructure. If we are unable to obtain adequate levels of reimbursement, our ability to successfully market and sell our product candidates will be adversely affected. The manner and level at which reimbursement is provided for services related to our product candidates (e.g., for administration of our product to patients) is also important. Inadequate reimbursement for such services may lead to physician resistance and adversely affect our ability to market or sell our product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in establishing and maintaining development or other strategic collaborations, which could adversely affect our ability to develop and commercialize product candidates and receive milestone and/or royalty payments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into development or other strategic collaborations with biotechnology and pharmaceutical companies in the past and may do so again in the future. Research activities under our collaboration agreements are subject to mutually agreed-on research plans and budgets, and if we and our strategic partners are unable to agree on the research plan or research budget in a timely fashion or at all, performance of research activities will be delayed. In addition, some of our strategic partners may terminate any agreements they enter into with us or allow such agreements to expire by their terms. If we fail to maintain our current or future strategic collaborations, we may not realize milestone and royalty payments or other revenues under the collaboration agreements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Governments may impose price controls, which may adversely affect our future profitability.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to seek approval to market our product candidates in both the U.S. and in foreign jurisdictions. If we obtain approval in one or more jurisdictions, we will be subject to rules and regulations in those jurisdictions relating to our product candidates. In some countries, including Member States of the European Economic Area (&#8220;EEA&#8221;), the pricing of prescription pharmaceuticals is subject to governmental control. Additional countries may adopt similar approaches to the pricing of prescription drugs. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product candidate. There can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after coverage and reimbursement have been obtained. Reference pricing used by various countries and parallel distribution, or arbitrage between low-priced and high-priced countries, can further reduce prices. Publication of discounts by third-party payers or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of our future products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, we may be unable to achieve or sustain profitability.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may form strategic alliances in the future, and we may not realize the benefits of such alliances.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may form strategic alliances, create joint ventures or collaborations, or enter into licensing arrangements with third parties that we believe will complement or augment our existing business, including for the continued development or commercialization of our product candidates. These relationships or those like them may require us to incur non-recurring and other charges, increase our near-and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because third parties may view the risk of failure in future clinical trials as too significant, or the commercial opportunity for our product candidate as too limited. We cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such transaction. Even if we are successful in our efforts to establish development partnerships, the terms that we agree upon may not be favorable to us, and we may not be able to maintain such development partnerships if, for example, development or approval of a product candidate is delayed or sales of an approved product candidate are disappointing. Any delay in entering into development partnership agreements related to our product candidates could delay the development and commercialization of our product candidates and reduce their competitiveness if they reach the market.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have no sales, marketing or distribution capabilities, and we would have to invest significant resources to develop these capabilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no internal sales, marketing, or distribution capabilities. If any of our product candidates ultimately receive regulatory approval, we may not be able to effectively market and distribute the product candidate. We would have to invest significant amounts of financial and management resources to develop internal sales, distribution and marketing capabilities, some of which will be committed prior to any confirmation that any of our product candidates will be approved, if at all. We may not be able to hire consultants or external service providers to assist us in sales, marketing and distribution functions on acceptable financial terms or at all. Even if we determine to perform sales, marketing and distribution functions ourselves, we could face a number of additional related risks, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to attract and build an effective marketing department or sales force;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of establishing a marketing department or sales force may exceed our available financial resources and the revenue generated by any product candidates that we may develop, in-license or acquire; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our direct sales and marketing efforts may not be successful.</span></div><div><span><br/></span></div><div id="i26ccaa4e5746469982cbf0d18a526b99_133"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Negative public opinion and increased regulatory scrutiny of gene therapy and genetic research may damage public perception of our product candidates or adversely affect our ability to conduct our business or obtain marketing approvals for our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public perception may be influenced by claims that gene therapy is unsafe, and gene therapy may not gain the acceptance of the public or the medical community. In particular, our success will depend upon physicians specializing in the treatment of those diseases that our product candidates target prescribing treatments that involve the use of our product candidates in lieu of, or in addition to, existing symptomatic treatments they are already familiar with and for which greater clinical data may be available.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More restrictive government regulations or negative public opinion would have a negative effect on our business or financial condition and may delay or impair the development and commercialization of our product candidates or demand for any products we may develop. Trials using early versions of retroviral vectors, which integrate into, and thereby alter, the host cell&#8217;s DNA, have led to several well-publicized adverse events. Although none of our current product candidates utilize retroviruses and we believe AAVs used in our product candidates have low-integrating potential and are not known to cause disease in humans, our product candidates do use a viral vector delivery system. The risk of serious adverse events, such as the dose-limiting toxicity at the 6E11 dose tested in our INFINITY trial, remains a concern for gene therapy and we cannot assure that it will not occur in any of our current or future clinical trials. In addition, there is the potential risk of delayed adverse events following exposure to gene therapy products due to persistent biological activity of the genetic material or other components of products used to carry the genetic material.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse events in trials or studies conducted by us or other parties, in particular involving the same or similar AAV serotypes to the ones we are using, even if not ultimately attributable to our product candidates or to an AAV serotype that we employ, and resulting publicity, could result in increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our product candidates, stricter labeling requirements for those product candidates that are approved and a decrease in demand for any such product candidates. Similarly, our lead product candidate, ADVM&#8209;022 expresses the aflibercept protein, which is also the active component in EYLEA. If safety or efficacy issues occur relating to EYLEA, even if not ultimately attributable to aflibercept, this may negatively impact our product candidate. If any such adverse events or issues occur, development and commercialization of our product candidates or advancement of any potential clinical trials could be halted or delayed, which would have a material adverse effect on our business and operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on the services of our key executives and clinical and scientific staff, and if we are not able to retain these members of our management or recruit additional management, clinical and scientific personnel, our business will suffer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on the principal members of our management, clinical and scientific staff. The loss of service of any of our management or clinical or scientific staff could harm our business. In addition, we are dependent on our continued ability to attract, retain and motivate highly qualified additional management, clinical and scientific personnel. If we are not able to retain our management, and to attract, on acceptable terms, additional qualified personnel necessary for the continued development of our business, we may not be able to sustain our operations or grow. Although we have executed employment agreements with each member of our current executive management team, these agreements are terminable at will with or without notice and, therefore, we may not be able to retain their services as expected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to attract or retain qualified management, scientific and clinical personnel in the future due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses, particularly in the San Francisco Bay Area. Our industry has experienced a high rate of turnover of management and scientific personnel in recent years. If we are not able to attract, retain and motivate necessary personnel to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we do not currently maintain &#8220;key person&#8221; life insurance on the lives of our executives or any of our employees. This lack of insurance means that we may not have adequate compensation for the loss of the services of these individuals.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our restructuring and the associated headcount reduction may not result in anticipated savings, could result in total costs and expenses that are greater than expected and could disrupt our business. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, we implemented a restructuring of operations, including reductions in both headcount and expenses. We may not realize, in full or in part, the anticipated benefits, savings and improvements in our cost structure from our restructuring efforts due to unforeseen difficulties, delays or unexpected costs. If we are unable to realize expected operational efficiencies and the cost savings from the restructuring, our operating results and financial condition would be adversely affected. Due to our restructuring, we may not be able to effectively manage our operations or retain qualified personnel, which may result in weaknesses to our infrastructure and operations, increased risk that we may be unable to comply with legal and regulatory requirements, increased risks to our internal controls and disclosure controls, and loss of employees and reduced productivity among remaining employees.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The restructuring resulted in the loss of institutional knowledge and expertise and the reallocation of and combination of certain roles and responsibilities across the organization, all of which could adversely affect our operations. Further, the restructuring and possible additional cost-containment measures may yield unintended consequences, such as attrition beyond our intended workforce reduction and reduced employee morale. We may be required to rely more heavily on temporary or part-time employees, third party contractors and consultants to assist with managing our operations. These consultants are not our employees and may have commitments to, or consulting or advisory contracts with, other entities that may limit their availability to us. We will have only limited control over the activities of these consultants and can generally expect these individuals to devote only limited time to our activities. Failure of any of these persons to devote sufficient time and resources to our business could harm our business. Employee litigation related to the headcount reduction could be costly and prevent management from fully concentrating on the business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our management is unable to successfully manage this transition and restructuring activities, our expenses may be more than expected and we may be unable to fund our Ixo-vec development plan or implement our business strategy. As a result, our business, prospects, financial condition and results of operations could be negatively affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may encounter difficulties in managing our growth and expanding our operations successfully.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will need to grow our organization, or certain functions within our organization, substantially to continue development and pursue the potential commercialization of our product candidates, as well as function as a public company. As we seek to advance our product candidates, we may need to expand our financial, development, regulatory, manufacturing, marketing and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales capabilities or contract with third parties to provide these capabilities for us. As our operations expand, we expect that we will need to manage additional relationships with various strategic partners, suppliers and other third parties. Future growth will impose significant added responsibilities on members of management and require us to retain or otherwise manage additional internal capabilities. Our future financial performance and our ability to commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To that end, we must be able to manage our development efforts and clinical trials effectively and hire, train and integrate any additional management, clinical and regulatory, financial, administrative and sales and marketing personnel. We may not be able to accomplish these tasks, and our failure to accomplish them could prevent us from successfully growing our company.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Russia&#8217;s invasion of Ukraine and current adverse economic conditions could adversely affect our revenue, financial condition, or results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global disruption to, and potential impacts on, the health of the global economy arising from, related to, or resulting from Russia&#8217;s invasion of Ukraine in February 2022 could affect our business and operations. For example, the credit and financial markets may be adversely affected by the war and measures taken in response thereto, potentially impacting our ability to raise adequate additional capital when needed or on favorable terms. In addition, current economic conditions, such as recent global supply chain disruptions, labor shortages and inflation, may adversely impact our operations, for example by increasing our costs, disrupting our suppliers&#8217; ability to provide us with materials and supplies needed for both our manufacturing and clinical trials, or causing delays to our clinical trial and manufacturing timelines, which may negatively impact our business. These economic conditions make it more difficult for us to accurately forecast and plan our future business activities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The coronavirus (&#8220;COVID-19&#8221;) pandemic has impacted our business practices and the effects of its continued impact on our business, results of operations, and financial condition will depend on future developments, which cannot be predicted. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic and the emergence of new variants has caused us to modify our business practices (including the adoption of a hybrid mix of virtual and in-person work, updating our policies and implementing new practices to align with guidance from state and federal governments and health authorities). We believe these measures and others have not allowed us to eliminate the effects and risks on our on-site operations posed by the COVID-19 pandemic, so we may take further actions that may be required by government authorities or that we determine are in the best interests of our employees, customers, and business partners. We are uncertain that such measures will be sufficient to mitigate future risks posed by the virus and its variants or otherwise be satisfactory to government authorities and how long we will be required to continue these measures. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, an increased reliance by us and the companies with which we do business on information technology systems to support a hybrid workforce may increase cyber security risk, create data accessibility issues, increase the risk for communication disruptions, or otherwise disrupt or delay normal business operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic may also affect our current and planned trials and development programs, possibly affecting our timelines for commercialization. We and our CROs and contract manufacturing organizations (&#8220;CMOs&#8221;) may face disruptions that may affect our ability to conduct and timely complete ongoing clinical trials including disruptions in procuring items that are essential for our development activities, such as materials used in the manufacturing of Ixo-vec. We and our CROs and CMOs, as well as clinical trial sites, may face disruptions that affect our ongoing clinical trials arising from staffing disruptions and limitations on our activities and the activities of our CROs and CMOs, and delays in the ability to obtain necessary institutional review board or other necessary site approvals or delays in site initiations or site monitoring visits, as well as other delays at clinical trial sites. We may also face limitations on enrollment and patients withdrawing from our clinical trials or not complying with the protocol procedures, which could delay completion of our clinical trials or adversely affect the data generated by our clinical trials. The current general reluctance of some people to make in-person visits to healthcare providers for treatment of non-life-threatening ailments may make initiating clinical trial sites, identifying potential patients and enrolling them in our clinical trials, retaining any such patients, ensuring that such patients comply with treatment protocols, and collecting sufficient trial data to progress our clinical programs more difficult. For example, patient concerns related to COVID-19 caused some of our OPTIC trial patients to miss scheduled appointments for fear of contracting the virus which, if this were to be repeated over longer periods of time, could impact our ability to collect data we need. Additionally, our ability to recruit and retain patients and principal investigators and site staff who believe they have heightened risks if exposed to COVID-19 may be limited which may adversely impact our clinical trial operations. The response to the COVID-19 pandemic also could redirect resources with respect to regulatory and intellectual property matters in a way that could adversely impact our ability to progress regulatory approvals and protect our intellectual property. In addition, we may face impediments to regulatory meetings and approvals due to measures that are intended to limit in-person interactions. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, due to the limited ability to access our facilities and our reliance on outside vendors who may be similarly affected, our development programs may not proceed along the timelines we previously anticipated. We rely on third-party research facilities, manufacturers, suppliers, and other service providers from other countries and from different parts of the U.S. to provide services and resources necessary to support our research and development plans, to produce our product candidates, and support our clinical trials. Our ability to obtain this necessary support or supplies could be disrupted, or the cost of this support or these supplies could increase, if the operations of these suppliers or service providers, or national and international supply chains, including transportation carriers and transportation hubs, are affected by the COVID-19 pandemic. In addition, if our relationships with our manufacturers, service providers, suppliers, or other vendors are terminated, materially altered, or scaled back as a result of the COVID-19 pandemic or other health epidemics, we may not be able to enter into arrangements with alternative manufacturers, service providers, suppliers, or other vendors or do so on commercially reasonable terms or in a timely or cost-effective manner. Further, we may be subject to the inability or unwillingness of clinical investigators or patients to follow our research protocols as a result of the COVID-19 pandemic. As a result, delays could occur which could adversely impact our ability to meet our desired clinical development and any future commercialization timelines. The COVID-19 pandemic may also affect the operations of the FDA or other health regulatory authorities outside the U.S., which could result in delays of meetings, reviews and approvals, including with respect to our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The spread of COVID-19 and the emergence of new variants, which have caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, the widespread pandemic could result in significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we are taking steps to mitigate all of these effects, the occurrence of any of these disruptions, including of our own operations, could delay our clinical trials and development programs, and otherwise harm our operations and financial condition and increase our costs and expenses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which the COVID-19 pandemic continues to impact our business, results of operations, and financial condition will depend on future developments, which are uncertain and cannot be predicted, including, but not limited to, the duration and spread or any future resurgence of the outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions can resume. Even after the COVID-19 outbreak has subsided, we may experience materially adverse impacts to our business as a result of its global human and economic impact, or as a result of our actions taken and not taken as mitigation measures during the COVID-19 pandemic.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our information technology systems or data, or those of third parties upon which we rely, are or were compromised, we could adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; significant fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; material disruption of our product development programs; and other adverse consequences.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the ordinary course of our business, we and other third parties on which we rely collect, receive, use, process, generate, transfer, make accessible, protect, secure, dispose of, transmit, share, and store sensitive, confidential, and proprietary information, including personal information (such as health-related information and medical information), intellectual property, trade secrets, research and development information, financial information, and other business information. We may rely upon third-party service providers and technologies to operate critical business systems to process sensitive information in a variety of contexts, including, without limitation, encryption and authentication technology, employee email, and other functions. Our ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place. We may share or receive sensitive, confidential, and proprietary information with or from third parties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cyberattacks, malicious internet-based activity, and online and offline fraud are prevalent and continue to increase.  These threats are becoming increasingly difficult to detect. These threats come from a variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, personnel (such as through theft or misuse), sophisticated nation-states, and nation-state-supported actors. Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities.  During times of war and other major conflicts, we and the third parties upon which we rely may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations and supply chain. We and the third parties upon which we rely may be subject to a variety of evolving threats, including but not limited to social-engineering attacks (including through phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-of-service attacks (such as credential stuffing), personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, telecommunications failures, and other similar threats. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Similarly, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties and infrastructure in our supply chain or our third-party partners&#8217; supply chains have not been compromised or that they do not </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">contain exploitable defects or bugs that could result in a breach of or disruption to our information technology or the third-party information technology systems that support us and our services. The secure processing, storage, maintenance, and transmission of this critical information is vital to our operations and business strategy. We use third parties for our business, may share personal information with them, and rely on them to manufacture our product candidates and conduct clinical trials, and similar events relating to their systems could also have a material adverse effect on our business. Despite the implementation of security measures to protect against unauthorized access or disclosure, we and our CROs, contractors, consultants, collaborators, and other related third parties are vulnerable to damage or attacks.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ransomware attacks, including by organized criminal threat actors, nation-states, and nation-state supported actors, are becoming increasingly prevalent and severe and can lead to significant interruptions in our operations, disruptions of clinical trials, loss of data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting payments. Further, the COVID-19 pandemic and remote workforce poses increased risks to our information technology systems and data, as more of our employees work from home, utilizing network connections outside our premises. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the previously identified or similar threats could cause a security incident or other interruption. A security incident or other interruption could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our sensitive information. A security incident or other interruption could result in delays to the development and commercialization of our product candidates, disruption of our programs, negative publicity and financial loss. We may expend significant resources or modify our business activities (including our clinical trial activities) to try to protect against security incidents.  Certain privacy, data protection, and data security obligations may require us to implement and maintain specific security measures, industry-standard or reasonable security measures to protect our information technology systems and sensitive information. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be unable in the future to detect vulnerabilities in our information technology systems because such threats and techniques change frequently, are often sophisticated in nature, and may not be detected until after a security incident has occurred. Despite our efforts to identify and remediate vulnerabilities, if any, in our information technology systems (including our products), our efforts may not be successful. Further, we may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities. While we are not aware of any such material system failure, accident, or any other security incident to date, any such event could compromise our networks and the information stored there could be accessed by unauthorized parties, publicly disclosed, lost or stolen. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Applicable privacy, data protection, and data security obligations may require us to notify relevant stakeholders of security incidents. Such disclosures are costly, and the disclosures or the failure to comply with such requirements could lead to adverse consequences. If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences. These consequences may include: government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive information (including personal information); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in our operations (including availability of data); financial loss; and other similar harms.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A security incident could also disrupt our operations, including our ability to conduct research and development activities, process and prepare company financial information, manage various general and administrative aspects of our business, delay or impede the development of our products, and damage our reputation, any of which could adversely affect our business. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security incident were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our product candidates could be delayed. In addition, there can be no assurance that we will promptly detect any such disruption or security incident, if at all.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our privacy, data protection, and data security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy, data protection, and data security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with applicable state and federal healthcare laws and regulations, we may be subject to civil or criminal penalties and/or exclusion from federal and/or state healthcare programs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to FDA restrictions on the marketing of pharmaceutical products, several other types of state and federal healthcare fraud and abuse laws restrict certain practices, including research and marketing, in the pharmaceutical industry. These laws include anti-kickback, false claims, and healthcare professional payment transparency laws and regulations. Because of the breadth of these laws and the narrowness of their exceptions and safe harbors, it is possible that some of our business activities could be subject to challenge under one or more of these laws.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration, directly or indirectly, in cash or in kind, to induce or reward the purchasing, leasing, ordering, arranging for, or recommending the purchase, lease or order of any healthcare item or service for which payment may be made, in whole or in part, under Medicare, Medicaid or other federally financed healthcare programs. Remuneration has been broadly defined to include anything of value, including cash, improper discounts, and free or reduced-price items and services. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formula managers on the other. Although there are several statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution, the exceptions and safe harbors are drawn narrowly, and practices may be subject to scrutiny if they do not qualify for an exception or safe harbor. Liability may be established under the federal Anti-Kickback Statute without proving actual knowledge of the statute or specific intent to violate it. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. Many states have similar laws that apply to their state health care programs as well as private payers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) imposes criminal liability for knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payers; knowingly and willfully embezzling or stealing from a healthcare benefit program; willfully obstructing a criminal investigation of a healthcare offense; and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal civil False Claims Act, which prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment of government funds, or knowingly making, using or causing to be made or used, a false record or statement material to an obligation to pay money to the government or knowingly concealing or knowingly and improperly avoiding, decreasing or concealing an obligation to pay money to the federal government. Actions under the False Claims Act may be brought by the Attorney General or as a qui tam action by a private individual in the name of the government. Violations of the False Claims Act can result in significant monetary penalties and treble damages. Pharmaceutical and other healthcare companies have faced enforcement actions under the federal civil False Claims Act for, among other things, allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product and for allegedly causing false claims to be submitted because of the companies&#8217; marketing of the product for unapproved, and thus non-reimbursable, uses. In addition, a claim can be deemed to be false due to failure to comply with legal or regulatory requirements material to the government&#8217;s payment decision. False Claims Act liability is potentially significant in the healthcare industry because the statute provides for treble damages and significant mandatory penalties per false claim or statement. Pharmaceutical and other healthcare companies also are subject to other federal false claims laws, including, among others, federal criminal healthcare fraud and false statement statutes.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there has been a recent trend of increased federal and state regulation of payments made to physicians and other healthcare providers. The Affordable Care Act, among other things, imposed new reporting requirements on drug manufacturers, under the federal Physician Payments Sunshine Act, for payments and other transfers of value made by them to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors), certain other healthcare professionals (such as a physician assistants and nurse practitioners), and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Failure to submit required information may result in significant civil monetary penalties, for all payments, transfers of value or ownership or investment interests that are not timely, accurately and completely reported in an annual submission. Certain states and localities also mandate implementation of commercial compliance programs, restrict the ability of manufacturers to offer co-pay support to patients for certain prescription drugs, impose restrictions on drug manufacturer marketing practices, require the tracking and reporting of gifts, compensation and other remuneration to physicians and/or require the registration of pharmaceutical sales representatives.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will need to build and maintain a robust compliance program with different compliance and/or reporting requirements. We cannot ensure that our compliance controls, policies, and procedures will be sufficient to protect against acts of our employees, vendors, or other third parties that may violate such laws. If our operations are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to significant penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, exclusion from </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">participation in federal and state healthcare programs, imprisonment, and additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, any of which could adversely affect our ability to operate our business and our financial results.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize our product candidates. For example, we may be sued if our product candidates allegedly caused or cause injury or are found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product candidate, negligence, strict liability, and a breach of warranties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims could also be asserted under state consumer protection acts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit or cease the commercialization of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injury to our reputation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial participants;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs to defend the related litigation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a diversion of management&#8217;s time and our resources;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to trial participants or patients;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenue;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to commercialize our product candidates; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decline in our stock price.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently hold $10 million in product liability insurance, which may not adequately cover all liabilities that we may incur. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. Our inability to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of our product candidates. Although we plan to maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies will also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to evolving and increasingly stringent obligations related to privacy, data protection, and data security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; interruption of our clinical trials; and other adverse business consequences. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share sensitive, proprietary, and confidential information, including personal information, business data, trade secrets, intellectual property, and data we collect about trial participants in connection with clinical trials. Our processing activities subject us to numerous privacy, data protection, and data security obligations, such as laws, regulations, guidance, industry standards, external and internal policies, contractual requirements, and other obligations that govern processing of personal information by us or on our behalf, including information that we collect or will collect about patients and healthcare providers in connection with clinical trials. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, federal, state, and local governments have enacted numerous privacy, data protection, and data security laws and regulations, including those relating to data breach notification, personal information privacy, and consumer protection (e.g., Section 5 of the Federal Trade Commission Act). The legislative and regulatory landscape for privacy, data protection, and data security continues to evolve, and there has been an increasing focus on privacy, data protection, and data security issues which may affect our business. Many of these laws differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Federal regulators, state attorneys general, and plaintiffs&#8217; attorneys, including class action attorneys, have been and will likely continue to be active in this space. For example, HIPAA, as amended </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH&#8221;), imposes, among other things, certain standards relating to the privacy, security, transmission and breach reporting of individually identifiable health information, upon health plans, healthcare clearinghouses and certain healthcare providers, and their respective business associates that perform services for them involving individually identifiable health information, as well as their covered subcontractors. We may obtain health information from third parties, such as research institutions, that are subject to privacy and security requirements under HIPAA. Although we are not directly subject to HIPAA other than with respect to providing certain employee benefits, we could potentially be subject to penalties if we, our affiliates, or our agents obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">States have begun to introduce comprehensive privacy, data protection, and data security laws and regulations. For example, California enacted the California Consumer Privacy Act ("CCPA"), which took effect on January 1, 2020. These obligations include, but are not limited to, providing specific disclosures in privacy notices and affording California residents certain rights related to their personal information.  The CCPA allows for statutory fines for noncompliance (up to $7,500 per violation). Although the CCPA exempts some data processed in the context of clinical trials, the CCPA may increase compliance costs and potential liability with respect to other personal information we maintain about California residents. Additionally, the CCPA will be expanded substantially on January 1, 2023, when the California Privacy Rights Act (&#8220;CPRA&#8221;) becomes fully operative. The CPRA will, among other things, give California residents the ability to limit use of certain sensitive personal information, expand the types of data breaches subject to the CCPA&#8217;s private right of action, and establish a new California Privacy Protection Agency to implement and enforce the new law. Other states have enacted privacy, data protection, and data security laws. For example, Virginia recently enacted a comprehensive privacy, data protection, and data security law, the Consumer Data Protection Act, Colorado similarly enacted the Colorado Privacy Act, Utah recently enacted the Utah Consumer Privacy Act, and Connecticut enacted the Act Concerning Personal Data and Online Monitoring. Each of these state laws will become effective in 2023 and share similarities with but differ from the CCPA and CPRA. The obligations to comply with the CCPA and other evolving legislation may require us, among other things, to update our notices and develop new processes internally and with our partners.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, an increasing number of laws, regulations, and industry standards apply to privacy, data protection, and data security. For example, the EU GDPR, the United Kingdom&#8217;s GDPR (&#8220;UK GDPR&#8221;), Brazil&#8217;s General Data Protection Law (Lei Geral de Prote&#231;&#227;o de Dados Pessoais, or &#8220;LGPD&#8221;) (Law No. 13,709/2018), and China&#8217;s Personal Information Protection Law (&#8220;PIPL&#8221;) impose strict requirements for processing personal information, and violators of these laws face significant penalties. The processing of sensitive personal information, such as physical health condition and medical information, may impose heightened compliance burdens under the EU GDPR and is a topic of active interest among foreign regulators. The EU GDPR and UK GDPR confer a private right of action to data subjects and consumer associations, the right to lodge complaints with supervisory authorities, the right to seek judicial remedies, and the right to obtain compensation for damages. The obligations under the EU GDPR and UK GDPR may be onerous and adversely affect our business, financial condition, results of operations and prospects. Compliance with the EU GDPR and UK GDPR is a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with any European activities. In the event we enroll subjects in our ongoing or future clinical trials in Europe, we may be subject to additional privacy, data protection, and data security restrictions, including restrictions relating to the collection, use, storage, transfer, and other processing of personal information, including personal health data, regarding individuals in Europe as governed by the EU GDPR and UK GDPR. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain jurisdictions have enacted data localization laws and cross-border personal information transfer laws, which could make it more difficult to transfer information across jurisdictions (such as transferring or receiving personal information that originates in the EU or in other foreign jurisdictions). Existing mechanisms that facilitate cross-border personal information transfers may change or be invalidated. For example, absent appropriate safeguards or other circumstances, the EU GDPR generally restricts the transfer of personal information to countries outside the EEA that the EC does not consider to provide an adequate level of data privacy and security, such as the United States. The EC released a set of Standard Contractual Clauses (&#8220;SCCs&#8221;), which is a valid mechanism to transfer personal information outside of the EEA. In addition, Switzerland and the UK similarly restrict personal information transfers outside of those jurisdictions to countries such as the United States that do not provide an adequate level of personal information protection, and certain countries outside Europe (e.g. Russia, China, Brazil) have also passed or are considering laws requiring local data residency or otherwise impeding the transfer of personal information across borders, any of which could increase the cost and complexity of doing business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we cannot implement a valid mechanism for cross-border data transfers, we may face increased exposure to regulatory actions, substantial fines, and injunctions against processing or transferring personal information from Europe or other jurisdictions. In the event that we expand our operations abroad, the inability to import personal information to the United States could significantly and negatively impact our business operations, including by limiting our ability to conduct clinical trials in Europe or elsewhere, limiting our ability to collaborate with contract research organizations, service providers, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contractors, and other companies subject to such cross-border data transfer or localization laws, or requiring us to increase our personal information processing capabilities and infrastructure in foreign jurisdictions at significant expense. European privacy, data protection, and data security laws may decrease demand for our products and services if affected customers seek alternatives that do not involve such transfers. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the UK&#8217;s departure from the EU, has created uncertainty with regard to data protection regulation in the UK. In particular, it is unclear how data transfers to and from the UK will be regulated. On June 28, 2021, the EC issued an adequacy decision under the EU GDPR which allows transfers of personal information from the EEA to the UK to continue without restriction for a period of four years ending June 27, 2025. If the adequacy decision is withdrawn or not renewed, transfers of personal information from the EEA to the UK will require a valid transfer mechanism and companies making such transfers may be required to implement new processes and put new agreements in place to continue making such transfers. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our obligations related to privacy, data protection, and data security are quickly changing in an increasingly stringent fashion, creating some uncertainty as to the effective future legal framework. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. Preparing for and complying with these obligations requires significant resources and may necessitate changes to our information technologies, systems, and practices and to those of any third parties that process personal information on our behalf.  In addition, these obligations may require us to change our business model. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we endeavor to comply with all applicable data privacy and security obligations, we may at times fail (or be perceived to have failed) to do so. Moreover, despite our efforts, our personnel or third parties upon whom we rely may fail to comply with such obligations, which could negatively impact our business operations and compliance posture. Any failure or perceived failure by us or our partners, CROs, CMOs, collaborators, and other related third parties to comply with privacy, data protection, and data security obligations, may result in significant consequences. These consequences may include, but are not limited to, government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-related claims); additional reporting requirements and/or oversight; bans on processing personal information; orders to destroy or not use personal information; and imprisonment of company officials (for example, under HIPAA). Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: loss of customers; interruptions or stoppages in our business operations (including, clinical trials); inability to process personal information or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or revision or restructuring of our operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations (collectively, &#8220;Trade Laws&#8221;). We can face serious consequences for violations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among other matters, Trade Laws prohibit companies and their employees, agents, CROs, legal counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, provide, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else or anything of value to or from recipients in the public or private sector. Violations of Trade laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax assessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We also expect our non-U.S. activities to increase in time. We engage third parties for clinical trials and/or obtain necessary permits, licenses, registrations, and other regulatory approvals. We can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our development partners, third-party manufacturer and suppliers use biological materials and use or may use hazardous materials, and any claims relating to improper handling, storage or disposal of these materials could be time consuming or costly.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our development partners, third-party manufacturer and suppliers use or may use hazardous materials, including chemicals and biological agents and compounds that could be dangerous to human health and safety or the environment. Our operations and the operations of our third-party manufacturers and suppliers also produce hazardous waste products. Federal, state and local laws and regulations govern the use, generation, manufacture, storage, handling and disposal of these materials and wastes. Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our product development efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and any of our future development partners will be required to report to regulatory authorities if any of our approved products cause or contribute to adverse medical events, and any failure to do so would result in sanctions that would materially harm our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we and any of our future development partners or CROs are successful in commercializing our products, the FDA and foreign regulatory authorities would require that we and any of our future development partners report certain information about adverse medical events if those products may have caused or contributed to those adverse events. The timing of our obligation to report would be triggered by the date we become aware of the adverse event as well as the nature of the event. We and any of our future development partners may fail to report adverse events we become aware of within the prescribed timeframe. We and any of our future development partners may also fail to appreciate that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of our product candidates. If we and any of our future development partners fail to comply with our or their reporting obligations, the FDA or a foreign regulatory authority could take action, including criminal prosecution, the imposition of civil monetary penalties, seizure of the product and delay in approval or clearance of other products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, principal investigators, CROs, consultants and vendors may engage in misconduct or other improper activities, including noncompliance with our code of conduct or regulatory standards and requirements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk that our employees, independent contractors, principal investigators, CROs, consultants and vendors may engage in misconduct including code of conduct violations, fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct, or disclosure of unauthorized activities to us that violates: (1) FDA regulations, including those laws requiring the reporting of true, complete and accurate information to regulatory authorities, (2) manufacturing standards, (3) federal and state health care fraud and abuse laws and regulations or (4) laws that require the reporting of financial information or data accurately. Specifically, sales, marketing, and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws also involve improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid, and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition, or results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislation enacted on December 22, 2017, known as the Tax Cuts &amp; Jobs Act (&#8220;TCJA&#8221;) enacted many significant changes to the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to the TCJA may affect us, and certain aspects of the TCJA could be repealed or modified in future legislation. In addition, in response to the COVID-19 pandemic, the CARES Act was signed into law in March 2020. The CARES Act modifies certain of the changes made by the TCJA. Changes in corporate tax rates, the realization of net deferred tax assets relating to our U.S. operations, and the deductibility of expenses under the TCJA, as amended by the CARES Act, or future tax reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges in the current or future taxable years, and could increase our future U.S. tax expense. The foregoing items, as well as any other future changes in tax laws, could have a material adverse effect on our business, cash flow, financial condition, or results of operations. For example, proposals have been made in Congress (which have not yet been enacted) that would make various changes to the federal income tax laws applicable to corporations.  In addition, it is uncertain if and to what extent various states will conform to the TCJA, as amended by the CARES Act, or any newly enacted federal tax legislation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use net operating loss carryforwards and other tax attributes may be limited by the Code. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred substantial losses during our history and do not expect to become profitable in the near future and we may never achieve profitability. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire, except as described below.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the TCJA, federal NOLs incurred in taxable years beginning after 2017 and in future years may be carried forward indefinitely, but the deductibility of such federal NOLs for taxable years beginning after 2020 is limited. In addition, under Section 382 of the Code, our ability to utilize NOL carryforwards or other tax attributes, such as research tax credits, in any taxable year may be limited if we experience an &#8220;ownership change.&#8221; Generally, a Section 382 ownership change occurs if there is a cumulative increase of more than 50 percentage points in the stock ownership of one or more stockholders or groups of stockholders who owns at least 5% of a corporation&#8217;s stock within a specified testing period. Similar rules may apply under state tax laws. In connection with our acquisition of Annapurna in May 2016, we determined that certain NOLs and research and developments tax credits for both federal and state purposes were severely limited and therefore we removed a significant amount of NOLs and research and development tax credits from our deferred tax assets. In addition, we may have experienced an ownership change as a result of the February 2018 underwritten public offering of our common stock, and may in the future experience ownership changes from future offerings or other changes in the ownership of our stock. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, the amount of the NOLs and research credit carryforwards presented in our financial statements could be limited and may expire unutilized. In addition, state suspensions of the ability to use NOLs, and research credits, may limit our ability to use our NOLs and research credits to offset state taxable income and taxes.</span></div><div><span><br/></span></div><div id="i26ccaa4e5746469982cbf0d18a526b99_136"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The trading price of the shares of our common stock has been and could continue to be highly volatile, and purchasers of our common stock could incur substantial losses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price has been and is likely to continue to be volatile. The stock market in general and the market for biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The market price for our common stock may be influenced by many factors, including those discussed above and others such as:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enroll and dose patients in any clinical trials that are on-going, or that we plan to conduct in the future;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain regulatory approvals for our product candidates and delays or failure to obtain such approvals;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to conduct additional nonclinical studies to determine the best gene therapy candidates to advance in development;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results of any clinical trials, and the results of trials of our competitors or those of other companies in our market sector;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">investor perception and analysis of the results of our clinical trials, which may be different than our own;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments in the U.S. and foreign countries;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in our financial results or those of companies that are perceived to be similar to us;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems, especially in light of current reforms to the U.S. healthcare system;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to maintain our existing third-party license and collaboration agreements;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in manufacturing adequate supply of our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse publicity relating to the gene therapy market generally, including with respect to other products and potential products in such markets;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market conditions in the pharmaceutical and biotechnology sectors and issuance of securities analysts&#8217; reports or recommendations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of our stock by insiders and stockholders;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trading volume of our common stock;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the continuing effects of the COVID-19 pandemic;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic, industry and market conditions other events or factors, many of which are beyond our control;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key personnel; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">intellectual property, product liability or other litigation against us.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in the past, stockholders have initiated class action lawsuits against biotechnology and pharmaceutical companies following periods of volatility in the market prices of these companies&#8217; stock, and similar litigation has been instituted against us. Such litigation could cause us to incur substantial costs and divert management&#8217;s attention and resources, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we sell shares of our common stock or securities convertible into or exercisable for shares of our common stock in future financings, pursuant to our at-the-market sales agreement, licensing or collaboration arrangements, or acquisitions, stockholders may experience immediate dilution and, as a result, our stock price may decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, licensing, collaboration or similar arrangements, grants and debt financings. We do not have any committed external source of funds. As a result, we may from time to time issue additional shares of common stock or securities convertible into or exercisable for shares of our common stock. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a holder of our common stock. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends or other distributions. Furthermore, we may issue common stock as consideration in acquisitions. If we issue common stock or securities convertible into common stock, our common stockholders would experience additional dilution and, as a result, our stock price may decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional funds through licensing, collaboration or similar arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, research and development programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws may delay or prevent an acquisition of us or a change in our management. These provisions include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the authorization of the issuance of &#8220;blank check&#8221; preferred stock, the terms of which may be established and shares of which may be issued without stockholder approval;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the limitation of the removal of directors by the stockholders;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a staggered board of directors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prohibition of stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of our stockholders;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the elimination of the ability of stockholders to call a special meeting of stockholders;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of our board of directors to accelerate the vesting of outstanding option grants, restricted stock units or other equity awards upon certain transactions that result in a change of control; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the establishment of advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at stockholder meetings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock to merge or combine with us. Although we believe these provisions collectively provide for an opportunity to obtain greater value for stockholders by requiring potential acquirers to negotiate with our board of directors, they would apply even if an offer rejected by our board were considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have been subject to securities class action lawsuits in the past, and could be subject to additional such lawsuits in the future, which could result in substantial losses and may divert management&#8217;s time and attention from our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, we and certain of our former officers were involved in purported securities class action lawsuits, which have since been settled. The purported securities class action lawsuits asserted that the defendants violated the Exchange Act and the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and alleged that the defendants who are no longer at Adverum made materially false and misleading statements and omitted allegedly material information related to, among other things, the Phase 2a clinical trial for AVA&#8209;101, a program which was discontinued in 2015, and the prospects of AVA-101. We settled these lawsuits for $13.0 million, of which $1.0 million we contributed to cover our indemnification obligations to the underwriters, and the remainder was contributed by our insurers. Any future litigation of this type could result in payment of damages or settlement fees and diversion of management&#8217;s attention and resources, any of which could adversely impact our business. Monitoring and defending against legal actions are time-consuming for our management and detracts from our ability to focus fully on our business activities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our quarterly operating results may fluctuate significantly.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in the level of expenses related to our clinical trial and development programs;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">addition or termination of clinical trials or addition of cohorts to clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any intellectual property infringement lawsuit or other litigation in which we may become involved;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments affecting our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our execution of any collaborative, licensing or similar arrangements and the timing of payments we may make or receive under these arrangements;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">nature and terms of stock-based compensation grants; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">derivative instruments recorded at fair value.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our certificate of incorporation and bylaws provide that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any derivative action or proceeding brought on our behalf;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any action asserting a breach of fiduciary duty;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any action asserting a claim against us arising under the Delaware General Corporation Law; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any action asserting a claim against us that is governed by the internal-affairs doctrine.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This provision would not apply to suits brought to enforce a duty or liability created by the Securities Exchange Act of 1934, as amended. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated bylaws provide</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our certificate of incorporation and bylaws. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.</span></div><div style="margin-top:6pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These exclusive forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find either exclusive-forum provision in our certificate of incorporation or bylaws to be inapplicable or unenforceable in an action, we may incur </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">further significant </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional costs associated with resolving the dispute in other jurisdictions, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">all of </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which could seriously harm our business.</span></div><div id="i26ccaa4e5746469982cbf0d18a526b99_139"></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-108pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;&#160;&#160;Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></div><div id="i26ccaa4e5746469982cbf0d18a526b99_142"></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-108pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.&#160;&#160;&#160;&#160;Defaults Upon Senior Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i26ccaa4e5746469982cbf0d18a526b99_145"></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-108pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.&#160;&#160;&#160;&#160;Mine Safety Disclosures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i26ccaa4e5746469982cbf0d18a526b99_148"></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-108pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.&#160;&#160;&#160;&#160;Other Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><div id="i26ccaa4e5746469982cbf0d18a526b99_151"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:10pt;padding-left:108pt;text-indent:-108pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.&#160;&#160;&#160;&#160;Exhibits</span></div><div style="margin-top:6pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">EXHIBIT INDEX</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.289%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">INCORPORATED BY REFERENCE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT<br/>NUMBER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT DESCRIPTION</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FILE NUMBER</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FORM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DATE</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT<br/>OR ITEM<br/>NUMBER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PROVIDED<br/>HEREWITH</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459017003759/advm-ex31_910.htm">Amended and Restated Certificate of Incorporation.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 9, 2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000119312520182655/d917807dex31.htm">Amended and Restated Bylaws.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 29, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reference is made to Exhibits </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459017003759/advm-ex31_910.htm">3.1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> through </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000119312520182655/d917807dex31.htm">3.2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex101ajrakowofferletter.htm">Employment Agreement between Adverum Biotechnologies, Inc. and John Rakow, dated as of January 2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex101ajrakowofferletter.htm">0</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex101ajrakowofferletter.htm">, 2020.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1B</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex101bjrakowpromotionlette.htm">Promotion Letter between Adverum Biotechnologies, Inc. and John Rakow, dated as of July 1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex101bjrakowpromotionlette.htm">5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex101bjrakowpromotionlette.htm">, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1C</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex101cjrakowpromotionsvp.htm">Promotion Letter between Adverum Biotechnologies, Inc. and John Rakow, dated as of June 4, 2022.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex102dsouzaseparationagree.htm">Separation Agreement and General Release of Claims between Adverum Biotechnologies, Inc. and Rupert D'Souza, dated as of June 7, 2022.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex103consultingagreementnp.htm">Consulting Agreement between Adverum Biotechnologies, Inc. and Nancy E. Pecota, dated as of June 29, 2022. </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1042014esppplanamended.htm">Amended and Restated</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1042014esppplanamended.htm"> 2014</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1042014esppplanamended.htm"> Employee </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1042014esppplanamended.htm">Stock </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1042014esppplanamended.htm">Purchase Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20220630ex311.htm">Certification of Principal Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20220630ex312.htm">Certification of Principal Financial Officer, as required by Rule 13a-14(a) or Rule 15d-14(a).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20220630ex321.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20220630ex322.htm">Certification of Principal Financial Officer pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document- the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="-sec-extract:summary;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.289%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">INCORPORATED BY REFERENCE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT<br/>NUMBER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT DESCRIPTION</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FILE NUMBER</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FORM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DATE</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT<br/>OR ITEM<br/>NUMBER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PROVIDED<br/>HEREWITH</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Labels Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL tags for the cover page from the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June&#160;30, 2022, are embedded with the Inline XBRL document.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:54pt;text-indent:-54pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;The certifications attached as Exhibit 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the SEC and are not to be incorporated by reference into any filing of Adverum Biotechnologies, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-Q, irrespective of any general incorporation language contained in such filing.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="-sec-extract:summary;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><div id="i26ccaa4e5746469982cbf0d18a526b99_154"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26ccaa4e5746469982cbf0d18a526b99_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:52.340%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.922%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ADVERUM BIOTECHNOLOGIES, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: August 11, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Laurent Fischer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laurent Fischer, M.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></div></td></tr></table></div><div style="text-indent:54pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:52.340%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.922%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: August 11, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ John Rakow</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Rakow</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, General Counsel and </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acting Chief Financial Officer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer)</span></div></td></tr></table></div><div style="padding-left:54pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:52.340%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.922%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: August 11, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Nancy Pecota</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nancy Pecota</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interim Controller</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Accounting Officer)</span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1A
<SEQUENCE>2
<FILENAME>ex101ajrakowofferletter.htm
<DESCRIPTION>EX-10.1A
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="iac83a5f5c8834d46a8b118862cf9c7c3_33"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">EXHIBIT 10.1A</font></div><div><font><br></font></div><div style="text-align:right"><img alt="imageb.jpg" src="imageb.jpg" style="height:50px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">January 20, 2020</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">John Rakow</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;Address&#93;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Re&#58; Employment Offer, Legal Advisor</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Dear John,</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">I am pleased to offer you a position with Adverum Biotechnologies, Inc. (the &#8220;Company&#8221;) as Legal Advisor, reporting to the Chief Legal Officer, Peter Soparkar. You will work at our office located in Redwood City. Of course, the Company may change your position, duties, and work location from time to time in its discretion.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">If you decide to join us, this letter agreement (the &#8220;Agreement&#8221;) memorializes your compensation and other employment terms. These terms will become effective on the date you join the Company (the &#8220;Hire Date&#8221;).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">1.&#160;&#160;&#160;&#160;Compensation and Benefits.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Base Compensation&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Your base salary will be $295,000 annually ($12,291.67 per pay period), subject to payroll deductions and all required withholdings, reflecting your full-time employment with the Company. Your salary will be paid in accordance with the Company&#8217;s standard payroll schedule (currently the 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> and last day of each month). As an exempt salaried employee, you will be expected to work the Company&#8217;s normal business hours as well as additional hours as required by the nature of your work assignments, and you will not be eligible for overtime compensation.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Annual Bonus&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">In addition, for each calendar year starting with 2020 you will be eligible to earn an annual performance bonus with a target bonus amount equal to 25% of your base salary (as of January 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> of the bonus year). Your annual bonus for the calendar year in which you were hired will be prorated based on your Hire Date, so long as you joined the Company prior to October 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> of that year. If you joined on or after October 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, you will not be eligible for a bonus for that year. Your annual bonus will be calculated based on attainment of individual goals (including corporate and personal objectives) to be determined by the Company&#8217;s management each year, as well as such other criteria deemed relevant by the Company. Bonus payments will be in the form of cash and will be granted entirely at the discretion of the Company&#8217;s CEO and Board of Directors or its Compensation Committee. Any cash bonus payments will be less payroll deductions and all required withholdings. The bonus is not earned until paid (that is, you must be employed by the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Company on the date the bonus is paid in order to be entitled to receive the bonus) and no pro- rated amount will be paid if your employment terminates for any reason prior to the payment date.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Annual Equity Award&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">For each calendar year starting with the year after you complete one full year of service, you may be eligible for a discretionary annual equity grant, provided that you are actively employed with the Company through and including the date of such annual equity grant. Whether any discretionary annual equity grant is granted, and the terms of any such equity grant, is entirely at the discretion of the Company&#8217;s Board of Directors or its Compensation Committee.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Benefits</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">As a regular, full time employee, you will be eligible to participate in the Company&#8217;s employee benefits programs in accordance with the terms, conditions and limitations of the benefit plans, including health, dental and vision plans, retirement, paid time off, and other benefits, to the extent such plans have been established by the Company. Our employee benefits are described in the Benefits Booklet.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">All forms of compensation referred to in this Agreement are subject to all applicable taxes, withholding and any other deductions required by applicable law.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The Company may change compensation and benefits from time to time in its discretion.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">2.&#160;&#160;&#160;&#160;New Hire Equity Grant.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">In addition, if you join the Company, it will be recommended at the first meeting of the Company&#8217;s Board of Directors or its Compensation Committee following your Hire Date, that the Company grant you options to purchase 125,000 shares of the Company&#8217;s common stock with an exercise price per share equal to the closing price of the common stock on the date of grant (the &#8220;Option&#8221;). The vesting commencement date shall be September 9, 2019, the date on which you first became a Service Provider to the Company. The option will vest and become exercisable as follows&#58; subject to you continuing employment with the Company through each vesting date, 25% of the shares of common stock subject to the award of the Option shall vest on September 9, 2020 and 1&#47;48</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> of the total shares granted shall vest and become exercisable monthly following such anniversary such that the entire award shall be vested and exercisable on the fourth anniversary of the vesting commencement date. The Option will be an incentive stock option to the maximum extent allowed by the tax code and shall be subject to the other terms and conditions set forth in the Company&#8217;s 2014 Equity Incentive Plan and the Company&#8217;s standard form of Stock Option Agreement. You should consult with your own tax advisor concerning the risks associated with accepting the Option.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">3.&#160;&#160;&#160;&#160;Confidentiality and Proprietary Information Obligations.</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:22.7pt">Company Policies and Proprietary Information Agreement. As a condition of employment, you will be required to sign the employee Proprietary Information and Invention Assignment Agreement (the &#8220;PIIAA&#8221;) attached hereto as Exhibit A, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">which requires, among other provisions, the assignment of patent rights to any invention made during your employment at the Company, and non-disclosure of Company proprietary information. Similarly, you agree not to bring any third-party confidential information to the Company, including that of your former employer, and that in performing your duties for the Company you will in no way utilize any such information. You agree to honor all obligations to former employers during your employment with the Company.</font></div><div style="padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:22.02pt">Adverse or Outside Business Activities. Throughout your employment with the Company, you may engage in civic, academic teaching and lectures, and not-for- profit activities so long as such activities do not interfere with the performance of your duties hereunder or present a conflict of interest with the Company. You may not engage in other employment or undertake any other commercial business activities unless you obtain the prior written consent of the Company&#8217;s CEO. The Company may rescind its consent to your service as a director of all other corporations or participation in other business or public activities, if the Company, in its sole discretion, determines that such activities compromise or threaten to compromise the Company&#8217;s reputational or business interests or conflict with your duties to the Company. In addition, throughout the term of your employment with the Company, you agree not to, directly or indirectly, without the prior written consent of the Company, own, manage, operate, join, control, finance or participate in the ownership, management, operation, control or financing of, or be connected as an officer, director, executive, partner, employee, principal, agent, representative, consultant, licensor, licensee or otherwise with, any business or enterprise engaged in any business which is competitive with or which is reasonably anticipated to be competitive with the Company&#8217;s business&#59; provided, however, that you may purchase or otherwise acquire up to (but not more than) 1% of any class of securities of any enterprise (but without participating in the activities of such enterprise) if such securities are listed on any national or regional securities exchange. You hereby represent and warrant that you have disclosed previously to the Company all other employment or other commercial business activities that you already undertake, or intend to undertake (to the extent currently known by you), during your period of employment with the Company.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">4.&#160;&#160;&#160;&#160;No Conflicts.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">By signing this Agreement you hereby represent to the Company that, except as previously disclosed to the Company&#58; (a) your employment with the Company is not prohibited under any employment agreement or other contractual arrangement&#59; and (b) you do not know of any conflicts which would restrict your employment with the Company. You hereby represent that you have</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">disclosed to the Company any contract you have signed that may restrict your activities on behalf of the Company, and that you are presently in compliance with such contracts, if any.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">5.&#160;&#160;&#160;&#160;Reserved.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">6.&#160;&#160;&#160;&#160;At Will Employment.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The Company is excited about your joining as a full time, regular, exempt employee and looks forward to a beneficial and productive relationship. Nevertheless, your employment relationship with the Company will be an &#8220;at-will&#8221; arrangement and is for no specific period. This means that either you or the Company may terminate your employment at any time, with or without cause, and with or without advance notice. This &#8220;at-will&#8221; employment relationship cannot be changed except in a written agreement approved by the Company and signed by you and by a duly authorized officer of the Company. We request that, in the event of resignation, you give the Company at least two weeks notice. You should note that the Company may modify job titles, salaries and benefits from time to time as it deems necessary.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">7.&#160;&#160;&#160;&#160;Miscellaneous.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">7.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:19.5pt">Conditions of employment. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">This offer is contingent upon a satisfactory reference check and satisfactory proof of your right to work in the United States. If the Company informs you that you are required to complete a background check, this offer is contingent upon satisfactory clearance of such background check. You agree to assist as needed and to complete any documentation at the Company&#8217;s request to meet these conditions.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">7.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:18pt">Dispute Resolution. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">To ensure the rapid and economical resolution of disputes that may arise in connection with your employment with the Company, you and the Company agree that any and all disputes, claims, or causes of action, in law or equity, including but not limited to statutory claims, arising from or relating to the enforcement, breach, performance, or interpretation of this Agreement, your employment with the Company, or the termination of your employment, shall be resolved pursuant to the Federal Arbitration Act, 9 U.S.C. &#167; 1-16, to the fullest extent permitted by law, by final, binding and confidential arbitration conducted by JAMS or its successor, under JAMS&#8217; then applicable rules and procedures for employment disputes before a single arbitrator (available upon request and also currently available at </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">http&#58;&#47;&#47;www.jamsadr.com&#47;rules-employment-arbitration&#47;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">You acknowledge that by agreeing to this arbitration procedure, both you and the Company waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">In addition, all claims, disputes, or causes of action under this section, whether by you or the Company, must be brought in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported class or representative proceeding, nor joined or consolidated with the claims of any other person or entity. The arbitrator may not consolidate the claims of more than one person or entity, and may not preside over any form of representative or class proceeding. To the extent that the preceding sentences regarding class claims or proceedings are found to violate applicable law or are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class shall proceed in a court of law rather than by arbitration. This paragraph shall not apply to any action or claim that cannot be subject to mandatory arbitration as a matter of law, including, without limitation, claims brought pursuant to the California Private Attorneys General Act of 2004, as amended, to the extent such claims are not permitted by applicable law to be submitted to mandatory arbitration (collectively, the &#8220;Excluded Claims&#8221;). In the event you intend to bring multiple claims, including one of the Excluded Claims listed above, the Excluded Claims may be publicly filed with a court, while any other claims will remain subject to mandatory arbitration. You will have the right to be represented by legal counsel at any arbitration proceeding. Questions of whether a claim is subject to arbitration under this agreement shall be decided by </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">the arbitrator. Likewise, procedural questions which grow out of the dispute and bear on the final disposition are also matters for the arbitrator. The arbitrator shall&#58; (a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law&#59; and (b) issue a written statement signed by the arbitrator regarding the disposition of each claim and the relief, if any, awarded as to each claim, the reasons for the award, and the arbitrator&#8217;s essential findings and conclusions on which the award is based. The arbitrator shall be authorized to award all relief that you or the Company would be entitled to seek in a court of law. The Company shall pay all JAMS arbitration fees in excess of the administrative fees that you would be required to pay if the dispute were decided in a court of law. Nothing in this letter agreement is intended to prevent either you or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">7.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:18pt">Succession and assignment. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">This Agreement is personal to you and shall not be assigned by you. Any purported assignment by you shall be null and void from the initial date of the purported assignment. The Company may assign this Agreement to any successor or assign (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company. This Agreement shall inure to the benefit of the Company and permitted successors and assigns.</font></div><div style="padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">7.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:18pt">Enforceability. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">If any provision of this Agreement is determined to be invalid or unenforceable, in whole or in part, this determination shall not affect any other provision of this Agreement and the provision in question shall be modified so as to be rendered enforceable in a manner consistent with the intent of the parties insofar as possible under applicable law.</font></div><div style="padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">7.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:18pt">Governing law and jurisdiction. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">This Agreement shall be construed and enforced in accordance with the laws of the State of California without regard to conflicts of law principles.</font></div><div style="padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">7.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:18pt">Headings and captions. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The captions of the sections of this Agreement are for convenience of reference only and in no way define, limit or affect the scope or substance of any section of this Agreement.</font></div><div style="padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">7.7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:18pt">No construction against drafter. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Any ambiguity in this Agreement shall not be construed against either party as the drafter.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">7.8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:18pt">Waiver. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Any waiver of a breach of this Agreement, or rights hereunder, shall be in writing and shall not be deemed to be a waiver of any successive breach or rights hereunder.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">7.9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:18pt">Counterparts. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">This letter may be delivered and executed via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and shall be deemed to have been duly and validly delivered and executed and be valid and effective for all purposes.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">7.10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:12pt">Entire agreement. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">This Agreement, together with your PIIAA (Exhibit A), forms the complete and exclusive statement of your employment agreement with the Company. The employment terms in this Agreement supersede any other agreements or promises made to you by anyone concerning your employment terms, including, but not limited to, any representations made during your recruitment, interviews or pre employment negotiations, whether written or oral.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">8.&#160;&#160;&#160;&#160;Acknowledgement of Full Understanding. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">YOU ACKNOWLEDGE AND AGREE THAT YOU HAVE FULLY READ, UNDERSTAND AND VOLUNTARILY ENTER INTO THIS AGREEMENT. YOU ACKNOWLEDGE AND AGREE THAT YOU HAVE HAD AN OPPORTUNITY TO ASK QUESTIONS AND CONSULT WITH AN ATTORNEY OF YOUR CHOICE BEFORE SIGNING THIS AGREEMENT.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Please sign and date this letter, and the attached Proprietary Information and Invention Assignment Agreement, and return them to me by the close of business on January 21, 2020 in order to confirm your acceptance of our offer and agreement to these employment terms. This offer of employment will terminate if it is not accepted, signed and returned by the specified date. If you accept our offer, your first day of employment will be no later than January 21, 2020.</font></div><div style="margin-bottom:18pt;margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">We look forward to a favorable reply and a productive and enjoyable work relationship with you. </font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Sincerely,</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Adverum Biotechnologies, Inc.&#58;</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.739%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.774%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#47;s&#47; P. Soparkar  </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Peter Soparkar </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chief Legal Officer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Understood and Accepted&#58;</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.739%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.774%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#47;s&#47; John Rakow</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; John Rakow</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58;  2020-01-21  &#124;  21&#58;50&#58;13 PST</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1B
<SEQUENCE>3
<FILENAME>ex101bjrakowpromotionlette.htm
<DESCRIPTION>EX-10.1B
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i7bff6bf265424057a5ab791b7cc5b3fd_33"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Exhibit 10.1B</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:right"><img alt="image.jpg" src="image.jpg" style="height:50px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">July 15, 2021</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">John Rakow</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Re&#58; Promotion Letter, General Counsel</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Dear John, </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">I am pleased to offer you a promotion with Adverum Technologies, Inc. (the &#8220;Company&#8221;) to the General Counsel role, reporting to the Chief Operating Officer, Peter Soparkar. The terms of this letter amend your January 20, 2020 Offer Letter (&#8220;Offer Letter&#8221;).  You will work at our office located in Redwood City, California, Of course, the Company may change your position, duties, and work location from time to time in its discretion. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">If you decide to accept this promotion, this letter agreement (the &#8220;Agreement&#8221;) memorializes your compensation and other employment terms. These terms will become effective on the date of your promotion (the &#8220;Promotion Date&#8221;).   </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">1.&#160;&#160;&#160;&#160;Compensation and Benefits.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Base Compensation&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Your base salary will be $375,000 annually ($15,625 per pay period), subject to payroll deductions and all required withholdings, reflecting your full-time employment with the Company. As an exempt salaried employee, you will be expected to work the Company&#8217;s normal business hours as well as additional hours as required by the nature of your work assignments, and you will not be eligible for overtime compensation.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Annual Bonus&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">In addition, for each calendar year starting with 2021 you will be eligible to earn an annual performance bonus with a target bonus amount equal to 30% of your base salary (as of January 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> of the bonus year).  Your target annual bonus for the 2021 calendar year may be prorated based on your Promotion Date.  Your annual bonus will be calculated based on attainment of individual goals (including corporate and personal objectives) to be determined by the Company&#8217;s management each year, as well as such other criteria deemed relevant by the Company. Bonus payments will be in the form of cash and will be granted entirely at the discretion of the Company&#8217;s CEO and Board of Directors or its Compensation Committee. Any cash bonus payments will be less payroll deductions and all required withholdings. The bonus is not earned until paid (that is, you must be employed by the Company on the date the bonus is paid in order to be entitled to receive the bonus) and no pro-rated amount will be paid if your employment terminates for any reason prior to the payment date. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">2.&#160;&#160;&#160;&#160;Promotion Equity Grant.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">In addition, if you accept this Promotion, it will be recommended at the first meeting of the Company&#8217;s Board of Directors or its Compensation Committee that the Company grant you options to purchase 50,000 shares of the Company&#8217;s common stock with an exercise price per share equal to the closing price of the common stock on the date of grant (the &#8220;Option&#8221;). The Option will be granted pursuant to the Company&#8217;s 2014 Equity Incentive Plan. The option will vest and become exercisable as follows&#58; subject to you continuing employment with the Company through each vesting date,  25% of the shares of common stock subject to the award of the Option shall vest on the first anniversary of the vesting commencement date (your Promotion Date)  and 1&#47;48</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> of the total shares granted shall vest and become exercisable monthly following such anniversary such that the entire award shall be vested and exercisable on the fourth anniversary of the vesting commencement date. The Option will be an incentive stock option to the maximum extent allowed by the tax code and shall be subject to the other terms and conditions set forth in the Company&#8217;s 2014 Equity Incentive Plan and the Company&#8217;s standard form of Stock Option Agreement.  You should consult with your own tax advisor concerning the risks associated with accepting the Option.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">3.&#160;&#160;&#160;&#160;At Will Employment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">This Promotion Letter does not alter the employment relationship with the Company will be an &#8220;at-will&#8221; nature of your employment arrangement with the Company. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">4.&#160;&#160;&#160;&#160;Offer Letter Remains in Force. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Except as explicitly amended herein, all other terms of your Offer Letter remain unchanged and in force.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">5.&#160;&#160;&#160;&#160;Acknowledgement of Full Understanding.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">YOU ACKNOWLEDGE AND AGREE THAT YOU HAVE FULLY READ, UNDERSTAND AND VOLUNTARILY ENTER INTO THIS AGREEMENT. YOU ACKNOWLEDGE AND AGREE THAT YOU HAVE HAD AN OPPORTUNITY TO ASK QUESTIONS AND CONSULT WITH AN ATTORNEY OF YOUR CHOICE BEFORE SIGNING THIS AGREEMENT. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Please sign and date this letter, and the attached Change of Control Agreement and the Proprietary Information and Invention Assignment Agreement, and return them to me in order to confirm your acceptance of our offer and agreement to these employment terms. This offer of employment will terminate if it is not accepted, signed and returned by July 19, 2021. If you accept this promotion, your Promotion Date will be July 15, 2021.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Signature Page Follows</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">We look forward to a favorable reply and a productive and enjoyable work relationship with you.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Sincerely, </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Adverum Biotechnologies, Inc.&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:25.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.360%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#160;&#47;s&#47; Peter Soparkar</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Peter Soparkar</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chief Operating Officer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Understood and Accepted&#58;</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:25.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.360%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#160;&#47;s&#47; John Rakow</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; John Rakow</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58;  2021-07-16  &#124;  17&#58;22&#58;24 PDT</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1C
<SEQUENCE>4
<FILENAME>ex101cjrakowpromotionsvp.htm
<DESCRIPTION>EX-10.1C
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i5befa8806eae47a6aace9a867c74306c_33"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Exhibit 10.1C</font></div><div><img alt="advmlogo.jpg" src="advmlogo.jpg" style="height:50px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">June 4, 2022</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">John Rakow</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#91;address&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Dear John,</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This letter confirms the terms of your promotion to Senior Vice President, General Counsel, and your agreement to serve as Adverum&#8217;s Acting Chief Financial Officer and Principal Financial Officer.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I am excited to share with you that your promotion is effective as of June 3, 2022.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">With this promotion, your job title is Senior Vice President, General Counsel, Acting Chief Financial Officer and Principal Financial Officer. This promotion, results in a new base salary of $450,000 annually commencing on June 6, 2022. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As part of your promotion, your target bonus percentage is increasing to 40% (75% of which is based on company achievement &#38; 25% based on individual achievement). </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition to your promotion, you have been approved for a grant of 250,000 options, with a grant </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">date upon the SEC&#8217;s issuance of your CIK code, but in no event late than June 10, 2022.  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">You will receive a notification from E*TRADE alerting you when your equity documents are ready to view and accept.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The documents will include the grant date, vesting schedule and plan details.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In this new role, you will report directly into me with a dotted line into Peter Soparkar for matters pertaining to your role as General Counsel.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">   </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I am excited for you in your new role and how this opportunity may help you in your career development goals. I appreciate you taking on these additional responsibilities in support of Adverum&#8217;s continued growth and success.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Sincerely, </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Laurent Fischer, M.D. </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">President and Chief Executive Officer  </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>5
<FILENAME>ex102dsouzaseparationagree.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ibdddb9b8aa8c49acad5d137ff53d1ecb_33"></div><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.2</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">SEPARATION AGREEMENT AND GENERAL RELEASE OF CLAIMS</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Rupert D&#8217;Souza (&#8220;You&#8221;) and Adverum Biotechnologies, Inc. (&#8220;Adverum&#8221; or the &#8220;Company&#8221;) (collectively, the &#8220;Parties&#8221;) have agreed to enter into this Separation Agreement and General Release (&#8220;Agreement&#8221;) on the following terms.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:27pt;text-decoration:underline">Separation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  You acknowledge that you resigned your positions as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer effective June 3, 2022 and your employment with Adverum terminated effective June 6, 2022 (&#8220;Separation Date&#8221;).  You acknowledge that on the Separation Date, you received all earned salary and other compensation accrued through the Separation Date. You acknowledge and agree that Adverum does not owe you any further compensation or benefits except as set forth in this Agreement.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">You acknowledge that you have submitted expense reports for all business expenses you incurred during your employment, along with receipts or other supporting documentation, and have been reimbursed for all valid business expenses in accordance with the Company&#8217;s standard expense reimbursement policies.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:27pt;text-decoration:underline">Return of Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  Pursuant to Paragraph 9 of your Employee Proprietary Information and Invention Assignment Agreement (&#8220;Confidentiality Agreement&#8221;) that you entered into with the Company upon hire, you must execute the Termination Certificate attached as Schedule B to your Confidentiality Agreement.  Your signatures on this Agreement and on your Termination Certificate constitute your certification that by the Separation Date, you have returned all documents and property provided to you by the Company, including but not limited to your Company issued laptop and other electronic and&#47;or storage devices, all office files and all electronic files.  Company electronic files stored on any of your personal storage devices, including cloud storage, shall be archived by you on the Company&#8217;s network and deleted from all personal devices.  Any Company-issued laptop and all other Company-issued electronic and&#47;or storage devices shall be returned with all files intact. </font></div><div style="text-indent:54pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:27pt;text-decoration:underline">Separation Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  Pursuant to Paragraph 3 of your Change in Control and Severance Agreement (&#8220;CIC and Severance Agreement&#8221;) that you entered into with the Company upon hire, and in consideration for your execution of, non-revocation, and compliance with this Agreement, including the waiver and release of claims in Section 5, the Company agrees to provide the following benefits&#58;</font></div><div style="text-indent:54pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:22.7pt">The Company will pay you an amount equal to nine (9) months of your Base Salary ($318,750), payable in a lump sum, less applicable withholdings, within five (5) business days after the Effective Date of this Agreement (as defined in Section 5(d)).</font></div><div style="text-indent:90pt"><font><br></font></div><div style="height:67.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:22.02pt">Provided that you enroll for continued healthcare coverage under the Consolidated Omnibus Budget Reconciliation Act (&#8220;COBRA&#8221;), the Company shall directly pay  the COBRA premiums for you and your covered dependents for nine  (9) month following the Separation Date.  Notwithstanding the foregoing, (i) if any plan pursuant to which such benefits are provided is not, or ceases prior to the expiration of the period of continuation coverage to be, exempt from the application of Section 409A of the Code under Treasury Regulation Section 1.409A-1(a)(5), or (ii) the Company is otherwise unable to continue to cover you under its group health plans without penalty under applicable law (including without limitation, Section 2716 of the Public Health Service Act), then, in either case, an amount equal to each remaining Company subsidy shall thereafter be paid to you in substantially equal monthly installments.  After the Company ceases to pay premiums pursuant to this Section 3(b), you may, if eligible, elect to continue healthcare coverage at your expense in accordance the provisions of COBRA.</font></div><div style="text-indent:90pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:22.7pt">Outplacement placement assistance through the Company&#8217;s provider for a period of nine (9) months.</font></div><div style="text-indent:90pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">The benefits set forth in subsections (a), (b), and (c) above shall be collectively referred to herein as the &#8220;Severance Benefits.&#8221;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">You understand, acknowledge and agree that these Severance Benefits are being provided to you in exchange for your executing, not revoking and complying with this Agreement.  You further acknowledge no entitlement to any additional payment or consideration not specifically referenced herein.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">To become effective, you must execute this Agreement and deliver it to the Company no later than twenty-one (21) days after the date you were provided this Agreement and not revoke it in accordance with Section 5(d). </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:27pt;text-decoration:underline">Equity Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  You currently hold various Company equity awards that were granted to you during your employment (the &#8220;Equity Awards&#8221;).  Your Equity Awards shall continue to be governed in all respects by the applicable stock or equity plan and all applicable grant notices and agreements. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:27pt;text-decoration:underline">General Release and Waiver of Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.</font></div><div style="text-indent:54pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:22.7pt;text-decoration:underline">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  In exchange for the consideration provided in this Agreement, you and your heirs, executors, representatives, agents, insurers, administrators, successors and assigns (the &#8220;Releasors&#8221;) hereby forever generally and completely release and discharge the Company, its parents, predecessors, subsidiaries and affiliates, all current and former directors, officers, partners (both general and limited), employees and agents of the Company, its parents, subsidiaries and affiliates (the &#8220;Released Parties&#8221;), of and from any and all claims, demands, obligations, liabilities, complaints, causes of action, charges and debts of every kind and nature, in law, equity or otherwise, known and unknown, suspected and unsuspected, disclosed and undisclosed, asserted or unasserted, and in particular of and from all claims and demands of every kind and nature, known </font></div><div style="height:67.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">and unknown, suspected and unsuspected, disclosed and undisclosed, for damages actual, consequential and exemplary, past, present and future, arising out of or in any way related to employment, agreements, events, acts or conduct at any time prior to and including the date you execute this Agreement, including without limitation any and all claims relating to or arising from your employment relationship with the Company, the termination of that relationship, any and all claims for wrongful discharge of employment, harassment, retaliation, breach of contract (both express and implied), breach of covenant of good faith and fair dealing (both express and implied), promissory estoppel, negligent or intentional infliction of emotional distress, fraud, negligent or intentional misrepresentation, negligent or intentional interference with contract or prospective contract economic advantage, unfair business practices, defamation, libel, slander, negligence, personal injury, assault, battery, invasion of privacy, conversion, and disability benefits (&#8220;Released Claims&#8221;).  The Released Claims include but are not limited to all claims and demands arising out of or in any way connected with your employment with the Company or the termination of that employment&#59; claims for damages, penalties, interest, attorneys&#8217; fees, costs or any other relief pursuant to any federal, state or local law, statute or cause of action, including (without limitation) Title VII of the Civil Rights Act, as amended, the Age Discrimination in Employment Act, as amended (&#8220;ADEA&#8221;), the Americans with Disabilities Act, as amended, the Family and Medical Leave Act, as amended, Section 1981 of U.S.C. Title 42, the Sarbanes-Oxley Act of 2002, as amended, the Worker Adjustment and Retraining Notification Act, as amended, the National Labor Relations Act, as amended, the Genetic Information Nondiscrimination Act of 2008, the California Labor Code and regulations promulgated thereunder (except as set forth in Section 5(b) below), the California Business &#38; Professions Code (including, but not limited to, section 17200 thereof), the California Fair Employment and Housing Act, as amended, the California Family Rights Act, and any other Federal, state or local law (statutory, regulatory or otherwise) that may be legally waived and released&#59; and any tort and&#47;or contract claims, including, but not limited to, any claims of wrongful discharge, defamation, emotional distress, tortious interference with contract, invasion of privacy, nonphysical injury, personal injury or sickness or any other harm.</font></div><div><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:22.02pt;text-decoration:underline">Excluded claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  The general release of claims in Section 5(a) above excludes, and you do not waive, release or discharge any (i) right to file an administrative charge or complaint with or report possible violations of law to the Equal Employment Opportunity Commission (EEOC), National Labor Relations Board (NLRB), Securities and Exchange Commission (SEC), or other governmental administrative agency, or to participate in any agency investigation&#59; (ii) claims under state workers&#8217; compensation or unemployment laws&#59; or (iii) indemnification rights you have against the Company, and&#47;or any other claims that cannot be waived by law.  While this Agreement does not limit your right to receive an award for information provided to the Securities and Exchange Commission, you understand and agree that, to maximum extent permitted by law, you are otherwise waiving any and all rights you may have to individual relief based on any claims that you have released and any rights you have waived by signing this Agreement.</font></div><div><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:22.7pt;text-decoration:underline">Waiver of California Civil Code Section 1542</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  You understand that you may later discover claims or facts that may be different from, or in addition to, those which you now know or believe to exist with regards to the subject matter of this Agreement, and which, if </font></div><div style="height:67.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">known at the time of signing this Agreement, may have materially affected this Agreement or your decision to enter into it.  Nevertheless, you hereby waive any right or claim that might arise as a result of such different or additional claims or facts.  You have been fully advised of the contents of section 1542 of the Civil Code of the State of California, and that section and the benefits thereof are hereby expressly waived.  Section 1542 reads as follows&#58; </font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.113%"><tr><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:69.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.&#8221;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:22.02pt;text-decoration:underline">Specific release of ADEA claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  In further consideration of the payments and benefits provided to you by this Agreement, the Releasors hereby unconditionally release and forever discharge the Released Parties from any and all Claims that the Releasors may have as of the date you sign this Agreement arising under the ADEA.  By signing this Agreement, you hereby acknowledge and confirm that&#58; (i) in connection with your termination of employment, you have been advised by the Company to consult with an attorney of your choice before signing this Agreement to have the attorney explain the terms and effect of signing this Agreement, including your release of claims under the ADEA&#59; (ii) you were given no less than twenty-one (21) days to consider the terms of the Agreement and consult with an attorney of your choice, although you may sign it sooner if desired&#59; (iii) you are providing this release in exchange for consideration in addition to that which you are already entitled&#59; (iv) you understand that you have seven (7) days from the date of signing this Agreement to revoke your acceptance by providing the Company with a written notice of your revocation of the release and waiver contained in this Section to the Company&#8217;s General Counsel, at the following address&#58; 100 Cardinal Way, Redwood City, California 94063, before the end of such seven-day period&#59; (v) you understand that this Agreement shall not be effective until this revocation period has expired, which shall be the 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:125%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> day after you execute it (the &#8220;Effective Date&#8221;)&#59; (vi) the release contained in this Section does not apply to rights and claims that may arise after the date on which you sign this Agreement and (vii) you knowingly and voluntarily accept the terms of this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">You further agree that any change to this Agreement, whether material or immaterial, will not restart the 21-day period for you to consider the terms of this Agreement.</font></div><div style="height:67.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:27pt;text-decoration:underline">Reminder and Acknowledgement of Post-termination Confidentiality Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:22.7pt;text-decoration:underline">Acknowledgment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  You reaffirm and agree to observe and abide by the terms of your Confidentiality Agreement with the Company.  You understand and acknowledge that by virtue of your employment with the Company, you had access to and knowledge of &#8220;Proprietary Information&#8221; (as that term is defined in Paragraph 2(a) of your Confidentiality Agreement), you were in a position of trust and confidence with the Company, and you benefitted from the Company&#8217;s goodwill.  You understand and acknowledge that the Company invested significant time and expense in developing the Confidential Information and goodwill.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">You further understand and acknowledge that the restrictive covenants articulated in your Confidentiality Agreement are necessary to protect the Company&#8217;s legitimate business interests in its Confidential Information and goodwill.  You further understand and acknowledge that the Company&#8217;s ability to reserve these for its exclusive knowledge and use is of great competitive importance and commercial value to the Company and that the Company would be irreparably harmed if you violate your contractual obligations set forth in your Confidentiality Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">The Parties understand and agree that notwithstanding any other provision in this Agreement, nothing in this Agreement prohibits or restricts you (or your attorney) from initiating communications directly with, or responding to any inquiry from, or providing testimony before, the SEC, the Financial Industry Regulatory Authority (FINRA), any other self-regulatory organization or any other state or federal regulatory authority, regarding Confidential Information that pertains to any allegation of violations of any federal or state laws, rules or regulations.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:22.02pt;text-decoration:underline">18 U.S.C. &#167; 1833(b) Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  The Company hereby provides you with notice that 18 U.S.C. &#167; 1833(b) states as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.113%"><tr><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:69.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8220;An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that&#8212;(A) is made&#8212;(i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney&#59; and (ii) solely for the purpose of reporting or investigating a suspected violation of law&#59; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.&#8221;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Accordingly, notwithstanding anything to the contrary in this Agreement or in your Confidentiality Agreement, you understand that you have the right to disclose in confidence trade secrets to Federal, State, and local government officials, or to an attorney, for the sole purpose of reporting or investigating a suspected violation of law.  You understand that you also have the right to disclose trade secrets in a document filed in a lawsuit or other proceeding, but only if the filing is made under seal and protected from public disclosure.  You understand and acknowledge that nothing in this Agreement or in your Confidentiality Agreement is intended to conflict with 18 </font></div><div style="height:67.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">U.S.C. &#167; 1833(b) or create liability for disclosures of trade secrets that are expressly allowed by 18 U.S.C. &#167; 1833(b).</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:22.7pt;text-decoration:underline">Duration of Confidentiality Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  You understand and acknowledge that your obligations under your Confidentiality Agreement with regard to any particular Confidential Information continue during and after your employment by the Company until such time as such Confidential Information has become public knowledge other than as a result of your breach of this Agreement or breach by those acting in concert with you or on your behalf.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:22.02pt;text-decoration:underline">Non-Interference</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  You agree and covenant that you will not use the Company&#8217;s Confidential Information or trade secrets to directly or indirectly interrupt, disturb or interfere with the relationships of the Company with any client, consultant or other business partner, or to compete unfairly with the Company.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:27pt;text-decoration:underline">Agreement Not to Sue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  You represent that you have not initiated, filed, or caused to be filed and agree not to initiate, file, cause to be filed, or otherwise pursue any Released Claims against any of the Released Parties.  You agree not to encourage any person, including any current or former Adverum employee or contractor, to file any kind of claim whatsoever against any of the Released Parties.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:27pt;text-decoration:underline">Non-disparagement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  You agree and covenant that you shall not at any time make, publish or communicate to any person or entity or in any public forum any defamatory or disparaging remarks, comments or statements concerning the Company or its businesses, or any of its employees, officers, directors, partners, and existing and prospective investors and other associated third parties, now or in the future, and agrees to refrain from any tortious interference with the contracts and relationships of any of the Released Parties.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">This Section 8 does not, in any way, restrict or impede you from exercising protected rights to the extent that such rights cannot be waived by agreement or from complying with any applicable law or regulation or a valid order of a court of competent jurisdiction or an authorized government agency, provided that such compliance does not exceed that required by the law, regulation or order.  You shall promptly provide written notice of any such order to the Company&#8217;s General Counsel.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:27pt;text-decoration:underline">No Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  You agree and covenant that you shall not assist, support or in any other way cooperate in the initiation or prosecution of any action or proceeding against the Company, except if compelled to do so by legal process such as a court order, subpoena or written request by an administrative agency or the legislature to testify regarding alleged criminal conduct or alleged sexual harassment.  If approached by anyone for counsel or assistance in the presentation or prosecution of any disputes, differences, grievances, claims, charges or complaints against any of the Released Parties, you shall state no more than that you cannot provide counsel or assistance.  Nothing in this Section 9 is intended to or shall limit your right to communicate or cooperate with any government agency or to report an alleged violation of law to any government agency.  With reference to Section of 162(q) of the Internal Revenue Code of 1986, as amended without limitation, nothing contained in this Agreement shall be interpreted or construed as </font></div><div style="height:67.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">requiring nondisclosure with respect to any sexual harassment or sexual abuse that may be a subject of the release contained herein.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:21pt;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  Subject to Section 5(b), you agree and covenant that you shall not disclose any of the terms of or amount paid under this Agreement or the negotiation thereof to any individual or entity&#59; provided, however, that you will not be prohibited from making disclosures to your attorney, tax advisors and&#47;or immediate family members, or as may be required by law.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">This Section 10 does not, in any way, restrict or impede you from exercising protected rights to the extent that such rights cannot be waived by agreement or from complying with any applicable law or regulation or a valid order of a court of competent jurisdiction or an authorized government agency, provided that such compliance does not exceed that required by the law, regulation or order.  You shall promptly provide written notice of any such order to the Company&#8217;s General Counsel.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Notwithstanding any of the foregoing, any non-disclosure provision in this Agreement does not prohibit or restrict you (or your attorney) from initiating communications directly with, or responding to any inquiry from, or providing testimony before, the SEC, FINRA, any other self-regulatory organization or any other state or federal regulatory authority, regarding this Agreement or its underlying facts or circumstances.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:21pt;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">. In the event of a breach or threatened breach by you of any of the provisions of this Agreement, you hereby consent and agree that the Company shall be entitled to seek, in addition to other available remedies, a temporary or permanent injunction or other equitable relief against such breach or threatened breach from any court of competent jurisdiction, without the necessity of showing any actual damages or that money damages would not afford an adequate remedy, and without the necessity of posting any bond or other security.  The aforementioned equitable relief shall be in addition to, not in lieu of, legal remedies, monetary damages or other available forms of relief.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Should you fail to abide by any of the terms of this Agreement or post-termination obligations contained herein, the Company may, in addition to any other remedies it may have, reclaim any amounts paid to you under the provisions of this Agreement or terminate any benefits or payments that are later due under this Agreement, without waiving the releases provided herein.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:3pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:22.7pt;text-decoration:underline">Assignment by the Employer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  The Company may assign this Agreement to any subsidiary or corporate affiliate, or to any successor or assign (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company.  This Agreement shall inure to the benefit of the Company and permitted successors and assigns.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:22.02pt;text-decoration:underline">No Assignment by the Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  You may not assign this Agreement or any part hereof, it being understood that this Agreement is personal to you.  Any purported assignment by </font></div><div style="height:67.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">you shall be null and void from the initial date of purported assignment.  You represent and warrant that you have not assigned or transferred to any person, firm or entity not a party to this Agreement any Released Claims.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:21pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  This Agreement, for all purposes, shall be construed in accordance with the laws of California without regard to conflicts-of-law principles.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:21pt;text-decoration:underline">Dispute Resolution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">. To ensure the timely and economical resolution of disputes that arise in connection with this Agreement, you and the Company agree that any and all disputes, claims, or causes of action arising from or relating to the enforcement, breach, performance or interpretation of this Agreement shall be resolved to the fullest extent permitted by law by final, binding and confidential arbitration, by a single arbitrator, in San Francisco County, California, conducted by Judicial Arbitration and Mediation Services, Inc. (&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:125%">JAMS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#34;) under the applicable JAMS employment rules. By agreeing to this arbitration procedure, both you and the Company waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding. The arbitrator shall&#58; (i) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law&#59; and (ii)&#160;issue a written arbitration decision, to include the arbitrator's essential findings and conclusions and a statement of the award. The arbitrator shall be authorized to award any or all remedies that you or the Company would be entitled to seek in a court of law. The Company shall pay all JAMS' arbitration fees in excess of the amount of court fees that would be required if the dispute were decided in a court of law. Nothing in this Agreement is intended to prevent either you or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Notwithstanding the foregoing, you and the Company each have the right to resolve any issue or dispute over intellectual property rights by Court action instead of arbitration.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:21pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  Except as specifically provided herein, this Agreement, including your Confidentiality Agreement, as incorporated into this Agreement, contains all the understandings and representations between you and the Company pertaining to the subject matter hereof and supersedes all prior and contemporaneous understandings, agreements, representations and warranties, both written and oral, with respect to such subject matter.  The Parties mutually agree that the Agreement can be specifically enforced in court and can be cited as evidence in legal proceedings alleging breach of the Agreement.  Nothing herein modifies, supersedes, voids or otherwise alters your pre-existing contractual obligations set forth in your Confidentiality Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:21pt;text-decoration:underline">Modification and Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">. No provision of this Agreement may be amended or modified unless such amendment or modification is agreed to in writing and signed by you and by an authorized executive of the Company.  No waiver by either of the Parties of any breach by the other party hereto of any condition or provision of this Agreement to be performed by the other party hereto shall be deemed a waiver of any similar or dissimilar provision or condition at the same or any prior or subsequent time, nor shall the failure of or delay by either of the Parties in </font></div><div style="height:67.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">exercising any right, power or privilege hereunder operate as a waiver thereof to preclude any other or further exercise thereof or the exercise of any other such right, power or privilege.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:21pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  Should any provision of this Agreement be held by a court of competent jurisdiction to be enforceable only if modified, or if any portion of this Agreement shall be held as unenforceable and thus stricken, such holding shall not affect the validity of the remainder of this Agreement, the balance of which shall continue to be binding upon the Parties with any such modification to become a part hereof and treated as though originally set forth in this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">The Parties further agree that any such court is expressly authorized to modify any such unenforceable provision of this Agreement in lieu of severing such unenforceable provision from this Agreement in its entirety, whether by rewriting the offending provision, deleting any or all of the offending provision, adding additional language to this Agreement or by making such other modifications as it deems warranted to carry out the intent and agreement of the Parties as embodied herein to the maximum extent permitted by law. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">The Parties expressly agree that this Agreement as so modified by the court shall be binding upon and enforceable against each of them.  In any event, should one or more of the provisions of this Agreement be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions hereof, and if such provision or provisions are not modified as provided above, this Agreement shall be construed as if such invalid, illegal or unenforceable provisions had not been set forth herein.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:21pt;text-decoration:underline">Captions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  Captions and headings of the sections and paragraphs of this Agreement are intended solely for convenience and no provision of this Agreement is to be construed by reference to the caption or heading of any section or paragraph.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:21pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which taken together shall constitute one and the same instrument.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:21pt;text-decoration:underline">Nonadmission</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  You understand and acknowledge that this Agreement constitutes a compromise and settlement of any and all actual or potential disputed claims by you.  Nothing in this Agreement shall be construed as an admission of wrongdoing or any fault or liability on the part of the Company.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:21pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  All notices under this Agreement must be given in writing and directed to the addresses indicated in this Agreement or any other address designated in writing by either party.  All written notices to Adverum Biotechnologies, Inc. must be directed to Adverum&#8217;s General Counsel, at the following address&#58; 100 Cardinal Way, Redwood City, California 94063.</font></div><div style="height:67.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:21pt;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  This Agreement is intended to comply with Section 409A of the Internal Revenue Code of 1986, as amended (Section 409A) or an exemption thereunder and shall be construed and administered in accordance with Section 409A.  Notwithstanding any other provision of this Agreement, payments provided under this Agreement may only be made upon an event and in a manner that complies with Section 409A or an applicable exemption.  Any payments under this Agreement that may be excluded from Section 409A either as separation pay due to an involuntary separation from service or as a short-term deferral shall be excluded from Section 409A to the maximum extent possible.  For purposes of Section 409A, each installment payment provided under this Agreement shall be treated as a separate payment.  Any payments to be made under this Agreement upon a termination of employment shall only be made upon a &#8220;separation from service&#8221; under Section 409A.  Notwithstanding the foregoing, the Company makes no representations that the payments and benefits provided under this Agreement comply with Section 409A and in no event shall the Company be liable for all or any portion of any taxes, penalties, interest or other expenses that may be incurred by you on account of non-compliance with Section 409A.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:21pt;text-decoration:underline">Acknowledgment of Full Understanding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  YOU ACKNOWLEDGE AND AGREE THAT YOU HAVE FULLY READ, UNDERSTAND AND VOLUNTARILY ENTER INTO THIS AGREEMENT AND AGREE TO ABIDE BY IT.  YOU ACKNOWLEDGE AND AGREE THAT YOU HAVE HAD AN OPPORTUNITY TO ASK QUESTIONS AND CONSULT WITH AN ATTORNEY OF YOUR CHOICE BEFORE SIGNING THIS AGREEMENT.  YOU FURTHER ACKNOWLEDGE THAT YOUR SIGNATURE BELOW IS AN AGREEMENT TO RELEASE THE COMPANY FROM ANY AND ALL CLAIMS.</font></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.553%"><tr><td style="width:1.0%"></td><td style="width:12.345%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.506%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">UNDERSTOOD AND AGREED&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Employee</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Signature&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#47;s&#47; Rupert D&#8217;Souza</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Name&#58; </font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rupert D&#8217;Souza</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Date&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; 2022-06-07 &#124; 10&#58;07&#58;16 PDT</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Adverum Biotechnologies, Inc.<br></font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">By&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#160;&#47;s&#47; Laurent Fischer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Laurent Fischer M.D.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Title&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">President and Chief Executive Officer<br></font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div><div><font><br></font></div><div style="height:67.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>6
<FILENAME>ex103consultingagreementnp.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="icee95a537c394ca2920683b962c54b44_33"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Exhibit 10.3</font></div><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">CONSULTING AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;THIS CONSULTING AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is effective as of June&#160;3, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), by and between</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> ADVERUM BIOTECHNOLOGIES, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NANCY E. PECOTA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, an individual (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Consultant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recitals</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Company has need for certain professional services, and Consultant desires to support Company by providing such professional services, as detailed in this Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Now Therefore</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, intending to be legally bound, the parties hereby agree as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Consulting Services.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Commencing on the Effective Date, the Company hereby retains Consultant, and Consultant hereby agrees to perform consulting services for the Company as set forth herein. Upon Company&#8217;s request, Consultant agrees to devote her best efforts to provide to Company consultation and advice pertaining to the Company&#8217;s Finance team operations and management, including serving as the Company&#8217;s Acting Controller (in which role she will be the Company&#8217;s Principal Accounting Officer for Securities and Exchange Commission (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) purposes), supporting the Company&#8217;s SEC compliance and reporting (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">SEC Compliance and Reporting Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), supporting the Finance team with audit and accounting compliance and budgeting and cost management (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">All Other</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) (together the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and in such role shall be subject to the provisions of Section 16 of the Securities Exchange Act of 1934.  The specific nature and amount of the Services to be performed shall be as determined by the Company during the term of this Agreement.  Consultant shall only devote such time as is requested by the Company and shall render the Services at such times as may be mutually agreed between the parties. Consultant shall perform the Services at any Company location or at other places, upon mutual agreement of the parties hereto. Consultant will perform Services, and provide the results thereof, with the highest degree of professional skill and expertise. Consultant may use the assistance of other individuals only with the prior written consent of the Company. The Company agrees to indemnify Consultant as provided in the Indemnity Agreement at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Attachment A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and include Consultant as a Company Officer under its directors and officers insurance policy.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Compensation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In full consideration for Consultant's performance of the Services, subject to the other terms of this Agreement, Adverum will pay Consultant Three Hundred Fifty Dollars ($350.00) per hour for SEC Compliance and Reporting Services and Two Hundred Seventy-Five Dollars ($275.00) per hour for All Other Services.  Upon execution of this Agreement, an authorized Purchase Order will be issued, which shall be referenced by Consultant on all applicable invoices. Payment for Services will be made to Consultant within thirty (30) days of Adverum's receipt of a detailed invoice itemizing all time actually worked (in 30-minute increments) and Services performed.  As a condition to receipt of reimbursement of approved expenses, </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Consultant shall be required to submit to Company reasonable evidence that the amount involved was expended and related to Services provided under this Agreement. Consultant shall include the purchase order number on all invoices, and shall submit them directly to Adverum, Attn&#58; Accounts Payable via e-mail at </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">invoices&#64;adverum.coupahost.com</font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">with a copy to </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">jrakow&#64;adverum.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Independent Consultant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties understand and agree that Consultant is an independent contractor and not an agent or employee of the Company. Consultant has no authority to obligate the Company by contract or otherwise. Consultant will not be eligible for any employee benefits, nor will Company make deductions from Consultant&#8217;s fees for taxes or insurance (except as otherwise required by applicable law or regulation). Any payroll and employment taxes, insurance, and benefits imposed on Consultant due to activities performed hereunder will be the sole responsibility of Consultant.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Recognition of Company&#8217;s Rights&#59; Nondisclosure.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Consultant recognizes that Company is engaged in a continuous program of research and development respecting its present and future business activities. Consultant agrees as follows&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">At all times during the term of this Agreement and for seven (7)&#160;years thereafter, Consultant will hold in strictest confidence and will not disclose, use, lecture upon or publish any of the Company&#8217;s Proprietary Information (defined below), except to the extent such disclosure, use or publication may be required in direct connection with Consultant&#8217;s performing requested Services for Company or is expressly authorized in writing by an authorized representative of Company. Consultant will only disclose Company&#8217;s Proprietary Information to those of its officers, employees or other agents who are directly involved with performance under this Agreement or who have a need to see such Proprietary Information to enable it to perform its obligations under this Agreement. It is understood that the Proprietary Information will remain the sole property of Company. Consultant further agrees to take all reasonable precautions to prevent any unauthorized disclosure of the Proprietary Information including, but not limited to, having each employee, agent or representative of Consultant, if any, with access to any Proprietary Information execute a nondisclosure agreement containing provisions in Company's favor at least as restrictive with regards to Proprietary Information as Article 4 of this Agreement. Consultant will also notify Company, promptly and in writing, of any actual or suspected unauthorized use or disclosure of Proprietary Information. Consultant shall be responsible for the breach by any of its officers, employees, or agents of the obligations of confidentiality and non-use set forth herein.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">The term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Proprietary Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; may include, without limitation&#58;  (a)&#160;intellectual property, such as, but not limited to, patents, patent applications, copyrights, copyright applications, and trade secrets and&#47;or (b) other proprietary or confidential information, including without limitation (i) information regarding ideas, technology and processes (such as, but not limited to, assays, techniques, sketches, schematics, drawings, works of authorship, models, designs, inventions, know-how, technical documentation, equipment, algorithms, software programs, software source documents, formulae)&#59; (ii) information concerning or resulting from research and development projects and other projects (such as, but not limited to, </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">preclinical and clinical data, design details and specifications, engineering information, and works in process)&#59; (iii) business and financial information (such as, but not limited to, current, future, and proposed products and services, financial information and models, information relating to procurement requirements, purchasing, manufacturing, customer lists, product plans, product ideas, business strategies, marketing or business plans, financial or personnel matters, investors, employees, business and contractual relationships, business forecasts, sales and merchandising, and information regarding third parties, suppliers, customers, employees, investors or facilities)&#59; (iv) any information created using the foregoing Proprietary Information&#59; and (v) any other information which is designated as &#8220;Confidential,&#8221; &#8220;Proprietary&#8221; or some similar designation Notwithstanding the foregoing, any information a reasonable person under the circumstances would understand to be confidential and proprietary to Company shall be considered the Proprietary Information. Proprietary Information may also include information previously disclosed to Consultant by third parties. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">Proprietary Information shall not, however, include any information that Consultant can demonstrate by competent contemporaneous written proof&#58;  (a) was publicly known and made generally available in the public domain prior to the time of disclosure by the disclosing party&#59; (b) becomes publicly known and made generally available after disclosure by Company to Consultant through no action or inaction of Consultant&#59; (c) is already in the possession of the Consultant at the time of disclosure by Company&#59; or (d) is obtained by Consultant from a third party without a breach of any obligations of confidentiality. Any combination of features or disclosures shall not be deemed to fall within the foregoing exclusions merely because certain individual features are published or available to the general public or in the rightful possession of the receiving party unless the combination as a whole falls within any of the above exceptions.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">Notwithstanding the provisions of Section 4.1, Proprietary Information may be disclosed to the extent required by applicable laws or regulations or as ordered by a court or other regulatory body having competent jurisdiction, provided that Consultant (a) provides notice of the requested disclosure to the Company as soon as reasonably practicable, and (b) cooperates fully with the Company to take all legally available steps to prevent or narrow such disclosure, including, without limitation, by seeking a protective order or confidential treatment.  Consultant will restrict any required disclosure to only that portion of the Company&#8217;s Proprietary Information which Consultant is advised by legal counsel is legally required to be disclosed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">In addition, Consultant understands that Company has received and in the future will receive from third parties confidential or proprietary information (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Third party Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) subject to a duty on Company&#8217;s part to maintain the confidentiality of such information and to use it only for certain limited purposes. During the term of Consultant&#8217;s association and thereafter, Consultant will hold Third party Information in the strictest confidence and will not disclose or use Third party Information, except in connection with Consultant&#8217;s performing requested Services for Company, or as expressly authorized in writing by an authorized representative of Company.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Intellectual Property Rights.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">As used herein, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means&#58;  (a) any and all information, data, results, inventions and discoveries, whether or not patentable or copyrightable, </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">made by Consultant individually or in conjunction with others in connection with the Services or based on any Proprietary Information, including, without limitation, all reports and other deliverables&#59; (b) all modifications and&#47;or improvements to the materials and any and all analogues, progeny, derivatives and&#47;or reproducible and&#47;or functional portions thereof made by Consultant individually or in conjunction with others, whether or not patentable&#59; and (c) all intellectual property rights in and to all items described in clauses (a) and (b) above.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">All Intellectual Property shall be the sole and exclusive property of the Company, and Consultant hereby assigns, and automatically will be deemed to have assigned, to the Company all Intellectual Property. Consultant shall promptly disclose to the Company any and all Intellectual Property.  At the Company&#8217;s request and expense, Consultant shall undertake all further actions required to perfect the Company&#8217;s title to, and enjoyment of, such Intellectual Property.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">Consultant hereby grants to the Company a nonexclusive, royalty-free, fully paid-up, worldwide, freely transferable and sublicenseable, irrevocable, perpetual license under any and all intellectual property rights now or hereafter owned and&#47;or controlled by Consultant to exercise, exploit and otherwise fully enjoy the Company&#8217;s rights in and to the Intellectual Property, including, without limitation, to research, develop, make, have made, use, sell, offer for sale and&#47;or import products and&#47;or services based on or incorporating any Intellectual Property or any modification or derivative thereof.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">Consultant will not incorporate any invention, improvement, development, concept, discovery or other proprietary information owned by any third party into any Intellectual Property without the Company&#8217;s prior written permission.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;No Conflicting Obligation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">Consultant represents that Consultant&#8217;s performance of all of the terms of this Agreement and the performing of the Services for Company do not and will not breach or conflict with any agreement with a third party, including an agreement to keep in confidence any confidential information of another entity acquired by Consultant in confidence or in trust prior to the date of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">Consultant hereby agrees not to enter into any agreement that conflicts with this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;No Improper Use of Materials.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Consultant agrees not to bring to Company or to use in the performance of Services for Company any materials or documents of a present or former employer or client of Consultant, or any materials or documents obtained by Consultant from a third party under a binder of confidentiality, unless such materials or documents are generally available to the public or Consultant has authorization from such third party for the possession and unrestricted use of such materials. Consultant understands that Consultant is not to breach any obligation of confidentiality that Consultant has to present or former employers or clients, and agrees to fulfill all such obligations during the term of this Agreement.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;Term and Termination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement, and Consultant&#8217;s Services hereunder, shall commence on the Effective Date and shall continue until terminated as provided below.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Company may terminate the Agreement at any time by giving written notice to the Consultant, and the Consultant may terminate the Agreement at any time by giving written notice to the Company. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The obligations set forth in Articles 4, 5 and 10 through 13 will survive any termination or expiration of this Agreement. Upon termination of this Agreement, Consultant will cease work immediately after giving or receiving such notice of termination, unless otherwise advised by the Company, and promptly deliver to the Company all documents and other materials of any nature pertaining to the Services, together with all documents and other items containing or pertaining to any Proprietary Information.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;Compliance with Laws.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">All Services performed under this Agreement by Consultant will at all times be in compliance with all applicable laws, regulations and guidelines, including, without limitation, any import&#47;export control laws and any labor laws, including all applicable national, state and local fair employment practices laws. Any clause required to be in a document of this type by any applicable law or administrative regulation having the effect of law shall be deemed to be incorporated herein. Consultant warrants that the goods and Services shall comply with all applicable laws, standards and regulations, whether governmental or industrial, in effect on the date of delivery or known in the industry to become effective after such date.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">Consultant&#8217;s performance under this Agreement shall comply with all applicable federal, state and local laws, rules and regulations and industry standards (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Regulatory Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">Consultant will be responsible for obtaining and maintaining, at its sole expense, all permits, licenses, authorizations, approvals and the like necessary for carrying out its obligations under this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">Consultant will retain all applicable records in the manner and for the period required by the Regulatory Requirements or for a period of five (5) years, whichever is greater. During such period, if the Company notifies Consultant that it desires to receive such records, Consultant will promptly deliver such records to the Company or its designee.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">In the event that any governmental or regulatory authority or any entity representing such an authority (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Regulatory Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) requests access to Consultant&#8217;s records, facilities and&#47;or personnel, or conducts an unannounced inspection, in each case relating to Services provided in connection with this Agreement, then Consultant shall promptly notify the contact set forth in the Notice section by phone. The Company shall have the right to be present at any audit or inspection by a Regulatory Authority that relates to Services and Consultant shall notify the Company of any such audit or inspection in advance when such notice is possible.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;Assignment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The rights and liabilities of the parties hereto shall bind and inure to the benefit of their respective successors, heirs, executors and administrators, as the case may be&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, as the Company has specifically contracted for Consultant&#8217;s Services, Consultant may not assign or delegate Consultant&#8217;s obligations under this Agreement either in whole or in part without the prior written consent of the Company. The Company may assign its rights and obligations hereunder to an affiliate or to any person or entity that succeeds to all or substantially all of the Company&#8217;s business to which this Agreement relates, whether by merger, acquisition or other means. Any assignment not in accordance with this Article 10 shall be void.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;Legal and Equitable Remedies.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Because Consultant&#8217;s Services are personal and unique and because Consultant may have access to and become acquainted with the Proprietary Information, the Company shall have the right to enforce this Agreement and any of its provisions by injunction, specific performance or other equitable relief without prejudice to any other rights and remedies that the Company may have for a breach of this Agreement. The remedies provided under this Agreement are cumulative and are not exclusive of other remedies available to either party in law or equity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;Governing Law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Agreement will be governed in all respects by the laws of the State of California as such laws are applied to agreements between California residents entered into and to be performed entirely within California and without giving effect to conflict of laws principles. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;Miscellaneous.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Entire Agreement, Modifications and Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement is the product of both of the parties hereto, constitutes the entire agreement between such parties pertaining to the subject matter hereof, and supersedes any and all previous agreements and understandings, oral or written, relating to the subject matter hereof. No waiver of any rights under this Agreement will be effective unless in writing signed by the party waiving such rights. No failure or delay by a party in exercising any right, power or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege hereunder.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Further Assurances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Consultant agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Headings included herein are for convenience only, and shall not be used to construe this Agreement. Ambiguities, if any, in this Agreement shall not be construed against any party, irrespective of which party may be deemed to have drafted the Agreement or authorized the ambiguous provision.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The invalidity or unenforceability of any provision of this Agreement will not affect the validity or enforceability of the other provisions of this Agreement&#59; and if any provision of this Agreement is held by a court to be unenforceable then the parties will </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ask the court making such determination to alter such provision so that it is valid and enforceable and to enforce it in its altered form for all purposes contemplated by this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Force Majeure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Except as otherwise herein provided, neither party shall be liable or deemed in default for failure to perform any duty or obligation that such party may have under this Agreement (other than a failure to make payment that is due and owing) where such failure has been occasioned by any act of terror, God, fire, inevitable accidents, war, civil unrest or any other cause outside the reasonable control of that party and occurring without its fault or negligence. The party whose performance has so been interrupted shall give the other party notice of the interruption and cause and shall use every reasonable means to resume full performance of this Agreement as soon as possible. In the event the period of non-performance exceeds sixty (60) days, the other party to this Agreement may terminate this Agreement without penalty immediately upon written notice of termination to the non-performing party.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement may be executed in one or more counterparts, each of which shall be deemed an original and all of which together shall constitute one instrument. Delivery of an executed counterpart of a signature page of this Agreement by facsimile or in electronic format (e.g., &#8220;pdf&#8221; or &#8220;tif&#8221;) shall be effective as delivery of a manually executed counterpart of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">In Witness Whereof</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the parties hereto have entered into this Agreement by their duly authorized representatives as of the Effective Date.</font></div><div style="text-align:justify"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.008%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">NANCY E. PECOTA</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">ADVERUM BIOTECHNOLOGIES, INC.</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Signature&#58;</font></td><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#47;s&#47; Nancy Pecota</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Signature&#58;</font></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#47;s&#47; John Rakow</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Print Name&#58;</font></td><td colspan="6" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Nancy Pecota</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Print Name&#58;</font></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">John Rakow</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Title&#58;</font></td><td colspan="6" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Consultant</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Title&#58;</font></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">SVP, General Counsel &#38; Acting CFO</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2202-06-29 &#124; 22&#58;39&#58;07 PDT</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Date&#58;</font></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2202-06-29 &#124; 23&#58;10&#58;38 PDT</font></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Reviewed by</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">ADVM Legal&#58;</font></td><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#47;s&#47; JR</font></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>7
<FILENAME>ex1042014esppplanamended.htm
<DESCRIPTION>EX-10.4
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i5f0025d4afc341daa5fa816091ff2213_33"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:right;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.4</font></div><div style="padding-left:36pt;text-align:right;text-indent:36pt"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ADVERUM BIOTECHNOLOGIES, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2014 EMPLOYEE STOCK PURCHASE PLAN</font></div><div style="margin-bottom:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMENDED AND RESTATED ON JUNE 10, 2022</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE I</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURPOSE, SCOPE AND ADMINISTRATION OF THE PLAN</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21pt">Purpose and Scope</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The purpose of the Adverum Biotechnologies, Inc. 2014 Employee Stock Purchase Plan, as it may be amended from time to time, (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is to assist employees of Adverum Biotechnologies, Inc., a Delaware corporation, (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and its Designated Subsidiaries in acquiring a stock ownership interest in the Company pursuant to a plan which is intended to qualify as an &#8220;employee stock purchase plan&#8221; under Section 423 of the Code and to help such employees provide for their future security and to encourage them to remain in the employment of the Company and its Subsidiaries.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE II</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DEFINITIONS</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Whenever the following terms are used in the Plan, they shall have the meaning specified below unless the context clearly indicates to the contrary. The singular pronoun shall include the plural where the context so indicates.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the brokerage firm, bank or other financial institution, entity or person(s), if any, engaged, retained, appointed or authorized to act as the agent of the Company or an Employee with regard to the Plan.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Administrator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean the Committee, or such individuals to which authority to administer the Plan has been delegated under Section 7.1 hereof.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean the Board of Directors of the Company.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean the Internal Revenue Code of 1986, as amended.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean the Compensation Committee of the Board.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean the common stock of the Company.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall have such meaning as set forth in Section 1.1 hereof.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of an Employee shall mean the regular straight-time earnings or base salary, bonuses and commissions paid to the Employee from the Company on each Payday as compensation for services to the Company or any Designated Subsidiary, before deduction for any salary deferral contributions made by the Employee to any tax-qualified or nonqualified deferred compensation plan, including overtime, shift differentials, vacation pay, salaried production schedule premiums, holiday pay, jury duty pay, funeral leave pay, paid time off, military pay, prior week adjustments and weekly bonus, but excluding education or tuition reimbursements, imputed income arising under any group insurance or benefit program, travel expenses, business and moving reimbursements, income received in connection with any stock options, restricted stock, restricted stock units or other compensatory equity awards and all contributions made by the Company or any Designated Subsidiary for the Employee&#8217;s benefit under any employee benefit plan now or hereafter established. Such Compensation shall be calculated before deduction of any income or employment tax withholdings, but shall be withheld from the Employee&#8217;s net income.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Designated Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean each Subsidiary that have been designated by the Board or Committee from time to time in its sole discretion as eligible to participate in the Plan, including any Subsidiary in existence on the Effective Date and any Subsidiary formed or acquired following the Effective Date, in accordance with Section 7.2 hereof.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean the date immediately preceding the date the Company&#8217;s registration statement relating to its initial public offering becomes effective, provided that the Board has adopted and the Company&#8217;s stockholders have approved the Plan prior to or on such date.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Eligible Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean an Employee who (a) is customarily scheduled to work at least twenty (20) hours per week, (b) whose customary employment is more than five (5) months in a calendar year and (c) after the granting of the Option would not be deemed for purposes of Section 423(b)(3) of the Code to possess five percent (5%) or more of the total combined voting power or value of all classes of stock of the Company or any Subsidiary. For purposes of clause (c), the rules of Section 424(d) of the Code with regard to the attribution of stock ownership shall apply in determining the stock ownership of an individual, and stock which an Employee may purchase under outstanding options shall be treated as stock owned by the Employee. Notwithstanding the foregoing, the Administrator may exclude from participation in the Plan as an Eligible Employee (x) any Employee that is a &#8220;highly compensated employee&#8221; of the Company or any Designated Subsidiary (within the meaning of Section 414(q) of the Code), or that is such a &#8220;highly compensated employee&#8221; (A) with compensation above a specified level, (B) who is an officer and&#47;or (C) is subject to the disclosure requirements of Section 16(a) of the Exchange Act and&#47;or (y) any Employee who is a citizen or resident of a foreign jurisdiction (without regard to whether they are also a citizen of the United States or a resident alien (within the meaning of Section 7701(b)(1)(A) of the Code)) if either (i) the grant of the Option is prohibited under the laws of the jurisdiction governing such Employee, or (ii) compliance with the laws of the foreign jurisdiction would cause the Plan or the Option to violate the requirements of Section 423 of the Code&#59; provided that any exclusion in clauses (x), and&#47;or (y) shall be applied in an identical manner under each Offering Period to all Employees of the Company and all Designated Subsidiaries, in accordance with Treasury Regulation Section 1.423-2(e).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean any person who renders services to the Company or a Designated Subsidiary in the status of an employee within the meaning of Section 3401(c) of the Code. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall not include any director of the Company or a Designated Subsidiary who does not render services to the Company or a Designated Subsidiary in the status of an employee within the meaning of Section 3401(c) of the Code. For purposes of the Plan, the employment relationship shall be treated as continuing intact while the individual is on military leave, sick leave or other leave of absence approved by the Company or Designated Subsidiary and meeting the requirements of Treasury Regulation Section 1.421-1(h)(2). Where the period of leave exceeds three (3) months, or such other period specified in Treasury Regulation Section 1.421-1(h)(2), and the individual&#8217;s right to reemployment is not guaranteed either by statute or by contract, the employment relationship shall be deemed to have terminated on the first day immediately following such three (3)-month period, or such other period specified in Treasury Regulation Section 1.421-1(h)(2).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Enrollment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean the first date of each Offering Period.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exercise Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean the last Trading Day of each Offering Period, except as provided in Section 5.2 hereof. 2.15 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean the Securities Exchange Act of 1934, as amended.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Market Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean, as of any date, the value of Common Stock determined as follows&#58;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">If the Common Stock is (i) listed on any established securities exchange (such as the New York Stock Exchange, the NASDAQ Global Market and the NASDAQ Global Select Market), (ii) listed on any national market system or (iii) listed, quoted or traded on any automated quotation system, its Fair Market Value shall be the closing sales price for a share of Common Stock as quoted on such exchange or system for such date or, if there is no closing sales price for a share of Common Stock on the date in question, the closing sales price for a share of Stock on the last preceding date for which such quotation exists, as reported in The Wall Street Journal or such other source as the Administrator deems reliable&#59;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">If the Common Stock is not listed on an established securities exchange, national market system or automated quotation system, but the Common Stock is regularly quoted by a recognized securities dealer, its Fair Market Value shall be the mean of the high bid and low asked prices for such date or, if there are no high bid and low asked prices for a share of Common Stock on such date, the high bid and low asked prices for a share of Common Stock on the last preceding date for which such information exists, as reported in The Wall Street Journal or such other source as the Administrator deems reliable&#59; or</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">If the Common Stock is neither listed on an established securities exchange, national market system or automated quotation system nor regularly quoted by a recognized securities dealer, its Fair Market Value shall be established by the Administrator in good faith.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean the first Trading Day of an Offering Period.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Exercise Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall have such meaning as set forth in Section 5.2(b) hereof.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Offering Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean such period of time, which shall be determined by the Committee, with respect to which Options are granted to Participants. The duration and timing of Offering Periods may be changed by the Board or Committee, in its sole discretion. In no event may an Offering Period exceed twenty-seven (27) months.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean the right to purchase shares of Common Stock pursuant to the Plan during each Offering Period.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Option Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean the purchase price of a share of Common Stock hereunder as provided in Section 4.2 hereof.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any entity that is a parent corporation of the Company within the meaning of Section 424 of the Code and the Treasury Regulations thereunder.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean any Eligible Employee who elects to participate in the Plan.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Payday</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean the regular and recurring established day for payment of Compensation to an Employee of the Company or any Designated Subsidiary.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall have such meaning as set forth in Section 1.1 hereof.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.25.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Plan Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean a bookkeeping account established and maintained by the Company in the name of each Participant.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.26.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Section 423 Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall have such meaning as set forth in Section 3.1(b) hereof.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.27.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean any entity that is a subsidiary corporation of the Company within the meaning of Section 424 of the Code and the Treasury Regulations thereunder. In addition, with respect to any sub-plans adopted under Section 7.1(d) hereof which are designed to be outside the scope of Section 423 of the Code, Subsidiary shall include any corporate or noncorporate entity in which the Company has a direct or indirect equity interest or significant business relationship.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.28.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trading Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean a day on which the principal securities exchange on which the Common Stock is listed is open for trading or, if the Common Stock is not listed on a securities exchange, shall mean a business day, as determined by the Administrator in good faith.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.29.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Withdrawal Election</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall have such meaning as set forth in Section 6.1(a) hereof.</font></div><div style="margin-bottom:9pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE III</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PARTICIPATION</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.1&#160;&#160;&#160;&#160;Eligibility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any Eligible Employee who shall be employed by the Company or a Designated Subsidiary on a given Enrollment Date for an Offering Period shall be eligible to participate in the Plan during such Offering Period, subject to the requirements of Articles IV and V hereof, and the limitations imposed by Section 423(b) of the Code and the Treasury Regulations thereunder.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">No Eligible Employee shall be granted an Option under the Plan which permits the Participant&#8217;s rights to purchase shares of Common Stock under the Plan, and to purchase stock under all other employee stock purchase plans of the Company, any Parent or any Subsidiary subject to the Section 423 of the Code (any such Option or other option, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Section 423 Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), to accrue at a rate which exceeds $25,000 of fair market value of such stock (determined at the time the Section 423 Option is granted) for each calendar year in which any Section 423 Option granted to the Participant is outstanding at any time. For purposes of the limitation imposed by this subsection,</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">the right to purchase stock under a Section 423 Option accrues when the Section 423 Option (or any portion thereof) first becomes exercisable during the calendar year,</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.8pt">the right to purchase stock under a Section 423 Option accrues at the rate provided in the Section 423 Option, but in no case may such rate exceed $25,000 of fair market value of such stock (determined at the time such option is granted) for any one calendar year, and (iii) a right to purchase stock which has accrued under a Section 423 Option may not be carried over to any other Section 423 Option&#59; provided that Participants may carry forward amounts so accrued that represent a fractional share of stock and were withheld but not applied towards the purchase of Common Stock under an earlier Offering Period, and may apply such amounts towards the purchase of additional shares of Common Stock under a subsequent Offering Period.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The limitation under this Section 3.1(b) shall be applied in accordance with Section 423(b)(8) of the Code and the Treasury Regulations thereunder.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.2&#160;&#160;&#160;&#160;Election to Participate&#59; Payroll Deductions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Except as provided in Section 3.3 hereof, an Eligible Employee may become a Participant in the Plan only by means of payroll deduction. Each individual who is an Eligible Employee as of an Offering Period&#8217;s Enrollment Date may elect to participate in such Offering Period and the Plan by delivering to the Company a payroll deduction authorization no later such period of time prior to the applicable Enrollment Date as determined by the Administrator, in its sole discretion.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Subject to Section 3.1(b) hereof, payroll deductions (i) shall be equal to at least one percent (1%) of the Participant&#8217;s Compensation as of each Payday of the Offering Period following the Enrollment Date, but not more than the lesser of fifteen percent (15%) of the Participant&#8217;s Compensation as of each Payday of the Offering Period following the Enrollment Date or $25,000 per Offering Period&#59; and (ii) may be expressed either as (A) a whole number percentage, or (B) a fixed dollar amount. Amounts deducted from a Participant&#8217;s Compensation with respect to an Offering Period pursuant to this Section 3.2 shall be deducted each Payday through payroll deduction and credited to the Participant&#8217;s Plan Account.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Following at least one (1) payroll deduction, a Participant may decrease (to as low as zero) the amount deducted from such Participant&#8217;s Compensation only once during an Offering Period upon ten (10) calendar days&#8217; prior written notice to the Company. A Participant may not increase the amount deducted from such Participant&#8217;s Compensation during an Offering Period.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Notwithstanding the foregoing, upon the termination of an Offering Period, each Participant in such Offering Period shall automatically participate in the immediately following Offering Period at the same payroll deduction percentage or fixed amount as in effect at the termination of the prior Offering Period, unless such Participant delivers to the Company a different election with respect to the successive Offering Period in accordance with Section 3.1(a) hereof, or unless such Participant becomes ineligible for participation in the Plan.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.3&#160;&#160;&#160;&#160;Leave of Absence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During leaves of absence approved by the Company meeting the requirements of Treasury Regulation Section 1.421-1(h)(2) under the Code, a Participant may continue participation in the Plan by making cash payments to the Company on his or her normal payday equal to his or her authorized payroll deduction.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE IV</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">URCHASE OF SHARES</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21pt">Grant of Option. Each Participant shall be granted an Option with respect to an Offering Period on the applicable Grant Date. Subject to the limitations of Section 3.1(b) hereof, the number of shares of Common Stock subject to a Participant&#8217;s Option shall be determined by dividing (a) such Participant&#8217;s payroll deductions accumulated prior to such Exercise Date and retained in the Participant&#8217;s Plan Account on such Exercise Date by (b) the applicable Option Price&#59; provided that in no event shall a Participant be permitted to purchase during each purchase period within an Offering Period more than 6,000 shares of Common Stock (subject to any adjustment pursuant to Section 5.2 hereof). The Administrator may, for future Offering Periods, increase or decrease, in its absolute discretion, the maximum number of shares of Common Stock that a Participant may purchase during such future purchase periods within Offering Periods. Each Option shall expire on the Exercise Date for the applicable Offering Period immediately after the automatic exercise of the Option in accordance with Section 4.3 hereof, unless such Option terminates earlier in accordance with Article 6 hereof.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21pt">Option Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Option Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; per share of Common Stock to be paid by a Participant upon exercise of the Participant&#8217;s Option on the applicable Exercise Date for an Offering Period shall be equal to eighty five percent (85%) of the lesser of the Fair Market Value of a share of Common Stock on (a) the applicable Grant Date and (b) the applicable Exercise Date&#59; provided that in no event shall the Option Price per share of Common Stock be less than the par value per share of the Common Stock.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21pt">Purchase of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">On the applicable Exercise Date for an Offering Period, each Participant shall automatically and without any action on such Participant&#8217;s part be deemed to have exercised his or her Option to purchase at the applicable per share Option Price the largest number of whole shares of Common Stock which can be purchased with the amount in the Participant&#8217;s Plan Account. Any balance less than the per share Option Price that is remaining in the Participant&#8217;s Plan Account (after exercise of such Participant&#8217;s Option) as of the Exercise Date shall be carried forward to the next Offering Period, unless the Participant has elected to withdraw from the Plan pursuant to Section 6.1 hereof or, pursuant to Section 6.2 hereof, such Participant has ceased to be an Eligible Employee. Any balance not carried forward to the next Offering Period in accordance with the prior sentence promptly shall be refunded to the applicable Participant. For the avoidance of doubt, in no event shall an amount greater than or equal to the per share Option Price as of an Exercise Date be carried forward to the next Offering Period.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">As soon as practicable following the applicable Exercise Date, the number of shares of Common Stock purchased by such Participant pursuant to Section 4.3(a) hereof shall be delivered (either in share certificate or book entry form), in the Company&#8217;s sole discretion, to either (i) the Participant or (ii) an account established in the Participant&#8217;s name at a stock brokerage or other financial services firm designated by the Company. If the Company is required to obtain from any commission or agency authority to issue any such shares of Common Stock, the Company shall seek to obtain such authority. Inability of the Company to obtain from any such commission or agency authority which counsel for the Company deems necessary for the lawful issuance of any such shares shall relieve the Company from liability to any Participant except to refund to the Participant such Participant&#8217;s Plan Account balance, without interest thereon.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21pt">Transferability of Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">An Option granted under the Plan shall not be transferable, other than by will or the applicable laws of descent and distribution, and is exercisable during the Participant&#8217;s lifetime only by the Participant. No option or interest or right to the Option shall be available to pay off any debts, contracts or engagements of the Participant or his or her successors in interest or shall be subject to disposition by pledge, encumbrance, assignment or any other means whether such disposition be voluntary or involuntary or by operation of law by judgment, levy, attachment, garnishment or any other legal or equitable proceedings (including bankruptcy), and any attempt at disposition of the option shall have no effect.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE V</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROVISIONS RELATING TO COMMON STOCK</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Common Stock Reserved</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subject to adjustment as provided in Section 5.2 hereof, the maximum number of shares of Common Stock that shall be made available for sale under the Plan shall be 8,800,000. Shares of Common Stock made available for sale under the Plan may be authorized but unissued shares, treasury shares of Common Stock, or reacquired shares reserved for issuance under the Plan.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Adjustments Upon Changes in Capitalization, Dissolution, Liquidation, Merger or Asset Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Changes in Capitalization. Subject to any required action by the stockholders of the Company, the number of shares of Common Stock which have been authorized for issuance under the Plan but not yet placed under Option, as well as the price per share and the number of shares of Common Stock covered by each Option under the Plan which has not yet been exercised shall be proportionately adjusted for any increase or decrease in the number of issued shares of Common Stock resulting from a stock split, reverse stock split, stock dividend, combination or reclassification of the Common Stock, or any other increase or decrease in the number of shares of Common Stock effected without receipt of consideration by the Company&#59; provided, however, that conversion of any convertible securities of the Company shall not be deemed to have been &#8220;effected without receipt of consideration.&#8221; Such adjustment shall be made by the Administrator, whose determination in that respect shall be final, binding and conclusive. Except as expressly provided herein, no issuance by the Company of shares of stock of any class, or securities convertible into shares of stock of any class, shall affect, and no adjustment by reason thereof shall be made with respect to, the number or price of shares of Common Stock subject to an Option.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Dissolution or Liquidation. In the event of the proposed dissolution or liquidation of the Company, the Offering Period then in progress shall be shortened by setting a new Exercise Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Exercise Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), and shall terminate immediately prior to the consummation of such proposed dissolution or liquidation, unless provided otherwise by the Administrator. The New Exercise Date shall be before the date of the Company&#8217;s proposed dissolution or liquidation. The Administrator shall notify each Participant in writing, at least ten (10) business days prior to the New Exercise Date, that the Exercise Date for the Participant&#8217;s Option has been changed to the New Exercise Date and that the Participant&#8217;s Option shall be exercised automatically on the New Exercise Date, unless prior to such date the Participant has withdrawn from the Offering Period as provided in Section 6.1 hereof.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Merger or Asset Sale. In the event of a proposed sale of all or substantially all of the assets of the Company, or the merger of the Company with or into another corporation, each outstanding Option shall be assumed or an equivalent Option substituted by the successor corporation or a Parent or Subsidiary of the successor corporation. In the event that the successor corporation refuses to assume or substitute for the Option, any Offering Periods then in progress shall be shortened by setting a New Exercise Date and any Offering Periods then in progress shall end on the New Exercise Date. The New Exercise Date shall be before the date of the Company&#8217;s proposed sale or merger. The Administrator shall notify each Participant in writing, at least ten (10) business days prior to the New Exercise Date, that the Exercise Date for the Participant&#8217;s Option has been changed to the New Exercise Date and that the Participant&#8217;s Option shall be exercised automatically on the New Exercise Date, unless prior to such date the Participant has withdrawn from the Offering Period as provided in Section 6.1 hereof.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Insufficient Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If the Administrator determines that, on a given Exercise Date, the number of shares of Common Stock with respect to which Options are to be exercised may exceed the number of shares of Common Stock remaining available for sale under the Plan on such Exercise Date, the Administrator shall make a pro rata allocation of the shares of Common Stock available for issuance on such Exercise Date in as uniform a manner as shall be practicable and as it shall determine in its sole discretion to be equitable among all Participants exercising Options to purchase Common Stock on such Exercise Date, and unless additional shares are authorized for issuance under the Plan, no further Offering Periods shall take place and the Plan shall terminate pursuant to Section 7.5 hereof. If an Offering Period is so terminated, then the balance of the amount credited to the Participant&#8217;s Plan Account which has not been applied to the purchase of shares of Common Stock shall be paid to such Participant in one lump sum in cash within thirty (30) days after such Exercise Date, without any interest thereon.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Rights as Stockholders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. With respect to shares of Common Stock subject to an Option, a Participant shall not be deemed to be a stockholder of the Company and shall not have any of the rights or privileges of a stockholder. A Participant shall have the rights and privileges of a stockholder of the Company when, but not until, shares of Common Stock have been deposited in the designated brokerage account following exercise of his or her Option.</font></div><div style="margin-bottom:9pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE VI</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TERMINATION OF PARTICIPATION</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Cessation of Contributions&#59; Voluntary Withdrawal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">A Participant may cease payroll deductions during an Offering Period and elect to withdraw from the Plan by delivering written notice of such election to the Company in such form and at such time prior to the Exercise Date for such Offering Period as may be established by the Administrator (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Withdrawal Election</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). A Participant electing to withdraw from the Plan may elect to either (i) withdraw all of the funds then credited to the Participant&#8217;s Plan Account as of the date on which the Withdrawal Election is received by the Company, in which case amounts credited to such Plan Account shall be returned to the Participant in one (1) lump-sum payment in cash within thirty (30) days after such election is received by the Company, without any interest thereon, and the Participant shall cease to participate in the Plan and the Participant&#8217;s Option for such Offering Period shall terminate&#59; or (ii) exercise the Option for the maximum number of whole shares of Common Stock on the applicable Exercise Date with any remaining Plan Account balance returned to the Participant in one (1) lump-sum payment in cash within thirty (30) days after such Exercise Date, without any interest thereon, and after such exercise cease to participate in the Plan. Upon receipt of a Withdrawal Election, the Participant&#8217;s payroll deduction authorization and his or her Option to purchase under the Plan shall terminate.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">A participant&#8217;s withdrawal from the Plan shall not have any effect upon his or her eligibility to participate in any similar plan which may hereafter be adopted by the Company or in succeeding Offering Periods which commence after the termination of the Offering Period from which the Participant withdraws.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">A Participant who ceases contributions to the Plan during any Offering Period shall not be permitted to resume contributions to the Plan during that Offering Period.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Termination of Eligibility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Upon a Participant&#8217;s ceasing to be an Eligible Employee, for any reason, such Participant&#8217;s Option for the applicable Offering Period shall automatically terminate, he or she shall be deemed to have elected to withdraw from the Plan, and such Participant&#8217;s Plan Account shall be paid to such Participant or, in the case of his or her death, to the person or persons entitled thereto pursuant to applicable law, within thirty (30) days after such cessation of being an Eligible Employee, without any interest thereon.</font></div><div style="margin-bottom:9pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE VII</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GENERAL PROVISIONS</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Administration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Plan shall be administered by the Committee, which shall be composed of members of the Board. The Committee may delegate administrative tasks under the Plan to the services of an Agent and&#47;or Employees to assist in the administration of the Plan, including establishing and maintaining an individual securities account under the Plan for each Participant.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">It shall be the duty of the Administrator to conduct the general administration of the Plan in accordance with the provisions of the Plan. The Administrator shall have the power, subject to, and within the limitations of, the express provisions of the Plan&#58;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">To establish Offering Periods&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.8pt">To determine when and how Options shall be granted and the provisions and terms of each Offering Period (which need not be identical)&#59;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.03pt">To select Designated Subsidiaries in accordance with Section 7.2 hereof&#59; and</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.57pt">To construe and interpret the Plan, the terms of any Offering Period and the terms of the Options and to adopt such rules for the administration, interpretation, and application of the Plan as are consistent therewith and to interpret, amend or revoke any such rules. The Administrator, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan, any Offering Period or any Option, in a manner and to the extent it shall deem necessary or expedient to make the Plan fully effect, subject to Section 423 of the Code and the Treasury Regulations thereunder.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">The Administrator may adopt rules or procedures relating to the operation and administration of the Plan to accommodate the specific requirements of local laws and procedures. Without limiting the generality of the foregoing, the Administrator is specifically authorized to adopt rules and procedures regarding handling of participation elections, payroll deductions, payment of interest, conversion of local currency, payroll tax, withholding procedures and handling of stock certificates which vary with local requirements. In its absolute discretion, the Board may at any time and from time to time exercise any and all rights and duties of the Administrator under the Plan.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">The Administrator may adopt sub-plans applicable to particular Designated Subsidiaries or locations, which sub-plans may be designed to be outside the scope of Section 423 of the Code. The rules of such sub-plans may take precedence over other provisions of this Plan, with the exception of Section 5.1 hereof, but unless otherwise superseded by the terms of such sub-plan, the provisions of this Plan shall govern the operation of such sub-plan.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All expenses and liabilities incurred by the Administrator in connection with the administration of the Plan shall be borne by the Company. The Administrator may, with the approval of the Committee, employ attorneys, consultants, accountants, appraisers, brokers or other persons. The Administrator, the Company and its officers and directors shall be entitled to rely upon the advice, opinions or valuations of any such persons. All actions taken and all interpretations and determinations made by the Administrator in good faith shall be final and binding upon all Participants, the Company and all other interested persons. No member of the Board or Administrator shall be personally liable for any action, determination or interpretation made in good faith with respect to the Plan or the options, and all members of the Board or Administrator shall be fully protected by the Company in respect to any such action, determination, or interpretation.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Designation of Subsidiary Corporations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Board or Committee shall designate from among the Subsidiaries, as determined from time to time, the Subsidiary or Subsidiaries that shall constitute Designated Subsidiaries. The Board or Committee may designate a Subsidiary, or terminate the designation of a Subsidiary, without the approval of the stockholders of the Company.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Individual accounts shall be maintained for each Participant in the Plan. Statements of Plan Accounts shall be given to Participants at least annually, which statements shall set forth the amounts of payroll deductions, the Option Price, the number of shares purchased and the remaining cash balance, if any.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">No Right to Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Nothing in the Plan shall be construed to give any person (including any Participant) the right to remain in the employ of the Company, a Parent or a Subsidiary or to affect the right of the Company, any Parent or any Subsidiary to terminate the employment of any person (including any Participant) at any time, with or without cause, which right is expressly reserved.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Amendment and Termination of the Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Board may, in its sole discretion, amend, suspend or terminate the Plan at any time and from time to time&#59; provided, however, that without approval of the Company&#8217;s stockholders given within twelve (12) months before or after action by the Board, the Plan may not be amended to increase the maximum number of shares of Common Stock subject to the Plan or change the designation or class of Eligible Employees&#59; and provided, further </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that without approval of the Company&#8217;s stockholders, the Plan may not be amended in any manner that would cause the Plan to no longer be an &#8220;employee stock purchase plan&#8221; within the meaning of Section 423(b) of the Code.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">In the event the Administrator determines that the ongoing operation of the Plan may result in unfavorable financial accounting consequences, the Administrator may, to the extent permitted under Section 423 of the Code, in its discretion and, to the extent necessary or desirable, modify or amend the Plan to reduce or eliminate such accounting consequence including, but not limited to&#58;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">altering the Option Price for any Offering Period including an Offering Period underway at the time of the change in Option Price&#59;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.8pt">shortening any Offering Period so that the Offering Period ends on a new Exercise Date, including an Offering Period underway at the time of the Administrator action&#59; and (iii) allocating shares of Common Stock.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such modifications or amendments shall not require stockholder approval or consent of any Participant.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Upon termination of the Plan, the balance in each Participant&#8217;s Plan Account shall be refunded as soon as practicable after such termination, without any interest thereon.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Use of Funds&#59; No Interest Paid</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All funds received by the Company by reason of purchase of Common Stock under the Plan shall be included in the general funds of the Company free of any trust or other restriction and may be used for any corporate purpose. No interest shall be paid to any Participant or credited under the Plan.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Term&#59; Approval by Stockholders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. No Option may be granted during any period of suspension of the Plan or after termination of the Plan. The Plan shall be submitted for the approval of the Company&#8217;s stockholders within twelve (12) months after the date of the Board&#8217;s initial adoption of the Plan. Options may be granted prior to such stockholder approval&#59; provided, however, that such Options shall not be exercisable prior to the time when the Plan is approved by the stockholders&#59; provided, further that if such approval has not been obtained by the end of said twelve (12)-month period, all Options previously granted under the Plan shall thereupon terminate and be canceled and become null and void without being exercised.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Effect Upon Other Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The adoption of the Plan shall not affect any other compensation or incentive plans in effect for the Company, any Parent or any Subsidiary. Nothing in the Plan shall be construed to limit the right of the Company, any Parent or any Subsidiary (a) to establish any other forms of incentives or compensation for Employees of the Company or any Parent or any Subsidiary, or (b) to grant or assume Options otherwise than under the Plan in connection with any proper corporate purpose, including, but not by way of limitation, the grant or assumption of options in connection with the acquisition, by purchase, lease, merger, consolidation or otherwise, of the business, stock or assets of any corporation, firm or association.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Conformity to Securities Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Notwithstanding any other provision of the Plan, the Plan and the participation in the Plan by any individual who is then subject to Section 16 of the Exchange Act shall be subject to any additional limitations set forth in any applicable exemption rule under Section 16 of the Exchange Act (including any amendment to Rule 16b-3 of the Exchange Act) that are requirements for the application of such exemptive rule. To the extent permitted by applicable law, the Plan shall be deemed amended to the extent necessary to conform to such applicable exemptive rule.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:18.5pt">Notice of Disposition of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Each Participant shall give the Company prompt notice of any disposition or other transfer of any shares of Common Stock, acquired pursuant to the exercise of an Option, if such disposition or transfer is made (a) within two (2) years after the applicable Grant Date or (b) within one (1) year after the transfer of such shares of Common Stock to such Participant upon exercise of such Option. The Company may direct that any certificates evidencing shares acquired pursuant to the Plan refer to such requirement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:18.5pt">Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company or any Parent or any Subsidiary shall be entitled to require payment in cash or deduction from other compensation payable to each Participant of any sums required by federal, state or local tax law to be withheld with respect to any purchase of shares of Common Stock under the Plan or any sale of such shares.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:18.5pt">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Plan and all rights and obligations thereunder shall be construed and enforced in accordance with the laws of the State of Delaware.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:18.5pt">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All notices or other communications by a participant to the Company under or in connection with the Plan shall be deemed to have been duly given when received in the form specified by the Company at the location, or by the person, designated by the Company for the receipt thereof.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:18.5pt">Conditions To Issuance of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Notwithstanding anything herein to the contrary, the Company shall not be required to issue or deliver any certificates or make any book entries evidencing shares of Common Stock pursuant to the exercise of an Option by a Participant, unless and until the Board or the Committee has determined, with advice of counsel, that the issuance of such shares of Common Stock is in compliance with all applicable laws, regulations of governmental authorities and, if applicable, the requirements of any securities exchange or automated quotation system on which the shares of Common Stock are listed or traded, and the shares of Common Stock are covered by an effective registration statement or applicable exemption from registration. In addition to the terms and conditions provided herein, the Board or the Committee may require that a Participant make such reasonable covenants, agreements, and representations as the Board or the Committee, in its discretion, deems advisable in order to comply with any such laws, regulations, or requirements.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">All certificates for shares of Common Stock delivered pursuant to the Plan and all shares of Common Stock issued pursuant to book entry procedures are subject to any stop-transfer orders and other restrictions as the Committee deems necessary or advisable to comply with federal, state, or foreign securities or other laws, rules and regulations and the rules of any securities exchange or automated quotation system on which the shares of Common Stock are listed, quoted, or traded. The Committee may place legends on any certificate or book entry evidencing shares of Common Stock to reference restrictions applicable to the shares of Common Stock.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">The Committee shall have the right to require any Participant to comply with any timing or other restrictions with respect to the settlement, distribution or exercise of any Option, including a window-period limitation, as may be imposed in the sole discretion of the Committee.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Notwithstanding any other provision of the Plan, unless otherwise determined by the Committee or required by any applicable law, rule or regulation, the Company may, in lieu of delivering to any Participant certificates evidencing shares of Common Stock issued in connection with any Option, record the issuance of shares of Common Stock in the books of the Company (or, as applicable, its transfer agent or stock plan administrator).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:18.5pt">Equal Rights and Privileges</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Except with respect to sub-plans designed to be outside the scope of Section 423 of the Code, all Eligible Employees of the Company (or of any Designated Subsidiary) shall have equal rights and privileges under this Plan to the extent required under Section 423 of the Code or the regulations promulgated thereunder so that this Plan qualifies as an &#8220;employee stock purchase plan&#8221; within the meaning of Section 423 of the Code or the Treasury Regulations thereunder. Any provision of this Plan that is inconsistent with Section 423 of the Code or the Treasury Regulations thereunder shall, without further act or amendment by the Company or the Board, be reformed to comply with the equal rights and privileges requirement of Section 423 of the Code or the Treasury Regulations thereunder.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>8
<FILENAME>advm-20220630ex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ibcae07240a64494bbea1f17fdd76946b_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Laurent Fischer, certify that&#58;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this Form 10-Q of Adverum Biotechnologies, Inc.&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; August&#160;11, 2022 </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.844%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Laurent Fischer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laurent Fischer, M.D.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>9
<FILENAME>advm-20220630ex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i69b43d476fee47a48cfac20a650f8a6f_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, John Rakow, certify that&#58;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this Form 10-Q of Adverum Biotechnologies, Inc.&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; August&#160;11, 2022</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tr><td style="width:1.0%"></td><td style="width:2.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.219%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.894%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John Rakow</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Rakow</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, General Counsel and Acting Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>10
<FILENAME>advm-20220630ex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i4abcab55094b4ceaa7ddccd1dfd49590_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Adverum Biotechnologies, Inc. for the fiscal quarter ended June&#160;30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), Laurent Fischer, in his capacity as Chief Executive Officer of Adverum Biotechnologies, Inc., hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge, the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Adverum Biotechnologies, Inc.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.508%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 11, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Laurent Fischer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laurent Fischer, M.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>11
<FILENAME>advm-20220630ex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="icda8e539e1b44559b053b3a381820986_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Adverum Biotechnologies, Inc. for the fiscal quarter ended June&#160;30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), John Rakow, in his capacity as Chief Financial Officer, of Adverum Biotechnologies, Inc., hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge, the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Adverum Biotechnologies, Inc.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.508%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 11, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John Rakow</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Rakow</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, General Counsel and Acting Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>advm-20220630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:4ac67419-c73c-4942-8754-fc53d915184d,g:dfc73ebd-49d4-42d9-8e60-60c5f25a86bb-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:advm="http://www.adverum.com/20220630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.adverum.com/20220630">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="advm-20220630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="advm-20220630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="advm-20220630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="advm-20220630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.adverum.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.adverum.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>1002003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquityParenthetical" roleURI="http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Stockholders Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentation" roleURI="http://www.adverum.com/role/OrganizationandBasisofPresentation">
        <link:definition>2101101 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationDetail" roleURI="http://www.adverum.com/role/OrganizationandBasisofPresentationDetail">
        <link:definition>2402401 - Disclosure - Organization and Basis of Presentation (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.adverum.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandFairValueofFinancialInstruments" roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments">
        <link:definition>2105103 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandFairValueofFinancialInstrumentsTables" roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables">
        <link:definition>2306301 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail" roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail">
        <link:definition>2407402 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Summary of Cash Equivalents and Short-term Investments (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail" roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail">
        <link:definition>2408403 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponents" roleURI="http://www.adverum.com/role/BalanceSheetComponents">
        <link:definition>2109104 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsTables" roleURI="http://www.adverum.com/role/BalanceSheetComponentsTables">
        <link:definition>2310302 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail">
        <link:definition>2411404 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail" roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail">
        <link:definition>2412405 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwards" roleURI="http://www.adverum.com/role/EquityIncentiveAwards">
        <link:definition>2113105 - Disclosure - Equity Incentive Awards</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwardsTables" roleURI="http://www.adverum.com/role/EquityIncentiveAwardsTables">
        <link:definition>2314303 - Disclosure - Equity Incentive Awards (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwardsSummaryofStockOptionsActivityDetail" roleURI="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetail">
        <link:definition>2415406 - Disclosure - Equity Incentive Awards - Summary of Stock Options Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwardsAdditionalInformationDetail" roleURI="http://www.adverum.com/role/EquityIncentiveAwardsAdditionalInformationDetail">
        <link:definition>2416407 - Disclosure - Equity Incentive Awards - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail" roleURI="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail">
        <link:definition>2417408 - Disclosure - Equity Incentive Awards - Summary of Restricted Stock Units Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwardsStockBasedCompensationExpenseDetail" roleURI="http://www.adverum.com/role/EquityIncentiveAwardsStockBasedCompensationExpenseDetail">
        <link:definition>2418409 - Disclosure - Equity Incentive Awards - Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShare" roleURI="http://www.adverum.com/role/NetLossperShare">
        <link:definition>2119106 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareTables" roleURI="http://www.adverum.com/role/NetLossperShareTables">
        <link:definition>2320304 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetail" roleURI="http://www.adverum.com/role/NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetail">
        <link:definition>2421410 - Disclosure - Net Loss per Share - Schedule of Common Stock Equivalents Outstanding (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvent" roleURI="http://www.adverum.com/role/SubsequentEvent">
        <link:definition>2122107 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventDetails" roleURI="http://www.adverum.com/role/SubsequentEventDetails">
        <link:definition>2423411 - Disclosure - Subsequent Event (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="advm_CashAndCashEquivalentGrossUnrealizedGain" abstract="false" name="CashAndCashEquivalentGrossUnrealizedGain" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_AccruedExpensesAndOtherCurrentLiabilities" abstract="false" name="AccruedExpensesAndOtherCurrentLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_CashAndCashEquivalentGrossUnrealizedLoss" abstract="false" name="CashAndCashEquivalentGrossUnrealizedLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset" abstract="false" name="IncreaseDecreaseOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities" abstract="false" name="OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_CashEquivalentsAndShortTermInvestmentsMember" abstract="true" name="CashEquivalentsAndShortTermInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="advm_CashAndCashEquivalentAmortizedCost" abstract="false" name="CashAndCashEquivalentAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable" abstract="false" name="IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts" abstract="false" name="AccruedNonclinicalClinicalAndDevelopmentProcessCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>advm-20220630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:4ac67419-c73c-4942-8754-fc53d915184d,g:dfc73ebd-49d4-42d9-8e60-60c5f25a86bb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.adverum.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="advm-20220630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f5b5a913-f1ea-4a3a-bf3a-1771d51ed093" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ef7b857d-2e3d-4977-ae80-238ac8f8ee14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f5b5a913-f1ea-4a3a-bf3a-1771d51ed093" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ef7b857d-2e3d-4977-ae80-238ac8f8ee14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_ad27cad0-bdec-4b97-b9e7-ea314cc2999d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f5b5a913-f1ea-4a3a-bf3a-1771d51ed093" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_ad27cad0-bdec-4b97-b9e7-ea314cc2999d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_f60cdca1-1921-4f9f-a154-c2614bda1e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f5b5a913-f1ea-4a3a-bf3a-1771d51ed093" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_f60cdca1-1921-4f9f-a154-c2614bda1e9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_bfaaee6d-a9fd-4fdb-8b4c-08136965942d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f5b5a913-f1ea-4a3a-bf3a-1771d51ed093" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_bfaaee6d-a9fd-4fdb-8b4c-08136965942d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9410d7ae-51c0-4802-8aed-68048e35e84a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f5b5a913-f1ea-4a3a-bf3a-1771d51ed093" xlink:to="loc_us-gaap_AssetsCurrent_9410d7ae-51c0-4802-8aed-68048e35e84a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentReceivablesNet_9c5df242-5316-4bb9-88a6-880aae74807f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentReceivablesNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f5b5a913-f1ea-4a3a-bf3a-1771d51ed093" xlink:to="loc_us-gaap_DeferredRentReceivablesNet_9c5df242-5316-4bb9-88a6-880aae74807f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_064ca705-dc70-4547-b95e-6df35a5bb729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_dcf501ce-de6b-46fc-9b2e-11bf14f03553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_064ca705-dc70-4547-b95e-6df35a5bb729" xlink:to="loc_us-gaap_Liabilities_dcf501ce-de6b-46fc-9b2e-11bf14f03553" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e6e0620b-4554-47d7-91c7-c4d3e7b08094" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_064ca705-dc70-4547-b95e-6df35a5bb729" xlink:to="loc_us-gaap_StockholdersEquity_e6e0620b-4554-47d7-91c7-c4d3e7b08094" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a4e59ad8-0992-4157-85d4-6c0cda51bffa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_e1856bb1-d16f-44d7-a308-368af6b4a93f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a4e59ad8-0992-4157-85d4-6c0cda51bffa" xlink:to="loc_us-gaap_AccountsPayableCurrent_e1856bb1-d16f-44d7-a308-368af6b4a93f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_d6c9b50a-836f-4698-84b1-491bd8759d3f" xlink:href="advm-20220630.xsd#advm_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a4e59ad8-0992-4157-85d4-6c0cda51bffa" xlink:to="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_d6c9b50a-836f-4698-84b1-491bd8759d3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_67cdf527-7a86-4dc2-a963-7ac32cd6f009" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a4e59ad8-0992-4157-85d4-6c0cda51bffa" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_67cdf527-7a86-4dc2-a963-7ac32cd6f009" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0c0cabb5-e2bd-4fe5-b757-44011b080d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b22ae096-2f61-43e3-a6da-0d0ec32749a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0c0cabb5-e2bd-4fe5-b757-44011b080d6e" xlink:to="loc_us-gaap_LiabilitiesCurrent_b22ae096-2f61-43e3-a6da-0d0ec32749a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4355663a-c581-4597-abb2-8ecf606cd858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0c0cabb5-e2bd-4fe5-b757-44011b080d6e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4355663a-c581-4597-abb2-8ecf606cd858" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_9caf9a6d-b1b8-4a03-ac70-c4270bdd2321" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0c0cabb5-e2bd-4fe5-b757-44011b080d6e" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_9caf9a6d-b1b8-4a03-ac70-c4270bdd2321" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_77645777-4125-4560-95cb-5d93964e8392" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_75180425-17f5-40f1-8a5d-8936313370ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_77645777-4125-4560-95cb-5d93964e8392" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_75180425-17f5-40f1-8a5d-8936313370ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_a2464c9d-1f17-43dd-bf06-b76a4b218ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_77645777-4125-4560-95cb-5d93964e8392" xlink:to="loc_us-gaap_ShortTermInvestments_a2464c9d-1f17-43dd-bf06-b76a4b218ba6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_47b79a58-c1d9-4e1c-95d9-824884c9234c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_77645777-4125-4560-95cb-5d93964e8392" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_47b79a58-c1d9-4e1c-95d9-824884c9234c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncentiveToLessee_5c0a40ba-f9b5-4900-88b1-eb98bcc25d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncentiveToLessee"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_77645777-4125-4560-95cb-5d93964e8392" xlink:to="loc_us-gaap_IncentiveToLessee_5c0a40ba-f9b5-4900-88b1-eb98bcc25d0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_527e396a-74b3-401e-9db5-a63155b14853" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_10ec388c-c997-46ca-a2ad-bb9550e57b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_527e396a-74b3-401e-9db5-a63155b14853" xlink:to="loc_us-gaap_PreferredStockValue_10ec388c-c997-46ca-a2ad-bb9550e57b8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_55b57d75-c490-433f-aa99-e6e1c07f6dd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_527e396a-74b3-401e-9db5-a63155b14853" xlink:to="loc_us-gaap_CommonStockValue_55b57d75-c490-433f-aa99-e6e1c07f6dd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_2cd39122-29b3-41d9-9b89-408104fe42fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_527e396a-74b3-401e-9db5-a63155b14853" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_2cd39122-29b3-41d9-9b89-408104fe42fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_cd22a6a6-a291-4ddc-9ff7-38ff96bb5669" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_527e396a-74b3-401e-9db5-a63155b14853" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_cd22a6a6-a291-4ddc-9ff7-38ff96bb5669" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0eb73818-ba40-4f43-a845-90f8aefe4b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_527e396a-74b3-401e-9db5-a63155b14853" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0eb73818-ba40-4f43-a845-90f8aefe4b5d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="advm-20220630.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_bcc7deb4-be53-4ab4-9fb7-a0054eac94cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d53c9954-8781-490f-8ca8-9445a25a1882" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_bcc7deb4-be53-4ab4-9fb7-a0054eac94cb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d53c9954-8781-490f-8ca8-9445a25a1882" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_1f0815e2-9980-496f-a55e-2aff1971a2a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_bcc7deb4-be53-4ab4-9fb7-a0054eac94cb" xlink:to="loc_us-gaap_OperatingExpenses_1f0815e2-9980-496f-a55e-2aff1971a2a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_97cefdef-2c8e-4335-8b92-8a8ab74a53e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_47dfcd4f-18ac-4799-beb9-bf33b11fa18b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_97cefdef-2c8e-4335-8b92-8a8ab74a53e8" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_47dfcd4f-18ac-4799-beb9-bf33b11fa18b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_801f0d3b-0c8e-4c4c-ae71-69ba951dc316" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_97cefdef-2c8e-4335-8b92-8a8ab74a53e8" xlink:to="loc_us-gaap_OperatingIncomeLoss_801f0d3b-0c8e-4c4c-ae71-69ba951dc316" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_732f6a63-c476-4aee-990d-b4cb48c469c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_378210fd-ea3d-43fc-a8b8-9e0659c4f0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_732f6a63-c476-4aee-990d-b4cb48c469c2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_378210fd-ea3d-43fc-a8b8-9e0659c4f0e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_61e16ec2-10c5-4328-a3cb-2192cb72dc63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_732f6a63-c476-4aee-990d-b4cb48c469c2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_61e16ec2-10c5-4328-a3cb-2192cb72dc63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2a9f01ae-fcab-42c7-8806-74471b930354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b3f81417-5d5c-4c9d-a4e9-cbc7ddddbfd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_2a9f01ae-fcab-42c7-8806-74471b930354" xlink:to="loc_us-gaap_NetIncomeLoss_b3f81417-5d5c-4c9d-a4e9-cbc7ddddbfd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_b0ddc734-7d26-4e07-9fee-8af7952f10e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_2a9f01ae-fcab-42c7-8806-74471b930354" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_b0ddc734-7d26-4e07-9fee-8af7952f10e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_034c9946-371c-4c2c-9da5-e397f37e8e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_2a9f01ae-fcab-42c7-8806-74471b930354" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_034c9946-371c-4c2c-9da5-e397f37e8e5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0a93894d-3371-4267-bec4-f624faed6fde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e1dafc51-a24e-4c43-99bc-81350c39e759" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0a93894d-3371-4267-bec4-f624faed6fde" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e1dafc51-a24e-4c43-99bc-81350c39e759" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1618bf9a-7724-4a95-980a-fa47d0154038" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0a93894d-3371-4267-bec4-f624faed6fde" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1618bf9a-7724-4a95-980a-fa47d0154038" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="advm-20220630.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_05b94d7e-8f1d-4149-8b0d-4063cdc13f25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b24a4761-04f7-4671-bbe2-bc3596dfe6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_05b94d7e-8f1d-4149-8b0d-4063cdc13f25" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b24a4761-04f7-4671-bbe2-bc3596dfe6b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_ccfc152a-e883-4fb8-9603-e5d100058f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_05b94d7e-8f1d-4149-8b0d-4063cdc13f25" xlink:to="loc_us-gaap_ShareBasedCompensation_ccfc152a-e883-4fb8-9603-e5d100058f6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0f1bac7f-143a-44d2-abb6-4b7e4f73038f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_05b94d7e-8f1d-4149-8b0d-4063cdc13f25" xlink:to="loc_us-gaap_NetIncomeLoss_0f1bac7f-143a-44d2-abb6-4b7e4f73038f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable_2b38646e-3065-4892-800f-699ba076ea53" xlink:href="advm-20220630.xsd#advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_05b94d7e-8f1d-4149-8b0d-4063cdc13f25" xlink:to="loc_advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable_2b38646e-3065-4892-800f-699ba076ea53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_7b1c7dd2-25bc-4221-a43f-055d586f91e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_05b94d7e-8f1d-4149-8b0d-4063cdc13f25" xlink:to="loc_us-gaap_DepreciationAndAmortization_7b1c7dd2-25bc-4221-a43f-055d586f91e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset_0bc03a03-157d-4919-8b97-f58833339f57" xlink:href="advm-20220630.xsd#advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_05b94d7e-8f1d-4149-8b0d-4063cdc13f25" xlink:to="loc_advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset_0bc03a03-157d-4919-8b97-f58833339f57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f7bbcc71-b694-4260-9188-1b802bcc42b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_05b94d7e-8f1d-4149-8b0d-4063cdc13f25" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f7bbcc71-b694-4260-9188-1b802bcc42b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_43a05e09-3d4b-4490-8dc6-5cd68d46c28b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_05b94d7e-8f1d-4149-8b0d-4063cdc13f25" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_43a05e09-3d4b-4490-8dc6-5cd68d46c28b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_54108b9d-4268-4489-9d64-a3e49ec3c5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_05b94d7e-8f1d-4149-8b0d-4063cdc13f25" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_54108b9d-4268-4489-9d64-a3e49ec3c5bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_1b9761b5-0935-4be8-ae07-76fb3c51b8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_05b94d7e-8f1d-4149-8b0d-4063cdc13f25" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_1b9761b5-0935-4be8-ae07-76fb3c51b8b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_932768ad-0111-43b3-aec1-14f62aa94843" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_05b94d7e-8f1d-4149-8b0d-4063cdc13f25" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_932768ad-0111-43b3-aec1-14f62aa94843" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_62f6b1fa-0a1f-4dac-9e76-42485bf4c647" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_05b94d7e-8f1d-4149-8b0d-4063cdc13f25" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_62f6b1fa-0a1f-4dac-9e76-42485bf4c647" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_7e3f58fa-99a5-4dd8-aecc-32ec46e55e47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_05b94d7e-8f1d-4149-8b0d-4063cdc13f25" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_7e3f58fa-99a5-4dd8-aecc-32ec46e55e47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_3986e930-d03b-4342-98f5-977cc35236cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_05b94d7e-8f1d-4149-8b0d-4063cdc13f25" xlink:to="loc_us-gaap_AssetImpairmentCharges_3986e930-d03b-4342-98f5-977cc35236cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d0adadd7-22b2-445f-95c4-3b2a90a095f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_49388149-f529-4b80-8b49-1a8ab1102f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d0adadd7-22b2-445f-95c4-3b2a90a095f2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_49388149-f529-4b80-8b49-1a8ab1102f3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_86a481db-9c7b-4bf7-841c-e1e821f0aa6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d0adadd7-22b2-445f-95c4-3b2a90a095f2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_86a481db-9c7b-4bf7-841c-e1e821f0aa6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fa1c65f7-a478-4b45-8513-4412305a7b92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d0adadd7-22b2-445f-95c4-3b2a90a095f2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fa1c65f7-a478-4b45-8513-4412305a7b92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2334f1af-3226-4da0-b018-8bb80943b8a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_26952775-41a2-41f6-8cb5-abe174af1ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2334f1af-3226-4da0-b018-8bb80943b8a2" xlink:to="loc_us-gaap_RepaymentsOfDebt_26952775-41a2-41f6-8cb5-abe174af1ef0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_aee3d00d-4741-4611-bdb1-b94ecb13f50b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2334f1af-3226-4da0-b018-8bb80943b8a2" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_aee3d00d-4741-4611-bdb1-b94ecb13f50b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_25f5aa69-dc46-4ed7-b2a5-1be4662587bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2334f1af-3226-4da0-b018-8bb80943b8a2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_25f5aa69-dc46-4ed7-b2a5-1be4662587bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_136f8be1-e217-4018-b3f2-17b6d8caa460" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2334f1af-3226-4da0-b018-8bb80943b8a2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_136f8be1-e217-4018-b3f2-17b6d8caa460" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_12500a29-556a-43e3-a77b-b3b72b4cd843" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_f3e01469-0c78-40ce-bb54-ed0e9eed7612" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_12500a29-556a-43e3-a77b-b3b72b4cd843" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_f3e01469-0c78-40ce-bb54-ed0e9eed7612" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_fd5f0421-8636-45ab-ab56-743cae325848" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_12500a29-556a-43e3-a77b-b3b72b4cd843" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_fd5f0421-8636-45ab-ab56-743cae325848" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d254130e-0b2b-4be3-8833-a27aef95c52b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_12500a29-556a-43e3-a77b-b3b72b4cd843" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d254130e-0b2b-4be3-8833-a27aef95c52b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_8777d932-499b-4cda-ad99-d5cdb5f3666e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_12500a29-556a-43e3-a77b-b3b72b4cd843" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_8777d932-499b-4cda-ad99-d5cdb5f3666e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_17d74ef8-9828-4786-9ec2-f1a4a5e3f2b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_67aa9620-701e-4b64-bd96-13f879ec2bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_17d74ef8-9828-4786-9ec2-f1a4a5e3f2b1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_67aa9620-701e-4b64-bd96-13f879ec2bcc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_aee7d468-f465-435e-b88f-379546504f38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_17d74ef8-9828-4786-9ec2-f1a4a5e3f2b1" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_aee7d468-f465-435e-b88f-379546504f38" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail" xlink:type="simple" xlink:href="advm-20220630.xsd#FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_97d7ae91-fd18-453b-84a9-0eb745440f42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c353e39e-35be-4781-a296-5b7dbb4786c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_97d7ae91-fd18-453b-84a9-0eb745440f42" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c353e39e-35be-4781-a296-5b7dbb4786c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_87374b2a-11c7-4282-8e1b-2bc220676e99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_97d7ae91-fd18-453b-84a9-0eb745440f42" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_87374b2a-11c7-4282-8e1b-2bc220676e99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f983050e-c5fc-4073-a37e-b74927bb9694" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_97d7ae91-fd18-453b-84a9-0eb745440f42" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f983050e-c5fc-4073-a37e-b74927bb9694" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentAmortizedCost_672f9571-4214-4e93-a046-7f2210e754ec" xlink:href="advm-20220630.xsd#advm_CashAndCashEquivalentAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedGain_80bc2426-b7ef-48a6-9943-65adaecfd8a0" xlink:href="advm-20220630.xsd#advm_CashAndCashEquivalentGrossUnrealizedGain"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_CashAndCashEquivalentAmortizedCost_672f9571-4214-4e93-a046-7f2210e754ec" xlink:to="loc_advm_CashAndCashEquivalentGrossUnrealizedGain_80bc2426-b7ef-48a6-9943-65adaecfd8a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a0426d9e-8117-4777-b957-2cd0f442d5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_CashAndCashEquivalentAmortizedCost_672f9571-4214-4e93-a046-7f2210e754ec" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a0426d9e-8117-4777-b957-2cd0f442d5ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss_9572c5cc-6aa9-4ae9-8f6d-d123a3f3e429" xlink:href="advm-20220630.xsd#advm_CashAndCashEquivalentGrossUnrealizedLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_CashAndCashEquivalentAmortizedCost_672f9571-4214-4e93-a046-7f2210e754ec" xlink:to="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss_9572c5cc-6aa9-4ae9-8f6d-d123a3f3e429" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="simple" xlink:href="advm-20220630.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3f49e4a9-7fac-46a1-a056-425c580c8ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1104d939-62f7-4953-9dda-5752bb36e564" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_3f49e4a9-7fac-46a1-a056-425c580c8ae2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1104d939-62f7-4953-9dda-5752bb36e564" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2128f24c-cc52-43a4-8132-2f2890ceea74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_3f49e4a9-7fac-46a1-a056-425c580c8ae2" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2128f24c-cc52-43a4-8132-2f2890ceea74" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail" xlink:type="simple" xlink:href="advm-20220630.xsd#BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_74b1fe2d-d535-4f3d-840f-76e9ef68d099" xlink:href="advm-20220630.xsd#advm_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_27190785-7f5e-45df-87fa-553325463ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_74b1fe2d-d535-4f3d-840f-76e9ef68d099" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_27190785-7f5e-45df-87fa-553325463ef6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_07d7541b-2ed1-4462-b812-0022f98a2e61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_74b1fe2d-d535-4f3d-840f-76e9ef68d099" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_07d7541b-2ed1-4462-b812-0022f98a2e61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_de663a7e-c29a-473e-aefc-48a4e2d5e00f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_74b1fe2d-d535-4f3d-840f-76e9ef68d099" xlink:to="loc_us-gaap_TaxesPayableCurrent_de663a7e-c29a-473e-aefc-48a4e2d5e00f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts_b1bedaee-31ec-44c6-a553-de9f21d57d1b" xlink:href="advm-20220630.xsd#advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_74b1fe2d-d535-4f3d-840f-76e9ef68d099" xlink:to="loc_advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts_b1bedaee-31ec-44c6-a553-de9f21d57d1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_c3a5e4fe-f0a2-4654-97b7-16746b4d2c37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_74b1fe2d-d535-4f3d-840f-76e9ef68d099" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_c3a5e4fe-f0a2-4654-97b7-16746b4d2c37" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>advm-20220630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:4ac67419-c73c-4942-8754-fc53d915184d,g:dfc73ebd-49d4-42d9-8e60-60c5f25a86bb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="advm-20220630.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i5ed78455ed2746a68fb897159e4cc041_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e174cf4f-0c45-413b-94c8-2693f22bcdc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d33802f5-f57a-4658-abd9-a3eb9794f5c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e174cf4f-0c45-413b-94c8-2693f22bcdc9" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d33802f5-f57a-4658-abd9-a3eb9794f5c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_73363219-9d73-4526-b2ac-3285240bea1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d33802f5-f57a-4658-abd9-a3eb9794f5c4" xlink:to="loc_us-gaap_SharesOutstanding_73363219-9d73-4526-b2ac-3285240bea1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b2e7d7ff-db31-43e9-9969-65acb7bbb6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d33802f5-f57a-4658-abd9-a3eb9794f5c4" xlink:to="loc_us-gaap_StockholdersEquity_b2e7d7ff-db31-43e9-9969-65acb7bbb6d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5fc7deeb-a2c1-4975-87e3-cb63c0928cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d33802f5-f57a-4658-abd9-a3eb9794f5c4" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5fc7deeb-a2c1-4975-87e3-cb63c0928cc3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_380cf236-d8ad-4a25-b11b-dc2b18ef8425" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d33802f5-f57a-4658-abd9-a3eb9794f5c4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_380cf236-d8ad-4a25-b11b-dc2b18ef8425" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4ecda0ae-a287-43fc-a48b-e2717509f853" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d33802f5-f57a-4658-abd9-a3eb9794f5c4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4ecda0ae-a287-43fc-a48b-e2717509f853" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_89906a4e-db46-4727-9638-bbe1676bcd0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d33802f5-f57a-4658-abd9-a3eb9794f5c4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_89906a4e-db46-4727-9638-bbe1676bcd0a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_c9dd5d73-c4f4-4311-96ab-4a3746dc58b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d33802f5-f57a-4658-abd9-a3eb9794f5c4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_c9dd5d73-c4f4-4311-96ab-4a3746dc58b1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_3bb14454-5bdf-4a9a-9724-535825336240" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d33802f5-f57a-4658-abd9-a3eb9794f5c4" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_3bb14454-5bdf-4a9a-9724-535825336240" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_67f5d234-da33-4707-9ee4-972540d726b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d33802f5-f57a-4658-abd9-a3eb9794f5c4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_67f5d234-da33-4707-9ee4-972540d726b7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a467e889-f11e-449a-838e-8f93f68ce168" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d33802f5-f57a-4658-abd9-a3eb9794f5c4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a467e889-f11e-449a-838e-8f93f68ce168" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_328d188d-1438-447f-8c0a-79b0b08f8fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d33802f5-f57a-4658-abd9-a3eb9794f5c4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_328d188d-1438-447f-8c0a-79b0b08f8fbf" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_c8199bf8-c4b3-4a70-a731-fe08d1d6d0bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d33802f5-f57a-4658-abd9-a3eb9794f5c4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_c8199bf8-c4b3-4a70-a731-fe08d1d6d0bc" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_4d85ce86-57d7-424c-a014-28e7b93a35f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d33802f5-f57a-4658-abd9-a3eb9794f5c4" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_4d85ce86-57d7-424c-a014-28e7b93a35f4" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ff85bf9c-5888-4af9-b479-66af68f4a596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d33802f5-f57a-4658-abd9-a3eb9794f5c4" xlink:to="loc_us-gaap_NetIncomeLoss_ff85bf9c-5888-4af9-b479-66af68f4a596" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_6035f85d-9572-4eba-81d8-e590bdd11353" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e64ee12f-5f9f-4bd0-ba27-3e559a4de205" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6b79633e-e3db-4989-b849-3ff387e788a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_e174cf4f-0c45-413b-94c8-2693f22bcdc9" xlink:to="loc_us-gaap_StatementTable_6b79633e-e3db-4989-b849-3ff387e788a6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_51b23726-78d1-40f2-a47c-dc81a988b47e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6b79633e-e3db-4989-b849-3ff387e788a6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_51b23726-78d1-40f2-a47c-dc81a988b47e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_51b23726-78d1-40f2-a47c-dc81a988b47e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_51b23726-78d1-40f2-a47c-dc81a988b47e" xlink:to="loc_us-gaap_EquityComponentDomain_51b23726-78d1-40f2-a47c-dc81a988b47e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2bdcea69-7a49-4ae3-bc3d-987b201ad96b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_51b23726-78d1-40f2-a47c-dc81a988b47e" xlink:to="loc_us-gaap_EquityComponentDomain_2bdcea69-7a49-4ae3-bc3d-987b201ad96b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ae20b129-4cea-41ed-84f2-d514a0cab866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2bdcea69-7a49-4ae3-bc3d-987b201ad96b" xlink:to="loc_us-gaap_CommonStockMember_ae20b129-4cea-41ed-84f2-d514a0cab866" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_64ff2c12-c444-4079-af28-00d9f2f5ae4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2bdcea69-7a49-4ae3-bc3d-987b201ad96b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_64ff2c12-c444-4079-af28-00d9f2f5ae4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3ce01a4d-d095-48cb-9779-a38b29a7f61b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2bdcea69-7a49-4ae3-bc3d-987b201ad96b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3ce01a4d-d095-48cb-9779-a38b29a7f61b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_a282b61b-2950-41e2-acc7-8b2c337cf063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2bdcea69-7a49-4ae3-bc3d-987b201ad96b" xlink:to="loc_us-gaap_RetainedEarningsMember_a282b61b-2950-41e2-acc7-8b2c337cf063" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail" xlink:type="simple" xlink:href="advm-20220630.xsd#FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail" xlink:type="extended" id="i9e93d38cff464b259fb0260c9c3fe96f_FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2b4e4940-6adc-4637-9e79-72516dfdc591" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4dc5ccbf-f213-4c81-b5cc-7c157005444c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2b4e4940-6adc-4637-9e79-72516dfdc591" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4dc5ccbf-f213-4c81-b5cc-7c157005444c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b29b4312-5a1a-486d-89a6-69d86a435a66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2b4e4940-6adc-4637-9e79-72516dfdc591" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b29b4312-5a1a-486d-89a6-69d86a435a66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_30071fb3-f145-4bf8-81b2-5a4554ed984d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2b4e4940-6adc-4637-9e79-72516dfdc591" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_30071fb3-f145-4bf8-81b2-5a4554ed984d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_084a388b-f7aa-46b1-aefa-89b9da95dd24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2b4e4940-6adc-4637-9e79-72516dfdc591" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_084a388b-f7aa-46b1-aefa-89b9da95dd24" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentAmortizedCost_88b2ed89-39a0-4955-91f4-476ec1184ee8" xlink:href="advm-20220630.xsd#advm_CashAndCashEquivalentAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2b4e4940-6adc-4637-9e79-72516dfdc591" xlink:to="loc_advm_CashAndCashEquivalentAmortizedCost_88b2ed89-39a0-4955-91f4-476ec1184ee8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedGain_601ca04a-fae7-49e9-af98-57db2b5bc680" xlink:href="advm-20220630.xsd#advm_CashAndCashEquivalentGrossUnrealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2b4e4940-6adc-4637-9e79-72516dfdc591" xlink:to="loc_advm_CashAndCashEquivalentGrossUnrealizedGain_601ca04a-fae7-49e9-af98-57db2b5bc680" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss_732bfa1e-5d79-46b7-bbba-3f1b8c4c5f57" xlink:href="advm-20220630.xsd#advm_CashAndCashEquivalentGrossUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2b4e4940-6adc-4637-9e79-72516dfdc591" xlink:to="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss_732bfa1e-5d79-46b7-bbba-3f1b8c4c5f57" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_833a7f1f-dbd0-4e17-9e20-83b85724c566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2b4e4940-6adc-4637-9e79-72516dfdc591" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_833a7f1f-dbd0-4e17-9e20-83b85724c566" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_843beb1c-f417-4386-8905-8a99ec65ff1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2b4e4940-6adc-4637-9e79-72516dfdc591" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_843beb1c-f417-4386-8905-8a99ec65ff1b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_acba3893-47c9-4b39-a25c-282e18dd8f18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_843beb1c-f417-4386-8905-8a99ec65ff1b" xlink:to="loc_us-gaap_FinancialInstrumentAxis_acba3893-47c9-4b39-a25c-282e18dd8f18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_acba3893-47c9-4b39-a25c-282e18dd8f18_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_acba3893-47c9-4b39-a25c-282e18dd8f18" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_acba3893-47c9-4b39-a25c-282e18dd8f18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ab9a1cad-fc66-433c-90cb-ad66f2e34d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_acba3893-47c9-4b39-a25c-282e18dd8f18" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ab9a1cad-fc66-433c-90cb-ad66f2e34d5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_9a5493b5-1b27-4c60-89d0-257ed00f437e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ab9a1cad-fc66-433c-90cb-ad66f2e34d5a" xlink:to="loc_us-gaap_MoneyMarketFundsMember_9a5493b5-1b27-4c60-89d0-257ed00f437e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_26864499-a97d-4378-901c-b5f6e587d230" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ab9a1cad-fc66-433c-90cb-ad66f2e34d5a" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_26864499-a97d-4378-901c-b5f6e587d230" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_5ad1e7c3-05b5-40c4-8d20-40342d9ffa25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ab9a1cad-fc66-433c-90cb-ad66f2e34d5a" xlink:to="loc_us-gaap_CommercialPaperMember_5ad1e7c3-05b5-40c4-8d20-40342d9ffa25" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_57ad1331-46f0-498a-969e-7ee67db33759" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ab9a1cad-fc66-433c-90cb-ad66f2e34d5a" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_57ad1331-46f0-498a-969e-7ee67db33759" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashEquivalentsAndShortTermInvestmentsMember_45381be8-6601-4a7b-acd2-597c0beb7f59" xlink:href="advm-20220630.xsd#advm_CashEquivalentsAndShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ab9a1cad-fc66-433c-90cb-ad66f2e34d5a" xlink:to="loc_advm_CashEquivalentsAndShortTermInvestmentsMember_45381be8-6601-4a7b-acd2-597c0beb7f59" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_649a91a7-1a5f-4e38-90f2-aad128e3ecf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_843beb1c-f417-4386-8905-8a99ec65ff1b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_649a91a7-1a5f-4e38-90f2-aad128e3ecf9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_649a91a7-1a5f-4e38-90f2-aad128e3ecf9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_649a91a7-1a5f-4e38-90f2-aad128e3ecf9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_649a91a7-1a5f-4e38-90f2-aad128e3ecf9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a1fa0b15-4b49-488a-97f2-9fc5bba523a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_649a91a7-1a5f-4e38-90f2-aad128e3ecf9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a1fa0b15-4b49-488a-97f2-9fc5bba523a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_7df9306f-4667-424d-a398-15bb0d367830" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a1fa0b15-4b49-488a-97f2-9fc5bba523a2" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_7df9306f-4667-424d-a398-15bb0d367830" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_d98f05cb-15db-492d-996e-872693694830" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a1fa0b15-4b49-488a-97f2-9fc5bba523a2" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_d98f05cb-15db-492d-996e-872693694830" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="simple" xlink:href="advm-20220630.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="extended" id="i60864184163a419086f467747731ce45_BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_268f0839-6ef0-4ce8-ad33-92ff6a8dfa87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_e207c811-79ba-4e8c-ac80-5b0702e34a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_268f0839-6ef0-4ce8-ad33-92ff6a8dfa87" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_e207c811-79ba-4e8c-ac80-5b0702e34a3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3f5de1dd-d97d-47a5-9745-39b14565eca4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_268f0839-6ef0-4ce8-ad33-92ff6a8dfa87" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3f5de1dd-d97d-47a5-9745-39b14565eca4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3db29878-e4d9-43f2-ad6e-e488f87e8c40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_268f0839-6ef0-4ce8-ad33-92ff6a8dfa87" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3db29878-e4d9-43f2-ad6e-e488f87e8c40" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_09dcfe84-042b-4465-8378-675338a4a97a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_268f0839-6ef0-4ce8-ad33-92ff6a8dfa87" xlink:to="loc_us-gaap_AssetImpairmentCharges_09dcfe84-042b-4465-8378-675338a4a97a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_372adaef-a0e9-429a-bfc6-e696f17d3444" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_268f0839-6ef0-4ce8-ad33-92ff6a8dfa87" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_372adaef-a0e9-429a-bfc6-e696f17d3444" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_691d689b-3ce8-4855-a492-85146e9997aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_372adaef-a0e9-429a-bfc6-e696f17d3444" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_691d689b-3ce8-4855-a492-85146e9997aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_691d689b-3ce8-4855-a492-85146e9997aa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_691d689b-3ce8-4855-a492-85146e9997aa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_691d689b-3ce8-4855-a492-85146e9997aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f7755ae-ff91-44f9-9a0e-af7921a56cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_691d689b-3ce8-4855-a492-85146e9997aa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f7755ae-ff91-44f9-9a0e-af7921a56cc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_c3e369f6-ba0a-402e-8e43-ece425eee162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f7755ae-ff91-44f9-9a0e-af7921a56cc3" xlink:to="loc_us-gaap_ComputerEquipmentMember_c3e369f6-ba0a-402e-8e43-ece425eee162" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_44c1ad86-7905-453a-a0e7-639e7ca54a09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f7755ae-ff91-44f9-9a0e-af7921a56cc3" xlink:to="loc_us-gaap_EquipmentMember_44c1ad86-7905-453a-a0e7-639e7ca54a09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_66d5498e-60d9-4dd4-8e26-50f07114898f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f7755ae-ff91-44f9-9a0e-af7921a56cc3" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_66d5498e-60d9-4dd4-8e26-50f07114898f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_a890746b-e1f1-4869-bd7f-4c983bc67922" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f7755ae-ff91-44f9-9a0e-af7921a56cc3" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_a890746b-e1f1-4869-bd7f-4c983bc67922" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_52c87d30-7f0b-46ee-be72-8c93ef02ce38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f7755ae-ff91-44f9-9a0e-af7921a56cc3" xlink:to="loc_us-gaap_ConstructionInProgressMember_52c87d30-7f0b-46ee-be72-8c93ef02ce38" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/EquityIncentiveAwardsAdditionalInformationDetail" xlink:type="simple" xlink:href="advm-20220630.xsd#EquityIncentiveAwardsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/EquityIncentiveAwardsAdditionalInformationDetail" xlink:type="extended" id="ib02654aebfa5426190839c89f43426ac_EquityIncentiveAwardsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_041733c9-c309-4bb6-9f69-296a4cc9fdfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_deaa0e99-17ef-45f2-98ae-2bf118395025" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_041733c9-c309-4bb6-9f69-296a4cc9fdfd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_deaa0e99-17ef-45f2-98ae-2bf118395025" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_18dc29cd-68b5-4bb3-918b-53e8d189dbaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_041733c9-c309-4bb6-9f69-296a4cc9fdfd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_18dc29cd-68b5-4bb3-918b-53e8d189dbaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_da3798ce-842f-4e0b-b9a2-f8a3637c767b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_041733c9-c309-4bb6-9f69-296a4cc9fdfd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_da3798ce-842f-4e0b-b9a2-f8a3637c767b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d17b6123-32fd-4b6e-abcb-27b9cf990fce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_da3798ce-842f-4e0b-b9a2-f8a3637c767b" xlink:to="loc_us-gaap_AwardTypeAxis_d17b6123-32fd-4b6e-abcb-27b9cf990fce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d17b6123-32fd-4b6e-abcb-27b9cf990fce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d17b6123-32fd-4b6e-abcb-27b9cf990fce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d17b6123-32fd-4b6e-abcb-27b9cf990fce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a483e594-279a-4bec-9897-261f454e0ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d17b6123-32fd-4b6e-abcb-27b9cf990fce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a483e594-279a-4bec-9897-261f454e0ee6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_4c8d6fbd-846e-4a3f-8a1f-096a1658a14c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a483e594-279a-4bec-9897-261f454e0ee6" xlink:to="loc_us-gaap_PerformanceSharesMember_4c8d6fbd-846e-4a3f-8a1f-096a1658a14c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail" xlink:type="simple" xlink:href="advm-20220630.xsd#EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail" xlink:type="extended" id="i8311e87423314c1c8f1e645495fd773d_EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2db1016-5b43-4913-8134-0fc02ae4ce6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d0483703-1334-4b6a-8bc6-af346a7c74bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2db1016-5b43-4913-8134-0fc02ae4ce6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d0483703-1334-4b6a-8bc6-af346a7c74bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_00457a22-cb15-41d4-9451-88a7f48d7927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d0483703-1334-4b6a-8bc6-af346a7c74bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_00457a22-cb15-41d4-9451-88a7f48d7927" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_74608b84-fa40-4219-a104-0f5c76bdd32e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d0483703-1334-4b6a-8bc6-af346a7c74bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_74608b84-fa40-4219-a104-0f5c76bdd32e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_73fd4e45-65a5-401e-a36f-d14259f86d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d0483703-1334-4b6a-8bc6-af346a7c74bd" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_73fd4e45-65a5-401e-a36f-d14259f86d8e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_26d6c1b8-4c2f-427e-9c4f-7bf4416f8923" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d0483703-1334-4b6a-8bc6-af346a7c74bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_26d6c1b8-4c2f-427e-9c4f-7bf4416f8923" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c57b5c3f-7427-48e9-bdef-664cee6b5259" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6c655933-b44e-41f4-ab38-5ae1d10321d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2db1016-5b43-4913-8134-0fc02ae4ce6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6c655933-b44e-41f4-ab38-5ae1d10321d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b3595945-b560-4674-a1c9-429852e5f829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6c655933-b44e-41f4-ab38-5ae1d10321d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b3595945-b560-4674-a1c9-429852e5f829" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f7a9e125-6310-402a-80a2-aa2aa15bad9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6c655933-b44e-41f4-ab38-5ae1d10321d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f7a9e125-6310-402a-80a2-aa2aa15bad9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_014030c1-97b3-4171-a0dc-f5396563b169" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6c655933-b44e-41f4-ab38-5ae1d10321d4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_014030c1-97b3-4171-a0dc-f5396563b169" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b8e5106d-3d42-425f-927b-ef7da190c5df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6c655933-b44e-41f4-ab38-5ae1d10321d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b8e5106d-3d42-425f-927b-ef7da190c5df" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_adbb8197-bc0c-4874-b116-783f5463ad39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e6bd0cb-1d4b-47e0-ae7d-1a4681d671e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2db1016-5b43-4913-8134-0fc02ae4ce6a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e6bd0cb-1d4b-47e0-ae7d-1a4681d671e9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8aed05d9-a176-41e1-bcb7-a7d8c117d154" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e6bd0cb-1d4b-47e0-ae7d-1a4681d671e9" xlink:to="loc_us-gaap_AwardTypeAxis_8aed05d9-a176-41e1-bcb7-a7d8c117d154" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8aed05d9-a176-41e1-bcb7-a7d8c117d154_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8aed05d9-a176-41e1-bcb7-a7d8c117d154" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8aed05d9-a176-41e1-bcb7-a7d8c117d154_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4045611f-74fb-4de9-99d7-ea570f48cc78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8aed05d9-a176-41e1-bcb7-a7d8c117d154" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4045611f-74fb-4de9-99d7-ea570f48cc78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a655d2e5-e7f0-4d3e-a8f1-f32f1d4268e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4045611f-74fb-4de9-99d7-ea570f48cc78" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a655d2e5-e7f0-4d3e-a8f1-f32f1d4268e7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/EquityIncentiveAwardsStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="advm-20220630.xsd#EquityIncentiveAwardsStockBasedCompensationExpenseDetail"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/EquityIncentiveAwardsStockBasedCompensationExpenseDetail" xlink:type="extended" id="i3cc25c04df044542be54d6deb6811405_EquityIncentiveAwardsStockBasedCompensationExpenseDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5ce32545-b8da-435e-a9ad-04ecb1170080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_bf2dc78c-d148-403a-a0f0-c6bedb016eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5ce32545-b8da-435e-a9ad-04ecb1170080" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_bf2dc78c-d148-403a-a0f0-c6bedb016eb3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_08239eee-33f0-451f-bb67-f2974284a21a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5ce32545-b8da-435e-a9ad-04ecb1170080" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_08239eee-33f0-451f-bb67-f2974284a21a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0c240068-cea4-4a1f-813b-f3803f5669b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_08239eee-33f0-451f-bb67-f2974284a21a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0c240068-cea4-4a1f-813b-f3803f5669b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0c240068-cea4-4a1f-813b-f3803f5669b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0c240068-cea4-4a1f-813b-f3803f5669b4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0c240068-cea4-4a1f-813b-f3803f5669b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5daeaf01-70c7-402d-9113-4e74ddfc0248" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0c240068-cea4-4a1f-813b-f3803f5669b4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5daeaf01-70c7-402d-9113-4e74ddfc0248" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_fab0fcde-dc4e-47a8-9af3-d1128f3c0745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5daeaf01-70c7-402d-9113-4e74ddfc0248" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_fab0fcde-dc4e-47a8-9af3-d1128f3c0745" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_9b545b5c-c869-4457-9c89-fdebeacd8b40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5daeaf01-70c7-402d-9113-4e74ddfc0248" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_9b545b5c-c869-4457-9c89-fdebeacd8b40" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetail" xlink:type="simple" xlink:href="advm-20220630.xsd#NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetail"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetail" xlink:type="extended" id="ib7710f12d48749529e6dfce0eaa741d6_NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0d910165-dee1-4bbb-be3d-00764b071302" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f5812373-cfed-4a16-ab13-b72aef7b6c41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0d910165-dee1-4bbb-be3d-00764b071302" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f5812373-cfed-4a16-ab13-b72aef7b6c41" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_dab1ea6f-f1ea-44c8-8898-9a30daef7a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0d910165-dee1-4bbb-be3d-00764b071302" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_dab1ea6f-f1ea-44c8-8898-9a30daef7a8b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8b1cb3ea-6210-436e-bfaa-0d0b5c0908f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_dab1ea6f-f1ea-44c8-8898-9a30daef7a8b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8b1cb3ea-6210-436e-bfaa-0d0b5c0908f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8b1cb3ea-6210-436e-bfaa-0d0b5c0908f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8b1cb3ea-6210-436e-bfaa-0d0b5c0908f2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8b1cb3ea-6210-436e-bfaa-0d0b5c0908f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ce79db44-12f7-424e-b9b3-bf13fa8c92eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8b1cb3ea-6210-436e-bfaa-0d0b5c0908f2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ce79db44-12f7-424e-b9b3-bf13fa8c92eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0594a539-dd4e-4e48-b0e2-af9b707fd937" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ce79db44-12f7-424e-b9b3-bf13fa8c92eb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0594a539-dd4e-4e48-b0e2-af9b707fd937" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_fd37d061-5ec8-426d-a20b-eb721637ae72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ce79db44-12f7-424e-b9b3-bf13fa8c92eb" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_fd37d061-5ec8-426d-a20b-eb721637ae72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_268f2172-cdd0-456d-ae62-89354b1c68f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ce79db44-12f7-424e-b9b3-bf13fa8c92eb" xlink:to="loc_us-gaap_EmployeeStockMember_268f2172-cdd0-456d-ae62-89354b1c68f3" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/SubsequentEventDetails" xlink:type="simple" xlink:href="advm-20220630.xsd#SubsequentEventDetails"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/SubsequentEventDetails" xlink:type="extended" id="i910f7846d53841adb7102676e9de47c5_SubsequentEventDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_eff9b17e-93f0-4bc7-98a9-3f94180799a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate_c57ed67d-18a7-44fc-8887-cc1c788b5260" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_eff9b17e-93f0-4bc7-98a9-3f94180799a5" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate_c57ed67d-18a7-44fc-8887-cc1c788b5260" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent_73e7b933-0e99-4459-b2a1-9998fa291012" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_eff9b17e-93f0-4bc7-98a9-3f94180799a5" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent_73e7b933-0e99-4459-b2a1-9998fa291012" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_f94ffa5a-6136-4684-b194-3c2e5cbad4b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_eff9b17e-93f0-4bc7-98a9-3f94180799a5" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_f94ffa5a-6136-4684-b194-3c2e5cbad4b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_cad83b4c-de53-4841-b0a9-f6ebb3b1b37d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_eff9b17e-93f0-4bc7-98a9-3f94180799a5" xlink:to="loc_us-gaap_PaymentsForRestructuring_cad83b4c-de53-4841-b0a9-f6ebb3b1b37d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_582491f5-518e-44d7-bfab-fbb07996a6d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_eff9b17e-93f0-4bc7-98a9-3f94180799a5" xlink:to="loc_us-gaap_SubsequentEventTable_582491f5-518e-44d7-bfab-fbb07996a6d2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8250de40-57bb-4d63-b281-76650f70efba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_582491f5-518e-44d7-bfab-fbb07996a6d2" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8250de40-57bb-4d63-b281-76650f70efba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8250de40-57bb-4d63-b281-76650f70efba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8250de40-57bb-4d63-b281-76650f70efba" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8250de40-57bb-4d63-b281-76650f70efba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7f8c7ea9-e4d3-4e1d-8257-7e5dc80ccf22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8250de40-57bb-4d63-b281-76650f70efba" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7f8c7ea9-e4d3-4e1d-8257-7e5dc80ccf22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_6f66f672-d57e-45ea-93c2-db7b947902a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7f8c7ea9-e4d3-4e1d-8257-7e5dc80ccf22" xlink:to="loc_us-gaap_SubsequentEventMember_6f66f672-d57e-45ea-93c2-db7b947902a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_dee2a65a-11de-4645-9965-05de87c072e4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_582491f5-518e-44d7-bfab-fbb07996a6d2" xlink:to="loc_srt_StatementScenarioAxis_dee2a65a-11de-4645-9965-05de87c072e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_dee2a65a-11de-4645-9965-05de87c072e4_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_dee2a65a-11de-4645-9965-05de87c072e4" xlink:to="loc_srt_ScenarioUnspecifiedDomain_dee2a65a-11de-4645-9965-05de87c072e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_4233bacb-ce7d-4bd7-8295-f8ca3c4a4dca" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_dee2a65a-11de-4645-9965-05de87c072e4" xlink:to="loc_srt_ScenarioUnspecifiedDomain_4233bacb-ce7d-4bd7-8295-f8ca3c4a4dca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_4abad1e5-6958-43b5-8d8b-79fe1d9c3b70" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_4233bacb-ce7d-4bd7-8295-f8ca3c4a4dca" xlink:to="loc_srt_ScenarioForecastMember_4abad1e5-6958-43b5-8d8b-79fe1d9c3b70" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>advm-20220630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:4ac67419-c73c-4942-8754-fc53d915184d,g:dfc73ebd-49d4-42d9-8e60-60c5f25a86bb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_15ef4f15-3301-425a-b83b-8b3026bf9031_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6871430e-fc50-4120-bc77-d70e4b8f9dff_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e559919f-f6a6-48c2-b77e-d91768567831_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_5f9ffec1-d952-48cf-8571-8968bd17d40f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_cb1ee6c0-343a-4dba-a3ed-12401fb0ca66_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_732c507a-074a-4b05-b304-8c99f3480535_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9e5d9fda-0194-4ab2-b475-ac422a77b3af_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_ab5a22f8-8e5a-434f-bdda-a9eca58678ee_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_8bc83674-b3f1-4aa2-a47e-d08f5bb19c80_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_94919592-cee1-455c-808a-0f63f2e05f19_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_dec2cf45-0e2b-4ed7-8420-1cfe84cac486_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ea5d9b79-8a46-46e8-8807-abec9edb7201_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares used to compute net loss per share - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3babe2a1-b24a-41d2-a55a-05cc116ce3c2_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss_923491a1-69c1-4c0f-9d50-f7af76e117a1_terseLabel_en-US" xlink:label="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: cash equivalents, unrealized losses</link:label>
    <link:label id="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss_label_en-US" xlink:label="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalent Gross Unrealized Loss</link:label>
    <link:label id="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss_documentation_en-US" xlink:label="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalent gross unrealized loss.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss" xlink:href="advm-20220630.xsd#advm_CashAndCashEquivalentGrossUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss" xlink:to="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_299d31b9-afe4-47bf-bc5d-dffa6392f18f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c6702d68-f67a-4395-8521-9813c0b2490f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_75428cf5-0669-46fc-b553-2f3b27030eee_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Cash Equivalents and Short-term Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_fe77f3d5-c58a-4c3d-b179-34eadfa8054f_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee compensation</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_0ac86872-398e-44a7-8570-24a24bd6a5a1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9811ec05-2ae3-4695-9607-0c8ac48067cb_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_71c9512e-3f66-4874-a41e-ff17b5270eb6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_86c2b1e9-5566-4744-bc41-dc10e34cae01_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6399ff67-f54d-474c-ae40-1fc650cabc01_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued upon exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c9c1fe9d-cab9-403f-aca2-9378c63af4e4_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_32b577b5-e266-426f-9b3e-0b0ff95df31d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued upon release of restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_12373ce6-f538-479c-a811-345c818ff034_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_96e68bb3-3a11-4bde-8270-4db17e4469cd_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_7b2f93dc-6d3d-4f66-9d71-125d8cf82191_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a01e8a55-6f1b-4283-9355-d57eed50c1c2_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fc87c8b9-fe52-414f-9e9c-12b9ddb5c53c_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b979e74d-fc6b-43ca-b199-03b25b6c3ec3_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_9bae46c8-3a4f-4140-a0a8-4ec9f8f8bd11_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of loan</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_d4805292-3fbe-49ac-88ff-5c932b6e1378_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_54fd35ff-d1f0-404d-a93d-287fe54d9a72_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_cd3c3e14-f54f-48ab-890d-6e9b0ddc7782_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock pursuant to option exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_1d5f5de7-e077-47c3-ae02-353df154a8bb_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_b7524161-0f2f-466b-ba05-f4e427dce6f6_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5511dc0c-c66e-4440-8de1-816efe9926fe_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e2fadd8e-bb6a-46ad-a954-342d7effe5a8_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_96049a32-6ba7-4051-be43-ae92ddf66ea1_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets in accounts payable, accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_f4b6ffd1-5e75-486c-b2f1-2a7def4864d7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_85dd597a-c62a-4428-a414-68963831c2ef_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_6da6f7d4-408d-4c22-8bef-4ff8b0da91c8_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_f14970ed-569d-4b39-8eef-52a9f7eef0ae_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_8849a17c-0246-4dfc-8435-c26da5873ec2_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_17429abe-6512-43d6-a628-5bac205116a3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_4caaac71-405c-48da-b668-75e9090a2d4c_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_9c90f555-7bdc-4673-a363-16c567d6134e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_286758f8-91e5-4029-8c6a-825ffb6c7e0d_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_21e2435f-ec85-4eac-9306-c2974ec215e3_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e43156f0-6701-49a6-b0f2-c2113cc287fc_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_cb0f4627-8808-4298-b9b2-aa5d289d1515_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_058ae8b6-4d3f-49b3-be00-542ab35ba211_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposit and other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5ceacab2-f4a1-402e-b6fe-97caeb7794d3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_8fc09be2-e01a-44fb-9391-139a4b528800_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected cash expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_f08d7fa1-d1ba-4906-a25f-d60e47afa132_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c82049cb-aae8-4f88-88c8-f6b6c139623c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options forfeited (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_f91989f9-4836-4895-a5a7-a1befc690114_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_277a30b6-f7db-4eac-80af-6d7d468ccc45_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_65dfcd7d-ae90-45c3-9f26-807b281b3f08_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1:</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_fd15c29d-2f32-485c-a472-7d7f49434699_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_03dd550a-9951-4866-b116-d1a543ad4813_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f23e7c0d-20d1-41c0-9d74-00a105abc146_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2af7ff12-3408-4cf0-bf1a-5a63295b1532_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_AccruedExpensesAndOtherCurrentLiabilities_6bb9943d-2159-4734-9889-9c16079a69ae_terseLabel_en-US" xlink:label="lab_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_advm_AccruedExpensesAndOtherCurrentLiabilities_82c901e5-5978-42d3-a7a9-917473878cd0_totalLabel_en-US" xlink:label="lab_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses and other current liabilities</link:label>
    <link:label id="lab_advm_AccruedExpensesAndOtherCurrentLiabilities_label_en-US" xlink:label="lab_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses And Other Current Liabilities</link:label>
    <link:label id="lab_advm_AccruedExpensesAndOtherCurrentLiabilities_documentation_en-US" xlink:label="lab_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:href="advm-20220630.xsd#advm_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="lab_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_571faca4-5091-4460-871a-131dea5711ca_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_8875cd38-8604-4d6e-9010-78f908df84f7_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_ccc61de8-f382-41e9-ad17-62b7c3cf31ec_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_959a892f-f473-40c4-b7d9-645baf67b1d4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability, current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d0b3fb4a-6ea3-4426-96f4-4bbf0fb50990_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_4cc3b51b-bc18-4cd6-8b7f-596e9333adbe_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_570dde31-13d0-49d1-afeb-e787b1cc7f76_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7d24a2c9-7045-4581-808a-31899b07068c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_19afd7c2-c587-4357-8199-7f948c35513b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9e8d3622-84ec-40c6-889b-b7db64b8ce14_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_07fe1ec2-270b-4ef4-9e7f-82adedb78bec_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_7cd90ff6-3f74-485a-be6a-212adfb43108_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_900df4b0-8a78-45b1-bd6c-480d5154587e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_30d0364a-0d1d-4484-bcec-0c535cb020d1_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_4e964ab2-52f4-43b9-84e1-b7bc2f619373_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf12b4d2-1a4a-4056-a227-237141034bbc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c5d2dd87-b931-46f8-a660-c2220a446788_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_f0bcb6af-c80c-40f2-86a4-0ce337ba24b2_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f26e002f-fded-4f7a-b9ca-3e6be5d52e65_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_600e6396-1e50-483c-89fe-e78ab452f8d6_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_4ee4ae6c-d787-4813-af50-ca3c3dda1165_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_d5ee0099-e763-4faf-8b8c-0697210f8786_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3f87f4f6-8b53-4d40-bd39-0232a5d68278_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_c451a586-a094-4106-bd97-60d461bf3379_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_40e83766-a485-4b76-9819-e86bde6e2b55_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_311ef6b1-029c-431d-88e5-7fc532a3bc7a_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income tax payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_6d293946-e9d1-452b-a577-379adff98240_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_d2a9dd7e-2edd-4c17-92af-6ebacddaa03e_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_80d6fd53-7caf-4af1-803a-521ab0617e7a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Grant- Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_f0a8f9f9-daea-413a-b5bd-23bf48e61982_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a36b1854-d32c-4cbc-8e0d-35b7ae752838_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Units (in thousands)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_6cc1556b-ba69-44a7-9b66-50c57fc63404_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_37683f1c-6379-475e-b359-047c442f3244_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_CashAndCashEquivalentAmortizedCost_9810e7a8-e58b-4cdc-9788-23643e38e1d9_negatedTotalLabel_en-US" xlink:label="lab_advm_CashAndCashEquivalentAmortizedCost" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: cash equivalents, amortized cost basis</link:label>
    <link:label id="lab_advm_CashAndCashEquivalentAmortizedCost_label_en-US" xlink:label="lab_advm_CashAndCashEquivalentAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalent Amortized Cost</link:label>
    <link:label id="lab_advm_CashAndCashEquivalentAmortizedCost_documentation_en-US" xlink:label="lab_advm_CashAndCashEquivalentAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalent amortized cost.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentAmortizedCost" xlink:href="advm-20220630.xsd#advm_CashAndCashEquivalentAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_CashAndCashEquivalentAmortizedCost" xlink:to="lab_advm_CashAndCashEquivalentAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0c37a24a-eac1-479e-ac69-66de4cf89b08_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f176b82b-a829-483c-a220-51abd242f3a7_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_600cf3a2-93ce-4b10-a317-c9630e719b46_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_20e3a2e3-b69d-4726-a89d-7755cbf3221d_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_8cc928c2-957b-4d3b-9755-64d4003e22b2_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_45387b8c-79eb-459b-afbe-f1b4d7d1c92a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options (in thousands)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_d5cfe9a9-4d49-449e-be01-9cf636368c94_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_ca83fba5-3788-49a2-8bee-af30a06c1a61_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_ad7e3d9e-a850-45df-a584-85147a2f9a56_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_02417f7b-9670-4599-8cb6-3f4c84604a7a_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_5e4dc2df-d8e1-4ed3-a50e-73d2c07ba10f_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_262b24b2-9185-4eab-a54d-3b12702e8566_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRentReceivablesNet_0ed44657-9950-46aa-985f-acbdb17753e7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentReceivablesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred rent receivable</link:label>
    <link:label id="lab_us-gaap_DeferredRentReceivablesNet_label_en-US" xlink:label="lab_us-gaap_DeferredRentReceivablesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Rent Receivables, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentReceivablesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentReceivablesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentReceivablesNet" xlink:to="lab_us-gaap_DeferredRentReceivablesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_53789714-0a82-4717-94b5-9275ab3512b4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_7258c367-6e5e-4ecf-a819-c288d8c009d6_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_fd1685b5-fc63-41d8-8231-0942968ac66f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_84bff718-6a07-43fe-88df-bc49d65ada28_negatedLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, additional issuance costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_4cd67cd6-7355-4dbd-8b93-7b4538b2b06e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_90cd9122-1371-4bf9-ae84-1a0266b14af9_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_d78b3240-9b6c-4d39-bfee-06fcf35c9cb9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premium and accrued interest on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_58b10116-cdea-4386-9d83-c816c62af60c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_2ae1378e-0295-4bf1-a125-ab97a841eb94_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e3a818bc-18d5-4c88-9ddd-3766b9d345ca_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_590afe45-5873-4c75-b364-e7f53d9aa8e1_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5c79d0be-ec22-41f3-ad37-12d420c7b6fb_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_42d0a363-5e9b-4159-b0e7-2031c6510a9e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_a736019c-bfb4-4b93-ab45-0e1943a41579_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_be2ed428-52d0-41ec-b349-55dae52bf20c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0a457bb7-c42c-48a9-b9dc-894302e94918_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost Basis</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_04ca0095-7030-4280-aed4-3739a50bbaec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_cc1df1e2-6759-47dc-b771-65c748e50d2f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_30d105b0-ee2a-4dc8-a05b-e4078f1c805f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_612600a2-99df-4107-88c4-9367c7204c3f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_313172c3-1dfb-485d-a000-d11268200fcc_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_3a8bbe93-6f16-45c4-9394-d0a592fab45c_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1bb499b3-9156-4bcf-b80a-21f60fc1b470_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_a484cbf9-e253-432f-86a7-12670b1556a4_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_29792a64-2cd9-4bbc-b091-15c84d19e87c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncentiveToLessee_654d5361-b25c-4f74-a0cd-b73102ad5187_terseLabel_en-US" xlink:label="lab_us-gaap_IncentiveToLessee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease incentive receivables</link:label>
    <link:label id="lab_us-gaap_IncentiveToLessee_label_en-US" xlink:label="lab_us-gaap_IncentiveToLessee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive to Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncentiveToLessee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncentiveToLessee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncentiveToLessee" xlink:to="lab_us-gaap_IncentiveToLessee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_831b1ed8-2a5b-45ea-b7f3-2d9d2921e5a5_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Components</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_dc9f98d7-a6c1-48b3-84b6-146df1b7acc3_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_a8013d70-43ff-4f76-89f1-c99146f104c6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from offerings of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_18de4286-34f8-494d-b52b-68e51fff2dc4_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares used to compute net loss per share - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a8d0c7a0-fd96-4acc-b02d-47237ed1f0de_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_3ad14ed0-d2b1-40ee-81d2-ed9685404f31_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_acaae5d3-e881-461d-b97e-8ea41890c338_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_281d1ad5-9fe8-4a8d-a0e7-8da4ebfd905e_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_f5f49948-9507-48e8-8fc3-59b60c43a54b_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0da37695-41cb-4687-bf4f-22c346ec409f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_776c982b-2518-4f82-b829-6c724a7d08dd_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_08d7ee27-d904-4491-a4a8-966bc61159f3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent_18751e49-ace4-429d-97ea-dd80de709286_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of employees percentage</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Inception to Date Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_865d43d8-8e86-4e2b-8c21-6b593e6e0e00_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_c43bf53c-0010-47ce-a163-305f8eefad46_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_1a24589b-dbc7-455a-ba6e-9d13a5eb681a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_f851d8bb-df01-443c-a16e-6836619c5827_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cbb1bd9a-88c7-4325-b08e-07ae8114d145_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_f6705c07-adae-4f9f-ab80-c982db2f8bfc_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_2e495a22-61a4-481e-8f3b-f38f5fed167f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_fbd39a1c-6ba1-4da1-9a41-9a44017e88b6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_b861a40f-a92b-49c4-b9a1-bf51643bc629_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_bbe97cbb-1292-4882-8c2d-9418b570bcf3_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_4b21e494-d78e-46ce-83df-6d5f85eae2e4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_70b573bd-27c0-46c7-8e48-7cf6b01c1b43_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_34dcefd2-92f6-471b-b64c-6b0032c46bb9_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_d60bf44c-a4a6-4e41-8a1f-b777a03aeb72_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements and Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_b2ea7de4-f404-49a1-81b5-78302b4d7743_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_c1d6dd99-fc58-41de-bb7a-7effa7e1838b_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_7fe750b4-144d-4ae1-9ccd-2501eae4a815_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities_c59fa9de-8729-4637-9f5f-3bddeb0a7540_terseLabel_en-US" xlink:label="lab_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities other-than-temporarily impaired</link:label>
    <link:label id="lab_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities_label_en-US" xlink:label="lab_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Than Temporary Impaired Investments Available For Sale Securities</link:label>
    <link:label id="lab_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities_documentation_en-US" xlink:label="lab_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than temporary impaired investments available for sale securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities" xlink:href="advm-20220630.xsd#advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities" xlink:to="lab_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_cff483b6-3b81-4d35-8c7b-d954d2c7d989_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_7dcbe332-8939-4629-abfa-3e7fb752ba15_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b1adec7c-2d38-4757-96fb-3fb65e59b05d_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_5a2d6227-bb2c-46e0-aeca-baa0997a122e_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_232dc620-7829-4d3a-ba1f-7c4f20aa0f12_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_ec174bf6-ec32-4d88-b58e-c45d1c6815e2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2:</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_1451e12c-65cc-436b-8f9b-797b88dc92e4_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_409a4d35-edf0-44a1-a676-cccc27d92707_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f9a6cbd0-37f2-4960-92ce-c678e5c08538_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate_eee07996-c572-4366-96f5-cb1742d74f93_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of employees</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Inception to Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_827c9a22-cb54-4492-9472-81c0900a650d_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_b865ca2f-1810-44c1-8ab3-0bb9ba94a1ac_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share &#8212; diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_c2c8a37a-7049-4cea-b755-bcc303186246_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_6c45a1a0-b5b2-41fd-a9b9-43a722eb1c0d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: cash equivalents, estimated fair value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_0cff533a-8cdc-4a42-8408-82489101fd62_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_71ed7531-7f45-4313-b9ec-6d50b6433bc9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_49c8da78-b1a8-41e2-abea-7ecb4f1afaf7_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8d3209d1-5642-43b1-9f68-549f15a3222a_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_94216f1c-c4dc-4c8a-a275-83e241314799_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_90ffc8b3-49ef-45b2-b49f-257670d0dd9a_negatedLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and released (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_5ef2f9b9-2adb-414c-97ea-8091d5d1f176_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_0703a2f6-1cad-43c2-bb79-ccaf4a0d2f84_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Restricted Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_baa77358-bf6b-4792-b5e4-ec62a9b7e991_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share &#8212; basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_64491798-e060-4f62-9fda-52c02fd76e7d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_2df48a6c-e12c-4f95-9b6a-33dacd6330d7_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_b63ff966-2fac-4573-a2f8-e389f0a659d8_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_22e9a203-5fa3-4a96-9768-0bb5c2bfcfb1_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_ca933292-1576-4fbc-96ac-7812ce6eb0d1_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease liability</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e96145bc-56e1-45a3-989b-b3575d522873_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_e8bd0033-988f-445d-9b80-c38bd75cf5d1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_625010c9-dace-4ec0-9d86-7c1c12458f76_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable_41b23e3e-210f-45f2-8cdb-a75b70879aa5_terseLabel_en-US" xlink:label="lab_advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability and lease incentive receivable</link:label>
    <link:label id="lab_advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable_label_en-US" xlink:label="lab_advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Lease Liabilities And Lease Incentive Receivable</link:label>
    <link:label id="lab_advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable_documentation_en-US" xlink:label="lab_advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase decrease in lease liabilities and lease incentive receivables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable" xlink:href="advm-20220630.xsd#advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable" xlink:to="lab_advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_039b43b5-f609-4d73-b97a-3a6d500ccac9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and released (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset_e7121c84-9a0d-42ea-9a51-4899a91b5477_negatedTerseLabel_en-US" xlink:label="lab_advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:label id="lab_advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Operating Lease Right-of-use Asset</link:label>
    <link:label id="lab_advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Operating Lease Right-of-use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset" xlink:href="advm-20220630.xsd#advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset" xlink:to="lab_advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_3386eb76-a28b-4a4f-a526-6830de114e98_terseLabel_en-US" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Awards</link:label>
    <link:label id="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity and Share-Based Payments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8e43c5c7-61a8-4764-aa0d-c318876b2d8d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_a736d39d-b517-424d-8377-a52d27937736_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government and agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7235150f-bc06-4f50-9402-2bf2c275c5dd_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_8d5ed6cb-d227-4725-9b63-6f84094a7895_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_ddb152b4-3d8e-4b60-8e1f-14e847e0b529_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized loss on marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_f7614026-9b43-4dd1-ae95-fe57e16d0b7a_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on marketable securities, net</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_ac842caf-9fc7-4cb9-89f2-1788f7c18bda_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_1a7abd3b-cbe8-4d83-947e-3efce878e870_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_20638b22-2c9e-451d-8272-341dba4544a6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_8827a09f-e8ca-45c4-9ebc-aaf03cf8a898_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_68700ef5-d18c-48a9-bf06-5f39cacd3ff8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_138cd267-feef-43ec-96e5-3cab267bf0f1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_17ebf2f0-3272-4121-a451-03d674768b52_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_71c654b8-e13c-4f24-9dc9-740a2e50f46b_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_f5a75ed1-f3b5-4905-8982-1d393439a4ae_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_5b7c7ed1-cd3b-4e5a-994f-99b702005792_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_10e595ca-e7a3-4cc8-80b6-3fce2e4b85a6_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_53107d54-c3e8-46c1-8dcb-c69ffe6d966d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f6446f19-2f49-4858-88eb-39a22d1fa72b_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_18c0a3e4-3d2d-40d3-b0c8-df4d3deca95a_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_95d507d4-48d4-4436-8c3f-ebcfe9b079e9_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_64dbbe23-2a59-415d-9e7a-00682a293587_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_e0a0902c-d51d-42c4-9489-4d8df7b78a8b_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_04c4aa72-ab23-4d8d-9735-e116191b5415_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_806102e8-d9a6-45b8-bd08-5f50c9f51139_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_fa891c05-473e-4e73-9278-253adf20b541_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_a43911f3-0342-43e3-a01b-5c74dac67a0f_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_CashEquivalentsAndShortTermInvestmentsMember_d310a6ad-f9d5-4de8-af29-8281e9b7aa5e_terseLabel_en-US" xlink:label="lab_advm_CashEquivalentsAndShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and short-term investments</link:label>
    <link:label id="lab_advm_CashEquivalentsAndShortTermInvestmentsMember_label_en-US" xlink:label="lab_advm_CashEquivalentsAndShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Short Term Investments [Member]</link:label>
    <link:label id="lab_advm_CashEquivalentsAndShortTermInvestmentsMember_documentation_en-US" xlink:label="lab_advm_CashEquivalentsAndShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents and short term investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashEquivalentsAndShortTermInvestmentsMember" xlink:href="advm-20220630.xsd#advm_CashEquivalentsAndShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_CashEquivalentsAndShortTermInvestmentsMember" xlink:to="lab_advm_CashEquivalentsAndShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff58a381-0c2c-4b8d-a38c-4eef7f4cd30d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_51e5ffc8-71c1-4793-a117-93c3748a1067_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_271c0a3e-1d06-4c00-947f-d94ac3dfc6d0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_62d0e51c-8813-4977-95a4-4283bc02b190_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2e40f841-698d-4ed0-8bf7-6d50db625642_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_514cccc3-0808-4629-aa6c-8a45a024344a_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_2199c3ad-a668-423f-83a3-8e1bda26640e_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional services</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_12ec15d0-cd47-46ee-b541-1a7f93ac24b8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_5e246f39-c14b-49a8-b2cc-2ced033da5d6_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_e106cca4-c585-4747-a5f7-1f3f13d348fc_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5006816a-36de-4176-bf9b-e9a098466ecb_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_cc2acbfc-125e-46fb-bc5e-736ac482d2b3_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_a16c4f8d-0fc4-42b3-96d7-2890cc084b9d_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_f7da0250-d3de-4ef7-9f98-303fe0cad223_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_716c87af-2309-43cb-981b-554034969a88_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_92a1960d-536e-44bf-a81c-eb15b279b268_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7bc31005-b5b0-4901-b7b6-3e2ecb7ab1de_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9a0b48a1-d478-46e1-9616-b13333741ffd_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_81932942-8288-4f6b-af68-7edb30c2b90c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3fa62ed2-419e-471b-a240-af39d4d2ee4f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive (Loss)/Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_e9c800bc-394d-4944-b5f3-031eec68466f_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental schedule of noncash investing and financing information</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_4effec39-6e53-401a-a492-3c5647babf41_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts_762d5ec9-700e-4f8d-9f0c-a87d9cd5c69e_terseLabel_en-US" xlink:label="lab_advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued nonclinical, clinical and process development costs</link:label>
    <link:label id="lab_advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts_label_en-US" xlink:label="lab_advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Nonclinical, Clinical, And Development Process Costs</link:label>
    <link:label id="lab_advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts_documentation_en-US" xlink:label="lab_advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued preclinical clinical and development process costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts" xlink:href="advm-20220630.xsd#advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts" xlink:to="lab_advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_550a888e-ae60-414b-bf86-b45ba7c2d7d3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_a77a57e7-8b8b-43fe-a66d-f53120e2aed6_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_48bad7ab-f230-426d-9b52-2e1e0d579341_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e8bd4579-f36b-4910-9dae-809b4c2f4af2_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_985a674a-aa35-4062-8951-1afc9a475607_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9637a4ba-61ef-46d4-afb3-d07426fd91ce_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Options Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_c098c234-a4e3-4a02-94c9-14ba348d71ac_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_a770bffb-c275-4471-9bcd-ba2661b16c44_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_459ebd52-263a-45ac-83ae-951e0f7ac000_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d2fba294-c797-4339-bcbe-4e73cfb9ce90_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_CashAndCashEquivalentGrossUnrealizedGain_0113988c-8358-4621-93da-84d4fbce5993_negatedTerseLabel_en-US" xlink:label="lab_advm_CashAndCashEquivalentGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: cash equivalents, unrealized gains</link:label>
    <link:label id="lab_advm_CashAndCashEquivalentGrossUnrealizedGain_label_en-US" xlink:label="lab_advm_CashAndCashEquivalentGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalent Gross Unrealized Gain</link:label>
    <link:label id="lab_advm_CashAndCashEquivalentGrossUnrealizedGain_documentation_en-US" xlink:label="lab_advm_CashAndCashEquivalentGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalent gross unrealized gain.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedGain" xlink:href="advm-20220630.xsd#advm_CashAndCashEquivalentGrossUnrealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_CashAndCashEquivalentGrossUnrealizedGain" xlink:to="lab_advm_CashAndCashEquivalentGrossUnrealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_392ebfc2-98d4-4f51-8e03-b229f13a50ee_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>advm-20220630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:4ac67419-c73c-4942-8754-fc53d915184d,g:dfc73ebd-49d4-42d9-8e60-60c5f25a86bb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.adverum.com/role/CoverPage" xlink:type="simple" xlink:href="advm-20220630.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_99bc3c0b-65b1-425a-b4a9-a52a67b440e1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_7c07dc2f-f15a-4ace-bc47-e3a3c511b275" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99bc3c0b-65b1-425a-b4a9-a52a67b440e1" xlink:to="loc_dei_DocumentType_7c07dc2f-f15a-4ace-bc47-e3a3c511b275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_db4033d8-8dd7-448a-95f5-9293debf7b5d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99bc3c0b-65b1-425a-b4a9-a52a67b440e1" xlink:to="loc_dei_DocumentQuarterlyReport_db4033d8-8dd7-448a-95f5-9293debf7b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_6d8e2020-61d4-4ee5-adcc-e9b86496f017" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99bc3c0b-65b1-425a-b4a9-a52a67b440e1" xlink:to="loc_dei_DocumentPeriodEndDate_6d8e2020-61d4-4ee5-adcc-e9b86496f017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_7d04055c-9f11-404d-a501-42aa1fff25bb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99bc3c0b-65b1-425a-b4a9-a52a67b440e1" xlink:to="loc_dei_DocumentTransitionReport_7d04055c-9f11-404d-a501-42aa1fff25bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_b013c592-882e-412a-b9fe-70b6ed35f9c2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99bc3c0b-65b1-425a-b4a9-a52a67b440e1" xlink:to="loc_dei_EntityFileNumber_b013c592-882e-412a-b9fe-70b6ed35f9c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_d4f77a77-cb36-4bde-8d41-8de5bf5f161c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99bc3c0b-65b1-425a-b4a9-a52a67b440e1" xlink:to="loc_dei_EntityRegistrantName_d4f77a77-cb36-4bde-8d41-8de5bf5f161c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_d1b677db-06a4-454d-aaaa-841eafc81bc4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99bc3c0b-65b1-425a-b4a9-a52a67b440e1" xlink:to="loc_dei_EntityIncorporationStateCountryCode_d1b677db-06a4-454d-aaaa-841eafc81bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_789b9508-3b48-4b96-b3ca-b3f3e0994687" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99bc3c0b-65b1-425a-b4a9-a52a67b440e1" xlink:to="loc_dei_EntityTaxIdentificationNumber_789b9508-3b48-4b96-b3ca-b3f3e0994687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_0c2f5ac8-406f-4e43-a4f8-92a089789352" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99bc3c0b-65b1-425a-b4a9-a52a67b440e1" xlink:to="loc_dei_EntityAddressAddressLine1_0c2f5ac8-406f-4e43-a4f8-92a089789352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_6f7d5805-be32-4fdf-8166-1bfd56314dd6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99bc3c0b-65b1-425a-b4a9-a52a67b440e1" xlink:to="loc_dei_EntityAddressCityOrTown_6f7d5805-be32-4fdf-8166-1bfd56314dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_e69dd1a7-fd40-4efa-aab9-5c287f22bf61" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99bc3c0b-65b1-425a-b4a9-a52a67b440e1" xlink:to="loc_dei_EntityAddressStateOrProvince_e69dd1a7-fd40-4efa-aab9-5c287f22bf61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_b1c05c0b-df69-4c88-b1fd-9ee081902542" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99bc3c0b-65b1-425a-b4a9-a52a67b440e1" xlink:to="loc_dei_EntityAddressPostalZipCode_b1c05c0b-df69-4c88-b1fd-9ee081902542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_ffca1b04-491a-4ff2-ab80-370921fd09a7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99bc3c0b-65b1-425a-b4a9-a52a67b440e1" xlink:to="loc_dei_CityAreaCode_ffca1b04-491a-4ff2-ab80-370921fd09a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_7617f656-7348-4663-8c0a-a4bbfd3acccd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99bc3c0b-65b1-425a-b4a9-a52a67b440e1" xlink:to="loc_dei_LocalPhoneNumber_7617f656-7348-4663-8c0a-a4bbfd3acccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_cdeb3cb1-c6df-4882-a189-61de8c55d596" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99bc3c0b-65b1-425a-b4a9-a52a67b440e1" xlink:to="loc_dei_Security12bTitle_cdeb3cb1-c6df-4882-a189-61de8c55d596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_15ee1652-719e-4189-91fb-8f8e18ba1abd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99bc3c0b-65b1-425a-b4a9-a52a67b440e1" xlink:to="loc_dei_TradingSymbol_15ee1652-719e-4189-91fb-8f8e18ba1abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_417a008c-c810-4719-b2fc-4608dc055076" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99bc3c0b-65b1-425a-b4a9-a52a67b440e1" xlink:to="loc_dei_SecurityExchangeName_417a008c-c810-4719-b2fc-4608dc055076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_d0ebbb0a-5834-4e51-b17f-cb8c9434eb81" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99bc3c0b-65b1-425a-b4a9-a52a67b440e1" xlink:to="loc_dei_EntityCurrentReportingStatus_d0ebbb0a-5834-4e51-b17f-cb8c9434eb81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_07b0ba11-f203-402e-bce4-dd9467eb620b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99bc3c0b-65b1-425a-b4a9-a52a67b440e1" xlink:to="loc_dei_EntityInteractiveDataCurrent_07b0ba11-f203-402e-bce4-dd9467eb620b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_37613d20-5417-4bc0-81ac-47022ce1034f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99bc3c0b-65b1-425a-b4a9-a52a67b440e1" xlink:to="loc_dei_EntityFilerCategory_37613d20-5417-4bc0-81ac-47022ce1034f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_78396ccf-2b6e-4fd5-92d6-0b25926c3633" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99bc3c0b-65b1-425a-b4a9-a52a67b440e1" xlink:to="loc_dei_EntitySmallBusiness_78396ccf-2b6e-4fd5-92d6-0b25926c3633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_4ffbd622-87b8-428c-af6c-63db7323014e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99bc3c0b-65b1-425a-b4a9-a52a67b440e1" xlink:to="loc_dei_EntityEmergingGrowthCompany_4ffbd622-87b8-428c-af6c-63db7323014e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_ff27ba92-bf9c-4f78-bd37-c4bd9eb8fe45" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99bc3c0b-65b1-425a-b4a9-a52a67b440e1" xlink:to="loc_dei_EntityShellCompany_ff27ba92-bf9c-4f78-bd37-c4bd9eb8fe45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_2d85db7f-414e-4b4a-8272-2f041b028cc9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99bc3c0b-65b1-425a-b4a9-a52a67b440e1" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_2d85db7f-414e-4b4a-8272-2f041b028cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_d51a632b-0cbc-4371-92ec-af14e44ce2d2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99bc3c0b-65b1-425a-b4a9-a52a67b440e1" xlink:to="loc_dei_AmendmentFlag_d51a632b-0cbc-4371-92ec-af14e44ce2d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_d8a0f8d3-322c-4af6-ad60-a8a9b12e66fa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99bc3c0b-65b1-425a-b4a9-a52a67b440e1" xlink:to="loc_dei_DocumentFiscalYearFocus_d8a0f8d3-322c-4af6-ad60-a8a9b12e66fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_09fe5415-d53d-4fb0-86ab-27f09fbb797a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99bc3c0b-65b1-425a-b4a9-a52a67b440e1" xlink:to="loc_dei_DocumentFiscalPeriodFocus_09fe5415-d53d-4fb0-86ab-27f09fbb797a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_742a0f6c-06f4-4407-bfca-50ca1b3e8f7f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99bc3c0b-65b1-425a-b4a9-a52a67b440e1" xlink:to="loc_dei_EntityCentralIndexKey_742a0f6c-06f4-4407-bfca-50ca1b3e8f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_5b2053a9-6a7e-4abd-8833-d63ae83aa030" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99bc3c0b-65b1-425a-b4a9-a52a67b440e1" xlink:to="loc_dei_CurrentFiscalYearEndDate_5b2053a9-6a7e-4abd-8833-d63ae83aa030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="advm-20220630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_44b37e1f-6b59-4d7a-9288-df6f084b6ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_3b06fa4f-0352-4ff3-8ad9-08bfdbb51c95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_44b37e1f-6b59-4d7a-9288-df6f084b6ae3" xlink:to="loc_us-gaap_AssetsAbstract_3b06fa4f-0352-4ff3-8ad9-08bfdbb51c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_61b08b6e-61f3-4674-849f-7182cddd44ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3b06fa4f-0352-4ff3-8ad9-08bfdbb51c95" xlink:to="loc_us-gaap_AssetsCurrentAbstract_61b08b6e-61f3-4674-849f-7182cddd44ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_af89817a-a149-4343-b768-cc418d89d548" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_61b08b6e-61f3-4674-849f-7182cddd44ec" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_af89817a-a149-4343-b768-cc418d89d548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_0140f7df-94f4-48da-b1fe-425aef9cd4a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_61b08b6e-61f3-4674-849f-7182cddd44ec" xlink:to="loc_us-gaap_ShortTermInvestments_0140f7df-94f4-48da-b1fe-425aef9cd4a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncentiveToLessee_b6d31899-35cb-404b-b2e3-37f470b77c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncentiveToLessee"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_61b08b6e-61f3-4674-849f-7182cddd44ec" xlink:to="loc_us-gaap_IncentiveToLessee_b6d31899-35cb-404b-b2e3-37f470b77c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0b62d4a8-ad89-4307-863c-f7af0bd2687b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_61b08b6e-61f3-4674-849f-7182cddd44ec" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0b62d4a8-ad89-4307-863c-f7af0bd2687b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f22393bb-465b-4b7a-8584-feebf3160af1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_61b08b6e-61f3-4674-849f-7182cddd44ec" xlink:to="loc_us-gaap_AssetsCurrent_f22393bb-465b-4b7a-8584-feebf3160af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_902fc0d6-2455-4c67-b767-0af2a4a97584" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3b06fa4f-0352-4ff3-8ad9-08bfdbb51c95" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_902fc0d6-2455-4c67-b767-0af2a4a97584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d6b31dbc-a6e1-4c97-970a-e081f8abf6b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3b06fa4f-0352-4ff3-8ad9-08bfdbb51c95" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d6b31dbc-a6e1-4c97-970a-e081f8abf6b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_6c1ecdf7-057f-468b-9384-3ff8819e41aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3b06fa4f-0352-4ff3-8ad9-08bfdbb51c95" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_6c1ecdf7-057f-468b-9384-3ff8819e41aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentReceivablesNet_5ca20c48-a503-4871-92af-f49537c4bac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentReceivablesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3b06fa4f-0352-4ff3-8ad9-08bfdbb51c95" xlink:to="loc_us-gaap_DeferredRentReceivablesNet_5ca20c48-a503-4871-92af-f49537c4bac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_5355be54-4eb4-42a5-bfd9-62b61c8d1eae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3b06fa4f-0352-4ff3-8ad9-08bfdbb51c95" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_5355be54-4eb4-42a5-bfd9-62b61c8d1eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_5bf89a91-df49-40c0-b745-41d745af9cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3b06fa4f-0352-4ff3-8ad9-08bfdbb51c95" xlink:to="loc_us-gaap_Assets_5bf89a91-df49-40c0-b745-41d745af9cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9a618bc1-5b83-4f38-9c03-f2c2ee61e740" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_44b37e1f-6b59-4d7a-9288-df6f084b6ae3" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9a618bc1-5b83-4f38-9c03-f2c2ee61e740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_e1fe3ce2-dffa-4609-ac23-b123fd6b9642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9a618bc1-5b83-4f38-9c03-f2c2ee61e740" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_e1fe3ce2-dffa-4609-ac23-b123fd6b9642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_93479996-1fdb-4dad-b188-9b1265bf1cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e1fe3ce2-dffa-4609-ac23-b123fd6b9642" xlink:to="loc_us-gaap_AccountsPayableCurrent_93479996-1fdb-4dad-b188-9b1265bf1cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_7263a6fd-cf6f-4cff-871d-64cd55b3f5d3" xlink:href="advm-20220630.xsd#advm_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e1fe3ce2-dffa-4609-ac23-b123fd6b9642" xlink:to="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_7263a6fd-cf6f-4cff-871d-64cd55b3f5d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_2293748f-2ce2-4ee5-981c-3b32cf2c8a90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e1fe3ce2-dffa-4609-ac23-b123fd6b9642" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_2293748f-2ce2-4ee5-981c-3b32cf2c8a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d02f89f0-7fb6-4d67-9b50-07b90e2411d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e1fe3ce2-dffa-4609-ac23-b123fd6b9642" xlink:to="loc_us-gaap_LiabilitiesCurrent_d02f89f0-7fb6-4d67-9b50-07b90e2411d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_17a787ae-0b37-4b36-8535-11b7fdcb4967" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9a618bc1-5b83-4f38-9c03-f2c2ee61e740" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_17a787ae-0b37-4b36-8535-11b7fdcb4967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_c270acf1-671c-46d3-aef0-4fa81b95a8a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9a618bc1-5b83-4f38-9c03-f2c2ee61e740" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_c270acf1-671c-46d3-aef0-4fa81b95a8a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0e6adcf5-6c9b-4eba-8295-09fb7b470d11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9a618bc1-5b83-4f38-9c03-f2c2ee61e740" xlink:to="loc_us-gaap_Liabilities_0e6adcf5-6c9b-4eba-8295-09fb7b470d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_6b684dd4-0d84-4d65-bafb-d09a3c837a20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9a618bc1-5b83-4f38-9c03-f2c2ee61e740" xlink:to="loc_us-gaap_StockholdersEquityAbstract_6b684dd4-0d84-4d65-bafb-d09a3c837a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_d34985b7-2bd2-4df1-8b55-95b7bd212bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6b684dd4-0d84-4d65-bafb-d09a3c837a20" xlink:to="loc_us-gaap_PreferredStockValue_d34985b7-2bd2-4df1-8b55-95b7bd212bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_78392e7c-61a8-405c-b240-dddd5cc8d235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6b684dd4-0d84-4d65-bafb-d09a3c837a20" xlink:to="loc_us-gaap_CommonStockValue_78392e7c-61a8-405c-b240-dddd5cc8d235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_89853168-d3d8-4240-a147-ad29c1eb777f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6b684dd4-0d84-4d65-bafb-d09a3c837a20" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_89853168-d3d8-4240-a147-ad29c1eb777f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ff7246f8-0e42-46fb-a410-09269456bcf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6b684dd4-0d84-4d65-bafb-d09a3c837a20" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ff7246f8-0e42-46fb-a410-09269456bcf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4d5005c7-a9ec-4f09-b487-5f01d8749efb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6b684dd4-0d84-4d65-bafb-d09a3c837a20" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4d5005c7-a9ec-4f09-b487-5f01d8749efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b9e2a44b-373b-44d4-8320-78b8922cf39c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6b684dd4-0d84-4d65-bafb-d09a3c837a20" xlink:to="loc_us-gaap_StockholdersEquity_b9e2a44b-373b-44d4-8320-78b8922cf39c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d29c3812-47a7-4c3b-95f0-6fde096d0fde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9a618bc1-5b83-4f38-9c03-f2c2ee61e740" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_d29c3812-47a7-4c3b-95f0-6fde096d0fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="advm-20220630.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_b01373d6-bbdc-4791-9314-4385227245a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5af62d43-9e7f-4ff9-9513-48ad25ad69e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b01373d6-bbdc-4791-9314-4385227245a3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5af62d43-9e7f-4ff9-9513-48ad25ad69e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_7345e4eb-c9b7-4e9d-b8e8-1283305fd384" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b01373d6-bbdc-4791-9314-4385227245a3" xlink:to="loc_us-gaap_OperatingExpensesAbstract_7345e4eb-c9b7-4e9d-b8e8-1283305fd384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_c8a4dad2-2b0f-4258-be77-c9b3fcbe5eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7345e4eb-c9b7-4e9d-b8e8-1283305fd384" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_c8a4dad2-2b0f-4258-be77-c9b3fcbe5eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_e139fdc5-e302-403d-8f73-b0b5dc3061ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7345e4eb-c9b7-4e9d-b8e8-1283305fd384" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_e139fdc5-e302-403d-8f73-b0b5dc3061ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_23614beb-2472-4023-982b-bd4bcdd09924" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7345e4eb-c9b7-4e9d-b8e8-1283305fd384" xlink:to="loc_us-gaap_OperatingExpenses_23614beb-2472-4023-982b-bd4bcdd09924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_34e4a514-36ba-4be2-85af-abb9e890cd35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b01373d6-bbdc-4791-9314-4385227245a3" xlink:to="loc_us-gaap_OperatingIncomeLoss_34e4a514-36ba-4be2-85af-abb9e890cd35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_e07f1518-6b66-48c5-9996-0074bc8b34d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b01373d6-bbdc-4791-9314-4385227245a3" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_e07f1518-6b66-48c5-9996-0074bc8b34d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_57464ec0-d1a4-43b4-84fc-0fecfa4fd6c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b01373d6-bbdc-4791-9314-4385227245a3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_57464ec0-d1a4-43b4-84fc-0fecfa4fd6c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d5d18f0d-01d8-46b2-ab4e-badc1c31d599" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b01373d6-bbdc-4791-9314-4385227245a3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_d5d18f0d-01d8-46b2-ab4e-badc1c31d599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_26e43d0f-0905-4efc-82f9-c4bd71bbb080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b01373d6-bbdc-4791-9314-4385227245a3" xlink:to="loc_us-gaap_NetIncomeLoss_26e43d0f-0905-4efc-82f9-c4bd71bbb080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_c1db8be0-db60-44fb-940c-3bd448d2c44f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b01373d6-bbdc-4791-9314-4385227245a3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_c1db8be0-db60-44fb-940c-3bd448d2c44f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_ecdbae00-a359-4ef7-bc81-be0ea9c37004" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_c1db8be0-db60-44fb-940c-3bd448d2c44f" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_ecdbae00-a359-4ef7-bc81-be0ea9c37004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_870b5fff-8c09-445d-a517-d777ad8a8818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_c1db8be0-db60-44fb-940c-3bd448d2c44f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_870b5fff-8c09-445d-a517-d777ad8a8818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_89ee58e4-6d8d-43b5-b0ab-572ca6a90fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b01373d6-bbdc-4791-9314-4385227245a3" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_89ee58e4-6d8d-43b5-b0ab-572ca6a90fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_8b8237a7-7be1-45ab-854a-330ef439cd2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b01373d6-bbdc-4791-9314-4385227245a3" xlink:to="loc_us-gaap_EarningsPerShareBasic_8b8237a7-7be1-45ab-854a-330ef439cd2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_bc1b03de-85ef-47fb-9007-e5eeb15e30a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b01373d6-bbdc-4791-9314-4385227245a3" xlink:to="loc_us-gaap_EarningsPerShareDiluted_bc1b03de-85ef-47fb-9007-e5eeb15e30a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_359a92f7-d975-4a37-a55e-a7db72e55ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b01373d6-bbdc-4791-9314-4385227245a3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_359a92f7-d975-4a37-a55e-a7db72e55ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_04f092f8-f591-4789-803d-a8b881d080fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b01373d6-bbdc-4791-9314-4385227245a3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_04f092f8-f591-4789-803d-a8b881d080fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="advm-20220630.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_03c67de0-a648-4e59-9544-db722cabfe08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6b79633e-e3db-4989-b849-3ff387e788a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_03c67de0-a648-4e59-9544-db722cabfe08" xlink:to="loc_us-gaap_StatementTable_6b79633e-e3db-4989-b849-3ff387e788a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_51b23726-78d1-40f2-a47c-dc81a988b47e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6b79633e-e3db-4989-b849-3ff387e788a6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_51b23726-78d1-40f2-a47c-dc81a988b47e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2bdcea69-7a49-4ae3-bc3d-987b201ad96b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_51b23726-78d1-40f2-a47c-dc81a988b47e" xlink:to="loc_us-gaap_EquityComponentDomain_2bdcea69-7a49-4ae3-bc3d-987b201ad96b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ae20b129-4cea-41ed-84f2-d514a0cab866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2bdcea69-7a49-4ae3-bc3d-987b201ad96b" xlink:to="loc_us-gaap_CommonStockMember_ae20b129-4cea-41ed-84f2-d514a0cab866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_64ff2c12-c444-4079-af28-00d9f2f5ae4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2bdcea69-7a49-4ae3-bc3d-987b201ad96b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_64ff2c12-c444-4079-af28-00d9f2f5ae4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3ce01a4d-d095-48cb-9779-a38b29a7f61b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2bdcea69-7a49-4ae3-bc3d-987b201ad96b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3ce01a4d-d095-48cb-9779-a38b29a7f61b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_a282b61b-2950-41e2-acc7-8b2c337cf063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2bdcea69-7a49-4ae3-bc3d-987b201ad96b" xlink:to="loc_us-gaap_RetainedEarningsMember_a282b61b-2950-41e2-acc7-8b2c337cf063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e174cf4f-0c45-413b-94c8-2693f22bcdc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6b79633e-e3db-4989-b849-3ff387e788a6" xlink:to="loc_us-gaap_StatementLineItems_e174cf4f-0c45-413b-94c8-2693f22bcdc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d33802f5-f57a-4658-abd9-a3eb9794f5c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e174cf4f-0c45-413b-94c8-2693f22bcdc9" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d33802f5-f57a-4658-abd9-a3eb9794f5c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_73363219-9d73-4526-b2ac-3285240bea1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d33802f5-f57a-4658-abd9-a3eb9794f5c4" xlink:to="loc_us-gaap_SharesOutstanding_73363219-9d73-4526-b2ac-3285240bea1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b2e7d7ff-db31-43e9-9969-65acb7bbb6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d33802f5-f57a-4658-abd9-a3eb9794f5c4" xlink:to="loc_us-gaap_StockholdersEquity_b2e7d7ff-db31-43e9-9969-65acb7bbb6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5fc7deeb-a2c1-4975-87e3-cb63c0928cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d33802f5-f57a-4658-abd9-a3eb9794f5c4" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5fc7deeb-a2c1-4975-87e3-cb63c0928cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_380cf236-d8ad-4a25-b11b-dc2b18ef8425" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d33802f5-f57a-4658-abd9-a3eb9794f5c4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_380cf236-d8ad-4a25-b11b-dc2b18ef8425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4ecda0ae-a287-43fc-a48b-e2717509f853" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d33802f5-f57a-4658-abd9-a3eb9794f5c4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4ecda0ae-a287-43fc-a48b-e2717509f853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_89906a4e-db46-4727-9638-bbe1676bcd0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d33802f5-f57a-4658-abd9-a3eb9794f5c4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_89906a4e-db46-4727-9638-bbe1676bcd0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_c9dd5d73-c4f4-4311-96ab-4a3746dc58b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d33802f5-f57a-4658-abd9-a3eb9794f5c4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_c9dd5d73-c4f4-4311-96ab-4a3746dc58b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_3bb14454-5bdf-4a9a-9724-535825336240" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d33802f5-f57a-4658-abd9-a3eb9794f5c4" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_3bb14454-5bdf-4a9a-9724-535825336240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_67f5d234-da33-4707-9ee4-972540d726b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d33802f5-f57a-4658-abd9-a3eb9794f5c4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_67f5d234-da33-4707-9ee4-972540d726b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a467e889-f11e-449a-838e-8f93f68ce168" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d33802f5-f57a-4658-abd9-a3eb9794f5c4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a467e889-f11e-449a-838e-8f93f68ce168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_328d188d-1438-447f-8c0a-79b0b08f8fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d33802f5-f57a-4658-abd9-a3eb9794f5c4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_328d188d-1438-447f-8c0a-79b0b08f8fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_c8199bf8-c4b3-4a70-a731-fe08d1d6d0bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d33802f5-f57a-4658-abd9-a3eb9794f5c4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_c8199bf8-c4b3-4a70-a731-fe08d1d6d0bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_4d85ce86-57d7-424c-a014-28e7b93a35f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d33802f5-f57a-4658-abd9-a3eb9794f5c4" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_4d85ce86-57d7-424c-a014-28e7b93a35f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ff85bf9c-5888-4af9-b479-66af68f4a596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d33802f5-f57a-4658-abd9-a3eb9794f5c4" xlink:to="loc_us-gaap_NetIncomeLoss_ff85bf9c-5888-4af9-b479-66af68f4a596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_6035f85d-9572-4eba-81d8-e590bdd11353" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d33802f5-f57a-4658-abd9-a3eb9794f5c4" xlink:to="loc_us-gaap_SharesOutstanding_6035f85d-9572-4eba-81d8-e590bdd11353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e64ee12f-5f9f-4bd0-ba27-3e559a4de205" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d33802f5-f57a-4658-abd9-a3eb9794f5c4" xlink:to="loc_us-gaap_StockholdersEquity_e64ee12f-5f9f-4bd0-ba27-3e559a4de205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="advm-20220630.xsd#CondensedConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_bdb5fd0e-633d-48d5-9cb8-b02179a0ef8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_3543dc2a-4f96-4831-97cd-5513ca780b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_bdb5fd0e-633d-48d5-9cb8-b02179a0ef8a" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_3543dc2a-4f96-4831-97cd-5513ca780b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="advm-20220630.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_99e87236-7128-49ce-9bb3-d99fc2db7274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ac21ef12-a488-4f50-969a-23344ec2f41b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_99e87236-7128-49ce-9bb3-d99fc2db7274" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ac21ef12-a488-4f50-969a-23344ec2f41b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_48801676-7394-4d57-b362-261c53313ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ac21ef12-a488-4f50-969a-23344ec2f41b" xlink:to="loc_us-gaap_NetIncomeLoss_48801676-7394-4d57-b362-261c53313ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bc74aa81-9f11-4090-9ebd-ab2c465ab518" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ac21ef12-a488-4f50-969a-23344ec2f41b" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bc74aa81-9f11-4090-9ebd-ab2c465ab518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_efc3cc75-83ce-478d-9717-bb5e0b21e4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bc74aa81-9f11-4090-9ebd-ab2c465ab518" xlink:to="loc_us-gaap_DepreciationAndAmortization_efc3cc75-83ce-478d-9717-bb5e0b21e4ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_b7785c13-5163-44a5-9a2f-be89a5498917" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bc74aa81-9f11-4090-9ebd-ab2c465ab518" xlink:to="loc_us-gaap_ShareBasedCompensation_b7785c13-5163-44a5-9a2f-be89a5498917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_c74d5168-81f6-4c8a-8129-2b2296e05e9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bc74aa81-9f11-4090-9ebd-ab2c465ab518" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_c74d5168-81f6-4c8a-8129-2b2296e05e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_9d925678-8d54-46d6-9fe8-7a6f46a26a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bc74aa81-9f11-4090-9ebd-ab2c465ab518" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_9d925678-8d54-46d6-9fe8-7a6f46a26a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_ea7d3670-208c-44ce-a60a-890571cb904e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bc74aa81-9f11-4090-9ebd-ab2c465ab518" xlink:to="loc_us-gaap_AssetImpairmentCharges_ea7d3670-208c-44ce-a60a-890571cb904e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_49bc90b5-4c74-4375-a11d-cf0857ca10e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bc74aa81-9f11-4090-9ebd-ab2c465ab518" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_49bc90b5-4c74-4375-a11d-cf0857ca10e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f952cab8-3825-4900-b7fa-9e46cf1d06cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ac21ef12-a488-4f50-969a-23344ec2f41b" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f952cab8-3825-4900-b7fa-9e46cf1d06cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_408e526f-de2b-4d1d-8a53-c2e23386aad4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f952cab8-3825-4900-b7fa-9e46cf1d06cf" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_408e526f-de2b-4d1d-8a53-c2e23386aad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_2a1f73f1-59c8-416f-9f81-ae21610d70da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f952cab8-3825-4900-b7fa-9e46cf1d06cf" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_2a1f73f1-59c8-416f-9f81-ae21610d70da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset_8cdb8b05-de6b-4269-ab62-51468f2602e5" xlink:href="advm-20220630.xsd#advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f952cab8-3825-4900-b7fa-9e46cf1d06cf" xlink:to="loc_advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset_8cdb8b05-de6b-4269-ab62-51468f2602e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_84619a06-6b6c-4bd3-ab00-e36a91277a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f952cab8-3825-4900-b7fa-9e46cf1d06cf" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_84619a06-6b6c-4bd3-ab00-e36a91277a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1677da7a-ef2f-4cea-ba32-67254f7538ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f952cab8-3825-4900-b7fa-9e46cf1d06cf" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1677da7a-ef2f-4cea-ba32-67254f7538ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_7acff4b7-7f28-49d5-92b3-5767d9301102" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f952cab8-3825-4900-b7fa-9e46cf1d06cf" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_7acff4b7-7f28-49d5-92b3-5767d9301102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable_66dbf7b7-e4dc-49cc-8e52-781f14c4c40a" xlink:href="advm-20220630.xsd#advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f952cab8-3825-4900-b7fa-9e46cf1d06cf" xlink:to="loc_advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable_66dbf7b7-e4dc-49cc-8e52-781f14c4c40a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_37005a5b-c120-4aed-8418-c65915c1b2f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ac21ef12-a488-4f50-969a-23344ec2f41b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_37005a5b-c120-4aed-8418-c65915c1b2f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1c852367-4610-44ea-a6ac-cb8430b4254a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_99e87236-7128-49ce-9bb3-d99fc2db7274" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1c852367-4610-44ea-a6ac-cb8430b4254a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_82d7862e-a087-4514-8a0f-5494e9423fa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1c852367-4610-44ea-a6ac-cb8430b4254a" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_82d7862e-a087-4514-8a0f-5494e9423fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_2cf5a3e1-4cbd-4d6f-90aa-e5fdbcc17a76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1c852367-4610-44ea-a6ac-cb8430b4254a" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_2cf5a3e1-4cbd-4d6f-90aa-e5fdbcc17a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_a29fa7e6-7068-4e73-a677-7a5d535aac9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1c852367-4610-44ea-a6ac-cb8430b4254a" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_a29fa7e6-7068-4e73-a677-7a5d535aac9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8f9274d3-7992-4962-904d-a5981e09b9b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1c852367-4610-44ea-a6ac-cb8430b4254a" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8f9274d3-7992-4962-904d-a5981e09b9b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bc9908fc-9669-481a-9f61-d0c5ff028d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1c852367-4610-44ea-a6ac-cb8430b4254a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bc9908fc-9669-481a-9f61-d0c5ff028d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1d62121c-e80a-4c0a-a7bf-a9c80c206ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_99e87236-7128-49ce-9bb3-d99fc2db7274" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1d62121c-e80a-4c0a-a7bf-a9c80c206ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6f3f120e-5879-48a7-a8d6-5f8ede74811d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1d62121c-e80a-4c0a-a7bf-a9c80c206ff4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6f3f120e-5879-48a7-a8d6-5f8ede74811d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_1377b60e-4fb2-4c0c-b472-afd321026267" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1d62121c-e80a-4c0a-a7bf-a9c80c206ff4" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_1377b60e-4fb2-4c0c-b472-afd321026267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_40bd76e2-5b15-41e9-8699-84e16d98000d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1d62121c-e80a-4c0a-a7bf-a9c80c206ff4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_40bd76e2-5b15-41e9-8699-84e16d98000d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_27be88b9-b909-4ae4-837f-8783da4a566e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1d62121c-e80a-4c0a-a7bf-a9c80c206ff4" xlink:to="loc_us-gaap_RepaymentsOfDebt_27be88b9-b909-4ae4-837f-8783da4a566e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_353b47a4-2144-4427-b8e3-7bcddd198062" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1d62121c-e80a-4c0a-a7bf-a9c80c206ff4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_353b47a4-2144-4427-b8e3-7bcddd198062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_054c2912-0246-4310-ba09-02624b11d267" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_99e87236-7128-49ce-9bb3-d99fc2db7274" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_054c2912-0246-4310-ba09-02624b11d267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_616c8e4b-86c7-4566-aba6-63274c8972ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_99e87236-7128-49ce-9bb3-d99fc2db7274" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_616c8e4b-86c7-4566-aba6-63274c8972ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ff773cba-e6d0-4715-b900-1f42956dd7fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_99e87236-7128-49ce-9bb3-d99fc2db7274" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ff773cba-e6d0-4715-b900-1f42956dd7fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_19a9e97a-7fa6-4d37-9c66-3657dcedcfc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_99e87236-7128-49ce-9bb3-d99fc2db7274" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_19a9e97a-7fa6-4d37-9c66-3657dcedcfc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_f5dc8b65-ace7-4c99-a4a1-e9d3cb8ac449" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_99e87236-7128-49ce-9bb3-d99fc2db7274" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_f5dc8b65-ace7-4c99-a4a1-e9d3cb8ac449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d5c55381-7e28-47a0-a5b4-28a6335826e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_99e87236-7128-49ce-9bb3-d99fc2db7274" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d5c55381-7e28-47a0-a5b4-28a6335826e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_de250496-6ba4-44a6-9ada-52b2b8ab7c43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_99e87236-7128-49ce-9bb3-d99fc2db7274" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_de250496-6ba4-44a6-9ada-52b2b8ab7c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_555b68d1-2b9d-495b-b41b-856dec8ca11d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_de250496-6ba4-44a6-9ada-52b2b8ab7c43" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_555b68d1-2b9d-495b-b41b-856dec8ca11d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_d61e8a61-5451-4ecb-8268-c8c7922254de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_de250496-6ba4-44a6-9ada-52b2b8ab7c43" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_d61e8a61-5451-4ecb-8268-c8c7922254de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="advm-20220630.xsd#OrganizationandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/OrganizationandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8b7dfe5e-9d3a-4d39-b518-e8e8c98b7651" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_52b1e5a1-a161-4223-b95d-06c7209aa88b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8b7dfe5e-9d3a-4d39-b518-e8e8c98b7651" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_52b1e5a1-a161-4223-b95d-06c7209aa88b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/OrganizationandBasisofPresentationDetail" xlink:type="simple" xlink:href="advm-20220630.xsd#OrganizationandBasisofPresentationDetail"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/OrganizationandBasisofPresentationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bc9558c3-7110-45f0-9052-8fe4b8fd247a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_385c371a-aa05-4002-a0c0-4453a16478a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bc9558c3-7110-45f0-9052-8fe4b8fd247a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_385c371a-aa05-4002-a0c0-4453a16478a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_fb6cafcd-cdbc-4a31-a2bf-a9fefc2dafcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bc9558c3-7110-45f0-9052-8fe4b8fd247a" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_fb6cafcd-cdbc-4a31-a2bf-a9fefc2dafcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="advm-20220630.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9ddbaed8-97e6-4f14-a8d3-5ee550727ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_c879d0d0-b405-4985-89f7-1e12806d82cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9ddbaed8-97e6-4f14-a8d3-5ee550727ddf" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_c879d0d0-b405-4985-89f7-1e12806d82cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="advm-20220630.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1d7ddfeb-e85c-4920-9a63-14884804ba2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0a77e0af-3e9e-4aa4-9e21-e413532d6eba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1d7ddfeb-e85c-4920-9a63-14884804ba2d" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0a77e0af-3e9e-4aa4-9e21-e413532d6eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_10a75692-7091-4524-b6b1-d8b4085a5622" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1d7ddfeb-e85c-4920-9a63-14884804ba2d" xlink:to="loc_us-gaap_UseOfEstimates_10a75692-7091-4524-b6b1-d8b4085a5622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a1d229f7-8729-48e5-b07f-0f24db7dda6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1d7ddfeb-e85c-4920-9a63-14884804ba2d" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a1d229f7-8729-48e5-b07f-0f24db7dda6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments" xlink:type="simple" xlink:href="advm-20220630.xsd#FairValueMeasurementsandFairValueofFinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e8e8b6e1-57a4-48c8-b7d1-911b62f4fe3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_4cf0b884-8598-4dde-be07-880ee0e820b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e8e8b6e1-57a4-48c8-b7d1-911b62f4fe3b" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_4cf0b884-8598-4dde-be07-880ee0e820b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables" xlink:type="simple" xlink:href="advm-20220630.xsd#FairValueMeasurementsandFairValueofFinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e9ba616e-8e13-4534-826a-d87fd9087553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_6f32e355-5201-497f-b965-ccd0eb28889f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e9ba616e-8e13-4534-826a-d87fd9087553" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_6f32e355-5201-497f-b965-ccd0eb28889f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail" xlink:type="simple" xlink:href="advm-20220630.xsd#FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5c836ceb-9136-4c21-8339-99b8f17b0590" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_843beb1c-f417-4386-8905-8a99ec65ff1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5c836ceb-9136-4c21-8339-99b8f17b0590" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_843beb1c-f417-4386-8905-8a99ec65ff1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_acba3893-47c9-4b39-a25c-282e18dd8f18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_843beb1c-f417-4386-8905-8a99ec65ff1b" xlink:to="loc_us-gaap_FinancialInstrumentAxis_acba3893-47c9-4b39-a25c-282e18dd8f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ab9a1cad-fc66-433c-90cb-ad66f2e34d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_acba3893-47c9-4b39-a25c-282e18dd8f18" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ab9a1cad-fc66-433c-90cb-ad66f2e34d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_9a5493b5-1b27-4c60-89d0-257ed00f437e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ab9a1cad-fc66-433c-90cb-ad66f2e34d5a" xlink:to="loc_us-gaap_MoneyMarketFundsMember_9a5493b5-1b27-4c60-89d0-257ed00f437e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_26864499-a97d-4378-901c-b5f6e587d230" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ab9a1cad-fc66-433c-90cb-ad66f2e34d5a" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_26864499-a97d-4378-901c-b5f6e587d230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_5ad1e7c3-05b5-40c4-8d20-40342d9ffa25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ab9a1cad-fc66-433c-90cb-ad66f2e34d5a" xlink:to="loc_us-gaap_CommercialPaperMember_5ad1e7c3-05b5-40c4-8d20-40342d9ffa25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_57ad1331-46f0-498a-969e-7ee67db33759" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ab9a1cad-fc66-433c-90cb-ad66f2e34d5a" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_57ad1331-46f0-498a-969e-7ee67db33759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashEquivalentsAndShortTermInvestmentsMember_45381be8-6601-4a7b-acd2-597c0beb7f59" xlink:href="advm-20220630.xsd#advm_CashEquivalentsAndShortTermInvestmentsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ab9a1cad-fc66-433c-90cb-ad66f2e34d5a" xlink:to="loc_advm_CashEquivalentsAndShortTermInvestmentsMember_45381be8-6601-4a7b-acd2-597c0beb7f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_649a91a7-1a5f-4e38-90f2-aad128e3ecf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_843beb1c-f417-4386-8905-8a99ec65ff1b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_649a91a7-1a5f-4e38-90f2-aad128e3ecf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a1fa0b15-4b49-488a-97f2-9fc5bba523a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_649a91a7-1a5f-4e38-90f2-aad128e3ecf9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a1fa0b15-4b49-488a-97f2-9fc5bba523a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_7df9306f-4667-424d-a398-15bb0d367830" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a1fa0b15-4b49-488a-97f2-9fc5bba523a2" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_7df9306f-4667-424d-a398-15bb0d367830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_d98f05cb-15db-492d-996e-872693694830" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a1fa0b15-4b49-488a-97f2-9fc5bba523a2" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_d98f05cb-15db-492d-996e-872693694830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2b4e4940-6adc-4637-9e79-72516dfdc591" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_843beb1c-f417-4386-8905-8a99ec65ff1b" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2b4e4940-6adc-4637-9e79-72516dfdc591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4dc5ccbf-f213-4c81-b5cc-7c157005444c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2b4e4940-6adc-4637-9e79-72516dfdc591" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4dc5ccbf-f213-4c81-b5cc-7c157005444c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b29b4312-5a1a-486d-89a6-69d86a435a66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2b4e4940-6adc-4637-9e79-72516dfdc591" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b29b4312-5a1a-486d-89a6-69d86a435a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_30071fb3-f145-4bf8-81b2-5a4554ed984d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2b4e4940-6adc-4637-9e79-72516dfdc591" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_30071fb3-f145-4bf8-81b2-5a4554ed984d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_084a388b-f7aa-46b1-aefa-89b9da95dd24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2b4e4940-6adc-4637-9e79-72516dfdc591" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_084a388b-f7aa-46b1-aefa-89b9da95dd24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentAmortizedCost_88b2ed89-39a0-4955-91f4-476ec1184ee8" xlink:href="advm-20220630.xsd#advm_CashAndCashEquivalentAmortizedCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2b4e4940-6adc-4637-9e79-72516dfdc591" xlink:to="loc_advm_CashAndCashEquivalentAmortizedCost_88b2ed89-39a0-4955-91f4-476ec1184ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedGain_601ca04a-fae7-49e9-af98-57db2b5bc680" xlink:href="advm-20220630.xsd#advm_CashAndCashEquivalentGrossUnrealizedGain"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2b4e4940-6adc-4637-9e79-72516dfdc591" xlink:to="loc_advm_CashAndCashEquivalentGrossUnrealizedGain_601ca04a-fae7-49e9-af98-57db2b5bc680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss_732bfa1e-5d79-46b7-bbba-3f1b8c4c5f57" xlink:href="advm-20220630.xsd#advm_CashAndCashEquivalentGrossUnrealizedLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2b4e4940-6adc-4637-9e79-72516dfdc591" xlink:to="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss_732bfa1e-5d79-46b7-bbba-3f1b8c4c5f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_833a7f1f-dbd0-4e17-9e20-83b85724c566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2b4e4940-6adc-4637-9e79-72516dfdc591" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_833a7f1f-dbd0-4e17-9e20-83b85724c566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail" xlink:type="simple" xlink:href="advm-20220630.xsd#FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_938fc825-4efc-428d-b102-72e99cfb8632" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities_95510308-9a17-4669-9d70-8f46aacf64be" xlink:href="advm-20220630.xsd#advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_938fc825-4efc-428d-b102-72e99cfb8632" xlink:to="loc_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities_95510308-9a17-4669-9d70-8f46aacf64be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponents" xlink:type="simple" xlink:href="advm-20220630.xsd#BalanceSheetComponents"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/BalanceSheetComponents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_044c6b61-8e05-4414-87d7-4139479fb7ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_b6aceedd-cb77-49d5-a5e2-fbf7726e360a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_044c6b61-8e05-4414-87d7-4139479fb7ad" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_b6aceedd-cb77-49d5-a5e2-fbf7726e360a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsTables" xlink:type="simple" xlink:href="advm-20220630.xsd#BalanceSheetComponentsTables"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_4793fee1-f5a1-477d-9cfd-c8d09f65ded1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_7fc9ef7e-bb46-4786-9519-8bf979d06e76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_4793fee1-f5a1-477d-9cfd-c8d09f65ded1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_7fc9ef7e-bb46-4786-9519-8bf979d06e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_7a730cfb-bbce-4444-944a-cb13e53c0236" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_4793fee1-f5a1-477d-9cfd-c8d09f65ded1" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_7a730cfb-bbce-4444-944a-cb13e53c0236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="simple" xlink:href="advm-20220630.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_7f77aab5-cdbe-43d3-bc35-db5f6c0b8700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_372adaef-a0e9-429a-bfc6-e696f17d3444" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_7f77aab5-cdbe-43d3-bc35-db5f6c0b8700" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_372adaef-a0e9-429a-bfc6-e696f17d3444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_691d689b-3ce8-4855-a492-85146e9997aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_372adaef-a0e9-429a-bfc6-e696f17d3444" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_691d689b-3ce8-4855-a492-85146e9997aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f7755ae-ff91-44f9-9a0e-af7921a56cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_691d689b-3ce8-4855-a492-85146e9997aa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f7755ae-ff91-44f9-9a0e-af7921a56cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_c3e369f6-ba0a-402e-8e43-ece425eee162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f7755ae-ff91-44f9-9a0e-af7921a56cc3" xlink:to="loc_us-gaap_ComputerEquipmentMember_c3e369f6-ba0a-402e-8e43-ece425eee162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_44c1ad86-7905-453a-a0e7-639e7ca54a09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f7755ae-ff91-44f9-9a0e-af7921a56cc3" xlink:to="loc_us-gaap_EquipmentMember_44c1ad86-7905-453a-a0e7-639e7ca54a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_66d5498e-60d9-4dd4-8e26-50f07114898f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f7755ae-ff91-44f9-9a0e-af7921a56cc3" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_66d5498e-60d9-4dd4-8e26-50f07114898f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_a890746b-e1f1-4869-bd7f-4c983bc67922" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f7755ae-ff91-44f9-9a0e-af7921a56cc3" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_a890746b-e1f1-4869-bd7f-4c983bc67922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_52c87d30-7f0b-46ee-be72-8c93ef02ce38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f7755ae-ff91-44f9-9a0e-af7921a56cc3" xlink:to="loc_us-gaap_ConstructionInProgressMember_52c87d30-7f0b-46ee-be72-8c93ef02ce38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_268f0839-6ef0-4ce8-ad33-92ff6a8dfa87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_372adaef-a0e9-429a-bfc6-e696f17d3444" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_268f0839-6ef0-4ce8-ad33-92ff6a8dfa87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_e207c811-79ba-4e8c-ac80-5b0702e34a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_268f0839-6ef0-4ce8-ad33-92ff6a8dfa87" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_e207c811-79ba-4e8c-ac80-5b0702e34a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3f5de1dd-d97d-47a5-9745-39b14565eca4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_268f0839-6ef0-4ce8-ad33-92ff6a8dfa87" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3f5de1dd-d97d-47a5-9745-39b14565eca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3db29878-e4d9-43f2-ad6e-e488f87e8c40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_268f0839-6ef0-4ce8-ad33-92ff6a8dfa87" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3db29878-e4d9-43f2-ad6e-e488f87e8c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_09dcfe84-042b-4465-8378-675338a4a97a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_268f0839-6ef0-4ce8-ad33-92ff6a8dfa87" xlink:to="loc_us-gaap_AssetImpairmentCharges_09dcfe84-042b-4465-8378-675338a4a97a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail" xlink:type="simple" xlink:href="advm-20220630.xsd#BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_20a86110-f5e4-46d5-b7be-64a71a80b04e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_687183a9-5b81-4dd6-b7ba-984ffdc1bbae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_20a86110-f5e4-46d5-b7be-64a71a80b04e" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_687183a9-5b81-4dd6-b7ba-984ffdc1bbae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts_3c85cb6b-84f7-42e8-965b-0a7b852a0a9d" xlink:href="advm-20220630.xsd#advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_20a86110-f5e4-46d5-b7be-64a71a80b04e" xlink:to="loc_advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts_3c85cb6b-84f7-42e8-965b-0a7b852a0a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_d5ec963f-5bb7-4aff-b784-e3cd9a58c419" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_20a86110-f5e4-46d5-b7be-64a71a80b04e" xlink:to="loc_us-gaap_TaxesPayableCurrent_d5ec963f-5bb7-4aff-b784-e3cd9a58c419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_5e35ccc6-4253-4bfa-878e-3176cfd9bb28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_20a86110-f5e4-46d5-b7be-64a71a80b04e" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_5e35ccc6-4253-4bfa-878e-3176cfd9bb28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_62b26831-a132-4ff2-8051-a11fa9e73aba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_20a86110-f5e4-46d5-b7be-64a71a80b04e" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_62b26831-a132-4ff2-8051-a11fa9e73aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_f7ddff15-461e-4d45-abc7-8b176e8618d2" xlink:href="advm-20220630.xsd#advm_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_20a86110-f5e4-46d5-b7be-64a71a80b04e" xlink:to="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_f7ddff15-461e-4d45-abc7-8b176e8618d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/EquityIncentiveAwards" xlink:type="simple" xlink:href="advm-20220630.xsd#EquityIncentiveAwards"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/EquityIncentiveAwards" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd925d60-116c-4bd1-8460-8091a563e474" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_9582c878-23cc-400d-90a6-5493cdf2e8e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd925d60-116c-4bd1-8460-8091a563e474" xlink:to="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_9582c878-23cc-400d-90a6-5493cdf2e8e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/EquityIncentiveAwardsTables" xlink:type="simple" xlink:href="advm-20220630.xsd#EquityIncentiveAwardsTables"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/EquityIncentiveAwardsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5307f9bc-a060-463a-a3ec-547ebcf7e831" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f1e948cb-19c5-43cf-8429-9d543afa8d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5307f9bc-a060-463a-a3ec-547ebcf7e831" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f1e948cb-19c5-43cf-8429-9d543afa8d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_99ab2247-009e-41af-804c-0cd32444fc6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5307f9bc-a060-463a-a3ec-547ebcf7e831" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_99ab2247-009e-41af-804c-0cd32444fc6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_f9da9ba0-4bc4-4ad9-886a-c813e55791d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5307f9bc-a060-463a-a3ec-547ebcf7e831" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_f9da9ba0-4bc4-4ad9-886a-c813e55791d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetail" xlink:type="simple" xlink:href="advm-20220630.xsd#EquityIncentiveAwardsSummaryofStockOptionsActivityDetail"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_787e11da-3913-466a-9200-8be7cceb5044" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c5e3fa62-eb47-4e00-9fac-28d46c78dafa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_787e11da-3913-466a-9200-8be7cceb5044" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c5e3fa62-eb47-4e00-9fac-28d46c78dafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_82f671c3-bcf5-4c18-955f-9f43228d37b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c5e3fa62-eb47-4e00-9fac-28d46c78dafa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_82f671c3-bcf5-4c18-955f-9f43228d37b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_44446615-8713-4b45-ab35-61d5cb771296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c5e3fa62-eb47-4e00-9fac-28d46c78dafa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_44446615-8713-4b45-ab35-61d5cb771296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e60d14bd-f6a2-467f-8cd9-bc955bfea54f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c5e3fa62-eb47-4e00-9fac-28d46c78dafa" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e60d14bd-f6a2-467f-8cd9-bc955bfea54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_ef19ff93-11bc-4758-bb61-95352b43da0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c5e3fa62-eb47-4e00-9fac-28d46c78dafa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_ef19ff93-11bc-4758-bb61-95352b43da0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d90bec36-0680-4cf9-bae5-54a3ef6b4639" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c5e3fa62-eb47-4e00-9fac-28d46c78dafa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d90bec36-0680-4cf9-bae5-54a3ef6b4639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_397f982f-d086-4580-849d-17356ac0981d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c5e3fa62-eb47-4e00-9fac-28d46c78dafa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_397f982f-d086-4580-849d-17356ac0981d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_11619958-76bc-47de-abfa-5499f82b5455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_787e11da-3913-466a-9200-8be7cceb5044" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_11619958-76bc-47de-abfa-5499f82b5455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a740a8ce-6597-46d5-91fb-6177af64ff86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_11619958-76bc-47de-abfa-5499f82b5455" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a740a8ce-6597-46d5-91fb-6177af64ff86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c2ecdf9a-aee5-471a-ac95-79999651d871" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_11619958-76bc-47de-abfa-5499f82b5455" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c2ecdf9a-aee5-471a-ac95-79999651d871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_03d95b99-90f1-4911-b15f-ba2799b4fba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_11619958-76bc-47de-abfa-5499f82b5455" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_03d95b99-90f1-4911-b15f-ba2799b4fba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_5e4c007a-97e4-4109-bd97-c3e62f5d6788" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_11619958-76bc-47de-abfa-5499f82b5455" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_5e4c007a-97e4-4109-bd97-c3e62f5d6788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_325bd0a6-2638-4ed0-a5e2-ecc6b9ae95a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_11619958-76bc-47de-abfa-5499f82b5455" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_325bd0a6-2638-4ed0-a5e2-ecc6b9ae95a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_51343210-5357-4022-8ed1-49c90e59bcd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_11619958-76bc-47de-abfa-5499f82b5455" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_51343210-5357-4022-8ed1-49c90e59bcd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/EquityIncentiveAwardsAdditionalInformationDetail" xlink:type="simple" xlink:href="advm-20220630.xsd#EquityIncentiveAwardsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/EquityIncentiveAwardsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1bf2323d-e58e-4838-ab35-afda1206269b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_da3798ce-842f-4e0b-b9a2-f8a3637c767b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1bf2323d-e58e-4838-ab35-afda1206269b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_da3798ce-842f-4e0b-b9a2-f8a3637c767b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d17b6123-32fd-4b6e-abcb-27b9cf990fce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_da3798ce-842f-4e0b-b9a2-f8a3637c767b" xlink:to="loc_us-gaap_AwardTypeAxis_d17b6123-32fd-4b6e-abcb-27b9cf990fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a483e594-279a-4bec-9897-261f454e0ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d17b6123-32fd-4b6e-abcb-27b9cf990fce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a483e594-279a-4bec-9897-261f454e0ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_4c8d6fbd-846e-4a3f-8a1f-096a1658a14c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a483e594-279a-4bec-9897-261f454e0ee6" xlink:to="loc_us-gaap_PerformanceSharesMember_4c8d6fbd-846e-4a3f-8a1f-096a1658a14c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_041733c9-c309-4bb6-9f69-296a4cc9fdfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_da3798ce-842f-4e0b-b9a2-f8a3637c767b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_041733c9-c309-4bb6-9f69-296a4cc9fdfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_deaa0e99-17ef-45f2-98ae-2bf118395025" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_041733c9-c309-4bb6-9f69-296a4cc9fdfd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_deaa0e99-17ef-45f2-98ae-2bf118395025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_18dc29cd-68b5-4bb3-918b-53e8d189dbaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_041733c9-c309-4bb6-9f69-296a4cc9fdfd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_18dc29cd-68b5-4bb3-918b-53e8d189dbaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail" xlink:type="simple" xlink:href="advm-20220630.xsd#EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_87f3bd59-4318-4bd8-8777-76c03a93873d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e6bd0cb-1d4b-47e0-ae7d-1a4681d671e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_87f3bd59-4318-4bd8-8777-76c03a93873d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e6bd0cb-1d4b-47e0-ae7d-1a4681d671e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8aed05d9-a176-41e1-bcb7-a7d8c117d154" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e6bd0cb-1d4b-47e0-ae7d-1a4681d671e9" xlink:to="loc_us-gaap_AwardTypeAxis_8aed05d9-a176-41e1-bcb7-a7d8c117d154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4045611f-74fb-4de9-99d7-ea570f48cc78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8aed05d9-a176-41e1-bcb7-a7d8c117d154" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4045611f-74fb-4de9-99d7-ea570f48cc78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a655d2e5-e7f0-4d3e-a8f1-f32f1d4268e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4045611f-74fb-4de9-99d7-ea570f48cc78" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a655d2e5-e7f0-4d3e-a8f1-f32f1d4268e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2db1016-5b43-4913-8134-0fc02ae4ce6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e6bd0cb-1d4b-47e0-ae7d-1a4681d671e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2db1016-5b43-4913-8134-0fc02ae4ce6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d0483703-1334-4b6a-8bc6-af346a7c74bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2db1016-5b43-4913-8134-0fc02ae4ce6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d0483703-1334-4b6a-8bc6-af346a7c74bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_00457a22-cb15-41d4-9451-88a7f48d7927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d0483703-1334-4b6a-8bc6-af346a7c74bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_00457a22-cb15-41d4-9451-88a7f48d7927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_74608b84-fa40-4219-a104-0f5c76bdd32e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d0483703-1334-4b6a-8bc6-af346a7c74bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_74608b84-fa40-4219-a104-0f5c76bdd32e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_73fd4e45-65a5-401e-a36f-d14259f86d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d0483703-1334-4b6a-8bc6-af346a7c74bd" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_73fd4e45-65a5-401e-a36f-d14259f86d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_26d6c1b8-4c2f-427e-9c4f-7bf4416f8923" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d0483703-1334-4b6a-8bc6-af346a7c74bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_26d6c1b8-4c2f-427e-9c4f-7bf4416f8923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c57b5c3f-7427-48e9-bdef-664cee6b5259" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d0483703-1334-4b6a-8bc6-af346a7c74bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c57b5c3f-7427-48e9-bdef-664cee6b5259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6c655933-b44e-41f4-ab38-5ae1d10321d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2db1016-5b43-4913-8134-0fc02ae4ce6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6c655933-b44e-41f4-ab38-5ae1d10321d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b3595945-b560-4674-a1c9-429852e5f829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6c655933-b44e-41f4-ab38-5ae1d10321d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b3595945-b560-4674-a1c9-429852e5f829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f7a9e125-6310-402a-80a2-aa2aa15bad9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6c655933-b44e-41f4-ab38-5ae1d10321d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f7a9e125-6310-402a-80a2-aa2aa15bad9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_014030c1-97b3-4171-a0dc-f5396563b169" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6c655933-b44e-41f4-ab38-5ae1d10321d4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_014030c1-97b3-4171-a0dc-f5396563b169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b8e5106d-3d42-425f-927b-ef7da190c5df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6c655933-b44e-41f4-ab38-5ae1d10321d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b8e5106d-3d42-425f-927b-ef7da190c5df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_adbb8197-bc0c-4874-b116-783f5463ad39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6c655933-b44e-41f4-ab38-5ae1d10321d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_adbb8197-bc0c-4874-b116-783f5463ad39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/EquityIncentiveAwardsStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="advm-20220630.xsd#EquityIncentiveAwardsStockBasedCompensationExpenseDetail"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/EquityIncentiveAwardsStockBasedCompensationExpenseDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5d688ab5-fc23-4ca7-b174-604b478135fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_08239eee-33f0-451f-bb67-f2974284a21a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5d688ab5-fc23-4ca7-b174-604b478135fe" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_08239eee-33f0-451f-bb67-f2974284a21a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0c240068-cea4-4a1f-813b-f3803f5669b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_08239eee-33f0-451f-bb67-f2974284a21a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0c240068-cea4-4a1f-813b-f3803f5669b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5daeaf01-70c7-402d-9113-4e74ddfc0248" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0c240068-cea4-4a1f-813b-f3803f5669b4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5daeaf01-70c7-402d-9113-4e74ddfc0248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_fab0fcde-dc4e-47a8-9af3-d1128f3c0745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5daeaf01-70c7-402d-9113-4e74ddfc0248" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_fab0fcde-dc4e-47a8-9af3-d1128f3c0745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_9b545b5c-c869-4457-9c89-fdebeacd8b40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5daeaf01-70c7-402d-9113-4e74ddfc0248" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_9b545b5c-c869-4457-9c89-fdebeacd8b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5ce32545-b8da-435e-a9ad-04ecb1170080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_08239eee-33f0-451f-bb67-f2974284a21a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5ce32545-b8da-435e-a9ad-04ecb1170080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_bf2dc78c-d148-403a-a0f0-c6bedb016eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5ce32545-b8da-435e-a9ad-04ecb1170080" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_bf2dc78c-d148-403a-a0f0-c6bedb016eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/NetLossperShare" xlink:type="simple" xlink:href="advm-20220630.xsd#NetLossperShare"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/NetLossperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_62dbec44-ced9-4d83-b09e-bd4fb2727329" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_743c1ee3-65ff-406b-be2d-e5ba0850db65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_62dbec44-ced9-4d83-b09e-bd4fb2727329" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_743c1ee3-65ff-406b-be2d-e5ba0850db65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/NetLossperShareTables" xlink:type="simple" xlink:href="advm-20220630.xsd#NetLossperShareTables"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/NetLossperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f4b4f992-c994-48e3-b10a-c03c9b12ca62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8d5302c2-be22-4391-b772-a23882aa1432" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f4b4f992-c994-48e3-b10a-c03c9b12ca62" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8d5302c2-be22-4391-b772-a23882aa1432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetail" xlink:type="simple" xlink:href="advm-20220630.xsd#NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetail"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_289f2284-2e3e-42bf-a989-fd849a2d7a88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_dab1ea6f-f1ea-44c8-8898-9a30daef7a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_289f2284-2e3e-42bf-a989-fd849a2d7a88" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_dab1ea6f-f1ea-44c8-8898-9a30daef7a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8b1cb3ea-6210-436e-bfaa-0d0b5c0908f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_dab1ea6f-f1ea-44c8-8898-9a30daef7a8b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8b1cb3ea-6210-436e-bfaa-0d0b5c0908f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ce79db44-12f7-424e-b9b3-bf13fa8c92eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8b1cb3ea-6210-436e-bfaa-0d0b5c0908f2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ce79db44-12f7-424e-b9b3-bf13fa8c92eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0594a539-dd4e-4e48-b0e2-af9b707fd937" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ce79db44-12f7-424e-b9b3-bf13fa8c92eb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0594a539-dd4e-4e48-b0e2-af9b707fd937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_fd37d061-5ec8-426d-a20b-eb721637ae72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ce79db44-12f7-424e-b9b3-bf13fa8c92eb" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_fd37d061-5ec8-426d-a20b-eb721637ae72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_268f2172-cdd0-456d-ae62-89354b1c68f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ce79db44-12f7-424e-b9b3-bf13fa8c92eb" xlink:to="loc_us-gaap_EmployeeStockMember_268f2172-cdd0-456d-ae62-89354b1c68f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0d910165-dee1-4bbb-be3d-00764b071302" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_dab1ea6f-f1ea-44c8-8898-9a30daef7a8b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0d910165-dee1-4bbb-be3d-00764b071302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f5812373-cfed-4a16-ab13-b72aef7b6c41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0d910165-dee1-4bbb-be3d-00764b071302" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f5812373-cfed-4a16-ab13-b72aef7b6c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/SubsequentEvent" xlink:type="simple" xlink:href="advm-20220630.xsd#SubsequentEvent"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/SubsequentEvent" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_a0217e33-6847-42a8-9183-f0333c83a706" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_09e53064-ab0b-4641-9412-7b4d563893b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_a0217e33-6847-42a8-9183-f0333c83a706" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_09e53064-ab0b-4641-9412-7b4d563893b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/SubsequentEventDetails" xlink:type="simple" xlink:href="advm-20220630.xsd#SubsequentEventDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/SubsequentEventDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_953f1dff-1ee7-4460-96b3-08ce9136d273" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_582491f5-518e-44d7-bfab-fbb07996a6d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_953f1dff-1ee7-4460-96b3-08ce9136d273" xlink:to="loc_us-gaap_SubsequentEventTable_582491f5-518e-44d7-bfab-fbb07996a6d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8250de40-57bb-4d63-b281-76650f70efba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_582491f5-518e-44d7-bfab-fbb07996a6d2" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8250de40-57bb-4d63-b281-76650f70efba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7f8c7ea9-e4d3-4e1d-8257-7e5dc80ccf22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8250de40-57bb-4d63-b281-76650f70efba" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7f8c7ea9-e4d3-4e1d-8257-7e5dc80ccf22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_6f66f672-d57e-45ea-93c2-db7b947902a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7f8c7ea9-e4d3-4e1d-8257-7e5dc80ccf22" xlink:to="loc_us-gaap_SubsequentEventMember_6f66f672-d57e-45ea-93c2-db7b947902a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_dee2a65a-11de-4645-9965-05de87c072e4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_582491f5-518e-44d7-bfab-fbb07996a6d2" xlink:to="loc_srt_StatementScenarioAxis_dee2a65a-11de-4645-9965-05de87c072e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_4233bacb-ce7d-4bd7-8295-f8ca3c4a4dca" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_dee2a65a-11de-4645-9965-05de87c072e4" xlink:to="loc_srt_ScenarioUnspecifiedDomain_4233bacb-ce7d-4bd7-8295-f8ca3c4a4dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_4abad1e5-6958-43b5-8d8b-79fe1d9c3b70" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_4233bacb-ce7d-4bd7-8295-f8ca3c4a4dca" xlink:to="loc_srt_ScenarioForecastMember_4abad1e5-6958-43b5-8d8b-79fe1d9c3b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_eff9b17e-93f0-4bc7-98a9-3f94180799a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_582491f5-518e-44d7-bfab-fbb07996a6d2" xlink:to="loc_us-gaap_SubsequentEventLineItems_eff9b17e-93f0-4bc7-98a9-3f94180799a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate_c57ed67d-18a7-44fc-8887-cc1c788b5260" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_eff9b17e-93f0-4bc7-98a9-3f94180799a5" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate_c57ed67d-18a7-44fc-8887-cc1c788b5260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent_73e7b933-0e99-4459-b2a1-9998fa291012" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_eff9b17e-93f0-4bc7-98a9-3f94180799a5" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent_73e7b933-0e99-4459-b2a1-9998fa291012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_f94ffa5a-6136-4684-b194-3c2e5cbad4b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_eff9b17e-93f0-4bc7-98a9-3f94180799a5" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_f94ffa5a-6136-4684-b194-3c2e5cbad4b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_cad83b4c-de53-4841-b0a9-f6ebb3b1b37d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_eff9b17e-93f0-4bc7-98a9-3f94180799a5" xlink:to="loc_us-gaap_PaymentsForRestructuring_cad83b4c-de53-4841-b0a9-f6ebb3b1b37d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>advmlogo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 advmlogo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !\ HH# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#1_PT;\/_P#H/1_]\&OB'_A#->_Z ][_ -^&_P *4>"]>8@#1[XD_P#3!O\
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M5Q4?XB/OL]_Y%M?T/E?X=_\ (]:#_P!?D?\ Z$*_2&OS>^'?_(]:#_U^1_\
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MTK\U?!O_ ".&A?\ 7_!_Z,6OTJ7[H^E8XO='N<&?PZ_JOU%HHHK@/T@****
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M .T%_P D>\2_]>__ +,*^ $^\OUKT\+\#/R+C'_?*?\ A_5GZ6^%/^17T?\
MZ\X?_0!6K65X4_Y%?1_^O.'_ - %:M>:]S]8I?PX^B"BBBD:A1110 4444 %
M?F7K_P#R'-0_Z[O_ .A&OTTK\R]?_P"0YJ'_ %W?_P!"-=^$WD?FO&GP4/\
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M.OBQX;^'MC)-J>H1F=0=MI"P:5SZ8'3\:$G)V0ZM:G0@ZE62275E'XX>/(O
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M/YFO9*\;_:R_Y)!<_P#7Y!_,UPTOC1^B9Q_R+J_^%_D?''@W_D<-"_Z_X/\
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MIMW/G\^RF>;4H1IR2<7UV/SLAU*[MXPD5U-$@Z*DA _+-2?VQ?\ _/\ 7/\
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MS+/+X;LS)(Q9B$QDGJ:ZZ-94TTT?%9]D-7-:L*U*:32MJ? ZZ]J:*%74;M5
MP )VP/UI?^$@U7_H)7G_ '_?_&OO'_A0/@'_ *%NS_[YH_X4#X!_Z%NS_P"^
M:Z/K4.Q\W_JEC_\ G['[W_D?!W_"0:K_ -!*\_[_ +_XT?\ "0:K_P!!*\_[
M_O\ XU]X_P#"@? /_0MV?_?-'_"@? /_ $+=G_WS1]:AV#_5+'_\_8_>_P#(
M^#O^$@U7_H)7G_?]_P#&C_A(-5_Z"5Y_W_?_ !K[Q_X4#X!_Z%NS_P"^:/\
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MWTK2K=;:TA& HZD]R3W)K54!0 !@#L*6N*I5E4W/O<KR;#Y5']WK)[M[_P#
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MU:JJC5CPL@RBIE-.<:LDW)]/(****YCZD**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
+ **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image.jpg
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M"JTJK:.Z $;Q>U&= NKR?*2]\MJ9:O]AZ(G!27",?]'(&]6G]2N1G4*;4KM
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M&]]'=PK-ZF#P]#7(U3.0LURQS$$^IN+71GF_IU\O&;*09+:Z%+9G-=+?0AY
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MP#>1G0*Z?Q>.FH^6% R*CNH68^Y5'T,^"R%@SW$MN8X.#? @5J<PHHQ>2W<
M[R^E41XZ1_U)1\6&HHGF'N<4H$SES2ET<@H$%17I/H6Z>PI_DV^/(81R"@3J
M[DPN=T4^?]%1W4*&X5K5?.3Q,@QBJ*7&<3L%-K# DSM ^YIALW8^3X3Z.0+O
M;@+-1M@&!8SU2,CD5N3S"QW5+5 /T_'>_?WB%"JP>*(G< DMZG$5&@<W@9>1
M]JR\Z^$[!1B;'F?J80@FH0*W7]N+\'8&*CNR4^"Z=7:748$OI>[H>0P>]%\S
M:IX8RU!K\SL#/(C5*:";&FEO1D\@/Z" +Z"<+^ZL'L#K']& ZW]+0I%3J,B2
MU)Z< H'TCH5L<0/AT\CC5;PW7C\J&6A5TF _@>^[K&HJQA"N2KE+6HFC=53)
M\)T"TKA)1Y4-E/UD<?1SE=M3+QR.[%.@MQ5RQ26E!^OHDG'M;/4M?@OYON>&
M.]2>.KH+\,YM"'_O#Z< F;Y!1Y4-&6J[4QT&WG9K,SA'B5XE-^O=?F(J&4+J
M%JE9ZB0(^YL44.X-@/#O*H';[N>IS\*X<3GA1H0%;)7KSTH"OA&G<-W,:&OV
M:8! VU8HSK,<R^88J<3/4^_G' <J=A2>MT&P[KAX=N]S#SL#%',(TMI>ME.8
MITY N;="@2_IP$\=KFQ5N\FNW@B[8B',IR!L'397/<I-<OX1)#X_T/H9#9YP
M G>2?% BQ"FTJF>@V*:.Z@)Q"IQ3B.@4$%9WYQ0(=.LO0+G:QMV'NHRX9IT]
M#<@!YW*6H45]$H>C)!Y&8M"MZG/@B=0O\KDK2H\2=><YA5;5PLE>-%@^PS@_
M#)JA]@Z[]EV.>6A5:>GEM*H;48_?]E<BZ5[-(3"ZLT9!AY#OY?)1!% 6H4/;
MP9OFP<WJL&('Q&$DR,R?J.,HWYR+%X4<(O:<PNN<H]!1)4/*UZK60&XSU GJ
M1W&XLDGM-H8Z%*)W-!YE@\V:@;*N@:Q>0MFF?O 9[0?R2G$N:^@L=8E\D* K
M!G/UT5RU&:WM)U%!<\#,>?B]"V'^B+GJ>0C*-OQ]+\<?]2<E XIS '?!<F6#
MC@H-KFT?>9=Z"L+W#NB\%VD60.--B..$U#L0K 8JI7X],I!F2B92RYUHODMV
M0].1O4 E@\+<)3S5 7R^&_&W]]22V2G@2,#+,\ #3L1M 3^X.]-%NC>QKL"/
MS>!'#HKP1?U%24 Z^X*F%Z!,61W5!6C-'3EZ@>P>_ZV.*ADP.G]&_;TYN$4=
MKJ,Z@&/'>&?RA"6J#31$;C5R)1T<UY/@"8W_8CC. GC2Q$8%?K<A;NJHV6H_
M_7HHI)K4GN#1X^ !]Z \CO0>YZ^$5O7$Z/G0'QBWL,<GP&#MCC+SC*8-H)/'
M3K#%[D"^9R+==4A_.0S917@O]"YL'^<L41^ T_PKTEH%'KR!P&$K+N,N0.8?
MP>]FA%8XC]"KC_1P#(_.&*ZC2@;R.QCYKAYYMQQQT8*_ SUA@)S?C?AFZ$J7
MY?([ \IW*+Z;B; 5?S\-^OY&NP$=N9=QR'?:2-UH2- -P*S/H (&09DL,(QK
MX;,26E7MB%8U% S\:=1#\3AN2R5'!7Q31T4"%&TOT'0!%&8V:%P*>A_&WU4P
MX$>%'6/M"3"D7-L\:N2"\H2%M,(P7P5A-#OP4P<(9MWP9C4NRFHN'X/N4/N"
MUK^"!ZT(+R#PN(\,C.*1^I508"L-1O\*MK9U5!>@-;L/RC4.>87>)\&])J!O
M"%MM.JH+T'CX.)3_BL&W=>\X2@4/7T19_@0#>RME!7QZ##RWT' XMIPQ9$[:
M@K[38$2KD*X)&:11#0+RJT'YSH]JO-GH IT<_U^,]%Y"F(_TKN*1+OJ5LH'>
MTU>1[I4(\U"7RR"/#R//-'ATW&DA5QWY@,Q\ C2/A+TX0D>5#/::45=_I>QV
MIRN(KP5MD\'W7A<0=$;J"?5!I'T,[-HDT$9GP+).@X,]Y8PR'&SEH-3_ Y29
27*>K%A?"     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>imageb.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 imageb.jpg
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M"JTJK:.Z $;Q>U&= NKR?*2]\MJ9:O]AZ(G!27",?]'(&]6G]2N1G4*;4KM
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M&]]'=PK-ZF#P]#7(U3.0LURQS$$^IN+71GF_IU\O&;*09+:Z%+9G-=+?0AY
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MP#>1G0*Z?Q>.FH^6% R*CNH68^Y5'T,^"R%@SW$MN8X.#? @5J<PHHQ>2W<
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27*>K%A?"     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139689993536992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Aug. 05, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Adverum Biotechnologies, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-5258327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 Cardinal Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Redwood City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">656-9323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ADVM<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,333,578<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001501756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139689996685584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 91,870<span></span>
</td>
<td class="nump">$ 34,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">143,971<span></span>
</td>
<td class="nump">270,993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncentiveToLessee', window );">Lease incentive receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">10,190<span></span>
</td>
<td class="nump">6,248<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">246,031<span></span>
</td>
<td class="nump">317,145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">83,766<span></span>
</td>
<td class="nump">86,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">38,233<span></span>
</td>
<td class="nump">33,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">2,503<span></span>
</td>
<td class="nump">2,503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentReceivablesNet', window );">Deferred rent receivable</a></td>
<td class="nump">4,145<span></span>
</td>
<td class="nump">769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Deposit and other long-term assets</a></td>
<td class="nump">277<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">374,955<span></span>
</td>
<td class="nump">439,727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,698<span></span>
</td>
<td class="nump">1,387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_AccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">19,630<span></span>
</td>
<td class="nump">18,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability, current portion</a></td>
<td class="nump">6,292<span></span>
</td>
<td class="nump">1,886<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">30,620<span></span>
</td>
<td class="nump">21,320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, net of current portion</a></td>
<td class="nump">99,193<span></span>
</td>
<td class="nump">101,108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">1,020<span></span>
</td>
<td class="nump">1,114<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">130,833<span></span>
</td>
<td class="nump">123,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">975,653<span></span>
</td>
<td class="nump">964,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,796)<span></span>
</td>
<td class="num">(714)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(729,745)<span></span>
</td>
<td class="num">(648,076)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">244,122<span></span>
</td>
<td class="nump">316,185<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 374,955<span></span>
</td>
<td class="nump">$ 439,727<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentReceivablesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental income recognized over rental payment required by lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123408481&amp;loc=SL77919140-209958<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123394697&amp;loc=d3e40879-112712<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39927-112707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39896-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentReceivablesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncentiveToLessee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of incentive granted by lessor to lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e40010-112707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e40019-112707<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 30<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123388062&amp;loc=SL77916639-209961<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncentiveToLessee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139689996565792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">30,265<span></span>
</td>
<td class="nump">22,608<span></span>
</td>
<td class="nump">53,229<span></span>
</td>
<td class="nump">42,588<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">13,760<span></span>
</td>
<td class="nump">21,930<span></span>
</td>
<td class="nump">28,929<span></span>
</td>
<td class="nump">38,093<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">44,025<span></span>
</td>
<td class="nump">44,538<span></span>
</td>
<td class="nump">82,158<span></span>
</td>
<td class="nump">80,681<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(44,025)<span></span>
</td>
<td class="num">(44,538)<span></span>
</td>
<td class="num">(82,158)<span></span>
</td>
<td class="num">(73,181)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">283<span></span>
</td>
<td class="nump">205<span></span>
</td>
<td class="nump">527<span></span>
</td>
<td class="nump">412<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income taxes</a></td>
<td class="num">(43,742)<span></span>
</td>
<td class="num">(44,333)<span></span>
</td>
<td class="num">(81,631)<span></span>
</td>
<td class="num">(72,769)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="num">(19)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(43,761)<span></span>
</td>
<td class="num">(44,333)<span></span>
</td>
<td class="num">(81,669)<span></span>
</td>
<td class="num">(72,769)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Net unrealized loss on marketable securities</a></td>
<td class="num">(339)<span></span>
</td>
<td class="num">(62)<span></span>
</td>
<td class="num">(1,062)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(34)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="num">(72)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (44,134)<span></span>
</td>
<td class="num">$ (44,434)<span></span>
</td>
<td class="num">$ (82,751)<span></span>
</td>
<td class="num">$ (72,925)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share &#8212; basic (in USD per share)</a></td>
<td class="num">$ (0.44)<span></span>
</td>
<td class="num">$ (0.45)<span></span>
</td>
<td class="num">$ (0.83)<span></span>
</td>
<td class="num">$ (0.74)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share &#8212; diluted (in USD per share)</a></td>
<td class="num">$ (0.44)<span></span>
</td>
<td class="num">$ (0.45)<span></span>
</td>
<td class="num">$ (0.83)<span></span>
</td>
<td class="num">$ (0.74)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares used to compute net loss per share - basic (in shares)</a></td>
<td class="nump">99,000<span></span>
</td>
<td class="nump">98,018<span></span>
</td>
<td class="nump">98,799<span></span>
</td>
<td class="nump">97,885<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares used to compute net loss per share - diluted (in shares)</a></td>
<td class="nump">99,000<span></span>
</td>
<td class="nump">98,018<span></span>
</td>
<td class="nump">98,799<span></span>
</td>
<td class="nump">97,885<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139689991135360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive (Loss)/Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,549,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 434,347<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 937,134<span></span>
</td>
<td class="num">$ (261)<span></span>
</td>
<td class="num">$ (502,536)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">7,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">1,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued upon exercise of stock options</a></td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Common stock issued upon release of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">248,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="num">(33)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized loss on marketable securities, net</a></td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(28,436)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,436)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,927,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">414,820<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">946,098<span></span>
</td>
<td class="num">(316)<span></span>
</td>
<td class="num">(530,972)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,549,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">434,347<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">937,134<span></span>
</td>
<td class="num">(261)<span></span>
</td>
<td class="num">(502,536)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="num">(72)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized loss on marketable securities, net</a></td>
<td class="num">(84)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(72,769)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">379,142<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">954,854<span></span>
</td>
<td class="num">(417)<span></span>
</td>
<td class="num">(575,305)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,927,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">414,820<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">946,098<span></span>
</td>
<td class="num">(316)<span></span>
</td>
<td class="num">(530,972)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">8,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance of common stock, additional issuance costs</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Common stock issued upon release of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued under employee stock purchase plan</a></td>
<td class="nump">526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="num">(39)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized loss on marketable securities, net</a></td>
<td class="num">(62)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(62)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(44,333)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44,333)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">379,142<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">954,854<span></span>
</td>
<td class="num">(417)<span></span>
</td>
<td class="num">(575,305)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,381,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">316,185<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">964,965<span></span>
</td>
<td class="num">(714)<span></span>
</td>
<td class="num">(648,076)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">5,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued upon exercise of stock options</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Common stock issued upon release of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">371,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized loss on marketable securities, net</a></td>
<td class="num">(723)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(723)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(37,908)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37,908)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,767,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">282,952<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">970,349<span></span>
</td>
<td class="num">(1,423)<span></span>
</td>
<td class="num">(685,984)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,381,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 316,185<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">964,965<span></span>
</td>
<td class="num">(714)<span></span>
</td>
<td class="num">(648,076)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of stock options (in shares)</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="num">$ (20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized loss on marketable securities, net</a></td>
<td class="num">(1,062)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(81,669)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,271,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">244,122<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">975,653<span></span>
</td>
<td class="num">(1,796)<span></span>
</td>
<td class="num">(729,745)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,767,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="nump">282,952<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">970,349<span></span>
</td>
<td class="num">(1,423)<span></span>
</td>
<td class="num">(685,984)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">4,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Common stock issued upon release of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">499,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued under employee stock purchase plan</a></td>
<td class="nump">362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="num">(34)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized loss on marketable securities, net</a></td>
<td class="num">(339)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(339)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(43,761)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,761)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,271,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">$ 244,122<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 975,653<span></span>
</td>
<td class="num">$ (1,796)<span></span>
</td>
<td class="num">$ (729,745)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139689998541728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders Equity (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139689991070160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (81,669)<span></span>
</td>
<td class="num">$ (72,769)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">3,028<span></span>
</td>
<td class="nump">2,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">10,323<span></span>
</td>
<td class="nump">15,458<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premium and accrued interest on marketable securities</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">1,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of long-lived assets</a></td>
<td class="nump">2,011<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="num">(76)<span></span>
</td>
<td class="num">(81)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(4,165)<span></span>
</td>
<td class="num">(1,653)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(3,403)<span></span>
</td>
<td class="num">(99)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">2,234<span></span>
</td>
<td class="nump">1,505<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">3,216<span></span>
</td>
<td class="num">(394)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">2,172<span></span>
</td>
<td class="num">(583)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="num">(38)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable', window );">Lease liability and lease incentive receivable</a></td>
<td class="nump">8,200<span></span>
</td>
<td class="num">(1,363)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(57,808)<span></span>
</td>
<td class="num">(56,220)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(57,674)<span></span>
</td>
<td class="num">(199,959)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">183,599<span></span>
</td>
<td class="nump">240,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sales of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(10,807)<span></span>
</td>
<td class="num">(5,052)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">115,118<span></span>
</td>
<td class="nump">44,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from offerings of common stock, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock pursuant to option exercises</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Proceeds from employee stock purchase plan</a></td>
<td class="nump">362<span></span>
</td>
<td class="nump">526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(240)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">365<span></span>
</td>
<td class="nump">2,022<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents and restricted cash</a></td>
<td class="nump">57,675<span></span>
</td>
<td class="num">(9,842)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">36,698<span></span>
</td>
<td class="nump">63,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash at end of period</a></td>
<td class="nump">94,373<span></span>
</td>
<td class="nump">53,581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">91,870<span></span>
</td>
<td class="nump">47,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">2,503<span></span>
</td>
<td class="nump">6,282<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash at end of period</a></td>
<td class="nump">94,373<span></span>
</td>
<td class="nump">53,581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental schedule of noncash investing and financing information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right-of-use assets obtained in exchange for lease liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">84,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Fixed assets in accounts payable, accrued expenses and other current liabilities</a></td>
<td class="nump">$ 908<span></span>
</td>
<td class="nump">$ 1,562<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in lease liabilities and lease incentive receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Operating Lease Right-of-use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139689991051664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text">Organization and Basis of Presentation<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverum Biotechnologies, Inc. (the &#8220;Company&#8221; or &#8220;Adverum&#8221;) was incorporated in Delaware on July 17, 2006 and is headquartered in Redwood City, California. The Company is a clinical-stage company that aims to establish gene therapy as a new standard of care for a number of highly prevalent ocular diseases. The Company develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not generated any revenue from the sale of products since its inception. The Company has experienced net losses since its inception and had an accumulated deficit of $729.7 million as of June&#160;30, 2022. The Company expects to incur losses and have negative net cash flows from operating activities as it engages in further research and development activities. As of June&#160;30, 2022, the Company had cash, cash equivalents and short-term investments of $235.8 million, which the Company believes will be sufficient to fund its operations for at least twelve months from the date of issuance of these financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation &#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and follow the requirements of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company&#8217;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair statement of the Company&#8217;s consolidated financial information. The results of operations for the three and six months ended June&#160;30, 2022 are not necessarily indicative of the results to be expected for the full year or any other future period. The balance sheet as of December&#160;31, 2021 is derived from the audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete consolidated financial statements. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021 filed with the SEC.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139690077598512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities and the reported amounts of expenses in the condensed consolidated financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to clinical trial accruals, fair value of assets and liabilities, impairment of long-lived assets, income taxes, and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8211; Credit Losses: Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Topic 326</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and also issued subsequent amendments to the initial guidance: ASU&#160;2018-19, ASU&#160;2019-04, ASU&#160;2019-05, and ASU&#160;2019-11. The standard requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect collectability. Topic&#160;326 also eliminates the concept of &#8220;other-than-temporary&#8221; impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an allowance for credit losses on available-for-sale debt securities rather than an other-than-temporary impairment that reduces the cost basis of the investment. Topic 326 will become effective for the Company on January 1, 2023. Early adoption is permitted. The Company does not expect the effect of adoption to be material.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139690077584368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements and Fair Value of Financial Instruments</a></td>
<td class="text">Fair Value Measurements and Fair Value of Financial Instruments<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authoritative guidance on the fair value hierarchy for disclosure of fair value measurements is as follows:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Level 1 securities is determined using quoted prices in active markets for identical assets. Level 1 securities consist of highly liquid money market funds. Financial assets and liabilities are considered Level 2 when their fair values are determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis. U.S. government and agency securities, commercial paper, and corporate bonds are valued primarily using market prices of comparable securities, bid/ask quotes, interest rate yields and prepayment spreads and are included in Level 2. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s cash equivalents and short-term investments:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost Basis</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Level 1:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Level 2:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government and agency securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,008)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,364&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(323)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,060&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash equivalents and short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,682&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,379)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,303&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: cash equivalents</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,342)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,332)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,340&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,369)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,971&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost Basis</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 2:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash equivalents and short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(318)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,808)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,807)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,309&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(317)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,993&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, all of the marketable securities have a remaining maturity of less than one year. Management regularly reviews all of the Company&#8217;s investments for other-than-temporary declines in estimated fair value. Management determined that the gross unrealized losses on the Company&#8217;s marketable securities as of June&#160;30, 2022 were temporary in nature and none were in a continuous loss position for 12 months or more. The Company does not intend to sell the investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases. Management concluded that none of the Company&#8217;s marketable securities were other-than-temporarily impaired as of June&#160;30, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June&#160;30, 2022, the Company performed an impairment test to measure certain laboratory equipment at fair value. The assets are measured at fair value using Level 3 inputs on a non-recurring basis as a result of the occurrence of certain triggering events indicating the carrying value of the assets may not be recoverable. Refer to Note 4, Balance Sheet Components for additional information.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139690077533264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text">Balance Sheet Components<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consists of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,096&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,874&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,234&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,641)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,174)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,233&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,060&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed an impairment analysis for certain laboratory equipment assets based on the identification of impairment indicators during the three months ended June&#160;30, 2022. The analysis determined that the fair value of the assets, which was determined using a market approach, was lower than the carrying value. As a result of the evaluation, an impairment charge of $2.0 million was recognized for the three months ended June&#160;30, 2022. The assets indicated as impaired were written down to their estimated fair value.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other Current Liabilities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consist of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued nonclinical, clinical and process development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,951&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,630&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,047&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI https://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139690077562672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Awards<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Equity Incentive Awards</a></td>
<td class="text">Equity Incentive Awards<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s option activity and related information:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Options<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,288&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,469)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,798&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.71&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,739&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.02&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted during the six months ended June&#160;30, 2022 include 0.9&#160;million shares of performance-based non-qualified options with both performance and service vesting conditions.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units (&#8220;RSUs&#8221;)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s RSUs activity and related information:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Units<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average Grant-<br/>Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(376)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,387&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs granted during the six months ended June&#160;30, 2022 include 0.4 million shares of performance units with both performance and service vesting conditions.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents, by operating expense, the Company&#8217;s stock-based compensation expense:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.332%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,918&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,942&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,234&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,323&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,458&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139689997360912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text">Net Loss per ShareBasic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period using the treasury stock method. Outstanding stock options, RSUs, rights under the employee stock purchase plan (&#8220;ESPP&#8221;) and warrants are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents outstanding at the end of the periods presented were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,435</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,488&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,130&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139689998345040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
<td class="text">Subsequent EventIn July 2022, the Company implemented a restructuring of operations, including reductions in both headcount and expenses, to prioritize its clinical development of ixoberogene soroparvovec (&#8220;Ixo-vec&#8221;), formerly referred to as ADVM-022, and focus its pipeline strategy on certain highly prevalent ocular diseases. The Company expects these restructuring measures will be sufficient to fully support its Ixo-vec development plan and extend its expected cash runway into 2025. The Company expects the restructuring to be completed in the fourth quarter of 2022.Under the restructuring plan, the Company reduced its workforce by 78 employees (approximately 38%) and will incur aggregate restructuring charges of approximately $4.2&#160;million, of which it expects approximately $4.1&#160;million will be cash expenditures. The restructuring costs will be recorded primarily in the third quarter of 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139689996749344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation &#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and follow the requirements of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company&#8217;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair statement of the Company&#8217;s consolidated financial information. The results of operations for the three and six months ended June&#160;30, 2022 are not necessarily indicative of the results to be expected for the full year or any other future period. The balance sheet as of December&#160;31, 2021 is derived from the audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete consolidated financial statements. </span>The accompanying unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021 filed with the SEC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities and the reported amounts of expenses in the condensed consolidated financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to clinical trial accruals, fair value of assets and liabilities, impairment of long-lived assets, income taxes, and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8211; Credit Losses: Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Topic 326</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and also issued subsequent amendments to the initial guidance: ASU&#160;2018-19, ASU&#160;2019-04, ASU&#160;2019-05, and ASU&#160;2019-11. The standard requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect collectability. Topic&#160;326 also eliminates the concept of &#8220;other-than-temporary&#8221; impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an allowance for credit losses on available-for-sale debt securities rather than an other-than-temporary impairment that reduces the cost basis of the investment. Topic 326 will become effective for the Company on January 1, 2023. Early adoption is permitted. The Company does not expect the effect of adoption to be material.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139689998648336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Summary of Cash Equivalents and Short-term Investments</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s cash equivalents and short-term investments:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost Basis</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Level 1:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Level 2:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government and agency securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,008)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,364&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(323)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,060&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash equivalents and short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,682&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,379)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,303&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: cash equivalents</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,342)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,332)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,340&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,369)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,971&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost Basis</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 2:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash equivalents and short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(318)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,808)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,807)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,309&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(317)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,993&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139689998402864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consists of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,096&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,874&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,234&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,641)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,174)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,233&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,060&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consist of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued nonclinical, clinical and process development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,951&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,630&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,047&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139689994425008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Awards (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Options Activity</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s option activity and related information:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Options<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,288&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,469)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,798&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.71&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,739&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.02&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Restricted Stock Units Activity</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s RSUs activity and related information:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Units<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average Grant-<br/>Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(376)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,387&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-Based Compensation Expense</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents, by operating expense, the Company&#8217;s stock-based compensation expense:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.332%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,918&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,942&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,234&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,323&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,458&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139689998912960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents outstanding at the end of the periods presented were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,435</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,488&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,130&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139689993423648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 729,745<span></span>
</td>
<td class="nump">$ 648,076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="nump">$ 235,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139689991367376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Fair Value of Financial Instruments - Summary of Cash Equivalents and Short-term Investments (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">$ 145,340<span></span>
</td>
<td class="nump">$ 271,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(1,369)<span></span>
</td>
<td class="num">(317)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">143,971<span></span>
</td>
<td class="nump">270,993<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_CashAndCashEquivalentAmortizedCost', window );">Less: cash equivalents, amortized cost basis</a></td>
<td class="num">(77,342)<span></span>
</td>
<td class="num">(25,808)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_CashAndCashEquivalentGrossUnrealizedGain', window );">Less: cash equivalents, unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_CashAndCashEquivalentGrossUnrealizedLoss', window );">Less: cash equivalents, unrealized losses</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Less: cash equivalents, estimated fair value</a></td>
<td class="num">(77,332)<span></span>
</td>
<td class="num">(25,807)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level 1:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">10,108<span></span>
</td>
<td class="nump">10,311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">10,108<span></span>
</td>
<td class="nump">10,311<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government and agency securities | Level 2:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">55,150<span></span>
</td>
<td class="nump">62,268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(1,008)<span></span>
</td>
<td class="num">(218)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">54,142<span></span>
</td>
<td class="nump">62,050<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 2:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">150,364<span></span>
</td>
<td class="nump">177,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(323)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">150,041<span></span>
</td>
<td class="nump">177,155<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Level 2:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">7,060<span></span>
</td>
<td class="nump">47,323<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(48)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">7,012<span></span>
</td>
<td class="nump">47,284<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=advm_CashEquivalentsAndShortTermInvestmentsMember', window );">Total cash equivalents and short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">222,682<span></span>
</td>
<td class="nump">297,117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(1,379)<span></span>
</td>
<td class="num">(318)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 221,303<span></span>
</td>
<td class="nump">$ 296,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_CashAndCashEquivalentAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalent amortized cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_CashAndCashEquivalentAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_CashAndCashEquivalentGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalent gross unrealized gain.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_CashAndCashEquivalentGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_CashAndCashEquivalentGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalent gross unrealized loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_CashAndCashEquivalentGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=advm_CashEquivalentsAndShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=advm_CashEquivalentsAndShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139689994429408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Detail)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities', window );">Marketable securities other-than-temporarily impaired</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other than temporary impaired investments available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139689994355632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Property and Equipment, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 53,874<span></span>
</td>
<td class="nump">$ 53,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(15,641)<span></span>
</td>
<td class="num">(15,641)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,174)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">38,233<span></span>
</td>
<td class="nump">38,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of long-lived assets</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">2,011<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">1,289<span></span>
</td>
<td class="nump">1,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,224<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">15,475<span></span>
</td>
<td class="nump">15,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,778<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">868<span></span>
</td>
<td class="nump">868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,136<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">34,146<span></span>
</td>
<td class="nump">34,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,701<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 2,096<span></span>
</td>
<td class="nump">$ 2,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,395<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139689988947072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Employee compensation</a></td>
<td class="nump">$ 8,128<span></span>
</td>
<td class="nump">$ 9,209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts', window );">Accrued nonclinical, clinical and process development costs</a></td>
<td class="nump">8,387<span></span>
</td>
<td class="nump">4,953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">State income tax payable</a></td>
<td class="nump">178<span></span>
</td>
<td class="nump">1,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional services</a></td>
<td class="nump">986<span></span>
</td>
<td class="nump">550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">1,951<span></span>
</td>
<td class="nump">2,017<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_AccruedExpensesAndOtherCurrentLiabilities', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 19,630<span></span>
</td>
<td class="nump">$ 18,047<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued preclinical clinical and development process costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139689993506768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Awards - Summary of Stock Options Activity (Detail)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options (in thousands)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">13,288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares) | shares</a></td>
<td class="nump">6,994<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares) | shares</a></td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited (in shares) | shares</a></td>
<td class="num">(3,469)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">16,798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares) | shares</a></td>
<td class="nump">4,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Grant- Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in USD per share) | $ / shares</a></td>
<td class="nump">$ 9.34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in USD per share) | $ / shares</a></td>
<td class="nump">1.33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (in USD per share) | $ / shares</a></td>
<td class="nump">0.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options forfeited (in USD per share) | $ / shares</a></td>
<td class="nump">5.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in USD per share) | $ / shares</a></td>
<td class="nump">6.71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in USD per share) | $ / shares</a></td>
<td class="nump">$ 12.02<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139689991312016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Awards - Additional Information (Detail)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">6,994<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs granted (in shares)</a></td>
<td class="nump">400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139689993509872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Awards - Summary of Restricted Stock Units Activity (Detail) - Restricted stock units<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Units (in thousands)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">2,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested and released (in shares) | shares</a></td>
<td class="num">(376)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(220)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">2,387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Grant- Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in USD per share) | $ / shares</a></td>
<td class="nump">$ 3.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in USD per share) | $ / shares</a></td>
<td class="nump">1.43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Vested and released (in USD per share) | $ / shares</a></td>
<td class="nump">4.64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in USD per share) | $ / shares</a></td>
<td class="nump">2.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in USD per share) | $ / shares</a></td>
<td class="nump">$ 2.90<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139689993361984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Awards - Stock-Based Compensation Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 4,942<span></span>
</td>
<td class="nump">$ 8,234<span></span>
</td>
<td class="nump">$ 10,323<span></span>
</td>
<td class="nump">$ 15,458<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">1,830<span></span>
</td>
<td class="nump">2,579<span></span>
</td>
<td class="nump">3,763<span></span>
</td>
<td class="nump">4,918<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 3,112<span></span>
</td>
<td class="nump">$ 5,655<span></span>
</td>
<td class="nump">$ 6,560<span></span>
</td>
<td class="nump">$ 10,540<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139689993374064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Schedule of Common Stock Equivalents Outstanding (Detail) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from net loss per share (in shares)</a></td>
<td class="nump">19,488<span></span>
</td>
<td class="nump">15,130<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from net loss per share (in shares)</a></td>
<td class="nump">16,798<span></span>
</td>
<td class="nump">14,435<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from net loss per share (in shares)</a></td>
<td class="nump">2,387<span></span>
</td>
<td class="nump">591<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from net loss per share (in shares)</a></td>
<td class="nump">303<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139689996519024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>USD ($) </div>
<div>employee</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Expected cash expenditures</a></td>
<td class="nump">$ 4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate', window );">Number of employees | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent', window );">Number of employees percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated as of the balance sheet date since inception of the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the total number of positions eliminated as of the balance sheet date since inception of the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>advm-20220630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:advm="http://www.adverum.com/20220630"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="advm-20220630.xsd" xlink:type="simple"/>
    <context id="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7e8682aed96f487494756de2720f7cd8_I20220805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <instant>2022-08-05</instant>
        </period>
    </context>
    <context id="i091c63ec0288436c847c3d7e1c66f29c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i38e7641014c24f42802a0e767f3da33c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ifcdb30088bf7428a9bf0c7fa1ccdf887_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i534d16e402214e46a2178eacb5f3be48_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2ad64833b2574d27bcaca620f8c24d6b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5f8ccf2148a9492d902f6f94eb01174d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2dfcbaeefa9147cbba60bd2882f576de_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie6634e2f52a847768604489aa9f3c9d0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie027bd425de348d4a1b5300009c35102_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if00e0b0ca7644910be332f543006ae0f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icc708e5b6b094b4eb7fec66b6dc66928_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9159386fd0b64a19afc5728875da6262_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3aa715f29516471b9cfbccd6ee4ca148_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0900f39f6ae64609b5f0340334613281_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i82b81bdc53d24ac3a2e37e5e289e00bd_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i336f4d10ad0f4bd6b4dc2747d0a2fc24_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i05db59da08cd4440a613ffe932afc6bb_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i91d4178a225048af85608fbbcfdf8470_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8c2897cfbbc9414b88969fe82f79f015_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0be82e64c27c4cbfa000b526606d88fc_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iff5e67a5e9f74fac86ac20f5900ace2a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic2429e191daf4063aea94b7ed34f5388_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2f9caab9d43a43f19ba39650948dd3f0_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i69ca4e98b7be4f1fa546888688ac9c03_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="icb516b66f76b47e181f2514f175fa2b4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icf31d645ca1d4dd890e884ed2b7dac54_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i00073676a06748c68637a40a8727c8cf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9949cffe4b48436aa01e854017183fe5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i68011d96733242bca48e8a0c3b302d00_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i69bcd14ab3b84bb88d6e42f9230125ce_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i15be9234201549dda36ced82a7e6393c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie4d154fca0034bb5b7b0269881994a59_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id91817d16c8345b4ada12e9b1a9a6273_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i53cdb9cd0dd642dc92e3c0646c561cff_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ide35349f92374b249c80c109cd124d77_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="idc847f307933433ba6f7b36aea3dfb93_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2d15881335174b83b764439f173aa254_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iaee3a372f64b4aad8aacb35b2978dd58_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i426bcccc21194024aad7653f13ebe0d4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3fb91db49e124d13ab1d36083ab22b1d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie945c879a02d4d6ba31708f37ae74b95_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibf886eae67904297903b8421e1e1c8fe_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie982d1e05e884a6482e7a9e4298e528e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i09c847c9c0fa46b89a2903bd45f6e881_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i8044234398d04dcab0c8561aec8f0bc0_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i9538b6ec79b846f7908793997055ff12_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie78b9ce6001d4e5ab1cc5c46bce0747b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i078c4a42f2414969902183a5d669406c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i482d42d854f34847aff3836171ba55a7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i675426f71ab9487190495924b6d0e2dd_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iae693632f44f47d4a8883d9933e4355c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i8e8996fffaaf4fa6a89db9103b7e7b7c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2861affa7475415584f86dff3b7e4c46_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">advm:CashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if5c48a2ec7314c31b6eca960c2f2a9ee_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i20a2357f1ee944a3981e58fb135760d0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7d29995dc41841af867793064df8a5d2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2089649fd507474b8a8f30cdaa43c325_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib2f748a77951427c94225f30126754e7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">advm:CashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if9056b729e8546fab8f001340cc9fdf3_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia76becc1500d43a2a228fe82d7febe92_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieffb39be45a94c67a589adccd5ca2de7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="idf62e11c42f84334ba360a7fcd68e94a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i02800f7274124fe1971aafbaacb2bacf_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ifbb879dcd01e4d5bacd3fcbb94f010f6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7566ab2be1484f1db090914aa37ba934_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="icbe21a83e6804a47850aa04b8d75d01a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i66e76679aad44f1985ba7be517dc7768_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2281372e2bd3421693ab7f4489600be1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7b6fb5c50aa542bf9198fb1cb8a23705_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i799e2367d7a44cd3ab31610e4082fe1a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i61c1bc0d431a4a5cb89f8a7d9bd2ef9a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic2977397029043bc8e1c6fb7a9d878ca_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie6819ea354434909b8b5bc79270cf986_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie97980ff64894dfe89ceaa2199851660_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icd2c662c3d65454a9af244685ed76367_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i11fb6fa11226421b9721333c446b487e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2f2c878dab744d72a09fd050e76b040e_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7921ddb1395c47e497a4d22dceba9142_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie8275590de8c4107a7250156ea0c4f5d_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia558ece0e92049239ba7ef43bde0bf94_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie17cab1a780b48bf993da64124f1616e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i00290c3bbf024183bc58b3da064c1719_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idf067933631d446ea2d6ff5ad2ba89f6_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id35485ffc22d4b6d97a32ff7a9e6516a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie7873e824c2c453082de63de06e7151c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7d3546d871c340909747af982e7e0cf1_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i76f0e181dd5b4835a9cf93e9fd673c58_I20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="ic30a812f292d467f80a69160b83e189b_D20220701-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="employee">
        <measure>advm:employee</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80L2ZyYWc6YTI3Nzc4MTlkYjY4NGU4YjlhMmUxZjYyZWU0NzVjMmEvdGFibGU6YTEyMzk3OTljMjQwNDQ0M2JiMDMyYTI1MGNjZGQ1ODIvdGFibGVyYW5nZTphMTIzOTc5OWMyNDA0NDQzYmIwMzJhMjUwY2NkZDU4Ml8zLTEtMS0xLTI1NTg1_72ce18c5-f2d0-46a6-89aa-68adbac89ca3">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80L2ZyYWc6YTI3Nzc4MTlkYjY4NGU4YjlhMmUxZjYyZWU0NzVjMmEvdGFibGU6YTEyMzk3OTljMjQwNDQ0M2JiMDMyYTI1MGNjZGQ1ODIvdGFibGVyYW5nZTphMTIzOTc5OWMyNDA0NDQzYmIwMzJhMjUwY2NkZDU4Ml80LTEtMS0xLTI1NTg1_ab939531-fbfb-46e5-a971-678810461920">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80L2ZyYWc6YTI3Nzc4MTlkYjY4NGU4YjlhMmUxZjYyZWU0NzVjMmEvdGFibGU6YTEyMzk3OTljMjQwNDQ0M2JiMDMyYTI1MGNjZGQ1ODIvdGFibGVyYW5nZTphMTIzOTc5OWMyNDA0NDQzYmIwMzJhMjUwY2NkZDU4Ml81LTEtMS0xLTI1NTg1_93883f81-bb7d-47f1-b7e5-5eb177ae263a">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80L2ZyYWc6YTI3Nzc4MTlkYjY4NGU4YjlhMmUxZjYyZWU0NzVjMmEvdGFibGU6YTEyMzk3OTljMjQwNDQ0M2JiMDMyYTI1MGNjZGQ1ODIvdGFibGVyYW5nZTphMTIzOTc5OWMyNDA0NDQzYmIwMzJhMjUwY2NkZDU4Ml82LTEtMS0xLTI1NTg1_cf618ea7-59c3-4126-8c7e-fa91af03a36a">0001501756</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80L2ZyYWc6YTI3Nzc4MTlkYjY4NGU4YjlhMmUxZjYyZWU0NzVjMmEvdGFibGU6YTEyMzk3OTljMjQwNDQ0M2JiMDMyYTI1MGNjZGQ1ODIvdGFibGVyYW5nZTphMTIzOTc5OWMyNDA0NDQzYmIwMzJhMjUwY2NkZDU4Ml83LTEtMS0xLTI1NTg1_d160ec34-c2ad-4d5d-a59b-a8f08c7cc8be">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGV4dHJlZ2lvbjplZWQzMGI1Yjc1MzI0MGU1YjFiNmRlZDJmOTYwMTc3MV8yNDI4_4e515436-188b-403c-95e0-8eb3c97ce22b">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGFibGU6NmU2MmIxZmQ4YTJjNGQ3MWI0YzJlM2U1YzY0MzhlMWUvdGFibGVyYW5nZTo2ZTYyYjFmZDhhMmM0ZDcxYjRjMmUzZTVjNjQzOGUxZV8wLTAtMS0xLTI1NTg1_219ad9ba-aff4-4410-8201-a47f09f9c87b">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGV4dHJlZ2lvbjplZWQzMGI1Yjc1MzI0MGU1YjFiNmRlZDJmOTYwMTc3MV8yNjY_f442c929-026d-4023-9634-d4ffc9518a7a">2022-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGFibGU6NDIwZjY5ZmMyZTNhNDA1NTk5Zjk4ZDBiOTEzNzE4YzkvdGFibGVyYW5nZTo0MjBmNjlmYzJlM2E0MDU1OTlmOThkMGI5MTM3MThjOV8wLTAtMS0xLTI1NTg1_fd5875fb-fcdb-434b-900d-44fe2ac4aa70">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGV4dHJlZ2lvbjplZWQzMGI1Yjc1MzI0MGU1YjFiNmRlZDJmOTYwMTc3MV8yNDM1_20c288af-436a-4d79-914a-aab8d4f6b5c5">001-36579</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGV4dHJlZ2lvbjplZWQzMGI1Yjc1MzI0MGU1YjFiNmRlZDJmOTYwMTc3MV8yNDI5_e5163b1d-3f9c-4005-b7a7-bad88cb326a7">Adverum Biotechnologies, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGFibGU6OGFiY2NkNzBkMmZmNDkwNmFhYTY1MjhmYTE4M2M3YjYvdGFibGVyYW5nZTo4YWJjY2Q3MGQyZmY0OTA2YWFhNjUyOGZhMTgzYzdiNl8wLTAtMS0xLTI1NTg1_7c372df2-a150-4d40-81a4-e72b34734c0a">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGFibGU6OGFiY2NkNzBkMmZmNDkwNmFhYTY1MjhmYTE4M2M3YjYvdGFibGVyYW5nZTo4YWJjY2Q3MGQyZmY0OTA2YWFhNjUyOGZhMTgzYzdiNl8wLTItMS0xLTI1NTg1_485af396-9be9-49c7-9163-9cae60591cbd">20-5258327</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGV4dHJlZ2lvbjplZWQzMGI1Yjc1MzI0MGU1YjFiNmRlZDJmOTYwMTc3MV8yNDMx_4b53ed4a-aa29-422f-8b18-b604af4ae837">100 Cardinal Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGV4dHJlZ2lvbjplZWQzMGI1Yjc1MzI0MGU1YjFiNmRlZDJmOTYwMTc3MV8yNDMy_e23cca69-0424-4640-a953-2b9bcd824c03">Redwood City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGV4dHJlZ2lvbjplZWQzMGI1Yjc1MzI0MGU1YjFiNmRlZDJmOTYwMTc3MV8yNDMz_6c5055f8-f3ab-4b5d-879d-bcc4df0c1383">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGV4dHJlZ2lvbjplZWQzMGI1Yjc1MzI0MGU1YjFiNmRlZDJmOTYwMTc3MV8yNDI0_9ce00c97-1487-4df5-ab07-fd37c8329d8e">94063</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGV4dHJlZ2lvbjplZWQzMGI1Yjc1MzI0MGU1YjFiNmRlZDJmOTYwMTc3MV82OTk_7d233fdd-c4c0-4a8e-86ab-268ff8b67526">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGV4dHJlZ2lvbjplZWQzMGI1Yjc1MzI0MGU1YjFiNmRlZDJmOTYwMTc3MV8yNDI1_5b62b5e0-2cf3-443c-9812-4a307d798189">656-9323</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGFibGU6NjBmYmNkMWRmYjlkNDA4ZTg4OTlhODY1NzMzNjc1MGUvdGFibGVyYW5nZTo2MGZiY2QxZGZiOWQ0MDhlODg5OWE4NjU3MzM2NzUwZV8xLTAtMS0xLTI1NTg1_0e81e76d-9c20-4257-ae85-64b865b82d44">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGFibGU6NjBmYmNkMWRmYjlkNDA4ZTg4OTlhODY1NzMzNjc1MGUvdGFibGVyYW5nZTo2MGZiY2QxZGZiOWQ0MDhlODg5OWE4NjU3MzM2NzUwZV8xLTEtMS0xLTI1NTg1_6e2af716-6da3-4dd6-aa80-2cc7c835bf18">ADVM</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGFibGU6NjBmYmNkMWRmYjlkNDA4ZTg4OTlhODY1NzMzNjc1MGUvdGFibGVyYW5nZTo2MGZiY2QxZGZiOWQ0MDhlODg5OWE4NjU3MzM2NzUwZV8xLTItMS0xLTI1NTg1_3411d1fa-c0d3-4019-b42c-fd252b705d70">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGV4dHJlZ2lvbjplZWQzMGI1Yjc1MzI0MGU1YjFiNmRlZDJmOTYwMTc3MV8yNDM0_5bfbac19-e7a4-494a-83aa-229706fc65cc">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGV4dHJlZ2lvbjplZWQzMGI1Yjc1MzI0MGU1YjFiNmRlZDJmOTYwMTc3MV8yNDI2_8dab60bf-3e43-42d7-a0a4-800a37921ea5">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGFibGU6MjhkMjc2Njc2OTQ1NDc4NDk2MTRmMjMxMWQwYzgzN2IvdGFibGVyYW5nZToyOGQyNzY2NzY5NDU0Nzg0OTYxNGYyMzExZDBjODM3Yl8xLTAtMS0xLTI1NTg1_1bb3a632-a37d-4a9a-8d2a-0fbb953b4fbd">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGFibGU6MjhkMjc2Njc2OTQ1NDc4NDk2MTRmMjMxMWQwYzgzN2IvdGFibGVyYW5nZToyOGQyNzY2NzY5NDU0Nzg0OTYxNGYyMzExZDBjODM3Yl8xLTQtMS0xLTI1NTg1_2bc87bd2-0d9b-438a-983c-f7285cae956f">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGFibGU6MjhkMjc2Njc2OTQ1NDc4NDk2MTRmMjMxMWQwYzgzN2IvdGFibGVyYW5nZToyOGQyNzY2NzY5NDU0Nzg0OTYxNGYyMzExZDBjODM3Yl8yLTQtMS0xLTI1NTg1_3c1860fd-a927-473f-983b-3f822a4d93d4">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGV4dHJlZ2lvbjplZWQzMGI1Yjc1MzI0MGU1YjFiNmRlZDJmOTYwMTc3MV8xMzc0Mzg5NTM0OTY0OQ_1ad39ec6-5e21-47c0-9b61-8b557cff8fb0">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i7e8682aed96f487494756de2720f7cd8_I20220805"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xL2ZyYWc6ZWVkMzBiNWI3NTMyNDBlNWIxYjZkZWQyZjk2MDE3NzEvdGV4dHJlZ2lvbjplZWQzMGI1Yjc1MzI0MGU1YjFiNmRlZDJmOTYwMTc3MV8yMzM4_15f4db5c-892f-4d5b-b670-02418dc43abc"
      unitRef="shares">99333578</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMy0xLTEtMS0yNTU4NQ_517207e3-2636-40f3-9503-19278b6af7a2"
      unitRef="usd">91870000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMy0zLTEtMS0yNTU4NQ_f8f5d9b0-978c-4cae-bd1d-2a8b50bd8d05"
      unitRef="usd">34195000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfNC0xLTEtMS0yNTU4NQ_3a06cfd8-3259-4f70-bc4f-787cae513ec3"
      unitRef="usd">143971000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfNC0zLTEtMS0yNTU4NQ_e0265e3c-551b-4d47-8f3e-346c2d414f33"
      unitRef="usd">270993000</us-gaap:ShortTermInvestments>
    <us-gaap:IncentiveToLessee
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfNS0xLTEtMS0yNTU4NQ_fd901910-70f1-4c31-a52b-63e61ca06a5f"
      unitRef="usd">0</us-gaap:IncentiveToLessee>
    <us-gaap:IncentiveToLessee
      contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfNS0zLTEtMS0yNTU4NQ_716bad88-c629-4069-9c33-38e991b19843"
      unitRef="usd">5709000</us-gaap:IncentiveToLessee>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfNi0xLTEtMS0yNTU4NQ_526b5a02-f072-4eed-8695-880aab90383f"
      unitRef="usd">10190000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfNi0zLTEtMS0yNTU4NQ_19ac6410-5ff0-4cea-bbb9-3a861b16fbd9"
      unitRef="usd">6248000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfNy0xLTEtMS0yNTU4NQ_ef58c7da-500e-4cc9-af75-c6b7c5e6b4da"
      unitRef="usd">246031000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfNy0zLTEtMS0yNTU4NQ_70e3f936-f330-4202-bf52-f600f39e8ad7"
      unitRef="usd">317145000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfOC0xLTEtMS0yNTU4NQ_34542e18-28d3-4bbb-93cc-38a3b0c96f16"
      unitRef="usd">83766000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfOC0zLTEtMS0yNTU4NQ_b7a725af-f864-4780-9a17-e26ba84e12aa"
      unitRef="usd">86000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfOS0xLTEtMS0yNTU4NQ_7d9c9919-f091-4a15-80ed-797a82feb7da"
      unitRef="usd">38233000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfOS0zLTEtMS0yNTU4NQ_f15e494b-cc01-4e5d-b373-b0020b810f41"
      unitRef="usd">33060000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMTEtMS0xLTEtMjU1ODU_6fad9ada-e277-4d57-a8d0-a25d0ec7b236"
      unitRef="usd">2503000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMTEtMy0xLTEtMjU1ODU_fa2df4b5-e79d-4c4c-a1fb-2cb155d53cc3"
      unitRef="usd">2503000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:DeferredRentReceivablesNet
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMTItMS0xLTEtMjU1ODU_121b1fa0-e8a7-4f4c-8fbc-a07a908f2537"
      unitRef="usd">4145000</us-gaap:DeferredRentReceivablesNet>
    <us-gaap:DeferredRentReceivablesNet
      contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMTItMy0xLTEtMjU1ODU_e48ed11e-aed9-44cf-b6ff-b22dcf243027"
      unitRef="usd">769000</us-gaap:DeferredRentReceivablesNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMTMtMS0xLTEtMjU1ODU_5d666cca-a920-4847-8f23-75984ec717ce"
      unitRef="usd">277000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMTMtMy0xLTEtMjU1ODU_f67dbfcd-d371-4f91-962a-0d6765b38ae7"
      unitRef="usd">250000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMTQtMS0xLTEtMjU1ODU_d84a1d6c-baf2-4465-a627-521cc2c63986"
      unitRef="usd">374955000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMTQtMy0xLTEtMjU1ODU_9cc3fafb-5226-4ecf-a7b6-ad8b6e3451a6"
      unitRef="usd">439727000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMTctMS0xLTEtMjU1ODU_fa29fce6-5975-4772-a512-117084fb6c98"
      unitRef="usd">4698000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMTctMy0xLTEtMjU1ODU_15916d41-0d72-4805-8a1e-1f3ac65d31f1"
      unitRef="usd">1387000</us-gaap:AccountsPayableCurrent>
    <advm:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMTgtMS0xLTEtMjU1ODU_1fbbdbef-d87f-4cbe-b07d-eabc5069f39a"
      unitRef="usd">19630000</advm:AccruedExpensesAndOtherCurrentLiabilities>
    <advm:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMTgtMy0xLTEtMjU1ODU_ac1f2b28-d4b5-4c5c-b2f8-71b874a0308f"
      unitRef="usd">18047000</advm:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMTktMS0xLTEtMjU1ODU_947b5156-2e44-43e8-b12f-3e57a19b4319"
      unitRef="usd">6292000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMTktMy0xLTEtMjU1ODU_b9753dd7-7458-48a8-b7dd-66c7532b538e"
      unitRef="usd">1886000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMjEtMS0xLTEtMjU1ODU_e46e6658-798e-4747-93d4-997547003ce8"
      unitRef="usd">30620000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMjEtMy0xLTEtMjU1ODU_77dd6f89-9390-4977-a3b4-ad170c2a2184"
      unitRef="usd">21320000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMjMtMS0xLTEtMjU1ODU_068bd2b4-202f-4423-b9ef-63148fa55e2d"
      unitRef="usd">99193000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMjMtMy0xLTEtMjU1ODU_e4b2b4f9-e942-4aac-9dd7-537d21bd305c"
      unitRef="usd">101108000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMjQtMS0xLTEtMjU1ODU_d7bfe519-198b-4eb0-a73a-c81bbcda0c2a"
      unitRef="usd">1020000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMjQtMy0xLTEtMjU1ODU_f66ec82b-4943-49b5-a190-af7d5b0dec81"
      unitRef="usd">1114000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMjUtMS0xLTEtMjU1ODU_d0d74c8a-1f9c-40a2-ba4d-0391197a0de7"
      unitRef="usd">130833000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMjUtMy0xLTEtMjU1ODU_6573ac7f-9b15-4174-be00-692f215d4537"
      unitRef="usd">123542000</us-gaap:Liabilities>
    <us-gaap:PreferredStockValue
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMjgtMS0xLTEtMjU1ODU_3bdf17da-dac4-4dcb-8920-3225e5e4dcd1"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMjgtMy0xLTEtMjU1ODU_7127adc4-366a-45c3-88cd-fd042f4b9350"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMjktMS0xLTEtMjU1ODU_6ae239e1-c15e-4620-9f0e-6e93c94d915a"
      unitRef="usd">10000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMjktMy0xLTEtMjU1ODU_c4fcb621-1e87-4902-aa58-82a268b944b8"
      unitRef="usd">10000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMzAtMS0xLTEtMjU1ODU_27c5f4a4-6e14-4514-b7b8-85cb7b8e0e68"
      unitRef="usd">975653000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMzAtMy0xLTEtMjU1ODU_0739e2ed-9d9a-4206-acd7-73ec91ad0ef8"
      unitRef="usd">964965000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMzEtMS0xLTEtMjU1ODU_d4e6fe15-216e-4bc5-9ece-15b358b99bfb"
      unitRef="usd">-1796000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMzEtMy0xLTEtMjU1ODU_24d4527e-e444-4db4-b7ab-2ad344fb7f42"
      unitRef="usd">-714000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMzItMS0xLTEtMjU1ODU_338c8af4-035a-4b05-a694-9c6092ae8dee"
      unitRef="usd">-729745000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMzItMy0xLTEtMjU1ODU_00cbf8d4-6676-47d1-971c-13d1654166b5"
      unitRef="usd">-648076000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMzMtMS0xLTEtMjU1ODU_a9e84a19-f661-467e-a1c7-2b12b472a900"
      unitRef="usd">244122000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMzMtMy0xLTEtMjU1ODU_7a771e13-0bbb-4824-ac35-4971b0834fd2"
      unitRef="usd">316185000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMzQtMS0xLTEtMjU1ODU_d6806a02-ea5b-4a26-8bd9-3dbb415666e1"
      unitRef="usd">374955000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8xOS9mcmFnOjI2NzYzNTc2MTJlZDRjZGZhZThlYTk2ODU3ZTgyMDY4L3RhYmxlOmNkNzZkZjhhMzE0NjRlYTdhMGU5ZGQyNmZhZTBlY2E0L3RhYmxlcmFuZ2U6Y2Q3NmRmOGEzMTQ2NGVhN2EwZTlkZDI2ZmFlMGVjYTRfMzQtMy0xLTEtMjU1ODU_9e1a6440-fbd4-4465-b36a-094e1d0cb156"
      unitRef="usd">439727000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMi0xLTEtMS0yNTU4NQ_f62e60c8-019c-4511-804e-34a7dba9f887"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMi0zLTEtMS0yNTU4NQ_8164808a-4911-46d3-80bc-1850bd2d648c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMi01LTEtMS0yNTU4NQ_f40e6eb8-1b65-4b6e-a515-55455d7cfe1a"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMi03LTEtMS0yNTU4NQ_0bb3000f-fa2f-4ac3-9008-81853f130c91"
      unitRef="usd">7500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfNS0xLTEtMS0yNTU4NQ_9545158c-6a80-418f-8ca8-cb0d36b28fc6"
      unitRef="usd">30265000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfNS0zLTEtMS0yNTU4NQ_fe0481d7-7284-4204-8e5e-b324d93e8da3"
      unitRef="usd">22608000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfNS01LTEtMS0yNTU4NQ_ee545c76-bc2c-4b50-b29d-44a456e19022"
      unitRef="usd">53229000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfNS03LTEtMS0yNTU4NQ_9d92ca60-dae2-454a-af7b-6cb5c95f3ad0"
      unitRef="usd">42588000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfNi0xLTEtMS0yNTU4NQ_5a4a1891-ffef-4e5d-936b-29c44a4dc39e"
      unitRef="usd">13760000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfNi0zLTEtMS0yNTU4NQ_585e90c3-2896-4250-aded-11c2f675eaaf"
      unitRef="usd">21930000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfNi01LTEtMS0yNTU4NQ_a283f9c4-4d23-4931-be30-f1efb7c77976"
      unitRef="usd">28929000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfNi03LTEtMS0yNTU4NQ_70da8e12-7938-4430-916d-f2dbd784658d"
      unitRef="usd">38093000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfOC0xLTEtMS0yNTU4NQ_12ed834a-7b07-4459-b312-6c3f66a01603"
      unitRef="usd">44025000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfOC0zLTEtMS0yNTU4NQ_3250046b-e701-40be-a526-f439ca3c16a3"
      unitRef="usd">44538000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfOC01LTEtMS0yNTU4NQ_1bfdc061-2613-4b59-8de3-44be3aa13302"
      unitRef="usd">82158000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfOC03LTEtMS0yNTU4NQ_3b5e1ee7-b6e5-4de3-bf24-22c244bde2f2"
      unitRef="usd">80681000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfOS0xLTEtMS0yNTU4NQ_1b964c84-cd30-4f49-94ba-05ade6f02e7b"
      unitRef="usd">-44025000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfOS0zLTEtMS0yNTU4NQ_537a541a-47e5-485c-9b8f-274e5845f338"
      unitRef="usd">-44538000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfOS01LTEtMS0yNTU4NQ_11f8de1d-a813-4bd5-ad7d-873134b1028a"
      unitRef="usd">-82158000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfOS03LTEtMS0yNTU4NQ_3a2bef43-d80b-4392-963e-c5c940559c39"
      unitRef="usd">-73181000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTAtMS0xLTEtMjU1ODU_e4cc63ac-6b79-41d5-86c1-8507ef992f0f"
      unitRef="usd">283000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTAtMy0xLTEtMjU1ODU_655dfa70-38d7-4a84-82c1-d3e856420063"
      unitRef="usd">205000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTAtNS0xLTEtMjU1ODU_59378717-bddc-4d21-80c2-986f9c19b13f"
      unitRef="usd">527000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTAtNy0xLTEtMjU1ODU_9d29d616-b13f-4f63-bbd7-2a5a08d21567"
      unitRef="usd">412000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTEtMS0xLTEtMjU1ODU_80660eaf-910c-4d30-a5f9-2160f2216ccb"
      unitRef="usd">-43742000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTEtMy0xLTEtMjU1ODU_4416563e-3051-4697-9ac9-a8802fecf713"
      unitRef="usd">-44333000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTEtNS0xLTEtMjU1ODU_958113bf-dafd-4e2e-aeed-47c53c10d583"
      unitRef="usd">-81631000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTEtNy0xLTEtMjU1ODU_faf04b79-e4b6-46e2-9720-0899523a7a2a"
      unitRef="usd">-72769000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTItMS0xLTEtMjU1ODU_94c497f7-1ada-4217-8286-ed71c8bbb2dc"
      unitRef="usd">19000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTItMy0xLTEtMjU1ODU_f4548fb1-0f72-489e-a369-f11be6d95720"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTItNS0xLTEtMjU1ODU_d3bac694-fd1e-4f94-a844-40d530063d50"
      unitRef="usd">38000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTItNy0xLTEtMjU1ODU_8bdf5f3c-acd2-4012-9f15-e2eebe9907a2"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTMtMS0xLTEtMjU1ODU_f188d11e-e9e3-4331-8f78-4fe0150484a9"
      unitRef="usd">-43761000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTMtMy0xLTEtMjU1ODU_d4abe721-603d-411c-ae7f-45d907d979e3"
      unitRef="usd">-44333000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTMtNS0xLTEtMjU1ODU_fb91d3dd-8b97-46ea-b1ff-e0915a401ee8"
      unitRef="usd">-81669000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTMtNy0xLTEtMjU1ODU_bdd9876b-e646-40ba-9e36-a0fae50d33af"
      unitRef="usd">-72769000</us-gaap:NetIncomeLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTUtMS0xLTEtMjU1ODU_0471de2e-5ccc-4968-84f6-d2c985ccae0e"
      unitRef="usd">-339000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTUtMy0xLTEtMjU1ODU_2f264cd7-4d09-4b5d-aed6-c86d1b72d980"
      unitRef="usd">-62000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTUtNS0xLTEtMjU1ODU_9bdf459c-10c1-4501-92b1-fc5ef1141abe"
      unitRef="usd">-1062000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTUtNy0xLTEtMjU1ODU_8733a66a-2de0-4665-a7e2-d7de1384f069"
      unitRef="usd">-84000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTYtMS0xLTEtMjU1ODU_57a95728-c3a6-4c6f-9a66-e000b52db2c6"
      unitRef="usd">-34000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTYtMy0xLTEtMjU1ODU_1630f49a-d121-4802-ac79-2f3a63c186bd"
      unitRef="usd">-39000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTYtNS0xLTEtMjU1ODU_beaba5e5-d9d2-46e8-b64f-b3c2e1957436"
      unitRef="usd">-20000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTYtNy0xLTEtMjU1ODU_8482453d-7d1c-484a-af3f-84fd8dd4f80a"
      unitRef="usd">-72000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTctMS0xLTEtMjU1ODU_c7d79aea-e438-41bb-a128-2b7381af8f55"
      unitRef="usd">-44134000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTctMy0xLTEtMjU1ODU_34d04c41-73a5-4692-a090-c72313403795"
      unitRef="usd">-44434000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTctNS0xLTEtMjU1ODU_6e5fda33-a376-44be-b90e-d56874008464"
      unitRef="usd">-82751000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTctNy0xLTEtMjU1ODU_511500f3-a414-4c3c-a092-09e328106a3c"
      unitRef="usd">-72925000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTgtMS0xLTEtMjU1ODU_205a0cce-bac1-4d38-b9a6-3c0d7e97ce58"
      unitRef="usdPerShare">-0.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTgtMS0xLTEtMjU1ODU_b8e2df86-e0a3-4046-bf5f-874c7ed87896"
      unitRef="usdPerShare">-0.44</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTgtMy0xLTEtMjU1ODU_37b8979e-6c04-4957-ae9b-87d101ace996"
      unitRef="usdPerShare">-0.45</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTgtMy0xLTEtMjU1ODU_aabc10eb-dab9-459d-b905-667f7f533406"
      unitRef="usdPerShare">-0.45</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTgtNS0xLTEtMjU1ODU_0f1c3ac9-26af-426b-971a-5551101ddf0b"
      unitRef="usdPerShare">-0.83</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTgtNS0xLTEtMjU1ODU_989b0d0c-6239-43f1-b398-0e4ef53553d9"
      unitRef="usdPerShare">-0.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTgtNy0xLTEtMjU1ODU_77a8ca7d-0423-46e2-8092-fe40f5353ec2"
      unitRef="usdPerShare">-0.74</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTgtNy0xLTEtMjU1ODU_ef6dc18e-e817-442c-af9c-92e4bba22b8e"
      unitRef="usdPerShare">-0.74</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTktMS0xLTEtMjU1ODU_87bda0ca-05cf-44a1-8826-285cb3d7dbe8"
      unitRef="shares">99000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTktMS0xLTEtMjU1ODU_940ca20d-c135-4d67-954b-56357e4779e3"
      unitRef="shares">99000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTktMy0xLTEtMjU1ODU_df229c5b-2039-4c16-94e3-e5f5c2a23428"
      unitRef="shares">98018000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTktMy0xLTEtMjU1ODU_e8dac063-7d25-44c8-a08c-340b1055753d"
      unitRef="shares">98018000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTktNS0xLTEtMjU1ODU_5d242f00-ef2a-46ef-9c47-a3ff34cd3ba1"
      unitRef="shares">98799000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTktNS0xLTEtMjU1ODU_e3b040f6-fab6-4df0-b9c9-2c3f1b1cff0f"
      unitRef="shares">98799000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTktNy0xLTEtMjU1ODU_0e60b495-76c5-42d5-88fa-ecf6f78d4b8d"
      unitRef="shares">97885000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yMi9mcmFnOmZhOGEzZWI0NTM3NDQ1YjA4Y2Q3YmI4NGM2MTkzYjMxL3RhYmxlOjQ1YWYwZGQ4ZTlhNjQ2NjI4MzE0ODI4YzY0M2Y0MmUwL3RhYmxlcmFuZ2U6NDVhZjBkZDhlOWE2NDY2MjgzMTQ4MjhjNjQzZjQyZTBfMTktNy0xLTEtMjU1ODU_97115788-d2ee-4e93-a487-6a8c94d91a3d"
      unitRef="shares">97885000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="ifcdb30088bf7428a9bf0c7fa1ccdf887_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMi0xLTEtMS0yNTU4NQ_9854d324-3d2b-4ffd-8877-a4d69f0c8958"
      unitRef="shares">98381000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ifcdb30088bf7428a9bf0c7fa1ccdf887_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMi0zLTEtMS0yNTU4NQ_ddc919f3-4c23-4864-8a3d-29becc426fdb"
      unitRef="usd">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i534d16e402214e46a2178eacb5f3be48_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMi01LTEtMS0yNTU4NQ_1a1044c7-16ed-44bd-af80-bc7c58fddb87"
      unitRef="usd">964965000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2ad64833b2574d27bcaca620f8c24d6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMi03LTEtMS0yNTU4NQ_c1af19dc-bc03-483a-8e70-a3a82b12e2da"
      unitRef="usd">-714000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5f8ccf2148a9492d902f6f94eb01174d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMi05LTEtMS0yNTU4NQ_408cb823-a405-4d1c-82de-099f0268df2d"
      unitRef="usd">-648076000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMi0xMS0xLTEtMjU1ODU_d5540da6-b8b3-4320-a139-deaceaef33a7"
      unitRef="usd">316185000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2dfcbaeefa9147cbba60bd2882f576de_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMy01LTEtMS0yNTU4NQ_3821b3c0-90f6-433e-8596-98d6525f9813"
      unitRef="usd">5381000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie6634e2f52a847768604489aa9f3c9d0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMy0xMS0xLTEtMjU1ODU_772dbf8e-15c2-4858-a6bf-433f56a4c5ba"
      unitRef="usd">5381000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie027bd425de348d4a1b5300009c35102_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfNC0xLTEtMS0yNTU4NQ_94cc8056-12e0-4e8a-ae72-6e66d28ce71c"
      unitRef="shares">15000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i2dfcbaeefa9147cbba60bd2882f576de_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfNC01LTEtMS0yNTU4NQ_286cac2a-0543-40db-916f-65b2aff75855"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie6634e2f52a847768604489aa9f3c9d0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfNC0xMS0xLTEtMjU1ODU_fccb90ca-e719-4577-8486-e748caac22c8"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ie027bd425de348d4a1b5300009c35102_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfNS0xLTEtMS0yNTU4NQ_fb20cf13-4f0d-4e27-b9dd-d422a6ceea32"
      unitRef="shares">371000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="if00e0b0ca7644910be332f543006ae0f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfNy03LTEtMS0yNTU4NQ_17f47c73-bfd6-46cd-8a92-ab4cf3498837"
      unitRef="usd">14000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ie6634e2f52a847768604489aa9f3c9d0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfNy0xMS0xLTEtMjU1ODU_c1bc4f4c-283b-4fbc-9407-13d38692760b"
      unitRef="usd">14000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="if00e0b0ca7644910be332f543006ae0f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfOC03LTEtMS0yNTU4NQ_eed1b09c-4168-4321-adb2-3f50c0971906"
      unitRef="usd">-723000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="ie6634e2f52a847768604489aa9f3c9d0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfOC0xMS0xLTEtMjU1ODU_5c3194f0-2ac1-47b6-9e5d-b353d10075b7"
      unitRef="usd">-723000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icc708e5b6b094b4eb7fec66b6dc66928_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfOS05LTEtMS0yNTU4NQ_63211526-0abf-4185-814f-c767348db56a"
      unitRef="usd">-37908000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie6634e2f52a847768604489aa9f3c9d0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfOS0xMS0xLTEtMjU1ODU_393ca379-82d5-4fc7-a3dd-bffa16975399"
      unitRef="usd">-37908000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i9159386fd0b64a19afc5728875da6262_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTAtMS0xLTEtMjU1ODU_aff223d6-9902-4394-9298-f2abdb1deb35"
      unitRef="shares">98767000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i9159386fd0b64a19afc5728875da6262_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTAtMy0xLTEtMjU1ODU_d713e408-f88b-48b6-a9fc-9efd0f538a54"
      unitRef="usd">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3aa715f29516471b9cfbccd6ee4ca148_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTAtNS0xLTEtMjU1ODU_3b94c8c8-e838-4df0-a020-d41518f479f5"
      unitRef="usd">970349000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0900f39f6ae64609b5f0340334613281_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTAtNy0xLTEtMjU1ODU_d9d56f63-51ea-46e0-8eea-259c665d77ec"
      unitRef="usd">-1423000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i82b81bdc53d24ac3a2e37e5e289e00bd_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTAtOS0xLTEtMjU1ODU_a1a9e25c-89e4-4374-8515-386082782d21"
      unitRef="usd">-685984000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i336f4d10ad0f4bd6b4dc2747d0a2fc24_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTAtMTEtMS0xLTI1NTg1_f13ae01a-be67-434f-9d27-539d20cb6e8b"
      unitRef="usd">282952000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i05db59da08cd4440a613ffe932afc6bb_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTEtNS0xLTEtMjU5MTM_23cad5af-4638-4893-b0a6-40b47bb6aaed"
      unitRef="usd">4942000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTEtMTEtMS0xLTI2MjQ3_1c59345d-2426-4fcd-a8fe-e5cef99df089"
      unitRef="usd">4942000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i91d4178a225048af85608fbbcfdf8470_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTItMS0xLTEtMjU5MjA_2bb365ee-eb72-40a4-8c30-62779e2bbf06"
      unitRef="shares">5000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i91d4178a225048af85608fbbcfdf8470_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTMtMS0xLTEtMjY3Nzk_9f325af7-32d4-4585-a30d-c76686c49877"
      unitRef="shares">499000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i05db59da08cd4440a613ffe932afc6bb_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTMtNS0xLTEtMjY3Nzk_1d41c7f6-9296-47da-97d5-1b3d468b9930"
      unitRef="usd">362000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTMtMTEtMS0xLTI3NDQw_93e22b52-d273-4261-a9aa-552de3724b2e"
      unitRef="usd">362000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i8c2897cfbbc9414b88969fe82f79f015_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTMtNy0xLTEtMjU5Mjk_8b2fa5cb-bd6c-4b5d-a1d3-bdea35b7bb52"
      unitRef="usd">-34000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTMtMTEtMS0xLTI2MjQ3_755d8894-d711-4222-8281-623ccac710ea"
      unitRef="usd">-34000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i8c2897cfbbc9414b88969fe82f79f015_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTQtNy0xLTEtMjU5Mjk_d45b2a68-60b2-4c0a-9e16-184757483d39"
      unitRef="usd">-339000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTQtMTEtMS0xLTI2MjQ3_be0c24f7-23fc-46fe-a014-d951fc952b66"
      unitRef="usd">-339000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0be82e64c27c4cbfa000b526606d88fc_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTUtOS0xLTEtMjU5Mjk_05000f35-2bc6-4b07-bb57-912cee66dc28"
      unitRef="usd">-43761000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTUtMTEtMS0xLTI2MjQ3_0c7656d1-0cab-403c-abc3-faee15d93af7"
      unitRef="usd">-43761000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="iff5e67a5e9f74fac86ac20f5900ace2a_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTYtMS0xLTEtMjYyNDU_4cc1a345-82e6-49f8-848f-6fd159e04baa"
      unitRef="shares">99271000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iff5e67a5e9f74fac86ac20f5900ace2a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTYtMy0xLTEtMjYyNDU_2b958e52-392d-4143-a0ca-c1ee41842298"
      unitRef="usd">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic2429e191daf4063aea94b7ed34f5388_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTYtNS0xLTEtMjYyNDU_1f2435fa-f134-4b3c-9d85-39def560a482"
      unitRef="usd">975653000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2f9caab9d43a43f19ba39650948dd3f0_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTYtNy0xLTEtMjYyNDU_ce5d50d9-fec9-4f6e-afa5-327d4a398370"
      unitRef="usd">-1796000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i69ca4e98b7be4f1fa546888688ac9c03_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTYtOS0xLTEtMjYyNDU_00abf1df-3a3b-4982-b69d-d96bfb298bc3"
      unitRef="usd">-729745000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjMyZjA0MzMwOTU2YTQ3NTVhYjUyN2Q4MzUzNzc1YjA5L3RhYmxlcmFuZ2U6MzJmMDQzMzA5NTZhNDc1NWFiNTI3ZDgzNTM3NzViMDlfMTYtMTEtMS0xLTI2MjQ1_297b5102-fe20-43b9-8205-bcc2ce2bf55a"
      unitRef="usd">244122000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="icb516b66f76b47e181f2514f175fa2b4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMi0xLTEtMS0yNTU4NQ_8abdb35e-a8bc-4b26-861a-c1653df220e3"
      unitRef="shares">97549000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="icb516b66f76b47e181f2514f175fa2b4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMi0zLTEtMS0yNTU4NQ_be8d5d46-e3c3-4d67-8bd0-b18513502136"
      unitRef="usd">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icf31d645ca1d4dd890e884ed2b7dac54_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMi01LTEtMS0yNTU4NQ_e578243c-1f5f-46ba-a2ac-8c8af7f00e3b"
      unitRef="usd">937134000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i00073676a06748c68637a40a8727c8cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMi03LTEtMS0yNTU4NQ_a847d74d-2a5c-490e-aadb-0f95c25ad3e8"
      unitRef="usd">-261000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9949cffe4b48436aa01e854017183fe5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMi05LTEtMS0yNTU4NQ_30ad9b33-14d3-47e2-9f76-e3e093cf98af"
      unitRef="usd">-502536000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i68011d96733242bca48e8a0c3b302d00_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMi0xMS0xLTEtMjU1ODU_1daae6c2-5656-4a0f-82c0-3a5bf2a81ccc"
      unitRef="usd">434347000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i69bcd14ab3b84bb88d6e42f9230125ce_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMy01LTEtMS0yNTU4NQ_ba5504b4-5be5-4c9d-8c95-7fbfe6f7b404"
      unitRef="usd">7224000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i15be9234201549dda36ced82a7e6393c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMy0xMS0xLTEtMjU1ODU_329917ee-0eef-4cb9-9aea-873964711d62"
      unitRef="usd">7224000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i15be9234201549dda36ced82a7e6393c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfNC0wLTEtMS0yNTU4NS90ZXh0cmVnaW9uOjE1MWYxODdiYmFjNjRiZjU5ZTY5YjA0NTZiNTRjODA1XzU1_c101c65f-737e-43db-9399-e00e37cdf853"
      unitRef="usd">5000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ie4d154fca0034bb5b7b0269881994a59_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfNC0xLTEtMS0yNTU4NQ_80469c0d-46b3-4d52-adef-2c6f6c04469b"
      unitRef="shares">121000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i69bcd14ab3b84bb88d6e42f9230125ce_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfNC01LTEtMS0yNTU4NQ_43f1668f-0911-4275-a512-f2b78cedecf1"
      unitRef="usd">1689000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i15be9234201549dda36ced82a7e6393c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfNC0xMS0xLTEtMjU1ODU_4b4b18f2-ed80-4e65-a3fe-9f17e7b551a7"
      unitRef="usd">1689000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie4d154fca0034bb5b7b0269881994a59_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfNS0xLTEtMS0yNTU4NQ_b75ae76b-fbdb-46cb-91b3-942ee6c23866"
      unitRef="shares">9000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i69bcd14ab3b84bb88d6e42f9230125ce_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfNS01LTEtMS0yNTU4NQ_88ee4c67-fe6e-4f36-b278-9a4a40211de7"
      unitRef="usd">51000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i15be9234201549dda36ced82a7e6393c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfNS0xMS0xLTEtMjU1ODU_160216cd-e396-422e-b95c-83b131214fca"
      unitRef="usd">51000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ie4d154fca0034bb5b7b0269881994a59_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfNi0xLTEtMS0yNTU4NQ_464256d3-7ad0-4027-aa58-a0d4e1038ad1"
      unitRef="shares">248000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="id91817d16c8345b4ada12e9b1a9a6273_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfOC03LTEtMS0yNTU4NQ_4b2dbcf5-9a72-41a4-b191-3fe38fefd2da"
      unitRef="usd">-33000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i15be9234201549dda36ced82a7e6393c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfOC0xMS0xLTEtMjU1ODU_40de1c35-62b4-4db4-a8d2-fcba925df930"
      unitRef="usd">-33000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="id91817d16c8345b4ada12e9b1a9a6273_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfOS03LTEtMS0yNTU4NQ_01a5ca0f-1c2f-4133-884a-36c6a92a3a9e"
      unitRef="usd">-22000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i15be9234201549dda36ced82a7e6393c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfOS0xMS0xLTEtMjU1ODU_7ab0ccaa-84b7-441c-8e38-1921b5ee1d4b"
      unitRef="usd">-22000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i53cdb9cd0dd642dc92e3c0646c561cff_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTAtOS0xLTEtMjU1ODU_150d790c-e268-4c52-a616-e3cbddaf85e3"
      unitRef="usd">-28436000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i15be9234201549dda36ced82a7e6393c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTAtMTEtMS0xLTI1NTg1_e069ae33-bccb-44d9-9a9d-3b40b994492f"
      unitRef="usd">-28436000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ide35349f92374b249c80c109cd124d77_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTEtMS0xLTEtMjU1ODU_1859996c-60c3-40ef-868b-156c7802c0ac"
      unitRef="shares">97927000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ide35349f92374b249c80c109cd124d77_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTEtMy0xLTEtMjU1ODU_f3b36994-0d46-4387-ad31-8ea4c41938a0"
      unitRef="usd">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idc847f307933433ba6f7b36aea3dfb93_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTEtNS0xLTEtMjU1ODU_b48f1aad-5bd1-47ca-9cfe-c994e406d104"
      unitRef="usd">946098000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2d15881335174b83b764439f173aa254_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTEtNy0xLTEtMjU1ODU_8c45c979-d7ed-4c5c-8f3e-a19849536c74"
      unitRef="usd">-316000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iaee3a372f64b4aad8aacb35b2978dd58_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTEtOS0xLTEtMjU1ODU_32540efa-b827-49b0-bed5-634587aa330d"
      unitRef="usd">-530972000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i426bcccc21194024aad7653f13ebe0d4_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTEtMTEtMS0xLTI1NTg1_26bf5c95-9311-42e1-917f-b91b63611be3"
      unitRef="usd">414820000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3fb91db49e124d13ab1d36083ab22b1d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTItNS0xLTEtMjU1ODU_ed862641-5071-4482-bae1-f440554fd848"
      unitRef="usd">8234000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTItMTEtMS0xLTI1NTg1_7b8fd20d-0137-4607-b85a-13f27164c2d4"
      unitRef="usd">8234000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i3fb91db49e124d13ab1d36083ab22b1d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTMtNS0xLTEtMjU1ODU_7aa8f6ad-decc-48bf-8ed0-117fb96a1011"
      unitRef="usd">4000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTMtMTEtMS0xLTI1NTg1_903f65ba-34eb-410b-865d-d4ccbd8def7d"
      unitRef="usd">4000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ie945c879a02d4d6ba31708f37ae74b95_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTQtMS0xLTEtMjU1ODU_c52afba2-00ba-498b-9d18-c3cf8d3d164d"
      unitRef="shares">17000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ie945c879a02d4d6ba31708f37ae74b95_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTUtMS0xLTEtMjU1ODU_072900e9-7b16-4b99-a5c9-07664e01b097"
      unitRef="shares">176000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i3fb91db49e124d13ab1d36083ab22b1d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTUtNS0xLTEtMjU1ODU_3110d9e7-e652-4867-b8f2-0bea819cd097"
      unitRef="usd">526000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTUtMTEtMS0xLTI1NTg1_42daff2a-a421-4f96-beb0-01cf5e3b1830"
      unitRef="usd">526000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ibf886eae67904297903b8421e1e1c8fe_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTYtNy0xLTEtMjU1ODU_0efc3389-cbf3-4bbd-be63-6a751a1f9f38"
      unitRef="usd">-39000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTYtMTEtMS0xLTI1NTg1_e7df4169-0a12-4a76-8a44-37af707cbafb"
      unitRef="usd">-39000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="ibf886eae67904297903b8421e1e1c8fe_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTctNy0xLTEtMjU1ODU_0da320b5-c55e-4aa8-939a-7d9173d35624"
      unitRef="usd">-62000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTctMTEtMS0xLTI1NTg1_1576fa81-7425-4864-9dd3-757371d72f5c"
      unitRef="usd">-62000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie982d1e05e884a6482e7a9e4298e528e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTgtOS0xLTEtMjU1ODU_9ab5bb93-98b8-4e6a-96e3-254fa220777d"
      unitRef="usd">-44333000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTgtMTEtMS0xLTI1NTg1_3537dd4c-89d9-4465-b40c-1266238ae42f"
      unitRef="usd">-44333000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i09c847c9c0fa46b89a2903bd45f6e881_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTktMS0xLTEtMjU1ODU_5007d170-8a9e-497c-aa5a-8c19d699fd5c"
      unitRef="shares">98120000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i09c847c9c0fa46b89a2903bd45f6e881_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTktMy0xLTEtMjU1ODU_96ca11d3-9218-415e-b2d0-161b764f4767"
      unitRef="usd">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8044234398d04dcab0c8561aec8f0bc0_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTktNS0xLTEtMjU1ODU_896a8c69-27a6-42d9-9f93-095f9ed00aaa"
      unitRef="usd">954854000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9538b6ec79b846f7908793997055ff12_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTktNy0xLTEtMjU1ODU_887dd1ae-9449-4104-9507-70b5de37d2c6"
      unitRef="usd">-417000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie78b9ce6001d4e5ab1cc5c46bce0747b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTktOS0xLTEtMjU1ODU_0919d371-c2f3-45af-862d-96009a80e93d"
      unitRef="usd">-575305000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i078c4a42f2414969902183a5d669406c_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yNS9mcmFnOjAwZmJmYTdmMTFjYTQwZTZiZTY0ZmQ1OTRmY2YwYzY5L3RhYmxlOjI5ZjAxMmQ2ZDUzNjQ2M2JiYjQyZTg2ODAxYzE5ZWYwL3RhYmxlcmFuZ2U6MjlmMDEyZDZkNTM2NDYzYmJiNDJlODY4MDFjMTllZjBfMTktMTEtMS0xLTI1NTg1_936ff70b-8ea6-4f22-953a-edd2bf5cba80"
      unitRef="usd">379142000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMy0xLTEtMS0yNTU4NQ_ac247d19-edbb-447a-948e-de676cf7e19d"
      unitRef="usd">-81669000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMy0zLTEtMS0yNTU4NQ_5060ac42-1fc4-417e-978d-1a408d8c683c"
      unitRef="usd">-72769000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfNS0xLTEtMS0yNTU4NQ_95b10397-a88c-48a5-b98c-4288342f0afe"
      unitRef="usd">3028000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfNS0zLTEtMS0yNTU4NQ_525f069d-b57b-4248-81e9-2bf1b282dcbe"
      unitRef="usd">2361000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfNi0xLTEtMS0yNTU4NQ_ca451dcc-4644-4767-b216-63dda2c50841"
      unitRef="usd">10323000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfNi0zLTEtMS0yNTU4NQ_cffc0b85-1acf-41bc-9d22-f6b02e3b0af5"
      unitRef="usd">15458000</us-gaap:ShareBasedCompensation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfNy0xLTEtMS0yNTU4NQ_df949be7-cfdf-4ae0-827d-50e45bbc3a86"
      unitRef="usd">-258000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfNy0zLTEtMS0yNTU4NQ_4108a1e9-a03d-491b-8b1f-b3f8ee75b0c7"
      unitRef="usd">-1398000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfOC0xLTEtMS0yNTU4NQ_39c47cc3-f7ea-40c0-ba8d-bbcef05bcb9d"
      unitRef="usd">-101000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfOC0zLTEtMS0yNTU4NQ_6c8bd5ef-0673-45fe-994d-d9298336f6fe"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:AssetImpairmentCharges
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfOS0xLTEtMS0yNzUyMQ_099ffd01-3921-48a2-a93b-7152c1452049"
      unitRef="usd">2011000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfOS0zLTEtMS0yNzUyMQ_0bacacc6-dc7f-420a-a5df-e3c02e66a4a6"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfOS0xLTEtMS0yNTU4NQ_72efaf7f-53a9-45c7-b834-a5980b547bdc"
      unitRef="usd">76000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfOS0zLTEtMS0yNTU4NQ_54f4ae72-81cf-493c-9a84-c5e14c5b1b9f"
      unitRef="usd">81000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMTEtMS0xLTEtMjU1ODU_31a2ff97-998d-4e3d-92e3-0a0ba63badca"
      unitRef="usd">4165000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMTEtMy0xLTEtMjU1ODU_76c0125f-6947-4368-a1ef-02767ffc7cd3"
      unitRef="usd">1653000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMTItMS0xLTEtMjU1ODU_ca760281-bd0e-4845-af4f-a20515f686bc"
      unitRef="usd">3403000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMTItMy0xLTEtMjU1ODU_915ffd75-6ed4-41a0-b070-9532305324c9"
      unitRef="usd">99000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <advm:IncreaseDecreaseOperatingLeaseRightOfUseAsset
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMTMtMS0xLTEtMjU1ODU_cf5f6ad2-e7ce-4fe0-9545-0a077db66840"
      unitRef="usd">-2234000</advm:IncreaseDecreaseOperatingLeaseRightOfUseAsset>
    <advm:IncreaseDecreaseOperatingLeaseRightOfUseAsset
      contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMTMtMy0xLTEtMjU1ODU_0eacc879-0c2d-425d-845f-4e404ea47188"
      unitRef="usd">-1505000</advm:IncreaseDecreaseOperatingLeaseRightOfUseAsset>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMTQtMS0xLTEtMjU1ODU_2b7d957c-318f-4b9e-88ed-9c60d3307d7a"
      unitRef="usd">3216000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMTQtMy0xLTEtMjU1ODU_48d5a207-2610-4cb2-bd75-d4b90696c7ff"
      unitRef="usd">-394000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMTUtMS0xLTEtMjU1ODU_6402f75b-eb14-455c-a88b-86af0834c776"
      unitRef="usd">2172000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMTUtMy0xLTEtMjU1ODU_c2012464-8354-4bcd-9528-518d90eb74e7"
      unitRef="usd">-583000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMTYtMS0xLTEtMjU1ODU_0a610738-df9a-441c-8722-cbc8357d990a"
      unitRef="usd">-38000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMTYtMy0xLTEtMjU1ODU_41d3c664-f7a2-4ab1-a9e5-ec7212f25dc2"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <advm:IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMTgtMS0xLTEtMjU1ODU_989f3141-8964-4c41-93a0-a991b272e583"
      unitRef="usd">8200000</advm:IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable>
    <advm:IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable
      contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMTgtMy0xLTEtMjU1ODU_c0cc8fac-90d8-4a7e-8606-8a9907da6c8d"
      unitRef="usd">-1363000</advm:IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMjAtMS0xLTEtMjU1ODU_31b19040-825f-4468-9c48-022ebf2cc852"
      unitRef="usd">-57808000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMjAtMy0xLTEtMjU1ODU_2ef03ad9-855c-4777-a51e-d15e9e904f5a"
      unitRef="usd">-56220000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMjItMS0xLTEtMjU1ODU_810521e3-295a-4ae5-a8c7-bfd5c459ef30"
      unitRef="usd">57674000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMjItMy0xLTEtMjU1ODU_a1196a3f-4706-42a0-8952-13a033a97484"
      unitRef="usd">199959000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMjMtMS0xLTEtMjU1ODU_fadf6a33-a8fd-455f-a4ae-bb156f89be03"
      unitRef="usd">183599000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMjMtMy0xLTEtMjU1ODU_6f236b02-eb1d-4193-bedc-623f2378ace3"
      unitRef="usd">240377000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMjQtMS0xLTEtMjU1ODU_65d59cb4-1154-4004-8b03-7581f169e286"
      unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMjQtMy0xLTEtMjU1ODU_b91cee59-c654-4816-8fd8-8b89c9ef7a8c"
      unitRef="usd">8990000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMjUtMS0xLTEtMjU1ODU_cd45310c-c26b-4104-8594-f21da6746d1d"
      unitRef="usd">10807000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMjUtMy0xLTEtMjU1ODU_cd9ee65d-3910-4822-848e-69bd78072eff"
      unitRef="usd">5052000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMjYtMS0xLTEtMjU1ODU_3df2f18f-9224-4ff6-9349-cb42d53270ae"
      unitRef="usd">115118000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMjYtMy0xLTEtMjU1ODU_d8b52230-bf75-4648-9d04-b7b078b199bf"
      unitRef="usd">44356000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMjgtMS0xLTEtMjU1ODU_19bc6799-7845-4633-967b-fdc1b97170bc"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMjgtMy0xLTEtMjU1ODU_72985551-724d-407d-9a6d-44d506552fbe"
      unitRef="usd">1685000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMzAtMS0xLTEtMjU1ODU_3ffeccf8-5100-475e-8568-f134a1b66c2a"
      unitRef="usd">3000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMzAtMy0xLTEtMjU1ODU_5bc3ad70-0d43-4ae0-ad6c-143a07fcfd2a"
      unitRef="usd">51000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMzItMS0xLTEtMjU1ODU_ee585514-ff05-4072-83df-903ee850b518"
      unitRef="usd">362000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMzItMy0xLTEtMjU1ODU_7d2e9d69-4828-48a7-b0ef-31de3f6b2e8b"
      unitRef="usd">526000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:RepaymentsOfDebt
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMzQtMS0xLTEtMjU1ODU_f89874fb-3d45-467c-a854-1b6e5d7bda51"
      unitRef="usd">0</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMzQtMy0xLTEtMjU1ODU_cab7f54c-fda7-49a9-82e8-79fc5438ed2e"
      unitRef="usd">240000</us-gaap:RepaymentsOfDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMzUtMS0xLTEtMjU1ODU_62eac42e-5dc4-456a-a541-1a83dcd47ba4"
      unitRef="usd">365000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMzUtMy0xLTEtMjU1ODU_b6ec8b33-3a82-4ab3-8873-26041f0970e6"
      unitRef="usd">2022000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMzYtMS0xLTEtMjU1ODU_741e93d2-7307-4a2e-9cf4-e9f48fee5a89"
      unitRef="usd">57675000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMzYtMy0xLTEtMjU1ODU_da5705d8-6161-45c6-b680-16aeead52b49"
      unitRef="usd">-9842000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMzctMS0xLTEtMjU1ODU_a0eb4c50-570e-4b43-ba87-1b87b9b4a7e1"
      unitRef="usd">36698000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i68011d96733242bca48e8a0c3b302d00_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMzctMy0xLTEtMjU1ODU_a8494d57-a237-42d9-aae5-987fdc242c9a"
      unitRef="usd">63423000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMzgtMS0xLTEtMjU1ODU_7224ffbe-d39a-4455-8864-4a6a2df0142e"
      unitRef="usd">94373000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i078c4a42f2414969902183a5d669406c_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMzgtMy0xLTEtMjU1ODU_7fb8c96c-cf94-4907-bf2a-08334b8bb66a"
      unitRef="usd">53581000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMzktMS0xLTEtMjU1ODU_517207e3-2636-40f3-9503-19278b6af7a2"
      unitRef="usd">91870000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i078c4a42f2414969902183a5d669406c_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfMzktMy0xLTEtMjU1ODU_f6307e2d-5cfe-4d3a-b797-c88824a0bd56"
      unitRef="usd">47299000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfNDAtMS0xLTEtMjU1ODU_6fad9ada-e277-4d57-a8d0-a25d0ec7b236"
      unitRef="usd">2503000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i078c4a42f2414969902183a5d669406c_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfNDAtMy0xLTEtMjU1ODU_88a1d28b-1562-4b52-80b1-0ac532f381e3"
      unitRef="usd">6282000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfNDEtMS0xLTEtMjU1ODU_231b0ae1-dbff-469c-855b-288a87d4b2ca"
      unitRef="usd">94373000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i078c4a42f2414969902183a5d669406c_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfNDEtMy0xLTEtMjU1ODU_6a5922d7-04d3-4523-9a24-181563a90932"
      unitRef="usd">53581000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfNDMtMS0xLTEtMjU1ODU_01b39afd-260d-419b-be58-7eb3d625c8ee"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfNDMtMy0xLTEtMjU1ODU_38446064-7596-4cc2-b351-f0216c363f54"
      unitRef="usd">84005000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfNDQtMS0xLTEtMjU1ODU_de1ff934-2fa5-42c0-b52d-c5577afce9a9"
      unitRef="usd">908000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8yOC9mcmFnOmYxZDA0MTZmMWNjNzRjZGI5ZTU4MjZkMDgyMzUzNGM5L3RhYmxlOjgwM2U5YTNjMDk0MjQ4NjI5ZGE1MzQ5NWU2OTUwNmExL3RhYmxlcmFuZ2U6ODAzZTlhM2MwOTQyNDg2MjlkYTUzNDk1ZTY5NTA2YTFfNDQtMy0xLTEtMjU1ODU_210112e5-80fb-41d0-9942-701ff10a08bc"
      unitRef="usd">1562000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8zNC9mcmFnOjk5ZGZkYjg4NzRjOTRkZWNiZWNhNjc1MjA3OTZmNDgzL3RleHRyZWdpb246OTlkZmRiODg3NGM5NGRlY2JlY2E2NzUyMDc5NmY0ODNfMjU0MA_179f87ff-d8f8-42a5-8599-ab89674ce655">Organization and Basis of Presentation&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adverum Biotechnologies, Inc. (the &#x201c;Company&#x201d; or &#x201c;Adverum&#x201d;) was incorporated in Delaware on July 17, 2006 and is headquartered in Redwood City, California. The Company is a clinical-stage company that aims to establish gene therapy as a new standard of care for a number of highly prevalent ocular diseases. The Company develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has not generated any revenue from the sale of products since its inception. The Company has experienced net losses since its inception and had an accumulated deficit of $729.7 million as of June&#160;30, 2022. The Company expects to incur losses and have negative net cash flows from operating activities as it engages in further research and development activities. As of June&#160;30, 2022, the Company had cash, cash equivalents and short-term investments of $235.8 million, which the Company believes will be sufficient to fund its operations for at least twelve months from the date of issuance of these financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation &#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) and follow the requirements of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company&#x2019;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair statement of the Company&#x2019;s consolidated financial information. The results of operations for the three and six months ended June&#160;30, 2022 are not necessarily indicative of the results to be expected for the full year or any other future period. The balance sheet as of December&#160;31, 2021 is derived from the audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2021 filed with the SEC.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8zNC9mcmFnOjk5ZGZkYjg4NzRjOTRkZWNiZWNhNjc1MjA3OTZmNDgzL3RleHRyZWdpb246OTlkZmRiODg3NGM5NGRlY2JlY2E2NzUyMDc5NmY0ODNfNjQ2_853bb8b5-8680-4a76-913b-a8b840657235"
      unitRef="usd">-729700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8zNC9mcmFnOjk5ZGZkYjg4NzRjOTRkZWNiZWNhNjc1MjA3OTZmNDgzL3RleHRyZWdpb246OTlkZmRiODg3NGM5NGRlY2JlY2E2NzUyMDc5NmY0ODNfODk1_3e50aa20-8b7f-4b94-9585-8571571c8d3f"
      unitRef="usd">235800000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8zNC9mcmFnOjk5ZGZkYjg4NzRjOTRkZWNiZWNhNjc1MjA3OTZmNDgzL3RleHRyZWdpb246OTlkZmRiODg3NGM5NGRlY2JlY2E2NzUyMDc5NmY0ODNfMjU0MQ_982fdefc-e86f-4ed0-99b2-f7a00d2af89f">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation &#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) and follow the requirements of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company&#x2019;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair statement of the Company&#x2019;s consolidated financial information. The results of operations for the three and six months ended June&#160;30, 2022 are not necessarily indicative of the results to be expected for the full year or any other future period. The balance sheet as of December&#160;31, 2021 is derived from the audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete consolidated financial statements. &lt;/span&gt;The accompanying unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2021 filed with the SEC</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8zNy9mcmFnOjgwZTg2ZTliMmQzMzRlNzU4MWY1NTk3NTBmYTRlNTIwL3RleHRyZWdpb246ODBlODZlOWIyZDMzNGU3NTgxZjU1OTc1MGZhNGU1MjBfMjMxMg_93ec7180-520e-4f9a-b422-a78258219f60">Summary of Significant Accounting Policies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities and the reported amounts of expenses in the condensed consolidated financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to clinical trial accruals, fair value of assets and liabilities, impairment of long-lived assets, income taxes, and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments &#x2013; Credit Losses: Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Topic 326&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) and also issued subsequent amendments to the initial guidance: ASU&#160;2018-19, ASU&#160;2019-04, ASU&#160;2019-05, and ASU&#160;2019-11. The standard requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect collectability. Topic&#160;326 also eliminates the concept of &#x201c;other-than-temporary&#x201d; impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an allowance for credit losses on available-for-sale debt securities rather than an other-than-temporary impairment that reduces the cost basis of the investment. Topic 326 will become effective for the Company on January 1, 2023. Early adoption is permitted. The Company does not expect the effect of adoption to be material.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8zNy9mcmFnOjgwZTg2ZTliMmQzMzRlNzU4MWY1NTk3NTBmYTRlNTIwL3RleHRyZWdpb246ODBlODZlOWIyZDMzNGU3NTgxZjU1OTc1MGZhNGU1MjBfMjMxMw_bf13e16a-268a-409a-aca2-5a4d400f311f">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities and the reported amounts of expenses in the condensed consolidated financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to clinical trial accruals, fair value of assets and liabilities, impairment of long-lived assets, income taxes, and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV8zNy9mcmFnOjgwZTg2ZTliMmQzMzRlNzU4MWY1NTk3NTBmYTRlNTIwL3RleHRyZWdpb246ODBlODZlOWIyZDMzNGU3NTgxZjU1OTc1MGZhNGU1MjBfMjMxNQ_d16e2a9b-f159-4254-9097-6dfe968dda3c">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments &#x2013; Credit Losses: Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Topic 326&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) and also issued subsequent amendments to the initial guidance: ASU&#160;2018-19, ASU&#160;2019-04, ASU&#160;2019-05, and ASU&#160;2019-11. The standard requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect collectability. Topic&#160;326 also eliminates the concept of &#x201c;other-than-temporary&#x201d; impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an allowance for credit losses on available-for-sale debt securities rather than an other-than-temporary impairment that reduces the cost basis of the investment. Topic 326 will become effective for the Company on January 1, 2023. Early adoption is permitted. The Company does not expect the effect of adoption to be material.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RleHRyZWdpb246ZTZmM2I3ZjdmMWRhNGRiZGJlMDc3Y2VhNmU2MTFhNzZfMjYwMw_1ff274d6-cc4f-4f3f-a1d6-3d234b21fab3">Fair Value Measurements and Fair Value of Financial Instruments&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The authoritative guidance on the fair value hierarchy for disclosure of fair value measurements is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;&#160;&#160;Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;&#160;&#160;Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of Level 1 securities is determined using quoted prices in active markets for identical assets. Level 1 securities consist of highly liquid money market funds. Financial assets and liabilities are considered Level 2 when their fair values are determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis. U.S. government and agency securities, commercial paper, and corporate bonds are valued primarily using market prices of comparable securities, bid/ask quotes, interest rate yields and prepayment spreads and are included in Level 2. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company&#x2019;s cash equivalents and short-term investments:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost Basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Level 1:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Level 2:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,008)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(323)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash equivalents and short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,379)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,342)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,332)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,369)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost Basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(218)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash equivalents and short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(318)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,808)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,807)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(317)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, all of the marketable securities have a remaining maturity of less than one year. Management regularly reviews all of the Company&#x2019;s investments for other-than-temporary declines in estimated fair value. Management determined that the gross unrealized losses on the Company&#x2019;s marketable securities as of June&#160;30, 2022 were temporary in nature and none were in a continuous loss position for 12 months or more. The Company does not intend to sell the investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases. Management concluded that none of the Company&#x2019;s marketable securities were other-than-temporarily impaired as of June&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended June&#160;30, 2022, the Company performed an impairment test to measure certain laboratory equipment at fair value. The assets are measured at fair value using Level 3 inputs on a non-recurring basis as a result of the occurrence of certain triggering events indicating the carrying value of the assets may not be recoverable. Refer to Note 4, Balance Sheet Components for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RleHRyZWdpb246ZTZmM2I3ZjdmMWRhNGRiZGJlMDc3Y2VhNmU2MTFhNzZfMjYwNA_989c995e-b98b-4508-b20d-3ab3e8e0e69e">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company&#x2019;s cash equivalents and short-term investments:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost Basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Level 1:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Level 2:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,008)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(323)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash equivalents and short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,379)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,342)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,332)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,369)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost Basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(218)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash equivalents and short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(318)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,808)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,807)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(317)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i482d42d854f34847aff3836171ba55a7_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfNC0xLTEtMS0yNTU4NQ_1f6c962a-3f0a-4631-90ab-bb8b7f8050a4"
      unitRef="usd">10108000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i482d42d854f34847aff3836171ba55a7_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfNC0zLTEtMS0yNTU4NQ_19abfc26-eb87-4644-b457-05bf27d0a7c1"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i482d42d854f34847aff3836171ba55a7_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfNC01LTEtMS0yNTU4NQ_848aa9ee-7961-4dd0-9e50-0173522d91b1"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i482d42d854f34847aff3836171ba55a7_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfNC03LTEtMS0yNTU4NQ_60e30462-506d-4ea3-ae07-0cdcc61b561d"
      unitRef="usd">10108000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i675426f71ab9487190495924b6d0e2dd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfNi0xLTEtMS0yNTU4NQ_a7985a92-b155-441c-977f-03da4b282405"
      unitRef="usd">55150000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i675426f71ab9487190495924b6d0e2dd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfNi0zLTEtMS0yNTU4NQ_9f4ca624-742f-4c5f-bdc5-55da5581ef85"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i675426f71ab9487190495924b6d0e2dd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfNi01LTEtMS0yNTU4NQ_83356ea4-f0ad-4b3f-bcae-9e0d9c7ac6be"
      unitRef="usd">1008000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i675426f71ab9487190495924b6d0e2dd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfNi03LTEtMS0yNTU4NQ_99b38257-9e40-4759-99dd-243721dc4694"
      unitRef="usd">54142000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iae693632f44f47d4a8883d9933e4355c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfNy0xLTEtMS0yNTU4NQ_75eddbb4-1d9c-4e67-a6e6-7609a76feff4"
      unitRef="usd">150364000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iae693632f44f47d4a8883d9933e4355c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfNy0zLTEtMS0yNTU4NQ_d7ad792b-deb4-4393-a9bf-45a75fcf1f39"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iae693632f44f47d4a8883d9933e4355c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfNy01LTEtMS0yNTU4NQ_742145de-206b-42cb-9ad8-1508e669ddd1"
      unitRef="usd">323000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iae693632f44f47d4a8883d9933e4355c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfNy03LTEtMS0yNTU4NQ_50c4a021-d874-467c-b33c-0329e35f6b46"
      unitRef="usd">150041000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8e8996fffaaf4fa6a89db9103b7e7b7c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfOC0xLTEtMS0yNTU4NQ_6017243d-47af-45e7-b747-8311c8daed65"
      unitRef="usd">7060000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8e8996fffaaf4fa6a89db9103b7e7b7c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfOC0zLTEtMS0yNTU4NQ_c76cdfd0-854d-435a-ab21-30bcc79a6fba"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8e8996fffaaf4fa6a89db9103b7e7b7c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfOC01LTEtMS0yNTU4NQ_f7e0db9d-8993-41bb-b76a-f5d550a1c4fd"
      unitRef="usd">48000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8e8996fffaaf4fa6a89db9103b7e7b7c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfOC03LTEtMS0yNTU4NQ_548d7b22-b800-4c7c-8d5c-9e3f0ac27a80"
      unitRef="usd">7012000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2861affa7475415584f86dff3b7e4c46_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfOS0xLTEtMS0yNTU4NQ_1235610f-4a80-4cc2-b5be-0afbf943630b"
      unitRef="usd">222682000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2861affa7475415584f86dff3b7e4c46_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfOS0zLTEtMS0yNTU4NQ_8c3f28f5-f0f9-4a87-98e1-1c1f7397d884"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2861affa7475415584f86dff3b7e4c46_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfOS01LTEtMS0yNTU4NQ_542bbf6e-c21c-4d32-88ca-74368d0acf29"
      unitRef="usd">1379000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2861affa7475415584f86dff3b7e4c46_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfOS03LTEtMS0yNTU4NQ_086a13e3-aa82-4049-8b5d-364a14064cf5"
      unitRef="usd">221303000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <advm:CashAndCashEquivalentAmortizedCost
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfMTAtMS0xLTEtMjU1ODU_6b6833bf-17b3-4f51-a4b6-193b95c30c30"
      unitRef="usd">77342000</advm:CashAndCashEquivalentAmortizedCost>
    <advm:CashAndCashEquivalentGrossUnrealizedGain
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfMTAtMy0xLTEtMjU1ODU_fd19ab53-eb22-45c4-b6a6-4da3d0f4c9e3"
      unitRef="usd">0</advm:CashAndCashEquivalentGrossUnrealizedGain>
    <advm:CashAndCashEquivalentGrossUnrealizedLoss
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfMTAtNS0xLTEtMjU1ODU_50807bad-1d09-4c12-909d-896b99f88c9e"
      unitRef="usd">10000</advm:CashAndCashEquivalentGrossUnrealizedLoss>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfMTAtNy0xLTEtMjU1ODU_07a94061-2f52-4b67-ad21-9ca1a64ade7d"
      unitRef="usd">77332000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfMTEtMS0xLTEtMjU1ODU_d8356d6a-c59d-4555-aa67-cff2e92e75df"
      unitRef="usd">145340000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfMTEtMy0xLTEtMjU1ODU_f57e87fd-f7cc-4f0d-adf8-64e401fe7062"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfMTEtNS0xLTEtMjU1ODU_0bdde4bc-67f2-4115-8d3c-fff0f651b1ff"
      unitRef="usd">1369000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOjIxZjJhNzRhMzI4YTRmNGE4NWYwMzQyOGMwMWJlMDhiL3RhYmxlcmFuZ2U6MjFmMmE3NGEzMjhhNGY0YTg1ZjAzNDI4YzAxYmUwOGJfMTEtNy0xLTEtMjU1ODU_14a8dc8f-2c48-42ae-9ff0-0e97292ca592"
      unitRef="usd">143971000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if5c48a2ec7314c31b6eca960c2f2a9ee_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfNC0xLTEtMS0yNTU4NQ_f5c0f261-a35a-47fe-94a8-d8d9598ad6ab"
      unitRef="usd">10311000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if5c48a2ec7314c31b6eca960c2f2a9ee_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfNC0zLTEtMS0yNTU4NQ_71984156-e5b8-4033-951f-b11e4f1b07ea"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if5c48a2ec7314c31b6eca960c2f2a9ee_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfNC01LTEtMS0yNTU4NQ_6d8f7af4-0a0c-4337-a897-6a8ea2be6503"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if5c48a2ec7314c31b6eca960c2f2a9ee_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfNC03LTEtMS0yNTU4NQ_886ed5de-f5b8-43b2-9d92-2d2fd5b0bf8e"
      unitRef="usd">10311000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i20a2357f1ee944a3981e58fb135760d0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfNi0xLTEtMS0yNTU4NQ_c3e251bd-0b15-4b03-8387-2fa8373273fc"
      unitRef="usd">62268000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i20a2357f1ee944a3981e58fb135760d0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfNi0zLTEtMS0yNTU4NQ_40ff631b-b39c-40f3-811b-dbac7b7981e8"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i20a2357f1ee944a3981e58fb135760d0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfNi01LTEtMS0yNTU4NQ_3803accd-7aa4-4a60-9dce-b3f1734819ef"
      unitRef="usd">218000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i20a2357f1ee944a3981e58fb135760d0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfNi03LTEtMS0yNTU4NQ_59270d01-0f1b-4eec-8d99-27e1869fa4d4"
      unitRef="usd">62050000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7d29995dc41841af867793064df8a5d2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfNy0xLTEtMS0yNTU4NQ_05e51554-281d-4154-bf67-4afd7351fa9f"
      unitRef="usd">177215000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7d29995dc41841af867793064df8a5d2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfNy0zLTEtMS0yNTU4NQ_7f8fb408-d8db-4b22-a012-d895a19ec83e"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7d29995dc41841af867793064df8a5d2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfNy01LTEtMS0yNTU4NQ_18905c0f-a74c-4511-820e-1918d99efaa6"
      unitRef="usd">61000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7d29995dc41841af867793064df8a5d2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfNy03LTEtMS0yNTU4NQ_1c37d873-57e2-4059-b141-add905c71239"
      unitRef="usd">177155000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2089649fd507474b8a8f30cdaa43c325_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfOC0xLTEtMS0yNTU4NQ_0b09bdbe-f226-4d7c-b6da-a356197aa382"
      unitRef="usd">47323000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2089649fd507474b8a8f30cdaa43c325_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfOC0zLTEtMS0yNTU4NQ_0388b77d-22ef-4427-820f-8df889685dd5"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2089649fd507474b8a8f30cdaa43c325_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfOC01LTEtMS0yNTU4NQ_3d383178-8705-4add-9e49-0b9fc3cf176d"
      unitRef="usd">39000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2089649fd507474b8a8f30cdaa43c325_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfOC03LTEtMS0yNTU4NQ_bfe0c31e-77ec-4ac6-ad2a-8cee955b518c"
      unitRef="usd">47284000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib2f748a77951427c94225f30126754e7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfMTAtMS0xLTEtMjU1ODU_4af2e5b7-6577-47af-a48f-27141b753d22"
      unitRef="usd">297117000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib2f748a77951427c94225f30126754e7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfMTAtMy0xLTEtMjU1ODU_704de7d9-6e07-4213-b677-d998826098a7"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib2f748a77951427c94225f30126754e7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfMTAtNS0xLTEtMjU1ODU_0f6db98e-f4ed-482d-8521-50584f7d1fd9"
      unitRef="usd">318000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib2f748a77951427c94225f30126754e7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfMTAtNy0xLTEtMjU1ODU_a1e6ad7d-9025-4fc7-88d2-583f8f46e5f4"
      unitRef="usd">296800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <advm:CashAndCashEquivalentAmortizedCost
      contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfMTEtMS0xLTEtMjU1ODU_1b2961c8-0552-45c7-a3d2-52194b1a3bb1"
      unitRef="usd">25808000</advm:CashAndCashEquivalentAmortizedCost>
    <advm:CashAndCashEquivalentGrossUnrealizedGain
      contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfMTEtMy0xLTEtMjU1ODU_6a807ec8-034a-49ea-bd23-295169ed4945"
      unitRef="usd">0</advm:CashAndCashEquivalentGrossUnrealizedGain>
    <advm:CashAndCashEquivalentGrossUnrealizedLoss
      contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfMTEtNS0xLTEtMjU1ODU_08b4e1db-d51b-4abd-adc8-4aff200e78c0"
      unitRef="usd">1000</advm:CashAndCashEquivalentGrossUnrealizedLoss>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfMTEtNy0xLTEtMjU1ODU_b0cebef0-5464-4160-bb10-1b868fa1cef1"
      unitRef="usd">25807000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfMTItMS0xLTEtMjU1ODU_988fa0a1-f954-4756-926d-6916bd6e0466"
      unitRef="usd">271309000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfMTItMy0xLTEtMjU1ODU_f92439ae-a11f-4d26-9748-efd0c838f43b"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfMTItNS0xLTEtMjU1ODU_a8da0be9-6adf-42d1-af7c-ff7717e90306"
      unitRef="usd">317000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RhYmxlOmZmZTViOGQyZGM0MDRiMzY5NTkwZDk2NzI5YzVmZDk2L3RhYmxlcmFuZ2U6ZmZlNWI4ZDJkYzQwNGIzNjk1OTBkOTY3MjljNWZkOTZfMTItNy0xLTEtMjU1ODU_d08750ae-6614-486e-9940-b9244f21cd03"
      unitRef="usd">270993000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <advm:OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80My9mcmFnOmU2ZjNiN2Y3ZjFkYTRkYmRiZTA3N2NlYTZlNjExYTc2L3RleHRyZWdpb246ZTZmM2I3ZjdmMWRhNGRiZGJlMDc3Y2VhNmU2MTFhNzZfMjUwMw_7e36ff89-b31e-4ae0-bdcd-eee9cf44eb26"
      unitRef="usd">0</advm:OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RleHRyZWdpb246ZDJkNmI4YzU2YmRiNDkyZmJkYTZiNWNiNTNjZDY1NTdfMjM5_4925a248-3004-4341-bf9a-0508c373f708">Balance Sheet Components&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consists of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,641)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performed an impairment analysis for certain laboratory equipment assets based on the identification of impairment indicators during the three months ended June&#160;30, 2022. The analysis determined that the fair value of the assets, which was determined using a market approach, was lower than the carrying value. As a result of the evaluation, an impairment charge of $2.0 million was recognized for the three months ended June&#160;30, 2022. The assets indicated as impaired were written down to their estimated fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consist of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued nonclinical, clinical and process development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income tax payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RleHRyZWdpb246ZDJkNmI4YzU2YmRiNDkyZmJkYTZiNWNiNTNjZDY1NTdfMjM3_794e86df-3ff9-4ed7-a5b0-ba6f03e9908a">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consists of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,641)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if9056b729e8546fab8f001340cc9fdf3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOmZhODhiNWQwYTViZTQ3MzY4MDljOWZiMDRlMGVhYjdjL3RhYmxlcmFuZ2U6ZmE4OGI1ZDBhNWJlNDczNjgwOWM5ZmIwNGUwZWFiN2NfMi0xLTEtMS0yNTU4NQ_42ef546f-e0d2-4977-9203-9f6ee5b8d0bb"
      unitRef="usd">1289000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia76becc1500d43a2a228fe82d7febe92_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOmZhODhiNWQwYTViZTQ3MzY4MDljOWZiMDRlMGVhYjdjL3RhYmxlcmFuZ2U6ZmE4OGI1ZDBhNWJlNDczNjgwOWM5ZmIwNGUwZWFiN2NfMi0zLTEtMS0yNTU4NQ_21fc4e89-2164-47dc-94fe-a07fc95208d7"
      unitRef="usd">1224000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ieffb39be45a94c67a589adccd5ca2de7_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOmZhODhiNWQwYTViZTQ3MzY4MDljOWZiMDRlMGVhYjdjL3RhYmxlcmFuZ2U6ZmE4OGI1ZDBhNWJlNDczNjgwOWM5ZmIwNGUwZWFiN2NfMy0xLTEtMS0yNTU4NQ_3cc0dc31-b38c-4245-8688-6c1bd6a6dd00"
      unitRef="usd">15475000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="idf62e11c42f84334ba360a7fcd68e94a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOmZhODhiNWQwYTViZTQ3MzY4MDljOWZiMDRlMGVhYjdjL3RhYmxlcmFuZ2U6ZmE4OGI1ZDBhNWJlNDczNjgwOWM5ZmIwNGUwZWFiN2NfMy0zLTEtMS0yNTU4NQ_9ccc410e-690d-49a1-ad3d-cbc891fd46e8"
      unitRef="usd">12778000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i02800f7274124fe1971aafbaacb2bacf_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOmZhODhiNWQwYTViZTQ3MzY4MDljOWZiMDRlMGVhYjdjL3RhYmxlcmFuZ2U6ZmE4OGI1ZDBhNWJlNDczNjgwOWM5ZmIwNGUwZWFiN2NfNC0xLTEtMS0yNTU4NQ_4b915a8d-f650-4dd4-8ea8-e6972cebda42"
      unitRef="usd">868000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ifbb879dcd01e4d5bacd3fcbb94f010f6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOmZhODhiNWQwYTViZTQ3MzY4MDljOWZiMDRlMGVhYjdjL3RhYmxlcmFuZ2U6ZmE4OGI1ZDBhNWJlNDczNjgwOWM5ZmIwNGUwZWFiN2NfNC0zLTEtMS0yNTU4NQ_d7714621-03d3-4950-962a-f9269e93bd06"
      unitRef="usd">1136000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7566ab2be1484f1db090914aa37ba934_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOmZhODhiNWQwYTViZTQ3MzY4MDljOWZiMDRlMGVhYjdjL3RhYmxlcmFuZ2U6ZmE4OGI1ZDBhNWJlNDczNjgwOWM5ZmIwNGUwZWFiN2NfNS0xLTEtMS0yNTU4NQ_49656911-f919-4129-af6b-f1ada1bac936"
      unitRef="usd">34146000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="icbe21a83e6804a47850aa04b8d75d01a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOmZhODhiNWQwYTViZTQ3MzY4MDljOWZiMDRlMGVhYjdjL3RhYmxlcmFuZ2U6ZmE4OGI1ZDBhNWJlNDczNjgwOWM5ZmIwNGUwZWFiN2NfNS0zLTEtMS0yNTU4NQ_3a6cd4d0-d33c-4230-b628-ffabd2470597"
      unitRef="usd">26701000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i66e76679aad44f1985ba7be517dc7768_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOmZhODhiNWQwYTViZTQ3MzY4MDljOWZiMDRlMGVhYjdjL3RhYmxlcmFuZ2U6ZmE4OGI1ZDBhNWJlNDczNjgwOWM5ZmIwNGUwZWFiN2NfNi0xLTEtMS0yNTU4NQ_0708d800-dee7-4db0-aa8d-abe9652eb387"
      unitRef="usd">2096000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2281372e2bd3421693ab7f4489600be1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOmZhODhiNWQwYTViZTQ3MzY4MDljOWZiMDRlMGVhYjdjL3RhYmxlcmFuZ2U6ZmE4OGI1ZDBhNWJlNDczNjgwOWM5ZmIwNGUwZWFiN2NfNi0zLTEtMS0yNTU4NQ_1547400e-3e14-4d3a-a7ad-7a928eb2003a"
      unitRef="usd">4395000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOmZhODhiNWQwYTViZTQ3MzY4MDljOWZiMDRlMGVhYjdjL3RhYmxlcmFuZ2U6ZmE4OGI1ZDBhNWJlNDczNjgwOWM5ZmIwNGUwZWFiN2NfNy0xLTEtMS0yNTU4NQ_4885a7df-a773-46e5-a3ef-d4918d8af851"
      unitRef="usd">53874000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOmZhODhiNWQwYTViZTQ3MzY4MDljOWZiMDRlMGVhYjdjL3RhYmxlcmFuZ2U6ZmE4OGI1ZDBhNWJlNDczNjgwOWM5ZmIwNGUwZWFiN2NfNy0zLTEtMS0yNTU4NQ_d27c9491-6d36-4dc5-b7d7-bbeba1537e40"
      unitRef="usd">46234000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOmZhODhiNWQwYTViZTQ3MzY4MDljOWZiMDRlMGVhYjdjL3RhYmxlcmFuZ2U6ZmE4OGI1ZDBhNWJlNDczNjgwOWM5ZmIwNGUwZWFiN2NfOC0xLTEtMS0yNTU4NQ_ed2cb535-3967-493f-b9ba-344c11ee00c1"
      unitRef="usd">15641000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOmZhODhiNWQwYTViZTQ3MzY4MDljOWZiMDRlMGVhYjdjL3RhYmxlcmFuZ2U6ZmE4OGI1ZDBhNWJlNDczNjgwOWM5ZmIwNGUwZWFiN2NfOC0zLTEtMS0yNTU4NQ_78ee2b30-9be8-4faf-9b76-9bcce3a17f0c"
      unitRef="usd">13174000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOmZhODhiNWQwYTViZTQ3MzY4MDljOWZiMDRlMGVhYjdjL3RhYmxlcmFuZ2U6ZmE4OGI1ZDBhNWJlNDczNjgwOWM5ZmIwNGUwZWFiN2NfOS0xLTEtMS0yNTU4NQ_4da52dd3-0858-4923-a7da-ba6d2c9630fe"
      unitRef="usd">38233000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOmZhODhiNWQwYTViZTQ3MzY4MDljOWZiMDRlMGVhYjdjL3RhYmxlcmFuZ2U6ZmE4OGI1ZDBhNWJlNDczNjgwOWM5ZmIwNGUwZWFiN2NfOS0zLTEtMS0yNTU4NQ_c3c50597-9d49-4e61-8090-902180fc8718"
      unitRef="usd">33060000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetImpairmentCharges
      contextRef="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RleHRyZWdpb246ZDJkNmI4YzU2YmRiNDkyZmJkYTZiNWNiNTNjZDY1NTdfMjE5OTAyMzI2MTUzMQ_36fd17ef-5cf3-474c-af9d-c9954f53d21f"
      unitRef="usd">2000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RleHRyZWdpb246ZDJkNmI4YzU2YmRiNDkyZmJkYTZiNWNiNTNjZDY1NTdfMjM4_74931b0b-67bc-498b-a8a5-4d8ac066f462">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consist of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued nonclinical, clinical and process development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income tax payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOjI5M2ExYjllYTQwZDQwMWE4OTE5OTNlY2E0Njg2MDk0L3RhYmxlcmFuZ2U6MjkzYTFiOWVhNDBkNDAxYTg5MTk5M2VjYTQ2ODYwOTRfMi0xLTEtMS0yNTU4NQ_b9f9c520-482f-4b4a-80ba-50109c1d3c75"
      unitRef="usd">8128000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOjI5M2ExYjllYTQwZDQwMWE4OTE5OTNlY2E0Njg2MDk0L3RhYmxlcmFuZ2U6MjkzYTFiOWVhNDBkNDAxYTg5MTk5M2VjYTQ2ODYwOTRfMi0zLTEtMS0yNTU4NQ_95c4a588-54a0-462f-8379-5046eb8d2ef0"
      unitRef="usd">9209000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <advm:AccruedNonclinicalClinicalAndDevelopmentProcessCosts
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOjI5M2ExYjllYTQwZDQwMWE4OTE5OTNlY2E0Njg2MDk0L3RhYmxlcmFuZ2U6MjkzYTFiOWVhNDBkNDAxYTg5MTk5M2VjYTQ2ODYwOTRfMy0xLTEtMS0yNTU4NQ_c971b87c-f59f-4ef6-9c6b-3a25ab5c5a22"
      unitRef="usd">8387000</advm:AccruedNonclinicalClinicalAndDevelopmentProcessCosts>
    <advm:AccruedNonclinicalClinicalAndDevelopmentProcessCosts
      contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOjI5M2ExYjllYTQwZDQwMWE4OTE5OTNlY2E0Njg2MDk0L3RhYmxlcmFuZ2U6MjkzYTFiOWVhNDBkNDAxYTg5MTk5M2VjYTQ2ODYwOTRfMy0zLTEtMS0yNTU4NQ_e06ce549-559e-485a-b2e0-c2fd4856b90b"
      unitRef="usd">4953000</advm:AccruedNonclinicalClinicalAndDevelopmentProcessCosts>
    <us-gaap:TaxesPayableCurrent
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOjI5M2ExYjllYTQwZDQwMWE4OTE5OTNlY2E0Njg2MDk0L3RhYmxlcmFuZ2U6MjkzYTFiOWVhNDBkNDAxYTg5MTk5M2VjYTQ2ODYwOTRfNC0xLTEtMS0yNTU4NQ_7db37464-a93d-473c-9975-7d20f79fea16"
      unitRef="usd">178000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOjI5M2ExYjllYTQwZDQwMWE4OTE5OTNlY2E0Njg2MDk0L3RhYmxlcmFuZ2U6MjkzYTFiOWVhNDBkNDAxYTg5MTk5M2VjYTQ2ODYwOTRfNC0zLTEtMS0yNTU4NQ_88ae60f1-94aa-45a8-b839-cc17412c8801"
      unitRef="usd">1318000</us-gaap:TaxesPayableCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOjI5M2ExYjllYTQwZDQwMWE4OTE5OTNlY2E0Njg2MDk0L3RhYmxlcmFuZ2U6MjkzYTFiOWVhNDBkNDAxYTg5MTk5M2VjYTQ2ODYwOTRfNS0xLTEtMS0yNTU4NQ_e6b85c34-da96-4079-8101-2333927c20ed"
      unitRef="usd">986000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOjI5M2ExYjllYTQwZDQwMWE4OTE5OTNlY2E0Njg2MDk0L3RhYmxlcmFuZ2U6MjkzYTFiOWVhNDBkNDAxYTg5MTk5M2VjYTQ2ODYwOTRfNS0zLTEtMS0yNTU4NQ_d6440f6e-5639-4f5c-9dae-ff2a6f8629a5"
      unitRef="usd">550000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOjI5M2ExYjllYTQwZDQwMWE4OTE5OTNlY2E0Njg2MDk0L3RhYmxlcmFuZ2U6MjkzYTFiOWVhNDBkNDAxYTg5MTk5M2VjYTQ2ODYwOTRfNi0xLTEtMS0yNTU4NQ_833a7ff9-aeeb-4961-8e5a-b438d304df4d"
      unitRef="usd">1951000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOjI5M2ExYjllYTQwZDQwMWE4OTE5OTNlY2E0Njg2MDk0L3RhYmxlcmFuZ2U6MjkzYTFiOWVhNDBkNDAxYTg5MTk5M2VjYTQ2ODYwOTRfNi0zLTEtMS0yNTU4NQ_809ffe0a-fed2-4e64-928d-d7984d50259f"
      unitRef="usd">2017000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <advm:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOjI5M2ExYjllYTQwZDQwMWE4OTE5OTNlY2E0Njg2MDk0L3RhYmxlcmFuZ2U6MjkzYTFiOWVhNDBkNDAxYTg5MTk5M2VjYTQ2ODYwOTRfNy0xLTEtMS0yNTU4NQ_5ab3790d-067d-4de4-8eec-55537908df9c"
      unitRef="usd">19630000</advm:AccruedExpensesAndOtherCurrentLiabilities>
    <advm:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV80Ni9mcmFnOmQyZDZiOGM1NmJkYjQ5MmZiZGE2YjVjYjUzY2Q2NTU3L3RhYmxlOjI5M2ExYjllYTQwZDQwMWE4OTE5OTNlY2E0Njg2MDk0L3RhYmxlcmFuZ2U6MjkzYTFiOWVhNDBkNDAxYTg5MTk5M2VjYTQ2ODYwOTRfNy0zLTEtMS0yNTU4NQ_5e4570b9-60f4-47ac-aa57-d69e197440f3"
      unitRef="usd">18047000</advm:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RleHRyZWdpb246MTg5Y2UwNjk3YmFiNDU3N2E5N2EzZGIzYTI4YzcyMjVfNjg4_dff13e4a-7c76-48ff-a1fb-027832bcd412">Equity Incentive Awards&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s option activity and related information:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Options&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted during the six months ended June&#160;30, 2022 include 0.9&#160;million shares of performance-based non-qualified options with both performance and service vesting conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units (&#x201c;RSUs&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s RSUs activity and related information:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Units&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average Grant-&lt;br/&gt;Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs granted during the six months ended June&#160;30, 2022 include 0.4 million shares of performance units with both performance and service vesting conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents, by operating expense, the Company&#x2019;s stock-based compensation expense:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RleHRyZWdpb246MTg5Y2UwNjk3YmFiNDU3N2E5N2EzZGIzYTI4YzcyMjVfNjg5_a405e3dd-12e7-431f-a25c-4226c6ff8a6c">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s option activity and related information:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Options&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjI5MmZlMzM5NzU3ZTQ3NjlhYzVkZjgyZTdkYzI0NjEwL3RhYmxlcmFuZ2U6MjkyZmUzMzk3NTdlNDc2OWFjNWRmODJlN2RjMjQ2MTBfMS0xLTEtMS0yNTU4NQ_edfb7d74-2836-401f-a2a2-243ee1e65a63"
      unitRef="shares">13288000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i38e7641014c24f42802a0e767f3da33c_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjI5MmZlMzM5NzU3ZTQ3NjlhYzVkZjgyZTdkYzI0NjEwL3RhYmxlcmFuZ2U6MjkyZmUzMzk3NTdlNDc2OWFjNWRmODJlN2RjMjQ2MTBfMS0zLTEtMS0yNTU4NQ_2074fe9c-f704-419b-bc8e-5fbcf326b38e"
      unitRef="usdPerShare">9.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjI5MmZlMzM5NzU3ZTQ3NjlhYzVkZjgyZTdkYzI0NjEwL3RhYmxlcmFuZ2U6MjkyZmUzMzk3NTdlNDc2OWFjNWRmODJlN2RjMjQ2MTBfMi0xLTEtMS0yNTU4NQ_2d743c1d-beea-462d-9b19-1840ec22286d"
      unitRef="shares">6994000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjI5MmZlMzM5NzU3ZTQ3NjlhYzVkZjgyZTdkYzI0NjEwL3RhYmxlcmFuZ2U6MjkyZmUzMzk3NTdlNDc2OWFjNWRmODJlN2RjMjQ2MTBfMi0zLTEtMS0yNTU4NQ_378647f4-d9b8-4125-aa80-12f14216dc01"
      unitRef="usdPerShare">1.33</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjI5MmZlMzM5NzU3ZTQ3NjlhYzVkZjgyZTdkYzI0NjEwL3RhYmxlcmFuZ2U6MjkyZmUzMzk3NTdlNDc2OWFjNWRmODJlN2RjMjQ2MTBfMy0xLTEtMS0yNTU4NQ_d1aaeff9-6088-402b-b56f-b66384492326"
      unitRef="shares">15000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjI5MmZlMzM5NzU3ZTQ3NjlhYzVkZjgyZTdkYzI0NjEwL3RhYmxlcmFuZ2U6MjkyZmUzMzk3NTdlNDc2OWFjNWRmODJlN2RjMjQ2MTBfMy0zLTEtMS0yNTU4NQ_213be4e5-5fb9-409d-b92f-ff62fd192aae"
      unitRef="usdPerShare">0.19</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjI5MmZlMzM5NzU3ZTQ3NjlhYzVkZjgyZTdkYzI0NjEwL3RhYmxlcmFuZ2U6MjkyZmUzMzk3NTdlNDc2OWFjNWRmODJlN2RjMjQ2MTBfNC0xLTEtMS0yNTU4NQ_94603295-7239-4a56-8b17-ca71711ad300"
      unitRef="shares">3469000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjI5MmZlMzM5NzU3ZTQ3NjlhYzVkZjgyZTdkYzI0NjEwL3RhYmxlcmFuZ2U6MjkyZmUzMzk3NTdlNDc2OWFjNWRmODJlN2RjMjQ2MTBfNC0zLTEtMS0yNTU4NQ_2438f829-6f57-4fd6-8e13-d8b0c342e026"
      unitRef="usdPerShare">5.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjI5MmZlMzM5NzU3ZTQ3NjlhYzVkZjgyZTdkYzI0NjEwL3RhYmxlcmFuZ2U6MjkyZmUzMzk3NTdlNDc2OWFjNWRmODJlN2RjMjQ2MTBfNS0xLTEtMS0yNTU4NQ_207fbf40-4628-429f-a259-8782ae385bf0"
      unitRef="shares">16798000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjI5MmZlMzM5NzU3ZTQ3NjlhYzVkZjgyZTdkYzI0NjEwL3RhYmxlcmFuZ2U6MjkyZmUzMzk3NTdlNDc2OWFjNWRmODJlN2RjMjQ2MTBfNS0zLTEtMS0yNTU4NQ_6f0bf50c-981a-4c40-ba36-203ab3540ff2"
      unitRef="usdPerShare">6.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjI5MmZlMzM5NzU3ZTQ3NjlhYzVkZjgyZTdkYzI0NjEwL3RhYmxlcmFuZ2U6MjkyZmUzMzk3NTdlNDc2OWFjNWRmODJlN2RjMjQ2MTBfNi0xLTEtMS0yNTU4NQ_ee8559de-5727-433b-a262-b06d37d9c147"
      unitRef="shares">4739000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i091c63ec0288436c847c3d7e1c66f29c_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjI5MmZlMzM5NzU3ZTQ3NjlhYzVkZjgyZTdkYzI0NjEwL3RhYmxlcmFuZ2U6MjkyZmUzMzk3NTdlNDc2OWFjNWRmODJlN2RjMjQ2MTBfNi0zLTEtMS0yNTU4NQ_baa9a9a4-90a2-4681-861e-ac94f5ffaa5b"
      unitRef="usdPerShare">12.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i7b6fb5c50aa542bf9198fb1cb8a23705_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RleHRyZWdpb246MTg5Y2UwNjk3YmFiNDU3N2E5N2EzZGIzYTI4YzcyMjVfMTkx_0ce5a170-b15d-424e-85e3-cfedb820b847"
      unitRef="shares">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RleHRyZWdpb246MTg5Y2UwNjk3YmFiNDU3N2E5N2EzZGIzYTI4YzcyMjVfNjkw_b757477a-8f18-4785-9e14-d5546c3b0013">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s RSUs activity and related information:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Units&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average Grant-&lt;br/&gt;Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i799e2367d7a44cd3ab31610e4082fe1a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjYyYWQ3NTcxZGUxZDQ0MzM5OWM4ZThjN2FiYWYyMmNhL3RhYmxlcmFuZ2U6NjJhZDc1NzFkZTFkNDQzMzk5YzhlOGM3YWJhZjIyY2FfMS0xLTEtMS0yNTU4NQ_496ecdc0-828e-4c71-a3f9-fdfe484e1391"
      unitRef="shares">2126000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i799e2367d7a44cd3ab31610e4082fe1a_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjYyYWQ3NTcxZGUxZDQ0MzM5OWM4ZThjN2FiYWYyMmNhL3RhYmxlcmFuZ2U6NjJhZDc1NzFkZTFkNDQzMzk5YzhlOGM3YWJhZjIyY2FfMS0zLTEtMS0yNTU4NQ_b96fbba6-b3c6-4e13-9d5b-d7e12f2a1fc7"
      unitRef="usdPerShare">3.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i61c1bc0d431a4a5cb89f8a7d9bd2ef9a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjYyYWQ3NTcxZGUxZDQ0MzM5OWM4ZThjN2FiYWYyMmNhL3RhYmxlcmFuZ2U6NjJhZDc1NzFkZTFkNDQzMzk5YzhlOGM3YWJhZjIyY2FfMi0xLTEtMS0yNTU4NQ_8637be6a-23c3-4ff7-9328-a27db5467bd7"
      unitRef="shares">857000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i61c1bc0d431a4a5cb89f8a7d9bd2ef9a_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjYyYWQ3NTcxZGUxZDQ0MzM5OWM4ZThjN2FiYWYyMmNhL3RhYmxlcmFuZ2U6NjJhZDc1NzFkZTFkNDQzMzk5YzhlOGM3YWJhZjIyY2FfMi0zLTEtMS0yNTU4NQ_67f7c0a7-97f4-406a-b341-1d47fbae506d"
      unitRef="usdPerShare">1.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="i61c1bc0d431a4a5cb89f8a7d9bd2ef9a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjYyYWQ3NTcxZGUxZDQ0MzM5OWM4ZThjN2FiYWYyMmNhL3RhYmxlcmFuZ2U6NjJhZDc1NzFkZTFkNDQzMzk5YzhlOGM3YWJhZjIyY2FfMy0xLTEtMS0yNTU4NQ_b8d62315-be03-48c6-a74c-1d74ad4cff36"
      unitRef="shares">376000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="i61c1bc0d431a4a5cb89f8a7d9bd2ef9a_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjYyYWQ3NTcxZGUxZDQ0MzM5OWM4ZThjN2FiYWYyMmNhL3RhYmxlcmFuZ2U6NjJhZDc1NzFkZTFkNDQzMzk5YzhlOGM3YWJhZjIyY2FfMy0zLTEtMS0yNTU4NQ_2ead4bc0-6933-472b-a58b-fa5270ae743d"
      unitRef="usdPerShare">4.64</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i61c1bc0d431a4a5cb89f8a7d9bd2ef9a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjYyYWQ3NTcxZGUxZDQ0MzM5OWM4ZThjN2FiYWYyMmNhL3RhYmxlcmFuZ2U6NjJhZDc1NzFkZTFkNDQzMzk5YzhlOGM3YWJhZjIyY2FfNC0xLTEtMS0yNTU4NQ_75088ca4-9f7d-4379-91ca-b8bb146a2729"
      unitRef="shares">220000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i61c1bc0d431a4a5cb89f8a7d9bd2ef9a_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjYyYWQ3NTcxZGUxZDQ0MzM5OWM4ZThjN2FiYWYyMmNhL3RhYmxlcmFuZ2U6NjJhZDc1NzFkZTFkNDQzMzk5YzhlOGM3YWJhZjIyY2FfNC0zLTEtMS0yNTU4NQ_e6c5b999-ce49-4faf-9579-3947d9ca563a"
      unitRef="usdPerShare">2.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ic2977397029043bc8e1c6fb7a9d878ca_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjYyYWQ3NTcxZGUxZDQ0MzM5OWM4ZThjN2FiYWYyMmNhL3RhYmxlcmFuZ2U6NjJhZDc1NzFkZTFkNDQzMzk5YzhlOGM3YWJhZjIyY2FfNS0xLTEtMS0yNTU4NQ_6c21fa0a-d88f-4f0e-ad9a-3e92ae1da989"
      unitRef="shares">2387000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ic2977397029043bc8e1c6fb7a9d878ca_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjYyYWQ3NTcxZGUxZDQ0MzM5OWM4ZThjN2FiYWYyMmNhL3RhYmxlcmFuZ2U6NjJhZDc1NzFkZTFkNDQzMzk5YzhlOGM3YWJhZjIyY2FfNS0zLTEtMS0yNTU4NQ_e4d9906a-e496-463b-86c0-a657d3ce9c2c"
      unitRef="usdPerShare">2.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i7b6fb5c50aa542bf9198fb1cb8a23705_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RleHRyZWdpb246MTg5Y2UwNjk3YmFiNDU3N2E5N2EzZGIzYTI4YzcyMjVfNDY5_d3816711-0d7a-40bd-80ed-c47d597d7bf9"
      unitRef="shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RleHRyZWdpb246MTg5Y2UwNjk3YmFiNDU3N2E5N2EzZGIzYTI4YzcyMjVfNjg3_4f2c7083-0099-4621-9446-43f594dcf8ab">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents, by operating expense, the Company&#x2019;s stock-based compensation expense:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie6819ea354434909b8b5bc79270cf986_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjlmZWIwNmZhMGZkMTQ3NzI5MWZkNzVjNDllZjJlZDVmL3RhYmxlcmFuZ2U6OWZlYjA2ZmEwZmQxNDc3MjkxZmQ3NWM0OWVmMmVkNWZfMy0xLTEtMS0yNTU4NQ_9b407cc8-a0e5-4376-a6e3-644b8f0f8b36"
      unitRef="usd">1830000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie97980ff64894dfe89ceaa2199851660_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjlmZWIwNmZhMGZkMTQ3NzI5MWZkNzVjNDllZjJlZDVmL3RhYmxlcmFuZ2U6OWZlYjA2ZmEwZmQxNDc3MjkxZmQ3NWM0OWVmMmVkNWZfMy0zLTEtMS0yNTU4NQ_e2d5fa0b-fbc4-4d0a-8aa0-05573bb649ac"
      unitRef="usd">2579000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icd2c662c3d65454a9af244685ed76367_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjlmZWIwNmZhMGZkMTQ3NzI5MWZkNzVjNDllZjJlZDVmL3RhYmxlcmFuZ2U6OWZlYjA2ZmEwZmQxNDc3MjkxZmQ3NWM0OWVmMmVkNWZfMy01LTEtMS0yNTU4NQ_d2f08435-5bb4-4a93-ba33-bdd257392fff"
      unitRef="usd">3763000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i11fb6fa11226421b9721333c446b487e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjlmZWIwNmZhMGZkMTQ3NzI5MWZkNzVjNDllZjJlZDVmL3RhYmxlcmFuZ2U6OWZlYjA2ZmEwZmQxNDc3MjkxZmQ3NWM0OWVmMmVkNWZfMy03LTEtMS0yNTU4NQ_521bdd7e-4114-4071-bbde-94023a9e7d47"
      unitRef="usd">4918000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2f2c878dab744d72a09fd050e76b040e_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjlmZWIwNmZhMGZkMTQ3NzI5MWZkNzVjNDllZjJlZDVmL3RhYmxlcmFuZ2U6OWZlYjA2ZmEwZmQxNDc3MjkxZmQ3NWM0OWVmMmVkNWZfNC0xLTEtMS0yNTU4NQ_b04a5d01-3ce1-480d-810b-98186ae0a3b0"
      unitRef="usd">3112000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7921ddb1395c47e497a4d22dceba9142_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjlmZWIwNmZhMGZkMTQ3NzI5MWZkNzVjNDllZjJlZDVmL3RhYmxlcmFuZ2U6OWZlYjA2ZmEwZmQxNDc3MjkxZmQ3NWM0OWVmMmVkNWZfNC0zLTEtMS0yNTU4NQ_dd669939-5bdb-49ba-a776-b429c497a383"
      unitRef="usd">5655000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie8275590de8c4107a7250156ea0c4f5d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjlmZWIwNmZhMGZkMTQ3NzI5MWZkNzVjNDllZjJlZDVmL3RhYmxlcmFuZ2U6OWZlYjA2ZmEwZmQxNDc3MjkxZmQ3NWM0OWVmMmVkNWZfNC01LTEtMS0yNTU4NQ_755cc9c9-972a-4b87-a62c-280174fd7c62"
      unitRef="usd">6560000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia558ece0e92049239ba7ef43bde0bf94_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjlmZWIwNmZhMGZkMTQ3NzI5MWZkNzVjNDllZjJlZDVmL3RhYmxlcmFuZ2U6OWZlYjA2ZmEwZmQxNDc3MjkxZmQ3NWM0OWVmMmVkNWZfNC03LTEtMS0yNTU4NQ_17965c24-6d34-4474-98c5-7f27300c725e"
      unitRef="usd">10540000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjlmZWIwNmZhMGZkMTQ3NzI5MWZkNzVjNDllZjJlZDVmL3RhYmxlcmFuZ2U6OWZlYjA2ZmEwZmQxNDc3MjkxZmQ3NWM0OWVmMmVkNWZfNS0xLTEtMS0yNTU4NQ_fd3226af-e1f5-4b27-ba15-c79242ff2e40"
      unitRef="usd">4942000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i800056eee9e94e64bfc8afc515868f0d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjlmZWIwNmZhMGZkMTQ3NzI5MWZkNzVjNDllZjJlZDVmL3RhYmxlcmFuZ2U6OWZlYjA2ZmEwZmQxNDc3MjkxZmQ3NWM0OWVmMmVkNWZfNS0zLTEtMS0yNTU4NQ_db2e588c-f073-44dd-aff9-e5f56537bf06"
      unitRef="usd">8234000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjlmZWIwNmZhMGZkMTQ3NzI5MWZkNzVjNDllZjJlZDVmL3RhYmxlcmFuZ2U6OWZlYjA2ZmEwZmQxNDc3MjkxZmQ3NWM0OWVmMmVkNWZfNS01LTEtMS0yNTU4NQ_7547a4b5-5e4b-47ae-9628-3afe2311f1b2"
      unitRef="usd">10323000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81Mi9mcmFnOjE4OWNlMDY5N2JhYjQ1NzdhOTdhM2RiM2EyOGM3MjI1L3RhYmxlOjlmZWIwNmZhMGZkMTQ3NzI5MWZkNzVjNDllZjJlZDVmL3RhYmxlcmFuZ2U6OWZlYjA2ZmEwZmQxNDc3MjkxZmQ3NWM0OWVmMmVkNWZfNS03LTEtMS0yNTU4NQ_72b8aca1-d57b-4990-8dee-3d4e2031600a"
      unitRef="usd">15458000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81NS9mcmFnOjFmZDZkNWMyM2E3YzQ3NmQ4OTFkMzBlMTEyZWM3ZTEyL3RleHRyZWdpb246MWZkNmQ1YzIzYTdjNDc2ZDg5MWQzMGUxMTJlYzdlMTJfODMz_27455c37-2ec3-4abe-b887-1d43ddcb7878">Net Loss per ShareBasic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period using the treasury stock method. Outstanding stock options, RSUs, rights under the employee stock purchase plan (&#x201c;ESPP&#x201d;) and warrants are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following common stock equivalents outstanding at the end of the periods presented were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,435&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81NS9mcmFnOjFmZDZkNWMyM2E3YzQ3NmQ4OTFkMzBlMTEyZWM3ZTEyL3RleHRyZWdpb246MWZkNmQ1YzIzYTdjNDc2ZDg5MWQzMGUxMTJlYzdlMTJfODM1_a4751694-63dc-40aa-98bb-feca84518aed">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following common stock equivalents outstanding at the end of the periods presented were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,435&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie17cab1a780b48bf993da64124f1616e_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81NS9mcmFnOjFmZDZkNWMyM2E3YzQ3NmQ4OTFkMzBlMTEyZWM3ZTEyL3RhYmxlOjA5MWVlMmExNDdiNDQ0YTQ5ODVkNGFmYjgyNzUzZGZkL3RhYmxlcmFuZ2U6MDkxZWUyYTE0N2I0NDRhNDk4NWQ0YWZiODI3NTNkZmRfMi0xLTEtMS0yNTU4NQ_cb8f367d-8ae3-48e6-a91a-18f4bf3a6214"
      unitRef="shares">16798000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i00290c3bbf024183bc58b3da064c1719_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81NS9mcmFnOjFmZDZkNWMyM2E3YzQ3NmQ4OTFkMzBlMTEyZWM3ZTEyL3RhYmxlOjA5MWVlMmExNDdiNDQ0YTQ5ODVkNGFmYjgyNzUzZGZkL3RhYmxlcmFuZ2U6MDkxZWUyYTE0N2I0NDRhNDk4NWQ0YWZiODI3NTNkZmRfMi0zLTEtMS0yNTU4NQ_882d8153-9e59-407d-b148-f6de7d885e79"
      unitRef="shares">14435000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idf067933631d446ea2d6ff5ad2ba89f6_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81NS9mcmFnOjFmZDZkNWMyM2E3YzQ3NmQ4OTFkMzBlMTEyZWM3ZTEyL3RhYmxlOjA5MWVlMmExNDdiNDQ0YTQ5ODVkNGFmYjgyNzUzZGZkL3RhYmxlcmFuZ2U6MDkxZWUyYTE0N2I0NDRhNDk4NWQ0YWZiODI3NTNkZmRfMy0xLTEtMS0yNTU4NQ_2fa62212-6761-4d23-aef0-a18627bcf18e"
      unitRef="shares">2387000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id35485ffc22d4b6d97a32ff7a9e6516a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81NS9mcmFnOjFmZDZkNWMyM2E3YzQ3NmQ4OTFkMzBlMTEyZWM3ZTEyL3RhYmxlOjA5MWVlMmExNDdiNDQ0YTQ5ODVkNGFmYjgyNzUzZGZkL3RhYmxlcmFuZ2U6MDkxZWUyYTE0N2I0NDRhNDk4NWQ0YWZiODI3NTNkZmRfMy0zLTEtMS0yNTU4NQ_84300546-239f-47d3-8d1d-dc2c0e16c63d"
      unitRef="shares">591000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie7873e824c2c453082de63de06e7151c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81NS9mcmFnOjFmZDZkNWMyM2E3YzQ3NmQ4OTFkMzBlMTEyZWM3ZTEyL3RhYmxlOjA5MWVlMmExNDdiNDQ0YTQ5ODVkNGFmYjgyNzUzZGZkL3RhYmxlcmFuZ2U6MDkxZWUyYTE0N2I0NDRhNDk4NWQ0YWZiODI3NTNkZmRfNC0xLTEtMS0yNTU4NQ_c35c07ba-a16f-4340-b93e-1db025cd6f67"
      unitRef="shares">303000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7d3546d871c340909747af982e7e0cf1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81NS9mcmFnOjFmZDZkNWMyM2E3YzQ3NmQ4OTFkMzBlMTEyZWM3ZTEyL3RhYmxlOjA5MWVlMmExNDdiNDQ0YTQ5ODVkNGFmYjgyNzUzZGZkL3RhYmxlcmFuZ2U6MDkxZWUyYTE0N2I0NDRhNDk4NWQ0YWZiODI3NTNkZmRfNC0zLTEtMS0yNTU4NQ_a1dee597-040f-4b2d-9c44-edaf86162c51"
      unitRef="shares">104000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81NS9mcmFnOjFmZDZkNWMyM2E3YzQ3NmQ4OTFkMzBlMTEyZWM3ZTEyL3RhYmxlOjA5MWVlMmExNDdiNDQ0YTQ5ODVkNGFmYjgyNzUzZGZkL3RhYmxlcmFuZ2U6MDkxZWUyYTE0N2I0NDRhNDk4NWQ0YWZiODI3NTNkZmRfNi0xLTEtMS0yNTU4NQ_f3ff6e59-cc4b-4b61-805e-3259a98f3bab"
      unitRef="shares">19488000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i30cb2b0aa7a14ba0b53a155e880936d1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV81NS9mcmFnOjFmZDZkNWMyM2E3YzQ3NmQ4OTFkMzBlMTEyZWM3ZTEyL3RhYmxlOjA5MWVlMmExNDdiNDQ0YTQ5ODVkNGFmYjgyNzUzZGZkL3RhYmxlcmFuZ2U6MDkxZWUyYTE0N2I0NDRhNDk4NWQ0YWZiODI3NTNkZmRfNi0zLTEtMS0yNTU4NQ_8ba495b3-79aa-4740-a4a7-5cbe88b49f26"
      unitRef="shares">15130000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV82MS9mcmFnOjI4MWY1NjcyYmYzNTRhYWE5ODU4Njk3ZTUzMmVkYmEzL3RleHRyZWdpb246MjgxZjU2NzJiZjM1NGFhYTk4NTg2OTdlNTMyZWRiYTNfMjY_0c374164-0f31-45c2-868d-de73f8d7f4ce">Subsequent EventIn July 2022, the Company implemented a restructuring of operations, including reductions in both headcount and expenses, to prioritize its clinical development of ixoberogene soroparvovec (&#x201c;Ixo-vec&#x201d;), formerly referred to as ADVM-022, and focus its pipeline strategy on certain highly prevalent ocular diseases. The Company expects these restructuring measures will be sufficient to fully support its Ixo-vec development plan and extend its expected cash runway into 2025. The Company expects the restructuring to be completed in the fourth quarter of 2022.Under the restructuring plan, the Company reduced its workforce by 78 employees (approximately 38%) and will incur aggregate restructuring charges of approximately $4.2&#160;million, of which it expects approximately $4.1&#160;million will be cash expenditures. The restructuring costs will be recorded primarily in the third quarter of 2022.</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate
      contextRef="i76f0e181dd5b4835a9cf93e9fd673c58_I20220731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV82MS9mcmFnOjI4MWY1NjcyYmYzNTRhYWE5ODU4Njk3ZTUzMmVkYmEzL3RleHRyZWdpb246MjgxZjU2NzJiZjM1NGFhYTk4NTg2OTdlNTMyZWRiYTNfMzg0ODI5MDcwOTgwNg_0ff223ec-7b94-4013-b7de-a9ff33854fc0"
      unitRef="employee">78</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent
      contextRef="i76f0e181dd5b4835a9cf93e9fd673c58_I20220731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV82MS9mcmFnOjI4MWY1NjcyYmYzNTRhYWE5ODU4Njk3ZTUzMmVkYmEzL3RleHRyZWdpb246MjgxZjU2NzJiZjM1NGFhYTk4NTg2OTdlNTMyZWRiYTNfMzg0ODI5MDcwOTgxMA_fa201976-2006-4054-96b2-4594970888da"
      unitRef="number">0.38</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="i76f0e181dd5b4835a9cf93e9fd673c58_I20220731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV82MS9mcmFnOjI4MWY1NjcyYmYzNTRhYWE5ODU4Njk3ZTUzMmVkYmEzL3RleHRyZWdpb246MjgxZjU2NzJiZjM1NGFhYTk4NTg2OTdlNTMyZWRiYTNfMzg0ODI5MDcwOTk0Nw_230c2d34-f131-48b4-a5e2-708a002e67ba"
      unitRef="usd">4200000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:PaymentsForRestructuring
      contextRef="ic30a812f292d467f80a69160b83e189b_D20220701-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2Y2NhYTRlNTc0NjQ2OTk4MmNiZjBkMThhNTI2Yjk5L3NlYzoyNmNjYWE0ZTU3NDY0Njk5ODJjYmYwZDE4YTUyNmI5OV82MS9mcmFnOjI4MWY1NjcyYmYzNTRhYWE5ODU4Njk3ZTUzMmVkYmEzL3RleHRyZWdpb246MjgxZjU2NzJiZjM1NGFhYTk4NTg2OTdlNTMyZWRiYTNfMzg0ODI5MDcwOTk2MQ_e5adbf0b-783c-44fb-b2a9-709be84ee066"
      unitRef="usd">4100000</us-gaap:PaymentsForRestructuring>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>50
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MCU3GJ!/QM%!\HV;:8ETCQ973.ON&E&:J19EV9T7YGXV0QW0CMF7<F>>;$8!
MB1D! $3,#0L$BHXM.J-HQ-.J\<H:ER#5R-HMJ<D&VVQ!G&_BEA N)E%@+34
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MI&J"2DUW4G$''^<.5V]L?2 [P)T;*2MX,ZP-)>4/I&J"2DTW].AIFSBIP';
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M9ZE<>'4%Y-_OJZK]^J;[=LW#%[S>_A]02P,$%     @ H($+57QPD_-# @
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M8_:.*P3)!\R(38WS#GW7B'OZ^AR:>]CAAJZLNYGO!2F'JR6%!]TQ$RG-[GY
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M,1LQTUQS-0].5_YJ::6=TZ7_F6.>$X8$\'ZMX5S[0 ;ZN\;K_P%02P,$%
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MKN8'C"9#&5?:]ZPRRLHI+O!LDM&]0YP081A#5L0CK<56+%JF9.J[19:4!U,
M7 (0;&#!-U8)?)J5!4TF\2Z0"4 3WR&2Z:XWB.\+(]K<+"JRV"_**,ZG]-S?
M97PT$'2,NO-CC\]!K]PP&QQV#Y/5Y3!0?!4?QK+W*%NI<!=X"=7X=(I!Q@RC
MSO#A]#J,%POM,*R$98/ID(T7P/E2:[?_\ 8.\^;\'U!+ P04    " "@@0M5
MP\>Z$E0$   _"@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6RE5MMN
MVS@0_96!6A0)H,BZVTYL W%ZV2S0;1 W[<-B'VAI;!.12(>DXF2_?H>4HSA=
MQXMV7R1>9LZ<N9$<;:2ZU2M$ P]U)?386QFS/NWU=+'"FNE KE'0SD*JFAF:
MJF5/KQ6RTBG552\.P[Q7,RZ\R<BM7:G)2#:FX@*O%.BFKIEZG&(E-V,O\IX6
MKOER9>Q";S):LR7.T-RLKQ3->AU*R6L4FDL!"A=C[SPZG:96W@E\X[C1.V.P
MGLREO+63RW+LA9805E@8B\#H=X\76%46B&C<;3&]SJ15W!T_H7]TOI,O<Z;Q
M0E;?>6E68V_@08D+UE3F6FY^PZT_F<4K9*7=%S:M;)IX4#3:R'JK3 QJ+MH_
M>]C&84=A$+ZB$&\58L>[->18OF>&349*;D!9:4*S ^>JTR9R7-BDS(RB74YZ
M9O+AKN'F$2Y%@<+&!\XW3)5ZU#,$;D5ZQ19HV@+%KP#E\%D*L]+P0918OM3O
M$:F.6?S$;!H?!/R]$0$DH0]Q&,<'\)+.T\3A):_@S59,X<F4,EC"%7NDPC)P
MKA032W3C/\_GVBBJDK_V.=]BI_NQ;>><ZC4K<.Q1:VA4]^A-WKV)\O#L /.T
M8YX>0O^9'!T$VD_S%728&5G<PI>U;1X-7U<("UE1#W.Q!,/F%6X;F?^-&@QM
M7\AZS<3CNS>#..J?:9#KY[ZS%I@HJ8TK9B@!7+3G"0F<PA]-/4<%<@'?71-A
M>0)35C%B!,S >RS0"221*X8(HL2/!P-X"\,@23N*2\JEQ<[]X3"%*$B2;@L?
M4!7<9OXHRHXA#*)AMT=$%LBMXE'BI_GP&+)@F.\2H$K$KA(AROW^T!K/@WX$
M'UID%P^FK0\OI5._GPQ).(J#,/X7U;)1+IP4/<T?H&X["&T'_8##15$U)1+U
M(1T#564CJVU%.YMK5"Z>1/AD[BI<2'%RU["*+SC-Y-;NAIL5S"5]=C1<8FPQ
M<!K?HS:64B%%R9U2 ->TIGAA";=%<2.XT7!D,QV'9]>S&^V&T=GQK]2)U?^I
M*FG-/]?*E\9H0WK6XMYZB?THSBD)2=#/X=,V]H.L3T62)O"-W*/YUC"Z\!TE
M_?P8TB!/X>-S?9"WQQ '6?2CR9>YBOUDT"=S<3 ,6^_^3[[3P_F&QD7CUS+K
MTKD]$VU:Z+)UT::RMF/<FTYW= BC?9@_4F6A8@X76Q5_;XZU,]269K%K:*MU
M2I84XHL[!&84HA<+;71=1KO1T:4@B[+1Y*L^MK6*3!4KYWJ)]_3J6+OCG5K0
M'R2A38N?]6U+)GX_3^B?^L-H )]0D">5TV,EW;3<W@;N0$S\*(HA\_,LH\,E
MRT.(0C]+0_@J#6G\EV^MB32F_\"/Z<!Z:_63V-J.,C_-!K#ODNCM7.HUJJ5[
MNFBRT C3WN_=:O<Z.F\?!<_B[=/J,U-+3NU?X8)4PZ"?>:#:YTH[,7+MG@A4
M0/3@<,,5O?!060':7TAIGB;60/=FG/P#4$L#!!0    ( *"!"U6FA'H+I ,
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M\>C]40;4WTS]PMLNW08L7;Y;TFL4,%(TX.^5M?YN$0,,?P^6_P%02P,$%
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M;*DTLTJ_'7C$>9B5.<1)6)85O.NUY)9JZ9%6_-7ZNE9%11AQ6L #4BMOE&B
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M05 [ WJ_4LKN-R[ ^*]F\2]02P,$%     @ H($+5:=.5Y,0!   ]0D  !D
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MTN!UX9H%7NB@; '.+Z4T3QU[9W2_B/0W4$L#!!0    ( *"!"U7])N]-!P8
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M+8W8?FI!ZW#A2[C9RNR"/9OLR(8^4/EMM^#JS*XHJS"FB0A9 CA=3ZT/\"9
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M^-<"M"O ]:52=C=QMU?[9Z7X"U!+ P04    " "@@0M5F% ^=W$#   (#
M&0   'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6RUEFN/VC@4AO^*E:ZJCM3)
M%0*9A4C0Z55J=U1VVL\F.1!K$CNU'9A*_?&U'0CLY**ATGXA<>)SSN,W]LN9
M[1E_$!F 1(]%3L7<RJ0L;QQ')!D46-BL!*K>;!@OL%1#OG5$R0&G)JC('=]U
M0Z? A%KQS#R[X_&,53(G%.XX$E518/YS"3G;SRW/.C[X2K:9U ^<>%;B+:Q
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M5T)CO[;#%!](D,8 ]]="Z/W$!&B?W.@'4$L#!!0    ( *"!"U4\I03R5P,
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M&:JHMXJ.D6E>LLREP0(H;\98HX*R$_#]0DJSZ=@ 5=4;_ %02P,$%     @
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M<I?8C3ZV/-[OV+G%34Y'@T+)36H3X@V6EY8L>J!B2,94\(GFX%70DHN5-_?
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MW8@CF +0@"%)XL[!O?,H7I]3\>:WG]$34$L#!!0    ( *"!"U67BKL<P
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M Q,ZI(R3CID9FUAP<79_)" _IH4LVZ81]B50E7*N)3XFM&<7565:[64$>4Q
M'J>%O!'2LD>A6F!?0;C6AISVK@LJMD60)P3D25K([8;8*0;79;,T.E#&N_B
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M7<T^ 5!+ 0(4 Q0    ( *"!"U4'04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ H($+597826#N
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ H($+59E<G",0!@  G"<  !,              ( !S $  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    " "@@0M5!EOV$\\%  #+'@  &
M            @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ H($+572I!C6"!0  $Q<  !@              ("!$@X  'AL+W=O
M<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( *"!"U5[$$=EQ04  "T:
M   8              " @<H3  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q0
M2P$"% ,4    " "@@0M5AGJ46A0,  #L=0  &               @('%&0
M>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ H($+57QPD_-#
M @  W00  !@              ("!#R8  'AL+W=O<FMS:&5E=',O<VAE970U
M+GAM;%!+ 0(4 Q0    ( *"!"U4]Z#/BH@<  % B   8              "
M@8@H  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " "@@0M5
M8_UP#V,&  ">#P  &               @(%@,   >&PO=V]R:W-H965T<R]S
M:&5E=#<N>&UL4$L! A0#%     @ H($+5;#<T?;!!0  NPT  !@
M     ("!^38  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (
M *"!"U65@;*@NP<  '<4   8              " @? \  !X;"]W;W)K<VAE
M971S+W-H965T.2YX;6Q02P$"% ,4    " "@@0M58B$I0ZX$  !["@  &0
M            @('A1   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4
M Q0    ( *"!"U7#Q[H25 0  #\*   9              " @<9)  !X;"]W
M;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ H($+5::$>@ND P
M:P@  !D              ("!44X  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX
M;6Q02P$"% ,4    " "@@0M5DQ+22+@#   J"   &0              @($L
M4@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( *"!"U75
M4F.DC0<  )T3   9              " @1M6  !X;"]W;W)K<VAE971S+W-H
M965T,30N>&UL4$L! A0#%     @ H($+5?B%*P7: P  =PD  !D
M     ("!WUT  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *"!"U7])N]-!P8  %8A   9              "
M@3YP  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ H($+
M50</LW\P @  <00  !D              ("!?'8  'AL+W=O<FMS:&5E=',O
M<VAE970R,2YX;6Q02P$"% ,4    " "@@0M55;%@@28%  !((0  &0
M        @('C>   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0
M   ( *"!"U67_D  *0,  +@(   9              " @4!^  !X;"]W;W)K
M<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ H($+59A0/G=Q P  " P
M !D              ("!H($  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q0
M2P$"% ,4    " "@@0M54>31**<"  !^!P  &0              @(%(A0
M>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( *"!"U4\I03R
M5P,  .8*   9              " @2:(  !X;"]W;W)K<VAE971S+W-H965T
M,C8N>&UL4$L! A0#%     @ H($+5<2*5M"M P  U1   !D
M ("!M(L  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " "@
M@0M5"&:??G(#   4#P  &0              @(&8CP  >&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( *"!"U7J M9Y]@(   $+   9
M          " @4&3  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#
M%     @ H($+56I1Y,DA P  "!(   T              ( !;I8  'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    " "@@0M5EXJ[',     3 @  "P
M    @ &ZF0  7W)E;',O+G)E;'-02P$"% ,4    " "@@0M54-@NX_X"   G
M%   #P              @ &CF@  >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ H($+5=JP!6U2 0  _A$  !H              ( !SIT  'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ H($+558,451_ 0  PQ(
M !,              ( !6)\  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/ "4 )0#Z"0  "*$

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>93</ContextCount>
  <ElementCount>166</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>25</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="advm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="advm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="advm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="advm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="advm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Stockholders Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="advm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="advm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/OrganizationandBasisofPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="advm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="advm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2105103 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments</Role>
      <ShortName>Fair Value Measurements and Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="advm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2109104 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/BalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="advm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2113105 - Disclosure - Equity Incentive Awards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/EquityIncentiveAwards</Role>
      <ShortName>Equity Incentive Awards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="advm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2119106 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/NetLossperShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="advm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2122107 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/SubsequentEvent</Role>
      <ShortName>Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="advm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.adverum.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>14</Position>
    </Report>
    <Report instance="advm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables</Role>
      <ShortName>Fair Value Measurements and Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="advm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2310302 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/BalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adverum.com/role/BalanceSheetComponents</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="advm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2314303 - Disclosure - Equity Incentive Awards (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/EquityIncentiveAwardsTables</Role>
      <ShortName>Equity Incentive Awards (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adverum.com/role/EquityIncentiveAwards</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="advm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2320304 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/NetLossperShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adverum.com/role/NetLossperShare</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="advm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Organization and Basis of Presentation (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/OrganizationandBasisofPresentationDetail</Role>
      <ShortName>Organization and Basis of Presentation (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adverum.com/role/OrganizationandBasisofPresentation</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="advm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Summary of Cash Equivalents and Short-term Investments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail</Role>
      <ShortName>Fair Value Measurements and Fair Value of Financial Instruments - Summary of Cash Equivalents and Short-term Investments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="advm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail</Role>
      <ShortName>Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="advm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2411404 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="advm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="advm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2415406 - Disclosure - Equity Incentive Awards - Summary of Stock Options Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetail</Role>
      <ShortName>Equity Incentive Awards - Summary of Stock Options Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="advm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2416407 - Disclosure - Equity Incentive Awards - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/EquityIncentiveAwardsAdditionalInformationDetail</Role>
      <ShortName>Equity Incentive Awards - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="advm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2417408 - Disclosure - Equity Incentive Awards - Summary of Restricted Stock Units Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail</Role>
      <ShortName>Equity Incentive Awards - Summary of Restricted Stock Units Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="advm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - Equity Incentive Awards - Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/EquityIncentiveAwardsStockBasedCompensationExpenseDetail</Role>
      <ShortName>Equity Incentive Awards - Stock-Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="advm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2421410 - Disclosure - Net Loss per Share - Schedule of Common Stock Equivalents Outstanding (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetail</Role>
      <ShortName>Net Loss per Share - Schedule of Common Stock Equivalents Outstanding (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="advm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2423411 - Disclosure - Subsequent Event (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/SubsequentEventDetails</Role>
      <ShortName>Subsequent Event (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adverum.com/role/SubsequentEvent</ParentRole>
      <Position>29</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="advm-20220630.htm">advm-20220630.htm</File>
    <File>advm-20220630.xsd</File>
    <File>advm-20220630_cal.xml</File>
    <File>advm-20220630_def.xml</File>
    <File>advm-20220630_lab.xml</File>
    <File>advm-20220630_pre.xml</File>
    <File>advm-20220630ex311.htm</File>
    <File>advm-20220630ex312.htm</File>
    <File>advm-20220630ex321.htm</File>
    <File>advm-20220630ex322.htm</File>
    <File>ex101ajrakowofferletter.htm</File>
    <File>ex101bjrakowpromotionlette.htm</File>
    <File>ex101cjrakowpromotionsvp.htm</File>
    <File>ex102dsouzaseparationagree.htm</File>
    <File>ex103consultingagreementnp.htm</File>
    <File>ex1042014esppplanamended.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="406">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>55
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "advm-20220630.htm": {
   "axisCustom": 0,
   "axisStandard": 9,
   "contextCount": 93,
   "dts": {
    "calculationLink": {
     "local": [
      "advm-20220630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "advm-20220630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "advm-20220630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "advm-20220630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "advm-20220630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "advm-20220630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 251,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 5
   },
   "keyCustom": 8,
   "keyStandard": 158,
   "memberCustom": 1,
   "memberStandard": 23,
   "nsprefix": "advm",
   "nsuri": "http://www.adverum.com/20220630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.adverum.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109104 - Disclosure - Balance Sheet Components",
     "role": "http://www.adverum.com/role/BalanceSheetComponents",
     "shortName": "Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113105 - Disclosure - Equity Incentive Awards",
     "role": "http://www.adverum.com/role/EquityIncentiveAwards",
     "shortName": "Equity Incentive Awards",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119106 - Disclosure - Net Loss per Share",
     "role": "http://www.adverum.com/role/NetLossperShare",
     "shortName": "Net Loss per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122107 - Disclosure - Subsequent Event",
     "role": "http://www.adverum.com/role/SubsequentEvent",
     "shortName": "Subsequent Event",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2306301 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments (Tables)",
     "role": "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables",
     "shortName": "Fair Value Measurements and Fair Value of Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310302 - Disclosure - Balance Sheet Components (Tables)",
     "role": "http://www.adverum.com/role/BalanceSheetComponentsTables",
     "shortName": "Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314303 - Disclosure - Equity Incentive Awards (Tables)",
     "role": "http://www.adverum.com/role/EquityIncentiveAwardsTables",
     "shortName": "Equity Incentive Awards (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320304 - Disclosure - Net Loss per Share (Tables)",
     "role": "http://www.adverum.com/role/NetLossperShareTables",
     "shortName": "Net Loss per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i091c63ec0288436c847c3d7e1c66f29c_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Organization and Basis of Presentation (Detail)",
     "role": "http://www.adverum.com/role/OrganizationandBasisofPresentationDetail",
     "shortName": "Organization and Basis of Presentation (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i091c63ec0288436c847c3d7e1c66f29c_I20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i091c63ec0288436c847c3d7e1c66f29c_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i091c63ec0288436c847c3d7e1c66f29c_I20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i091c63ec0288436c847c3d7e1c66f29c_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Summary of Cash Equivalents and Short-term Investments (Detail)",
     "role": "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail",
     "shortName": "Fair Value Measurements and Fair Value of Financial Instruments - Summary of Cash Equivalents and Short-term Investments (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i091c63ec0288436c847c3d7e1c66f29c_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i091c63ec0288436c847c3d7e1c66f29c_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "advm:OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Detail)",
     "role": "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail",
     "shortName": "Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i091c63ec0288436c847c3d7e1c66f29c_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "advm:OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i091c63ec0288436c847c3d7e1c66f29c_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411404 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)",
     "role": "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
     "shortName": "Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i38e7641014c24f42802a0e767f3da33c_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i091c63ec0288436c847c3d7e1c66f29c_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedEmployeeBenefitsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412405 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Detail)",
     "role": "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail",
     "shortName": "Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i091c63ec0288436c847c3d7e1c66f29c_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedEmployeeBenefitsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i38e7641014c24f42802a0e767f3da33c_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415406 - Disclosure - Equity Incentive Awards - Summary of Stock Options Activity (Detail)",
     "role": "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetail",
     "shortName": "Equity Incentive Awards - Summary of Stock Options Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i38e7641014c24f42802a0e767f3da33c_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416407 - Disclosure - Equity Incentive Awards - Additional Information (Detail)",
     "role": "http://www.adverum.com/role/EquityIncentiveAwardsAdditionalInformationDetail",
     "shortName": "Equity Incentive Awards - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i7b6fb5c50aa542bf9198fb1cb8a23705_D20220101-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i799e2367d7a44cd3ab31610e4082fe1a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417408 - Disclosure - Equity Incentive Awards - Summary of Restricted Stock Units Activity (Detail)",
     "role": "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail",
     "shortName": "Equity Incentive Awards - Summary of Restricted Stock Units Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i799e2367d7a44cd3ab31610e4082fe1a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418409 - Disclosure - Equity Incentive Awards - Stock-Based Compensation Expense (Detail)",
     "role": "http://www.adverum.com/role/EquityIncentiveAwardsStockBasedCompensationExpenseDetail",
     "shortName": "Equity Incentive Awards - Stock-Based Compensation Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421410 - Disclosure - Net Loss per Share - Schedule of Common Stock Equivalents Outstanding (Detail)",
     "role": "http://www.adverum.com/role/NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetail",
     "shortName": "Net Loss per Share - Schedule of Common Stock Equivalents Outstanding (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "ic30a812f292d467f80a69160b83e189b_D20220701-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRestructuring",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423411 - Disclosure - Subsequent Event (Details)",
     "role": "http://www.adverum.com/role/SubsequentEventDetails",
     "shortName": "Subsequent Event (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "ic30a812f292d467f80a69160b83e189b_D20220701-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRestructuring",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "ia2656a69beee4e59adf970ff4d33ed2d_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "icb516b66f76b47e181f2514f175fa2b4_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "role": "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i15be9234201549dda36ced82a7e6393c_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i15be9234201549dda36ced82a7e6393c_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Stockholders Equity (Parenthetical)",
     "role": "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical",
     "shortName": "Condensed Consolidated Statements of Stockholders Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i15be9234201549dda36ced82a7e6393c_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Basis of Presentation",
     "role": "http://www.adverum.com/role/OrganizationandBasisofPresentation",
     "shortName": "Organization and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.adverum.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105103 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments",
     "role": "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments",
     "shortName": "Fair Value Measurements and Fair Value of Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20220630.htm",
      "contextRef": "i065af25e5ab44481b53816a2cb3be5df_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 25,
   "tag": {
    "advm_AccruedExpensesAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses and other current liabilities.",
        "label": "Accrued Expenses And Other Current Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherCurrentLiabilities",
     "nsuri": "http://www.adverum.com/20220630",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail",
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_AccruedNonclinicalClinicalAndDevelopmentProcessCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail": {
       "order": 4.0,
       "parentTag": "advm_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued preclinical clinical and development process costs.",
        "label": "Accrued Nonclinical, Clinical, And Development Process Costs",
        "terseLabel": "Accrued nonclinical, clinical and process development costs"
       }
      }
     },
     "localname": "AccruedNonclinicalClinicalAndDevelopmentProcessCosts",
     "nsuri": "http://www.adverum.com/20220630",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_CashAndCashEquivalentAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalent amortized cost.",
        "label": "Cash And Cash Equivalent Amortized Cost",
        "negatedTotalLabel": "Less: cash equivalents, amortized cost basis"
       }
      }
     },
     "localname": "CashAndCashEquivalentAmortizedCost",
     "nsuri": "http://www.adverum.com/20220630",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_CashAndCashEquivalentGrossUnrealizedGain": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail": {
       "order": 1.0,
       "parentTag": "advm_CashAndCashEquivalentAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalent gross unrealized gain.",
        "label": "Cash And Cash Equivalent Gross Unrealized Gain",
        "negatedTerseLabel": "Less: cash equivalents, unrealized gains"
       }
      }
     },
     "localname": "CashAndCashEquivalentGrossUnrealizedGain",
     "nsuri": "http://www.adverum.com/20220630",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_CashAndCashEquivalentGrossUnrealizedLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail": {
       "order": 3.0,
       "parentTag": "advm_CashAndCashEquivalentAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalent gross unrealized loss.",
        "label": "Cash And Cash Equivalent Gross Unrealized Loss",
        "terseLabel": "Less: cash equivalents, unrealized losses"
       }
      }
     },
     "localname": "CashAndCashEquivalentGrossUnrealizedLoss",
     "nsuri": "http://www.adverum.com/20220630",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_CashEquivalentsAndShortTermInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and short term investments.",
        "label": "Cash Equivalents And Short Term Investments [Member]",
        "terseLabel": "Total cash equivalents and short-term investments"
       }
      }
     },
     "localname": "CashEquivalentsAndShortTermInvestmentsMember",
     "nsuri": "http://www.adverum.com/20220630",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "advm_IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in lease liabilities and lease incentive receivables.",
        "label": "Increase (Decrease) In Lease Liabilities And Lease Incentive Receivable",
        "terseLabel": "Lease liability and lease incentive receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable",
     "nsuri": "http://www.adverum.com/20220630",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) Operating Lease Right-of-use Asset",
        "label": "Increase (Decrease) Operating Lease Right-of-use Asset",
        "negatedTerseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "IncreaseDecreaseOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.adverum.com/20220630",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other than temporary impaired investments available for sale securities.",
        "label": "Other Than Temporary Impaired Investments Available For Sale Securities",
        "terseLabel": "Marketable securities other-than-temporarily impaired"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities",
     "nsuri": "http://www.adverum.com/20220630",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r79",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.adverum.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r79",
      "r84",
      "r165",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.adverum.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r79",
      "r84",
      "r165",
      "r196",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.adverum.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r21",
      "r283"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Amortization of premium and accrued interest on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "advm_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Employee compensation"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "advm_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional services"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r8",
      "r156"
     ],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r15",
      "r30",
      "r31",
      "r32",
      "r337",
      "r350",
      "r351"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r29",
      "r32",
      "r38",
      "r39",
      "r40",
      "r71",
      "r72",
      "r73",
      "r250",
      "r280",
      "r346",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive (Loss)/Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r71",
      "r72",
      "r73",
      "r232",
      "r233",
      "r234",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r198",
      "r236",
      "r237"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r183",
      "r184"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "negatedLabel": "Issuance of common stock, additional issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r230"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "verboseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from net loss per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r60",
      "r153"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r10",
      "r68",
      "r109",
      "r112",
      "r118",
      "r141",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r247",
      "r251",
      "r260",
      "r281",
      "r283",
      "r321",
      "r336"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r20",
      "r68",
      "r141",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r247",
      "r251",
      "r260",
      "r281",
      "r283"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r126",
      "r148"
     ],
     "calculation": {
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost Basis"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r124",
      "r127",
      "r148",
      "r325"
     ],
     "calculation": {
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r219",
      "r220",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsAdditionalInformationDetail",
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]",
        "terseLabel": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r63",
      "r64",
      "r65"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Fixed assets in accounts payable, accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r6",
      "r62"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail": {
       "order": 2.0,
       "parentTag": "advm_CashAndCashEquivalentAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "negatedTerseLabel": "Less: cash equivalents, estimated fair value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r20"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash, cash equivalents, and short-term investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/OrganizationandBasisofPresentationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r57",
      "r62",
      "r66"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash and cash equivalents and restricted cash at beginning of period",
        "totalLabel": "Cash and cash equivalents and restricted cash at end of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r57",
      "r261"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental schedule of noncash investing and financing information"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r71",
      "r72",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r12",
      "r283"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r34",
      "r36",
      "r37",
      "r43",
      "r328",
      "r342"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredRentReceivablesNet": {
     "auth_ref": [
      "r269",
      "r270",
      "r273",
      "r279"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of rental income recognized over rental payment required by lease.",
        "label": "Deferred Rent Receivables, Net",
        "terseLabel": "Deferred rent receivable"
       }
      }
     },
     "localname": "DeferredRentReceivablesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r60",
      "r154"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r44",
      "r76",
      "r77",
      "r78",
      "r79",
      "r80",
      "r85",
      "r87",
      "r89",
      "r90",
      "r91",
      "r95",
      "r96",
      "r256",
      "r257",
      "r329",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share \u2014 basic (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r44",
      "r76",
      "r77",
      "r78",
      "r79",
      "r80",
      "r87",
      "r89",
      "r90",
      "r91",
      "r95",
      "r96",
      "r256",
      "r257",
      "r329",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Net loss per share \u2014 diluted (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r92",
      "r93",
      "r94",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r38",
      "r39",
      "r40",
      "r71",
      "r72",
      "r73",
      "r75",
      "r81",
      "r83",
      "r98",
      "r142",
      "r183",
      "r184",
      "r232",
      "r233",
      "r234",
      "r241",
      "r242",
      "r255",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r280",
      "r346",
      "r347",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r178",
      "r180",
      "r181",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r258",
      "r291",
      "r292",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements and Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r178",
      "r188",
      "r189",
      "r194",
      "r195",
      "r258",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1:"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r178",
      "r180",
      "r181",
      "r188",
      "r189",
      "r194",
      "r195",
      "r258",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2:"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r178",
      "r180",
      "r181",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r291",
      "r292",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r132",
      "r133",
      "r138",
      "r139",
      "r140",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r149",
      "r150",
      "r151",
      "r152",
      "r179",
      "r182",
      "r254",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedTerseLabel": "Loss on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncentiveToLessee": {
     "auth_ref": [
      "r271",
      "r272",
      "r274"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of incentive granted by lessor to lessee.",
        "label": "Incentive to Lessee",
        "terseLabel": "Lease incentive receivables"
       }
      }
     },
     "localname": "IncentiveToLessee",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r41",
      "r109",
      "r111",
      "r114",
      "r117",
      "r119",
      "r320",
      "r326",
      "r330",
      "r344"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r158",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r69",
      "r82",
      "r83",
      "r108",
      "r240",
      "r243",
      "r244",
      "r345"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Income tax provision"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r23",
      "r68",
      "r113",
      "r141",
      "r167",
      "r168",
      "r169",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r248",
      "r251",
      "r252",
      "r260",
      "r281",
      "r282"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r18",
      "r68",
      "r141",
      "r260",
      "r283",
      "r322",
      "r339"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r5",
      "r25",
      "r68",
      "r141",
      "r167",
      "r168",
      "r169",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r248",
      "r251",
      "r252",
      "r260",
      "r281",
      "r282",
      "r283"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security.",
        "label": "Marketable Securities, Unrealized Gain (Loss)",
        "terseLabel": "Net unrealized loss on marketable securities",
        "verboseLabel": "Unrealized loss on marketable securities, net"
       }
      }
     },
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r57",
      "r58",
      "r61"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r33",
      "r35",
      "r40",
      "r42",
      "r61",
      "r68",
      "r74",
      "r76",
      "r77",
      "r78",
      "r79",
      "r82",
      "r83",
      "r88",
      "r109",
      "r111",
      "r114",
      "r117",
      "r119",
      "r141",
      "r167",
      "r168",
      "r169",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r257",
      "r260",
      "r327",
      "r341"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r109",
      "r111",
      "r114",
      "r117",
      "r119"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r276"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liability, current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r276"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liability, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r275"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r2",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/OrganizationandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail": {
       "order": 5.0,
       "parentTag": "advm_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Deposit and other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r245",
      "r246",
      "r249"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation adjustment",
        "verboseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Tax [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r56",
      "r160"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "terseLabel": "Expected cash expenditures"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r55"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Stock issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r49",
      "r51",
      "r125"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Units"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r11",
      "r283"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from offerings of common stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": {
     "auth_ref": [
      "r53",
      "r231"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised",
        "terseLabel": "Proceeds from employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r49",
      "r50",
      "r125"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "terseLabel": "Maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Sales of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r53",
      "r231"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of common stock pursuant to option exercises"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r7",
      "r155"
     ],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r157",
      "r283",
      "r334",
      "r340"
     ],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "negatedLabel": "Repayment of loan"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r239",
      "r318",
      "r353"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r9",
      "r66",
      "r352"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail",
      "http://www.adverum.com/role/NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "auth_ref": [
      "r159",
      "r162",
      "r163",
      "r164"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Expected Cost",
        "terseLabel": "Restructuring charges"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of positions eliminated as of the balance sheet date since inception of the restructuring plan(s).",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Inception to Date",
        "terseLabel": "Number of employees"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the total number of positions eliminated as of the balance sheet date since inception of the restructuring plan(s).",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Inception to Date Percent",
        "terseLabel": "Number of employees percentage"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r14",
      "r184",
      "r283",
      "r338",
      "r349",
      "r351"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.adverum.com/role/OrganizationandBasisofPresentationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r71",
      "r72",
      "r73",
      "r75",
      "r81",
      "r83",
      "r142",
      "r232",
      "r233",
      "r234",
      "r241",
      "r242",
      "r255",
      "r346",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r106",
      "r107",
      "r110",
      "r115",
      "r116",
      "r120",
      "r121",
      "r122",
      "r186",
      "r187",
      "r319"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "License revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r277",
      "r278"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for lease liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareScheduleofCommonStockEquivalentsOutstandingDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r130",
      "r131",
      "r134",
      "r135",
      "r136",
      "r137",
      "r332",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-Sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Summary of Cash Equivalents and Short-term Investments"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r229",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r197",
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r219",
      "r220",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsAdditionalInformationDetail",
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Units Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r203",
      "r218",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Options Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "RSUs granted (in shares)",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsAdditionalInformationDetail",
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r212",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Units (in thousands)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r212",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance (in USD per share)",
        "periodStartLabel": "Beginning balance (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsAdditionalInformationDetail",
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsAdditionalInformationDetail",
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r204",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Options (in thousands)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r204",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in USD per share)",
        "periodStartLabel": "Beginning balance (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Grant- Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail",
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r219",
      "r220",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsAdditionalInformationDetail",
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options forfeited (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "negatedLabel": "Vested and released (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested and released (in USD per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r185",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).",
        "label": "Shareholders' Equity and Share-Based Payments [Text Block]",
        "terseLabel": "Equity Incentive Awards"
       }
      }
     },
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwards"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r19",
      "r323",
      "r324",
      "r335"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-Term Investments",
        "verboseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r67",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r27",
      "r38",
      "r39",
      "r40",
      "r71",
      "r72",
      "r73",
      "r75",
      "r81",
      "r83",
      "r98",
      "r142",
      "r183",
      "r184",
      "r232",
      "r233",
      "r234",
      "r241",
      "r242",
      "r255",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r280",
      "r346",
      "r347",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r71",
      "r72",
      "r73",
      "r98",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r11",
      "r12",
      "r183",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Common stock issued under employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r11",
      "r12",
      "r183",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r11",
      "r12",
      "r183",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Common stock issued upon release of restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r11",
      "r12",
      "r183",
      "r184",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options exercised (in shares)",
        "terseLabel": "Common stock issued upon exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r11",
      "r12",
      "r183",
      "r184"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Common stock issued under employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r11",
      "r12",
      "r183",
      "r184"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r27",
      "r183",
      "r184"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Common stock issued upon exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r12",
      "r16",
      "r17",
      "r68",
      "r123",
      "r141",
      "r260",
      "r283"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r268",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r268",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r268",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r268",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r284",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SubsequentEvent"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "advm_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "State income tax payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r132",
      "r133",
      "r138",
      "r139",
      "r140",
      "r179",
      "r182",
      "r254",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "terseLabel": "U.S. government and agency securities"
       }
      }
     },
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r86",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "verboseLabel": "Weighted-average common shares used to compute net loss per share - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r85",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares used to compute net loss per share - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27340-111563"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123415192&loc=d3e39896-112707"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123415192&loc=d3e39927-112707"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123415192&loc=d3e40010-112707"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123415192&loc=d3e40019-112707"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123394697&loc=d3e40879-112712"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123388062&loc=SL77916639-209961"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123408481&loc=SL77919140-209958"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "https://asc.fasb.org/topic&trid=2122208"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r354": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r355": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r356": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r357": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r358": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r359": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r360": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r361": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r362": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r363": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r364": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r365": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r366": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>56
<FILENAME>0001628280-22-022469-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-22-022469-xbrl.zip
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M3^KIE^?_[]%7K"!JT#L+5OW'RZO(TU[YW=Y^(_H3W&NWUVT..]"(B2HOO!^
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M.%NKU-14:CL?GHQY@^* [W;A88('*K<D#[8^[(Y\R%DHJNI7CK-P.4&R 7V
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M.W51'96?9-WR\70<RHP#"\A?SCB+%E^'PL',/&4C .<B94*IE.I>P:!$W=X
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M M8(>(.  GH2)P!_TDGN$JY]6,=B8A*+1'A<(B 9(2"I$7"!$?!Z @$%2;C
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M8,R1=I@A)31)1)I(=2-;#Y78RBIQE5OH>.$E=U3T.5[B# %Q"(.\S(H.^(W
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M;_:+7"?\9H=?:MVH$JUY8R*L[>IK*AG4SUTEYT^K,0]/\D-/LN6#>*&@;2*
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M=F]MN[>VW5M_S(_RLG_>&UZ"@FC ;@/)LS(EHVV-^$1=8VM,,$'MI2*FW]W
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MA4A)QIDR>,*QC+=VDFZ:)"UK/UW6=I*))%&1==)P&@DM6!+1)'4Z,MPGMO6
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MU_LU9S=9M8?46X0]?"_/,/AT/D'*'@)'32I+!W3'(8BX2;<! #C)20BA PZ
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M0*/#P="<PM]T0\?^_<5!K287P895^L;V;.UU@DZ9;%F'!ZKTF:OR<XHX_Q_
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MDYF&1G];@$TXN4CSELX9&H)-F%=ZF5;S6NW)HZX-;8<!0T7+/$4+%;^/0Z_
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MKM<O&9A$\TQ"V\_3%1ZMR3N]DG9^L\]3N,&+4B]XE%L.XL&?9VE]#CJXO)S
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M5[Z[$G>TPT@%!21X2.R!(@'8/.GPPPV0P(V0QJFS02U.:^DT-8W]7FH*382
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MR*N-T5OJ;W".L2[I4='#\4<1"[1PI8TW,M.VWNKCM)Y6JD?<V7 +OP5_*:-
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M;=O<58>!11@P#,8+(E;KN,4S[Y)EH^W]#6G]#+,T%I5)92-&9%;C415*1]Q
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MQ+.:A%>9H*&H9&NEQ!AFJ>C1&J(KQFCADR+O" <&WB0& L!5R.MY1&M*MM<
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M"+%SB+A5TL3$=9S7UZW:<%*S,Y-(8>:BC<DTO(*7P+[.MU!OY1N$H2)/XGC
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M$&Z+\;=))8IL*DMQB*XO&$:&%2*5W$Y )^_$E.P$JO3)F,-4ZIA,>,8;P2D
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MBU?"^&7O2P$SQ%<!P]9,#QC7260^%CN5B5#3+0U7$"\\M3)I.;LNB0@N=N*
MW$BL&P3=4Y20#8N'4W.;N*-2YQH-"#'@8 JP=%=;#/6@.1E@E"7@YSW$Y"?3
MS2'3#BLYCF*..V25(Z/B 'OJD#=CQ*E99_;;[T_^36[PQ==?78V6G/>D?;%
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M@M3K#3M;2BDV'MH)#82(0J<Z1SR:9T@GX%;I'8'1O8;X7LMWY:WFAW>.PF*
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M!V(Z?\4#P#VURM_I8FB701(/@88O4DP(=PK6,GH>G2$P3K5@,JDI?V+<7L9
M^^H:5)HCS2GA,V%"EG"58% N%]^SF(,S6FHYWM4V#6S1/TLRQJ42'A )E5PX
M_V5&4-:>&K*OZ._^[2G4?4;&/E\WVI[D[LX_EC\[*Y@M_M'G-^.G1<Z&_C)E
M.OD1GTEB:K7ODY_1(GY&U#UAIL)B?*G+YBO58OR^1HGXNZ8N@^T)W[E</)=6
M TX"<. -RR_[#"U:;)LE&J8]Y9.S_,:<LX09()OL$PFV=?'L8<OPYDE2@FD=
M(?D%[RFK>%ANQK@"5'EG>A-2)^YNK3U;WMJ+X #6IMK*SA*<QAI&Q*^4I!5=
M[Q.OIG\O6HT3J;\TL53OB9<!M/SCA#!G>H>IX-C;_/_:^]*NMK$M[;^BE=MO
M==++.+;!C'UK+0).%55)H(%4W?[42[9EK(HL^6J N'[]>_9T!ED&0C#81!\J
ME=BR='2&/>_G^:8DTAPY1^^S]\OQV7G#'N3O:DS#9*+E$UR@)?+GW_'?QE=Z
ME_I_AY&YF,&BRF?S@W_CO?X0A.H"^%I-"W[YTS\ZF^T#]6=GYP"J1-7OADFF
MSHOR-_R0C%1^\H=?SHZU+G@-]_N4-+WV9F.GM?>VTVKO,JK&D=IMOAZ//GFV
MOU@>%S_A[.3L0PD%4#J#'+N?PHTZ6EZM$V H9"8D:5:*[6&/6&7O.9U'-Q1_
ME_81WX9@&#2B#E+5A!JZ88(@LG-L,S-Y4=JZ 5CNEJG1+U*E)FWP*]XQM"^A
M94X=,F72L=JZ#C2"!XL ]31UY]@**M([VO?A3849)*3!6Z 2=6R:U:GF>B;I
M+$ZJ^'3R>U#K"6")XHN!P9-)DG0*_FN&Q#'D?)"[Z/PV"X(O4,,0<C\IS&1@
M/&9S(;ND#FK&2).\9/.RMGI693:XL  08Q)F_[Z5>Z=A=>'HM6]( RSF45T.
M;X"810ZA)L3>R[VYE6/"%5<OG.@A03WQ!B*QLD8GRB-=*C+'MH/&40)[VZ2*
M4\]E;6.*12>?;(&8D,H0@NTDTS%L 5WB869?G"HCUS^N2&@WK(RWT(^7$M=5
MV2@(WO<*2$SZ-HXOHIDA@-LU40$I"R%-HLCL7J'EBJ\2KCY=0'^D+J0'+,"Q
ML+J^O\6DLNM;2QCQ!ENF'-WB]!W%H++ 8ILW*6=C+-R=5:Q,#[,(HWQPBHUC
M;DC)FA.0?90QHUC!@KV[ZM$#@2?Z2ZU--I39=^QR7#W"+.(:+QT9&*BSG&WT
M"9:\TMF3U6$CPVZUQ[J ,">\>K 7E3T;D;,B/[+OY./#2@/54%CRDW0.VKUZ
M6 AAHT2*DETYQ0-X :GHBY'F6(LXSWP#_.0A=69/ I 9839AT:-4+/ATV.=Z
M[ZFA)D,1/BGAT5RKV0:C=5@RG_Q^ANZ5Q<L%\-A7!=IG&AQG$*:#8@*&VT T
MBVQ.SJ5%YB!F@LM$D[XH#X\V>A&KGP2&$ASOW#LT$)&](R5G RFIB^&BU 08
ML4E=5T9&8(!KM[4J]&GLC#E[EA7Z$;)L8NL@5J'![2Z$OOC(JDPXBGP,2HO=
M=7%TE!F#DC8F2G"<>K.TSH:LG!A-CSZ2Z2A!2EXH@?UWD$8^P\+CN_QN^8H:
MQ^N.C>(\"320>QJ<%5HX<;16C+M^Z[(LR+N[PMT@RI?W!@M*S,-[YX62QTJL
MHJ$L!OP;DC18\3CU,P8/("!(VCKH\1'/"*AJ_"=6*^"6X8#*8*9W/F(*( 6A
MT"C<N:]9L-!1K48%T>8$J:),$]2I,_E5""P=ZV+%O42GG=V*VLQM?L2%LT49
MSKO>D=HR0.?"0$L&7Z?$%.A6_?FB]>UV)4:H(I?SKR+FS6RUT6M=GKIROG(Y
M,>3 6T_+0^><E$PD,=8XGE:&"D/>"A*A3G$V>##IHA.;5!P[VDHN*R1"-3+K
M:H1>D5^RKQ<0A/9G%#0,%Y.%+C3GL/4]R@+D\FO<<I\H\OL$QD/U3RQ-33XK
M2:_4-OE;5Y@Q_8B5X*OK(99?#[%=UT.LPE!^C'H(*RMN>UP&N-D&.D2"R(7:
M _LARWY%P_CER,.0,<2N<><7626B)0;^U 6=4M>EOF =8@B[TK"'KAD[/ 8(
MZ#'TY6@O^YNSIZ 9!=IB ;*%2U.$1+(89(&(F$9;QV"0\DTA,(U0I8X-1\4/
M#'FI5?.J>YYSC#F??]?QTR&P5N-BZ01"[W,#2R0'"&X%F$)L>)KDXQ5R;R7E
MU;%1K=G/^_P[V@!4K*V^2X643=T52EB\<7)3LG2(CV%H!J0,>$E%\@/ 63N-
MO=^*./ ZNYA\;#?$*<*2S*&QLP<SC>Y>$9$CXY/SQ0Z6\6*;1[MBB8R/C &J
M:11(42O*0K#)<,<P06CP$>S+F7K_S&,>,GJ7'7R7+B*I8N9R[@W"3#<Z(V43
M;,M4.9HWT%#UX/'C_$J,3FQ3+3V,D2K&. D@)FEQ3T,5\IRQ>]T,$$;G"OI4
MPPQ2S4 $9JX]K94/6_6C!ST'W]\=A'Z:FLW!EXC#%Q0L<_-,3DO2R,_&>#,\
MQ3AQD%ZTS[*?R08P24>.3Q*S@I+ED^ F2;]45 B4JD3F0Y:4EL1&"XOLW#0V
M !.<9A_5U=,8D4&/-,NYHQ"2!A%X[)1O*/D79RD(,"K?3HVO"(Q#-@JENP:X
M,3-'!6FD#%-M':":HQ 3AHPRP>]Q'!"I3:0ZM%D&C$%E=C8_YMH5ZKU!Q[<"
M55F"Z]6Q#[LGH^G-\:!5K,C=0?=),@RB53]$=ND=U'[[U\3L[=#?0FFAH<!=
M&.9R&W78I?8)@#XC8MW7%!DT+7AY(MPQ810,W^#N5B97TO0^*NL&(M,-G:Y
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MXJ&2(V,+K@8UJ$*](71PY+I!31#RP&V?3*E:I/QCAGA&NFH-6<P86%3@8^(
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M*./8+9JD$TR7J8V/.1C$\J,L&$IM!(I#:K:[5E)F'[=!!@0MO!F"/(\ G O
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M?+N6=;H+OHH_T@(.",8;/L41_5-K 0/91RPHF/JVT*::\-5@5 %;V[9L.\F
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M(;/_^9BKD['D5S/.W_T74$L#!!0    ( *"!"U7MD H[D!4  .;$   5
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MX#V@(<O*;#$YV]9Q\!4,0XIR&NM]*W&WR^]R'M>QA\E[\JYOIB_"\7@>)I?
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MC6<8H\#GXY[KI",+ELA8MCNX >*BS,2$+"73V3I>N^=DA^)]'SI[65NVH]D
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M="L.7-O.=!M;W)=VD$UD^M[.=*MVIEO19!=](7>Q\7WAKZ12:<;*;F/&T9W
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M*^HI?^AY8@F):YSXF.$DIE2VH@LDT)Q8)Y3$.1-_7;NV:@6,!\:";16]]D"
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M!S,;+BJV:S5<?KB;T?"K7JV74[FVNQB^^KJ][+*=2B0-SD&JD0!8*P(H1BF
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MY?.3 ><'7I/E+]_PM7['I\O*?"%0LAPB#3)3N'RR! ..H0;&0")R1%(M@B)
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MCKHO=SDVJMS)$/]09XB7$;/J[X+M1W]Q(>R9X@[RZR?;_/HWR:[C?>])]D_
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M3@2X>B:93DB%Y[EHQR%6]HHSO0R;DZ)=U:-,$Q<>[T8'U:GH9VM/E?&D']P
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M&AL3;<5,G)R!#!1GH/RH:G#X>^8T)_].7)*UAAH%@146.!7MS[9J):5>R<&
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MVOR<[?9%]S>7P+BTA;GX?L<$M75V?-M+6?GB4:[+F[0)-3)E0B.@4^CB"HT
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M4#Z>X/*6@1A)>/DI";^K /,6B&.'F+=U%34E7YG_;^<HIJGDH=6$I:DR6*2
M<A?FG L(A"JD72!2E<,<YY0$N5,$2S V6_=D&KX'^Q/=U"2P.]Y5]W/9\"'R
MY/@^@>^;P5M2[=7I1*M'FM5XHT3O.?8NX]=O=KV6_L>05^\R/)X9]3P:&MB6
M=BX3SIG?6?QEU8<R,OG+5S[?IV\71U1;8UFJTJS '*0**H QQ4!(+4$J\RR7
M(G6IN@:RL<.E'Y_M_>X%;>X.H]^S+=[3B'XW-GJE?[(#0)TH8VTA.++@JW#8
MT=COW0?OI>WZ#I)_'_9^]R&)M@^X0H1NB^%NWA>LF5VJ! (Y<G$<F6#N%M2:
M_T1(9 K(,I*%N/F./HM1<(JB4ZCYD?PXDPWY9!(*IL2S.6RNIJS!\]FTJ'0X
MY>-EINE,'A^F<_U^K>]7$V$@$E@A +FU/7&:NY+(B "4$8AAFF$AXI:UO"C2
MV#;UNXZRE\T/<6Q^)+\[W9)2N5!GA>L'6.8**44)$"R# !>& EX4*9 (H91C
M7!!*)T]Z*1;C'.)=T?[O()\9Y)ZW#YT&;NR[ K\1&\[,/P+YI:WWK4#?AU%^
M!& T6_NXY2LS,#0YZR8F%5(4W !)4^=$:!"@!<<@E3K+B. ("Q1B2!_U,$YS
M>IMJJDFIV#&_P@9(/P:\"IZ>"6V;1>'M)4RZ)TTXU#MVGH1-^R^3&N%0O;/9
M$(X>C)IX[OW\2:_V4T-MJ^JB0J>I2[-B7P#8$&XM,\E!I@NA<Y4C77B5Q>PN
MPM@,[#)7FBF+Q)8>HM-&])T\=(%%\SJ,BQ^!](MVSPQS(3'=1HF=Q'2]E.WM
M#F*_N>K:!!A#SCH/@#QSU_FTU#%9KI2/]X^E9UN5C==:6DO]U9+M]$F[[%;W
M^L-BM;)R?31?^+=)D::ZR%@!H,Y35VE< LJ,=@D#N, Y,E050>ETP_H?&Q?N
MB-\DF-Y5()E9V0-3\08.B!\/]@ASSR2XBW"=+'T/X4KXY <G_H]E"@+GM&%U
MB)CVMQMXL1(#!_8^;.K@;M <)1?NV$Q\SZE?]!_E;]R=B<9<%Q(HX@)1*<P
M-Y;S),]DIA2',,SP\^IU;/SFI"H++-DY)7>\I<HL*>Z'T^8!Z4*#X[E';<?!
M\ZPL-KI]'X===H.R8E</]%]=]#1, W@[;?L<C8?3$0PA7DW'+W=-+5SY)I9]
M515(=XH4352N[::4,6MV%9G=E'(#J* 2I 4C"*:&$NIEA?EU-S92JO/AUMZ;
MGRL^JJ3>K1<6FE2X%?%V%HJ/8\_T<RV$'=()^R!S13;AUN8'3B;LH^IQ+F&O
MM[I9/)O"\'_5?/6X+ _/5YL?_J^I7MHFOSZ_6=SSZ7R26?XPV+AD>[EE%X53
M(%3&0(HRQ'-54$1HB.43U/O8R,;)6:W(R4;2,J+OE]M_#S-WP@;!S^SI#=J>
M^:<-U>3W2MR()UB=8(ID_H3U/:@9U F60W.H6R/=>,R=C=W.E?O#^=,]\9GK
M[';]FB^7SY8FRRXG$N>0Y[0 /&488)@6EK\8 46J< &%R3+"0OC+J]>Q\59Y
M<.QF5%DS1F_E#B,M/\3]R"HZCCV3U ;"\B\[(M\DW)W,5U)7-!:/JX)0BL11
M?GT.RDU!,!QR4MC+'4_.5RN]7C4E G"J:48*RSF8Y@ +4@!&H=V@T4(H76@D
M\CS$,6"O]7$Z!305%W@I:N I]QYXGF?872'I^X2ZE*N'T@DG%8YUJKS7]K!G
MQJ?4.CH1/OE0MYGZA7_3JT_\V:63:3ZY#$)M"@'MIH9)@#.H *4Z!\3(W.YR
M,B%)4%G($WV,S2*H"@9-J_N2-?^6/%3BALW<4V#ZS=\K(>IY%I?2);5X/4SF
M%NTC3>E3/0PZL5M4/)S>;8]&+B2PK;-1*,0RA@N@79Y[G",!>$X(L-L!KHQA
M%.&@NB:7NQP=!>RD?]M+?^^9Q+TK\GX$$1?/GOFB-15^G1.OG_(F_C#UG1[_
MA<J:^ /@G2K_VG(F[A3W35W<W!7)G2C$F5)$ Z25 EA" ACB!A1:<*D4YVGF
ME6OCL.&Q,4HC6T#1Z2.L+M^M=$6@9P[P4S[HKN24IIUN1?8:&NS^XY3XNS<=
M)W__,HG3=FY7_J:G=U_76MT^Z26_TTTZBD_+J=2_+F8SLUBZ%R<T5851>0:(
MM%,9<^,*5V0<Y ARD1:0Z+!-P_ JC(T^&K%!4@N>_,4JOP;)&[=7V=X2#)M]
MK<.GX6?AC'O >V;+F+G;=H"X21HH-M]0 T92HM&+3_3+C>1+AYEU5^#["$N[
M>H!BIXZ[0I*NSD>?[_EL]NIQ-9WKE0MZX]0PPX#BF@,,[8HG<J$ RH3!5!?0
M[IS#O(WVVA_;FE3[QI0R)HV0H<Y$^PA>MG"OQ*5GZ@Z#I(-ST$G%K_ &VF]O
M8/>?D\H<^_N<?FQLF<]^692Q)UHY?GE76SL\*P2D.08J0]+N;H4$5*<*9+D@
M7),<T2S(0VA8\<=&.+\\NFHI[DSNM_ETO2HSH*V_+AY7EO3'DP3MY(?0L]G;
M^_".W^3U3(6V <+^=?,YU0Z=OSMPDAJ=,=C 5PWK2]N_W83_/FS?JP9FN%1I
MK5)<L8#N>7P74L(\+P00O&  8TX $T4!\E3FQ,@BPRF>/)2N_Y_7?+D.6.FZ
M.H4?]M8?<;W2=].Y*\:2"#XKXWNN2\NYAVQ&"IH9*$&1$8LLR3406<Y BHG$
M&)D,X0;9M_.0Y*G7X=KTU:<9K7J"-& ='FE$0B7;3=SH@XN*QUQ,AH\XN*C>
M24J.$%? U=/]:2>[V_O%<NT*AKK:*!-&8:H)IT#G5-A]@I* $4H!R@J<Z8QJ
MJ%B3)/G+9><XSVZ]ONK][,9?!O":^V"W>7\^<L>]27@C>QE#:=EA-?4\;O =
MAG9VB(GJ@(ZYM\>.N<E&X/;"2IU 5/7556G%# GF7L<]@WK"8?S@^_SI>E8.
MQ*CB:/=22;QID:4E^?HV,P@5!^K4$'/H:Z,]'3HXF2YO\=P=WB809)+*C'"$
M.=!<0FOU,0VXM)9U42B-I:%,I+2C/?W"JGU/)OQOG]\D5H;*[AS?V=+ES\A
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M11 >7;PU3ZA]C;/F;G-#^VJ>4.6$J^:IIUX\;&G7$0_G&24N!21AVD[XG G
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MD=FY>F^DWCA]^ZR(W0? CW)BP]HS]T1 M$,@DC]$T<*0/+H<. C)'X3C$*2
M=[N>)+Z]U\L[NU7YRW+QQ_JK"_+D\^>)M5URD@D%$)&I8R$"J,84$&D*D4)7
M5#NP-LO)?L9&//5Y62-K4@F;U-*&GBF>AM;W7/%JP(8Y6PS%JL/I8BL25YPP
MGFYWX%/&5N6.3QK;'P\C@=5R/?DL]9POIXMW"VOT\-4FTRQ64AN% $.F )A
M 42!W:FC51))7 CA=;YPOHNQ3?U&.K])W@)=^_R. TC/4[L1+.(5XF6]VTP
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M;=DM$7LO" NWO?;.]/(>2I4"$1<<X((2P!3,0*H0X90+I)17M/E9"U,C@LK
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MQO A</40KPR![TB"%0NOF3U.OKS1=XOSR1<XE$C%%[!688KSP\83H_CZ=R1
M\?YPM_7QVZJ<W=<?4FZ^2)LU8Z^]WJ<Y12213/$$D$)@@%4:@T)"!%B2$!4C
MFD+I=<_KUNS4S@!JJR-K=E3;?9#-P"GO:9]N<%ONA@=W8)H/@JOWFM8/ID!K
M6,=&1UVS^@%QND;U_'0331WVZZ_ZU5__LOT7_<.D*OCK7_X/4$L#!!0    (
M *"!"U7_=YA=Q$   *+N @ 5    861V;2TR,#(R,#8S,%]P<F4N>&UL[;W9
MEILYDB9X7T\1DWT[EH%]R5-9?10**5MGE"&UI*CLGAL>+ :)DW121=(54CW]
M&.CT?1&=Q,\?KNJH+"WN+L*6#P8S@YGA7__[UY/93U]PN9HNYG_]$_\S^]-/
M.$^+/)U__.N??O_P$MR?_ON__<N__.O_!?"_?GGW^J=?%^GT!.?KGYXO,:PQ
M__3'=/WIIW]D7/WSI[)<G/STC\7RG],O >#?-O_H^>+SM^7TXZ?U3X()<?.[
MR[^HD(Q5W$.R,H'R2H"S6D%)6F;/-7<J_]\?_Y(+?1]CII_("I3('AP:!H8E
M780.SL2X^=#9=/[/O]1?8ECA3\3<?+7YZU__]&F]_OR7GW_^XX\__OPU+F=_
M7BP__BP8DS^?__2?MC_^]=;/_R$W/\V]]S]OOGOQHZOI73]('\M__E]_?_T^
M?<*3 -/Y:AWFJ2ZPFOYEM?GBZT4*ZXW,OTO73_?^1/T;G/\8U"\!%R#YG[^N
M\I_^[5]^^NE,',O%#-]A^:G^_ON[5]>6#)F4?WKRY[0X^;E^_^?G"_K"V_"Q
M4KOYU^MOG_&O?UI-3S[/+K[V:8GEKW^B?WL"5:W,2%;7_&^7__CGR^4_+W%%
MB-FP^YJ^L/V,NMI>I.#7-<XSGG%XOLALD:[]T*S*=[$\_Y>S$'&V^>HDXW2R
M^>1G<;5>AK2>>!^33"R"T9$3N'2 J(*'H$4P-BK%D%_GO%*](K(WZEAA^O/'
MQ9>?Z8-_KM*H?]B(92.26\N=B68_NL]WWP?ZV8E-S.8D"A1.%--&0HA)64 9
M9-*<1V'U061?7>TZU5=5^FR9?EHL,R[)?)PO%Y;IEGJO0W?[$S]_#DOZ($B?
MIK-\_J^K'6FAJ_6B@>3.U$+D_NDGXKK@<HGY]9E6[F5NP]F:C"IN?K*%QO_G
M:5C2)\Z^O<//B^5ZDJ-B4F8'+F<+2KD 7A<-7GB9,18;=6ZB_!L+[X0#T3\.
M#I%G)Y!XB\OI(K^8YU_I()Z8[) 42$<BKR<DHH:04P+TT1GE36'<-@'$M65W
M@H/L'P[[R[(3,'Q8AOEJ6@6_!;3-3#&M$_C"22),91(&J[()@9="3E.,;4Z'
M&ROO! G5/R0.DNC(J'@Q7T_7WUY.9_C;Z4G$Y20R3B>;)^?:"03%!0G#%P3+
MHL$L=?%)'(2&FRONA +=+PH.DF 7VG^''Z=5"//U;^$$)UD5:X.UD*(TH&)&
M.NH4IU]0QZ(+-SPU0,#U57="@>D=!0=(L@LDO** ?DDF;"/X]R1_?+XXG:^7
MWYXO,K'#H[$V1V FT&&GJUFC_\ ICJ$DQ\DU;@",!XG8"2>V=YRTDW,7L/D0
MOK[*)+YIF9[E*K:6T#H?O68.9%2.\.\-1)E(4K)(9-XKXP[S-!]<?B>HN-ZA
MTD*V78#D6<ZD@M7VM]?3.?()H]!:AT3T,U/(?582@BJ.8JG G"<6I6[A;-RQ
M]$[@\+V#XU"9]@2,Y_3'-\L/BS_F$U-LUHYIB"@%J)(+.&X,\%BR-I*KG$T[
M6%PNO%OJBCT15.PIT)XPL3D:WRS?+A=?IO.$$S0^9QXLE*P88;L$.AFC!YV$
MLT6(6,QA^=>'5M\-'1UG-IN)MB>(O%VLUF'V_TX_;URGR!/3532Y& \J.0>1
MEPP>D3GNF="JX8%R;>W=X-%QPK.16$<&1[5ZSY88-G27D@*/C)QHSP/9O2(@
M1,= 6N8%,<!\.,P!O;K:;@#H.,6YM^A&5GF](9V]_;28GV=@K.&V&&W RNH;
M&R/!)48&344Z\&1(*1UVY7%SQ=U4WW$J\R 1CJS^]YA.EP1=+N*'Z7J&DY21
M0B'B/QER=)1S!%WN?,W1HTM:9^T/<Q]OKKB;^CO.81XDPI'5_V$9:@W*^V\G
M<3&;<(W(C19@N:_)5Z+9\Q+!%8?<Q<!#/&SK7UMN-\5WG+;<7WB=;/H77].G
M,/^(FWRKXC8PYA(DQ\F')2X@BI+(?#&7R8/1S+;9^%=7W0T#':<D#Q9E%^'
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M3VH9QR+]\_TGDMOJS>FZ]G'4R'HBLM,$WD+AM"*31T(!)ZP 49CBD1'$DV\
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M(B=K4PWZ:3$CH:^JP[7^=ED9$ QW,7'0T9$)+-*!3V0,BT@"T7"TZJ':B'T
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M<V1?$=T53I*P+*3"P5A>AQQE"0%I"ZD2'(]>!Q=:7\'?3TTW9]R V&JCB@Y
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MZ9>S8>LFQV*)4U3UK4>?$M1P"JSCA:M$_W=S MJ.3MZCR.AM@-3P3M]P6NK
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MI>RT)1YV]0/W5$[/>*L,;5L7%.U3K0-"*74"O"H>/$D/0K%>\*!-2JW'B>Y
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M5V4TN#I7V5@MI0LJ>-OZTNAN2CH-2QO9LL.%_T1+,[;E*2^^?L;Y"FO3QJ9
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M?D&X;?33.6 HC(-E:3/#.X/G]9E'M"KG>NFI6C?_/DC0N$!LIO;=X+2'#CH
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M>':R.)VO)T4[+J25D KF6B9J@'1!EL2**O=HDN)][8 SPGMT&H?&7%O@[P&
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ML0]_M[O]1OVE3OW\MW_Y_P%02P,$%     @ H($+53=RQB%*"   5B<  !8
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M=#*[AK6RV%O;&\+]^AM[(:&BN>:D]*ZI+HH0NS.>>>:9&7MPYU5_V)M\O!I
MJA<97%V?7ISWH.+Z_H>HY_O]21_>3GZ]@)H7A#"1A"NFF> D\_W!904JJ=9Y
MR_>7RZ6WC#PAY_YDY!M3-3\30E$OT4GEI&/>X"<ER<E/G5>N"WT1%PO*-<22
M$DT3*!3C<_B04'4#KKO6ZHE\)=D\U5 -JE7X(.0-NR6E7#.=T9.-G8Y?/G=\
MZZ0S%<GJI).P6V#)FPJ+$]*@]:A)PVFM5J\WIT$]FD8D:H2-:M!L'/T1(D@?
MU<LU2J\R^J:R8-Q-J?'?.J[FNKUDB4Y;81#\7+%Z)YV9X!J=25Q<?BUM[%C2
M]$Z[)&-SWK+Q5,JE&W$L,B%;>X']:QN).R,+EJU:KR=L015<TB6,Q(+PUX["
M'+B*2C8K%17[DR(FA&<?EVN\:"=CG&[PAU4#>G"7LBG3$%6]ZN>(MZ,F<HZ!
M:Y&79K>PQ\@TE?\1^-Y@-#D_.^]U)^?#RT?1?R]HKZY'X^ONY00FP^\>:]B
M:V_L]3P8#WJ&70BC>N!\][B[8^CVAU>301]>$MT;DIO!$0S/8/)V ./NZ+1[
M.1B[P]\O!A^AVYL8234(_F&;,IY@9*UZ+?_V6TSMB\&=<X@%YS0VQP0LF4Y!
MIQ3>%T0BX]D*1C074@,*SX1<0!BX[T',H)O<4EDLX)0)3>.4(]PYH\J!<QY[
M,!/2FIDQ%9,,/I76@&*X";PK.-W?"X^"=A0XY4E!%*IF*+L',*9Q(?'LPD@)
M3V!P%Z>$SRD>,8L%4\J Q7^CF>!Y!"F5%%$=F!?[>XUJ-6B7P.U#V#YTX)U(
M.8S(C5@ZP#BD3$%,<A(SO3+^>RFC,SACG/"8(>;A;,9B*IVO!NM8Y],5H+9F
M,_L^+Z0J"&93"]CJUC7+MEN-3Y*(W!RFV^H;)5-MZ-IR0>24<*K<X5U&5]"-
MM9&8:G-03K1CUAG%*5569&*[X6*)C,ZI8T7K-,Z*#',:BT6>&6KOZ9;T4\$D
M-4>S,A8>H!Z00\!LAO6#Y/ >T$-R[A.S1A4VHYIC4V84&<=*6!!K"LM,$ZR_
MQ+"_#8DP4V>YI,IXM\DA60:X#$L:,X&"'.$H9UU2FPRAP<1.-]8=:A59"5[D
M5%J?ZJO)V[2K)M.,;GIO*F1"I8LMF)%<T=;F2SMA*L_(JL6X;22[J+UN[*G0
M6BQ:=>RZ6U,(6/?KS<MV>BE^&$F\H!Q+-,XB.MEX7HL]*_)ULBNK><?UHT>E
M@1<^*OM;JT=>%!T_N]FJUVPVGQ]LZ-6#QI/,^I;>DF+,HLH)?U.)*IL%.4D2
M'&-;U?P.PL]'IXS.=A)9YO#?WZAMI?2Q'?;WZHWV_0FS#OZ%Q]4MY@7N6F%8
M'@4_6'2GJQ\Q9_M[M>.VLI];Q^IG03ZQ\P(3:^5)Q#ROZGJ/M^-8C@2*C"6P
M8>XEY>*%\O^2*!Y3SG $^@WG0;C".8.9H=V!7RC'.2/#D;3@BF9V"L$IR-R+
M/#),_I^A;Y2A@RO)D.D<J=XA_7"7==].;E_XD;9]>Y2+\NZL)6F&T^0MW;E/
M>MA+[.@7/"PA4]Q0"KV[Y"M74.O/\C;,WLN=_ 502P,$%     @ H($+51+,
MDN4A'@  C90  !L   !E>#$P,6%J<F%K;W=O9F9E<FQE='1E<BYH=&WM7>M3
M&SFV_W[_"BW9G84J8["!0"";*H<P";L98(%L;C[=DKME6Z'=\K:Z<;Q__3T/
M2:WV(R'9S  SF:H)X.Y6'TGG\3L/'3__TZOSX^L/%R=B5(XS<?'NY=O38[&V
MN;7U?N=X:^O5]2OQYOJ7MV*WO=T1UX7,K2ZUR66VM75RMB;61F4Y.=S:FDZG
M[>E.VQ3#K>O++1QJ=RLSQJIV6J9K+Y[C)_"ODNF+_WG^I\U-\<HDU5CEI4@*
M)4N5BLKJ?"C>I\K>B,U-=]>QF<P*/1R5HKO=[8KWIKC1MY*OE[K,U L_SO,M
M_OOY%KWD>=^DLQ?/4WTK=/JW-2V3@QVY-]A+#@YV=M/=I_*@W^D<'#SM)H-G
MR7ZR\W\[.T#E%MS/#]EREJF_K8UUOCE22,#A?G=2'DUU6HX..]O;?UEKW%>J
M3^6FS/0P/R1RX>K Y"604<"H_"L/OO"*%8_ZRXG)3''X9)O^.\(KFP,YUMGL
M\*_7>JRL.%-3<6G&,O]KR\+N;%I5Z '?:/5_U&&G W33GU,W$1@GT[GR$^MT
MNC";D_]]<_KR]%ITMMN=7I-D^F?%=#X_$3T>"IF5L/YC.53]]L?)<$W8(IG[
M@)]WY.QM3SX=C64QA*7OF[(TX\,]F,&M*DJ=R,R]@5[&E]VF=/'!M06:O]\Z
M=N?6<7?I.OY=YI4L9L"O+>39[:]:RB]?^\VG8T:YN)0W9OI "/KIR;/.42]-
M"V4M_+YS] @6\5+]]&3OX$B<C">9F9'6.Q\,5-$2;]509J*7WFIKBD<PDU=*
M%@)YHO7?JHB/E2WU8/;=M=W=YG$JY%A,,B4M6)[2"(/;(6:F$E),#)LX,=7E
M"/=&%=58O-2F5,DH!P*'6MF6.,V3ME@O1TK\].2@V]T^.C;CB<QG]%?G:$-(
MV]S>EBC4Q( 6 S,'K\0GCT=:#=Q=P!$Z09ZX4"70<F4FLKB115M\ *JF.LO$
M%*R?D*4P58$$P]TB,PD93PU"JM*I,:DXUN6L#:.)!.ZSJL4O8MK$6,Y$,I+Y
M4.%DBS#7EDBKDJ8E\Y1?1$/C,@P*,Q8EK#Y1C3_A;;JT(M46C#?>TW[DW#"@
MK4]5HE.:Y4<#4ZPLKIVV(E,E[H@<%DJ1\,:[WO.?AGT?J[$I-,SK/T AK7("
MJZ]RR\N)"VQ@@$*H6AW ^&/;%M<C917_P5O>5_"L$@K8,RGUK1(P +X\A5TG
MFHG2>(=CVM[H0HE7<*NG[>OVZ=?>C.5 I-/^Z4GGZ?;1XK_'\\OX4N5J )SX
MR-GO)6@A$4^.K,7CGM,'Y/L^3LS*#/&08V?QY^ZSO1:\&S80@%*6 <?^N=-M
M=9]UVD_WQ03$8@(Z"GYJDVZTA*WZ'X'U42CA\\+ (*E*JP27R1(3P!B@6/]=
M :^GI+)')DM!QUK4MX,,Y084+LGAH,JR3=)@D>B1EH\DB!1N,4_V1&K2LC))
M3)'*''3O_(,H9)W](PM+#73)(@T4VV0$-&=*K"=54<!+8=;X8&?/;^1WW:*G
M[=W].VS2D5?^AX7*)&J7H]),#C=WVKL'BX ;]Q)'6'M1CGX5JN_(6+3GF;0E
MZ, 9F$&A9#(28WANM-$6/>0)H3[!_I:\A1JX@G=;@2V<>5L*6ZH^38 YV/Z3
MQ5NVE[DIQF"<^^B= N(4(S2J:-JG"D:!GS)-G4-<7POLV.=]SF59@28V V9#
MMN/6PK(B!SJC&TC+34GDP;+K/C#-P("YI]T QHU-R2-7>SU2 .*ER2O[.]!X
MIWG@A1;M&3$F")!"92!FB)Q!,S#^(]V![F&3(_V6 T?"[6CDG)I$A3A 5D3%
MT\<5XR&D@!&'JG2?R;&I8.; ?O (#-+=^TO@NE@9KP.3PN?>5^T\1C5DRWM5
M0[!\*-J\[KBY&\YPN WC"\@'>%N3#<".3$<:N(,V7X%J&#GKY8Q-80J"]7WR
M3P#MT X&. =FT0 ^!SZ2-J! 5&01#IR  2V0!\Z3TO3!K/[8Y&_<9/"X<-?:
MPKD);K%A5V"!Y0!=@Q]K_,UKW/J\X9,-00I;L2AI7G9@ADF5-:5'EJ749&MQ
M1W4.YD.G^.C0R,R*=9TG6868$<QK,2'9(Y,,2M>293<$0F%%[0:*%+PF12=]
M3(S@C/P\<H"5D4/V%\D2(.&M&#G8"CYE3S I- RG)0P+3Z0 (#)U*^')YMAM
M-I:(*PDXA$D['Q M!,XPD7;$CKR[/BQ@, 1">0DZ!- G+"2YD<&#]_IL?A;'
M)^?L:AD$M'#3*Q@ N!V #NP(1@$:7AG\,=;@+2N 8J"$B)#^<IHSA%-?B^G)
M178C:DL<@X82TP<PM8QA^CHQBK;,6F- !<16# +#?JU$%'&\?U&D5F4 7*AZ
MNWY$]JW)JG+QD2_D!OC?4>%'G@ ;;?8+)6\V2=L<RFPJ9W;M'A,5]XNTO(F+
M8R%ES!;>60-/315.8)'URXS1/G"PPF!*>&B#N"XW:'DW!=M>AZ6:#J##4G.1
M&PT 7[&.0KI@JT!MU!887^/8GXC]?>#V$Q#/<B9Z4U ,OP/X_O-=$#ON)'W,
M9A_5"SID&1@#X$9% 0:^ 30E$'*K$^=T8N!UT;;5^A=AN+-GBA>6='8+.1*,
M%8$[M'X8H084*,D:@2(/6FT^&@&_%Z8:LAVH#5P0&"00#="2E[;%^Y$BNX3C
M?)%&E#AG8-B3Q7=P#!->@D/0BYK3@F>^WAA]M1%Z4.'.%<$_%\-\W-*#<1?0
M>T- 7@!R2 RB.-M"Y"7R<R<H7XF>($\V0]EAV_T@\"BO%0H%\!$PV(J(''%?
M"V0S9X><446F@2TD_^W=-QY13#*8?"N2DY&263EJ 3#)2^!W?/Q66^0N=RMR
M:D'PKL6V@>9K!H-6%.'W!+>\&8#]0BM  D$#B9&\13)4+A3HFGZF[6@!4[;%
M>3 Z\3*@)D@52(WN<PX(G_$,!=)B;D S/08AZ %?('BE?6ED2PHU4$7!9ILF
M"(HCI%QH :((,<)&.9EDX.80=\E/F-&*\".#2X0.M#T1ZHQ#=M$0F9P^AO6[
M7I[B6\@[!<[Y[CF]^\D5=5?FBO %%"]Q,.4U&;;'K60;$48]6)K_@PLU9BTP
M>PB"@O#!&=F!+L =&BM%H.8[V5F0W2PSTY!GB0)5A%IB6,*0 4DW$Q8]- )5
M 2QKE>AT.3ED1R#:=A5]."MXORU-<N/BH!3T+Q)M,7J&F7',)-$H=324 G&9
MH3HSOLF-WQ@O]BK@.M,;9U7/)YRC<RE5\DAO07ES_ #7.U$!ZR,-O!E7:E*J
M,4:)GF%E4.=9*WI/'!#D+>JK1()82GB.8*2X8" 8/(I@&_#]O):\\4B+DW9.
M'O/"D#Z3UNT51]QCY<E@%C!97N%,/I,A"]"2\+*?>DK[[2+.>'>]AXWUC5Z)
M=\FIXS7\@Y?6K1G- _Z:6[CN-DVN\].3W?VCW8/'&'&[YPR:6^S2(+)QN^0C
M1-'2KV A2K4!:J]EWOL1,/_"HI- 'P3)9YSO-CJ( [X"U1*\)![=^$A6593-
M01W5*R6-!>$\$H0^1O$0TR$%@+*<?/,=COW&\I,>5V,/S"3.J<9?@"#@12E'
M P/I<QS,6((='KPO0IU6E8AK8"8KH"WH@5UOHDX#H1>9S(,GM3*[[*-]5S0M
M-_& C;ANR(Y,E1%)MLJ<)).*-M.<9B>Y-@GO2%21>Q>QT/8&4YG6))JB(:QE
MDP1DT=_#;WP,,&'G,R4E^4 CQL=ZG7)&BPZ*%JR#*I'I3G/*NM'2G@,X'[+[
ML#CI$(?CPE54 T3<!"UV/MS,U,!%YA;A!'^D<Z0#E,?3R?>O ;Z;9EB7&_>G
MF)I+U>VV]W$=O,FY, #)M;*?W:&(^<DA#9)(=0+!H#6=T8#\09PQ)<\ZR_M:
MJUZ%9)SFM\@Y^.*0S(^<DQ@S7)R>]GIU96!92BP) 2\3L+9!JWSR::3[ -UZ
MK1^!Z:\-3'^+S-V3A#'*<RR'A1]CS.*R!:%('X88+"/#ND($V1<#)/ ;K0UA
M9I0*'3AP+,%*I541,'B$WYH(O.5BW?DF^GH AUUI2ITXKCE>UQS?%E<:%D06
MV8SEA\HA*0.# ?:"O6LTF[I(-S&J,T/Y"]HU'FL.PK8:\4E9AI(%?"#426)I
M+-M$3.[DOB(B3)@+6$/&W4\GB#H\DAL!#"K@1BS.K$.3C6E^"',#*D<FQT!M
MABG H/WQPAQI=M7:+U27K93N%5R[Q"Q\WEU]7!:G_Y LSG87%X(JOL&/A(T_
MKTJ+)<$O??E7#^/N&AD-X29Y0:8JO[CK=0Y Y4/0FLB,"0R4 $LG(+ECG0"
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M"#IR,!#K2!K2"QI[0_ ?%J,%5)'M\H"@TK&S'2A/ES KYM*0T5ZTL*=.:*)
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M5-/@.Q5^>Q]$'JQ0@,$H(3WFDT"^>H,.]".+U\FN/'PQ7;?C.O[&7^9")?P
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M'Y>)(2@G$!%/#:M6:VA-[WXN)L) M5*JGFVJO%O9CPMMQ'2UW])/VRC"&;#
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M&_5Z,'[?&0/=?M_YM0=OKR\N/L"HUSDOP/7@O#>Z&MNA^/_7X<7U8-P9]7%
M;S#NC: _& ]Q?O_*B?H%KY;@<U=ZWR&Q,+R\'([&UX/^^ .@M,[5S_"?Z][5
MN#\<7-FY7?SC^F(,-_WQ>YK0&8^'HT'O PS?DK 1=-\/^]T>G/7>#D<]N.J_
M&_0'[[;4.H"XW.W92_M* M S#)N)R7%0]H"WD%$4.DSTYIBP7?=0'>.TB^*5
M#-9\)!N,-08;,FZ(T_4C>W:=/67L1W=$@8C'9,].UB+<@HICU;!L*B0&YA[$
M9P=22&.PSP@=NCBZ8H_&4:7DY0%Z,DWG:9EBCL9IOO/YLM#)'!2PT4]A&F9'
M5-2*"Y.>OKE5N5^P6Y? F-/:,4OWIM5K]Z95"?K;?7SNB?J.#BBKK!NO;'U)
M@"1BRM67BT,KL26P'Q'>9T3F%>KDN,,EPW![Z]KAO\1"OQT,?O[!X)-"KQMZ
M14C>$GFPC2>]LP)3=B>5[3,5CXFF$!!0MMFC]CO7Y_'HHUS90?8I[C;)Q90\
M!#:R+[>H#^3!ZB#>N-O-N-+7Z,Z$-%MOTOUS#Z.-#;(,4JB$%7$+ A9KWDK_
M:/M"QP%;M41D#;&3_LJ+RZ]?EU[57Q-"&%34^.G""7B4+'B4C;]]K]8L58[K
M>V]72M6]]SXEMGI2JC=??Q-;/]Y_.R^V;/WF?(?1H;$9_NFH?K2N'#ZU ZU:
M? ]5#(A<R 5\NGT::6/C*X%,VN0T3MK:_GSP;FF61\F>?,+<"AE[]%B&_H&/
MDB2G0^(JO;TD ^$#;7?[B7C/4HQ#]M7Q4\LGZY$]KVP_+M?8_2[;^O6T">=N
M4I$<RM"+Z,0B.TD7N)M.?-KJ;\3@B57P;\3@BQ&#'=_E>A1H]HT4;):@ 0N3
M;ZL=JL>>)C5P7V8AO]A3PF+EI%@]!L!$JS7P6O7$WJS5W*\&7)Z/'Y?;=M.&
MO]F//XYCO[+[6KG]@ON;_P%02P,$%     @ H($+5=?FSZY&!0  014  !P
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M/QS0_U[C+WMC/0NCQ:N_==)01W]K97#X>YE)PS'_G(6_F5?M0U@4?;SC=9[
MVU$8&[ON]B$NM?ME&@[#7+4/]@^KZURWA^;5C^"X3?KPY0_"F<G4E;E3_62F
MX]^]D?8A;.2F^[[3[PQZUU>J\Z;?[;[K7@U4Y^I<O>E>=?N=2]7O7G8[-UUU
M?:'.+CN]=S=?O:7?=Q />"N, WCCU='S^5=<_N\\O>,E,'@&I]<OYB;-U?F/
M/[PX;)^\ODF*W[3:P4^'!Z\_)07]U7Z]JW0<J$YP:])BID[#)#>C:0QKG(0F
M:ZE>/-IW;\E3\J9*4I5/C9(?SY+97,<+-^P.;#0RHSR\-=&BY3_Y7J<Y#.Z>
MG.I;H_0D-4 :\D312:LPAC_S:9BI&S/7J49*I#KX$)$27/0;$YM41ZIO(J,S
M4R[3/N5F@%=Q_C&L*+E#V@,SS++]K[W"K;CWMMO6GS_[Z[D. CC?O<B,\U>'
M)_ *G4I@1@E?X:L"#BC%]P"_W<4^WHJ?_+RO%&"#TJ//<7(7F6!B %9TKA;P
M96HR0'X 2_B0JGG"##%3.E-GT]",U448ZW@$)%M=C\?AR*0M]3X-X9LY?+7T
M(T%M^7MG-$J*.$=XM ^8\9A11OVCB(TZ:C$SQ/=H"68VCY(%8<!=F$\=WB(\
MPVS(7&M#/)<A+')XV'0.SUL4674*@CFUMUIR.B,#\P1*1Y$R.L6#RG2DTP4M
M.($74S4"LF#BC-_5HU%:()9/TZ283)N&WE]:!XY%U(%79+<<)  #<0)+O#.T
M'" ^:ERDR[,"G1H"J1B'>:;,EY&9YWB!F<F!(,#C0&J8T#BZ\=<D#"NAG.AO
M5@QG84X ] 6/SL#USN%X,CPDNN$ABFTFR^P#&;T,P%RD*;P6%"E"<@U,6_!J
M E\3M!+ S&%(&)&A(ROF. F^&(AT1W?6HENGA0V-B>'-<#8LT@SFL<NY!<8<
M-"PJ)#!+T@!PS_"\"&8>>P)N"->?PPPZ];<K4Q!VS9,H' &3^FN"PN'6\(B^
MR8L44'@,=#-!@6;QR+SB/8!(H6%J$$] D '"I.=3]1)72*#?)= '8H7K34.3
M(SGLQ0"U,Z&! -B]^!8@@"2:##D,@5PIW.PXD2H>AP@KP$/"?*&6!1N'PR0T
M 7:0V%0'>E7,8:IIF KAGA59#G!O1D5NZ+F!L ]<T1D<<@C<"&BQTGFN1U.D
M\""&X1]%9-0I;IWVNG)]S$T O6%O&BX0;B"I$UGF$3&/M&H!(^"VH.SA.NFY
MD?LMI %A]\/%:@Y%!"0E$!(V9:E,1M//!:;PCUO822!;LX/*^;60RD4%0BT0
MG)RX3A0"N70OI.ZHPRQ##A?I>9[,/3YH4!9.DS@<X9<__G!\\AH(698#S ,M
M#LPM\/^L16M,2!A0XS RO$SBK^7[] ,<L9VR_A.-:NAP\6<+F;#3#+7YY4G+
MW8VBI CL RV538GP R"DHRFQ>C@8/!\1"^I$-3;Y'>CMM.@ EH4'-$Z3&>W
MS2_SP@XZL#P98V_YX.@LZ/!JSSSH+,O%.P @O, O^9@ 5_0(8/5!U/K9\7:1
M^*.M(?$>YIZ*F+:1-/[(8=+95,< :"!I  4$0(P(7&\,"*8D=#10\M[9JF?^
M UJ.(\(BD$@"\9(S1/F(A3 B\"0 CUM L^*]U-PF(T^^0BDY"GTYR2?0/EW
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MPAFC[^%"+:<@LKR$1A R_8]AMU) @\TM*"G9+B4T)>H!"99/L=]R9A/9?,9
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M&RFM][LEK:^=9.YD^L0*S.Q -@4);.L>999D2LOK"$3V:XHM:?49S$!.2/,
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MRPVGMP+-^B?L -5RT.8#C0@-N@3>*0I2CY +Y9CT4M.4:EOO/*8H/'B]<+#
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M!Y8+AK69@S:0]?S!-;&Q&02*),J,*7Q ;(S#,M.9*IQ1#+1N,IDJ=,FZQ$I
M/S.J-%O*.6 G%N $*E"62Z/""5:>RCCY]18DDTWEL9D$^ HH15,NLL3<3>LQ
MHPP;4-L" ]5FXMI/R% 'Y%I81@,Z[% !Y.KS("$-HC&+HZ8Z2A>3S)3C"06W
M(I=R"QP]JKS[E3^.0(JHC81,@/SCA5^S04TW]ZE4]:S(XH[%>Q<:#HYJ>TSC
MFR'Z+9;RITA-E $5+KRJ+IV=;IT%=YO>'+^"G1UJR__@F9&B3.Z\[D/(*TQ$
M)A2C2X,XPP@_]5E8(;]7'P%-V=<"HD5A*2:ZHL#*=[6W00F[GY64;/;68G0L
M"P[4XH\]:X=B=%2<M(P4-BJ3EH.@W*M;CUC AA-R+2&7#I9/J:OS"7K?<%VY
M6UC@-I9#<ZNL#QC7MID>BL-N<;\VL=M>GW#8'_3N%&U#59=<@8]^=5PWKP=V
MZ4\,"6<L9_%YP),RJ\+9[FF3885QO'!NSXK!?@#5,X]UQ&JXS\IJ,FGDL?;+
MG'R!57)JY></N$6]@I(J/0UCKE=%L" =>1<MCQ5"Y*&1X<I*#!>429A:'W!%
M[T)VY=,5^0$DLYH/&?8BE5EFYLO1C\!'O.Q%H'XQN5(WE'.)JR]LP2RGG37=
M$P4JE<NE'M9ISFY:P<ET]H#K^T7A"MIW2JD-V?.G12Y8_6RD5\2 G8P;M%6(
M'VD..C]\Y_8N3/T+\?)KQH#7RD:.NL5&SH .8DZXK<42*Z6[$:*>2)L<?&L3
M*IT0XP"SQ3#ZGJ5N3?.M8ZFI^]AJ]G,G':_7@?[0+<?K=IB-+T5<8A!LN78=
M0<<G4,4L7.BL&5T 4B?NU'0SP'NHBNB"V4/8$L0Y-UR%<E^\7@YQMX1H99Z;
M2 =3W!?97G$"#@L_/>J-R(>K63&@CUGK]*N&FGM63G[%6//#2%8ZZEBRTED8
MF7COXLJ<H[2)"NQ1YQ)B<J2_V$8M>]\ITG8G#K:>>0>8.QB#,$C@87"UMUQC
M$# M=G[;4M0PDL.A$>!]8(IEY,N<3[A('%52X(L<3".ME91)&SEC??A'-*3C
MT1#RZ-1='I6G(%E8BQ\$V8<R#209V65YFXRK55FC]U[:S-L[\DKNM6$XSV9&
M_7"JB%RL$D"6##$MK]Q7^.S4Q%7 )HS1ZBG5?E$0PYEW  /LG;3!GI!"9"H3
M,Z8 *<8B%4IAT&[U+6%I;6"4LAC7H#R.X/.1W3;TH;!!Y N]Q7^T]W?08>#E
MC[8MJ;=$R]F'0X=HE31ZM%!3\OU'F1ZR:A$EZ$G*+0-A Y=<,YLISCJ6,8+5
MHNTZ@P]#^#0UKO4G5]]M/6DM,+%7MK?*;9B>T+N$@\$P/Y=>VB3WRM7(67ST
M!I:;-CTAJV!N:[_@<JR\ MT<+*"X%8.*XZ+5B6!59M\#(<5\U"4(R"3USA:?
MRF=+&4+' 6KC9 JUS$4]V#F! F=+/]C: ^S80%;/*M@WDD@Z%K)9QN9Q)@,>
M[G$)L]L\A8!"8Q8R*18[HPP3(]D5-Y,ZWBEGE-22Q"##\1OX'AU7> G B$4*
M!]')[XUXQ?J,SC)U:ZRS#PYXINBT[3,V'EE7LN[@O*FA*A=ON@HS3]DYXL0'
M!:JQJ5HS+H%9LQ]5%FG$>$#]Q-B>455I#:^6$+6=>)KLG[MRM"#QO?*9*JXY
ME:;G\FAZ5#348TZ"HLZFB^<P/B98CFQS-PRN-T0TMOP,<QG<5[X'GU<J2$3Z
M!L_4#FNQ@IO::J=0-:"PBY?G3BYOIE3K6)2AK?BL.BD73[5&1B_4RWIA(E:/
M\[=F^*FU01957&"5#Y#)R*;/AJ$[H$9S!XHXU&ZCEGI+G!EV4**HU\;5&+5;
ML(_[JRY@.*?P[2C17!]TX:.<#\2S_KC_O1JXWD\[@Z<-VO'.N[P9S&IZ$%VG
M%6K)-?+NTY:.*LY?&OH>F_W#PAJ7V-@*UL 9ZB+?'#U"W+!E!*X5%$UDR]8#
M"@Q37JDDUCT*='FCU,P:/)4#=K$R>Y;#[LP(\%O,;H^JH&/-J K'M#'L#+"P
MGBL1(U]:KB1X*%C^O7HC?0&6U_OO(GY145!!F6F68P>H@H3@T"YW7H=O=69K
MY,E/[N+)9U/6)L4?7.7USGDQ-F[Q]Q:]UO%BF-GDU* &SP68TI"O.8[8RM2X
MJ-TY?E /="GEW+G(E< :4E(QF]4F:W+(/-&VF5!84.4TS!7#?G*"D;4BQ%#3
M+\NY1#V74T-VYXKY,+FG+57+M:3T&3V-K@,N=&0;>R%XW(PQ@- 5*@7)/R@>
MRM2E"+C2J%$#Q/X]H>(PZN_/FT1-/<.JK;:I.00NAC,H5IQD7AVE\XKX\CXP
MGD9<-I;P$L+LKOO[9/[P>W]R0ZF::$"&TYT;%YZN9,#7>.S4(XY:J3XD??AI
MM^)]=W4<PLU?;W\AS )H-/&+VY1T+X-\8Y&>=4Y&?*>!:K_1(&C_95LZH).I
MT(DH+.)Q=KY/>:/"^2]Q.G84%SOEK+\/%RTC6"]*5BU[%A62$&K5^NR2:P03
MI-&7RNFZSKEA,R.]:[5^;T8CU_KK36.K[A\*YG;*@WX7YEZ5P)MN9;)V3EJO
M7J_*TT&MMZ7^N3CLB2-"P\&>+R48'+!C(J>%L->@J,B16FY]G.G,:X[-7@'4
MF[7VQG)WUJ9#,U+8NQ&K_80&#AYK0'_4L\F/;S&=XL(N&9ZTR"#IN)K.J_.5
M[S[(>%V*[%4!-8Y_MP7G C/ A\L#.X$+%FP;^>4K8ZI.O?Y& ';EK!B98\9!
MZP<NS M&O2/X_^5I:-U2%I^M5!:#;L.TC6_E?",SP9YU2S/DT/ER0^#V[C1U
MJYM;@H2=E8:*_83UHVKT3L;RA5ZM> &)8%QJ),64ZSCO3F3!L <%N"BF!6P)
M8UTVRL?5$2X)!:QU(".>,7":U@%B!B(3T"8+IR[B70:)&$F=A2WR;)D"K!2'
MM-5(E-C13)VG!F*.S#TK+!8SY4(JRXWZ9 S,3%/M&W+@:H=<K0:5AI!JBR/B
M6SZ[H4HZH,E]C"CVMVF%!R<S&_AU?7[&QL1YO3>TUZQGKO*B]1S)]4!]9KB_
MKS_5*K=FC!&GE'H6).PYCDOT<.".PSZY%:4U![+ER^29XMHYZYBR;R]XK5AE
M%]Z.3)*#JSM@H,UD$)U2UT,G8FNXI)51W(L\(X5M[UM(SG*'TA6+-_F$/_X*
M\;8B0V%(0(!DT8E4ULNJUNHRJ/CO0#+K%UPIVP62Z)0=L!R8;VE!Q9YJ=[F8
MJ_C@HOR">E%1,II/N+*7[$RI=:Q-A4&':NA(QK^I[[[+LT1^F.@;$&$*VV2@
M4DAU(<#?%Z1"EL6GM8#;2*3H>+8&WYG99'S8?!29EI5F $>J,M]PTD9>M(EK
MQ9_X\0J>8EWR&&WA][ B&D7AUM&VH(:5]IX++,7'B,"8.EYDOD:(;P"F=ZF=
M76@%4:LW+!RKU9X3_H8W#+N*,[[#BQ>X;.PMF5SAXTW[R]B[=ZC5A=I00=Z]
M:D/2(&]] !AWNJF=!77"5>-LU^6:4P1\0H7'GZI:"B\UP5@3L*J.2>)C!V 7
MQ+#+NLV#II$MBI8GIJJ;39C+YQOW]&P6B<OVPP:+:6I*NLQ&I]R8F&L$N-%E
M),EFJ;H4+5_'T5J74/?G #K5NH$WDI5MITA;Y5A@=_6:0PJ_.&=G3FZGP<O)
M)R95]8O1>%Q*@O1]$]SU?*[-,F,SW_O)+=-GU9A2M"$"$P'?29+7-J&1_.U;
M2;CE>#;%3B"F@9:ID?_'MVP*XUZ%_BO82@S]HL;P(]3Y($*=@[V5[JMCJ@+8
MR+R:U3<\V.1G,MZT'#H&U7JIHW-5Z-05K@?-(>PE _9-G?E>ZJQ4((.D5F3X
M';;\H@ZZ[D:^P&U"#]D;MHG#<8,-KN595S'[J@YZ07^-=4JD7N-*<DKY\-WZ
M,.W%-7I3<>.*NJ7(;*\9U**<1T)]3A/'1A.%:AOB/A-%*&V[K-E^-YR"2"7U
M8<KQY]^Z2?W%&$94.0.D#F&J+K,@3[R0HQ'@.SFK,N><MPW5C,^E)/E""*Q8
MQ:7$4M1\A^B^P*2;9!%FFS83IGTC/7B7FWHT=L4*K\K9!L)NJK(QQL8IDS/7
M+GQC QA8S,J>2^EYDLTLI[NRL[CRW/)DMD/T8*]R-]X:_56;@JPQ07 P6,FT
MWU*?%,2$4]A)+L^]1#\K=I';M-6W4_^OML/57>D6,G.] NUNE-3Q5O#U,,WW
MB9ZX\BUHAQX[7RTB)3I#7$?\.UH"]FIL:94.J/ %NH1N*3\[:/P=-&<:8@F#
MJP;M51="US(>';DH?_! :5J-/*\!O?,#*'P<>Z^:0 ;<([.84GG90XY#"V'#
MO>J UHRIDI!UP]QY3QX=4E1.2]8,>?GP$1)V5>SH;RWV@]92&BV+=64>+BY!
M>_!YG2ZZ@/ KR'U_);F_(4L8[:&W<KYQRUVEIM6PQ'DKV>BW%]UP5ZH9]66V
MSB9N,6;K&0H;DCF!%0+&IEI2%R\T93C8AI<74&M6+H!VL^7^;O'@39B)\DUS
MSDTG$"R':-ZWCD*4VO#9IG;A_&GL*='F"=@P$@SBJRDX2$9E1VFD9\D7]?[L
M)A8?K,3B=SJ/5))PE\Q-])O!VCH3(A\<W9WV<THH&KI$WC6[)HB_)'H[UYX8
M5.,#.G<M"ZF--! *(,*DW7*C\D' _J(D+PEZ$'G5536)HW/V)=NWEU-B7),L
M[C(MN%+4WLY:HH:A8O*]5)6_KKUOR%18 W%9[]Q:WV3LO+1Z?Z_FVEHY=5^<
M@UI-Q^,\.59^MXI8QSRK<+--.0HZ1W&MOV.CMM>I#)*7> *:>02BEVX[(<M(
M+MA1Y:6O+4UV!;GT8D_,S)S+)X"IW6JPIU1@FK".9+LFVN:@O+S";3;>2LB/
MD5(%H[,M1:<&F^@*HGV##6KU[KKW&M<LPS4 6'K<!C'\YZZO:Z4=W;V&#>58
MG8G9W\>Q?K,'=YS;:Q[7&I6N-\BL*D?L'4EHPV+R1Z+B,>NTM=B10T*-#:/=
M7196DXA-4';B>E6P=\AV7:UBIJB%S[@.6M)UZ;:O)^H2&$H5WKE@&^Q9#U81
MYO9L=# 5,+@S(?;[,/B$^H/S):IKQMW?E20!Y#J<NVPK4HE'')*Y5:FVM0G)
M(KR*W':F+FW?WXB7U31D^^)X.M3C4O,=".Z^,8J>M*3<V$'=8%B-)9$\V#]E
MJX>SP+T*Z,N.)98[KB-QO8=-G*&S/VYDIB/95"T2J=<T@6HOS&1[>T.IH3.Y
M!?=1PY6B[EUTC^[:=4SDG;=@,,4V9ERFUCLCJXM^"1$==K04UOOR>#GR;83"
M,9='Q"=\+XN@!7=]X*JAE[X?"(W*;U)KI,W6:;"B1''\,]28"?@?P;R.]^N3
M^8T-2N/!3N6-U\YC%58PD,/>)Y16^)(;GP4#B$+(:?M95:AAU1#GG=3D7T=/
M)(W(H90I.P#1SG&*A;WE(J'47;ZY9/-5B\[DP=RK'--9O9,?%-AEZTQ;66.;
MB4>OA#AMN63>:C;."PV69,U=[$-#& E.K%%+2@3>&JQ&$G1\0G=G]0:WU%*#
ME)+9>U">[J)GH6Y"ZDBK=;[%(@!>PM3[8!;LH(5WWE=]+_!>)AN_,'@WWS9&
MSS*;O^;>Q##H$)T:)HHDDGW5#4FRRP3H.#-93[S!S+F1YFL$U*V-%\@H8D=G
M#_/M>R)"4]=6][M\*@:9(RA@8Z!GE(,;U25-KJR!9!3>"$!;0:!'>)%9>.\A
MLA?>:&QGJ<:PDZAY<AS!^B+H0N,PU$'A7L-+19,FR\H9,A\^T+'MZ>4$+ U2
MO_7!O^0Z&/!Z*D47_U*4RQ^LB^*0MN<9F&[4:*W9=*(9XJBNCO"),Z*1U*:"
M-$B\HS4<$7N*8QPVUQ\Q2^WQWK:(^1+'QOK(9U2;NEF@V=!8;$A(I=@GKU;*
M1O=Y-XHUZX5KSD,50.NO?=E0?O]X4_C]B2D1>7&OU^T&N5Y&N*%R?A!BHL"!
MD*ZG)B/-Q0/>$RY\R(9<LR9(HCM# [;8Z*U--[#I!*XVT=?'6T\O35<Y5OKB
MM2_(0?6Y@BP A;N^\.5T5!0)^F4+'0,7'<F(;K-S:1P*ZS<RD^I(</A7;*G^
MN.^+.6;Q*+@-SWY8Z%%U_X);=% +E =%1 @87K%("1>K8/^J#9#6%!D"?OB7
M+BAGY"]VR:XWN:@E$XQD>"WZMXP@G 86E_4K&NK7,.2DH(Q:.CZL/KJ5Y]1B
MP-"/PEXE9$TQ] ON8+V1G.7JN?OE1:QST-D7SW5*>T OO:BC";(BP$7J%FPA
M(&#XZ\JLZN^Q:54 .$7L9K9?]^FKW2)>_NY)?__@8.6W>_W!RN_N&O6P_W3_
MV5<?=;#7?S;X!L,>]9\^??)%P]X]Y9/]+]O9;S/J]\>";S/JX G@^M-O,NQ@
M_Y.&W24B8T(#6LYG,OW[H\'^H\I!0LK$\_W91S%HY?)+)&UF7YWQ#^YC_+3:
M\^/SDW^*T[YX?WIR<7WL69G= [^\@Z75[0DJ#_F/'MW033M^_>?IY1_OQ*]G
M%]>G)[^?7[R]>'-V>M439^<G_=H6MJ+*XT]9-&JBS14ST__FBUX2RK3H*Z>@
MT9TF*Q&E6IP5>T[?F158NZAC@:"^V*254]U,3C_%.=B$"_$>[()"?F=B^8$V
M>YN,.?\PDU1<RALS?Z@<XGT&:CE0R/3KL C[);#Y368>/QC&6K'H3D3:-%QZ
M^"SD&F]Z^<$]_'Y4:4X_>,?W1)\'Q3:N_GS?$V_L=?(G]O[FGW\Z>/I"'//-
M$B>_73Q CD(>,73L?29&;#C/V-_?V]_9>[RS_PP.>;!_^$+L[],.'#RC__:>
MB/>OKW_PDT_8RJ^"/ \ ?PYH$P9[C$9/E_#'\HM&QM(^5[I\>^0Z^ P*_EZ#
M;-*CZ]BU5A'3H3U9TZ.;R2<OU:U6<TIU^0YRY0?J/"#4.7[]YSM!)?/_K_W*
M_[A<%JB[%!#N;$;P[M#$"_AO4DR35_\'4$L#!!0    ( *"!"U6@85=>^#0
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MZO37CTC$=%EU1)@A_6]-&6O;@"+*$$:>SM(IYAHLU:U?JKHUZN0QX[W!.GD
MGJ'I$_+%"U_>E^"NH]&6==90%(VC$2 %-4(0Z^?!F6?:8SUUASR^#Z/=#2<,
M355SI!)DOQ:J(R'_;X#O.WC,6F^P3K_#CB>EN -Y/LOXNAC.&=S<&'T.MZ3X
M,\:H_DU5+&$$H40/I+'RU]A9^1T-__S=,397W@I] M[.M]^,G^^_;O\_IR.0
M#N5!KZ_/J+<?*RR#"LOCWIR3@]#S;[N(;?IX@.@ROTD1,]8@OM!M/5IP,_>V
M^QG3#6Z'M&>KVK_!1MADU3G&1V(IX?EOY.G\IA6KX[#)TD5::7<G72#W$$T]
M9!G]O'GF?[LBHL/&6CP6$7VJ+AE@(>9%T:%*[,$VT%<\_ RW<FR6=*K9N5BB
M-5]Q89X710[II-0FD+_P\?I\^U_S/H5CY-) 2U>F#&Y00Z\HCA$&5F***3"T
MILWWV]1$/1&+:(=#)18I[#C&F#TW=AROP[*O!QGK12IE["8_+6MD1L;Z,;P^
M6+@,&]K_/7@6PVAP&V98.Z8+U2SO ^T&"\".3_O E;[<^Z.QHXZO50OZ+EUU
ME T)N:]MB(G$I?T(#R/>. 3D7GOLRIHK%<?3S97GKC+_)JOF3-JK^-WQYS.N
MQOLO'TXCIL/1B,]'SU[@0O1 E'W%TR4!++T*:8KS/D';T?H&2Y]3+J%&,V97
M%X[9%@E<+82ES,9L(E8%7R*W1@ &) &'HY>?00"TPB$-YJ-YNV6"N0A2JNV8
MXGNPM(-4&4>XN:+C,^@^KJ3O5GC<)+ I84SX3Y0GHG=!6"M2L)WFGZQ;(IR;
M;@LP%25UW4/F:Y-ZX NT_;TNOFF_$H>>BP\DF!*V@HO$ A/B6$5CQT5?*^42
MS [B H]FR%#)1<\6F,V3XDY\I=<X#3<)1VX(JZN".\X%2.]N8X8Z6)7PK;+M
M]W"2?J6)_IGO1H^\[PTF>V-&W6=#<9X)'"F<[+]:*&$TQ9=0%-V6PG5X,QH[
M$22YD?_MY!;OZ92EFT^\_,R>X=<51SKHCR/I9?(+WRK-KO%.K#!&$)V:_H3J
M,=:TC;&FL[4\C(>C0R\4T^%)<MDCMR(-K6(O-%3DV/)TI:L,X"@NM7#9YI>C
MZ$P0EXPE?78]+MHO-?1P3;5G_=%F?(OZD&3:[6L$L+H"5E9%T/ GV.@V2V_Y
M$PWB;=&>##)JS(LR_2>K,KCXL0%#V57*ZEI8X3-)HTW)+&S.X/ZD6F]AZ78<
MG0&&5JY<**$3HQ2W18-I\EQ<%3L?DW5DVCVAE6:;(8W_9B^NKJA+@-'F,^&W
M@38]2QJBW6@[&<I9; TAUSF*?%:IE"3N^EDZJ[ KIQODLR\^2@S&&(MYV3:[
M^ +3QNVNJ<R6']$R5([4',:"#6 $JAHX,7F]F#!].,Y+W.CN+#_B)V;I1X3)
MPQ@01T\&W"@ZUH8<;Z[4S7?%_8O01N6TIA]6Q@9&T(%?]Z[?["]H-2^+^F;>
MI9:PN7@ID[0[D&$'Z\-BMT1[#)#=Z2<KX<'AWQGOMK<N;ERN*-*)G*+]"M]
M$5*:WBWZIRP+[ES$<MH03[J#[I50NK +-*=U>*)#1.LE6HY(0##>WW6>)8B@
MT@\U?=!+)#[ >[#"0MGP_H1CU)J9;IW!L_L79]([_BT1[&0X@NTR#FN[Q+'<
MS%T7"-O[O(,DO %;[[77=#L]9C+##E/8]K2=J.QN+M$R_CBJHA [W]:B[H+
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M.9$']92K=6F*+)U)PC4;R'?C@Z/HHC!%2L0#Y#BZ; &2%V!QM1ZW(LV$92!
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MS*M%]L/_ E!+ 0(4 Q0    ( *"!"U6C>Q' C28" *+S$@ 1
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M:6]N;&5T=&4N:'1M4$L! A0#%     @ H($+5=?FSZY&!0  014  !P
M         ( !5UP# &5X,3 Q8VIR86MO=W!R;VUO=&EO;G-V<"YH=&U02P$"
M% ,4    " "@@0M5@;[Z!>HM   _\0  '@              @ '780, 97@Q
M,#)D<V]U>F%S97!A<F%T:6]N86=R964N:'1M4$L! A0#%     @ H($+56^Q
MEK^O(P  \=,  !X              ( !_8\# &5X,3 S8V]N<W5L=&EN9V%G
M<F5E;65N=&YP+FAT;5!+ 0(4 Q0    ( *"!"U6@85=>^#0  *QX 0 <
M          "  >BS P!E>#$P-#(P,31E<W!P<&QA;F%M96YD960N:'1M4$L%
3!@     0 !  6P0  !KI P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
